Mass spectrometry and gas chromatography in chemical analysis and identification : experimental factors and case studies by Davies, Noel William
Mass Spectrometry and Gas 
Chromatography in Chemical Analysis 
and Identification; Experimental 
Factors and Case Studies 
by 
Noel William Davies, B.Sc.Agr.(Hons) 
Submitted in fulfilment of the requirements for the degree of 
Doctor of Philosophy 
University of Tasmania, November, 1993 
This thesis contains no material that has been accepted 
for the award of a higher degree or graduate diploma in 
any tertiary institution. To the best of my knowledge and 
belief, the thesis contains no material previously 
published or written by another person, except where due 
reference is made in the text of the thesis. 
Noel William Davies 
This thesis may be made available for loan and limited 
photocopying in accordance with the Copyright Act 1968. 
Noel William Davies 
2 
ABSTRACT 
This thesis is based on developments in mass spectrometry 
(MS), gas chromatography (GC) and combined gas 
chromatography-mass spectrometry (GC-MS) as analytical 
techniques, and specific applications of these 
developments and traditional MS and GC-MS to the analysis 
of organic samples. The majority of this work has been 
published in the refereed scientific literature. 
A detailed theoretical study was undertaken into the 
relationships between chromatographic resolution in 
combined GC-MS and carrier gas flow rate. The influence 
that the type of GC-MS interface has on optimum flow rate 
requirements was quantified. A simple equation relating 
column length, column 'hold-up' time and volumetric flow 
rates in directly coupled capillary GC-MS was derived, 
facilitating the setting of the appropriate optimum gas 
flow in this mode. 
Average linear gas velocities and flow rates required to 
deliver optimum performance for a variety of column 
diameters, carrier gases and types of GC-MS interface 
were reported, together with the 'hold-up' times and 
inlet pressures necessary to deliver these values. The 
dependence between carrier gas flow rates, average linear 
velocities and temperature programming was determined for 
a number of GC-MS interface and flow control 
combinations. Discrimination caused by the 'open-split' 
interface in GC-MS was examined, and a numerical 
relationship was established between GC oven temperature 
and effluent yield in temperature programmed analyses. 
A GC-MS screening procedure for a large group of target 
analytes was created using a 'bench-top' quadrupole mass 
spectrometer, enabling automatic detection at trace 
levels of genuine or potential 'positives' from crude 
extracts. Two representative ions of the target substance 
had to occur in the correct ratio and at a specific and 
automatically adjusted retention time for a 'positive' 
report. For maximum sensitivity a number of time windows 
were created, and selected ion monitoring of the two 
characteristic ions for each target compound was carried 
out. Although the protocol was developed for screening 
extracts of biological fluids for drugs, it could be 
applied to screening for target compounds from any 
matrix. 
The technique of 'Selected Reaction Monitoring' of 
fragmentations within the first field-free region of a 
double-focussing instrument of Nier-Johnson geometry was 
developed, and applied to the quantitative determination 
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of drugs and drug metabolites from body fluid extracts 
using stable isotope labelled internal standards. This 
method, an aspect of the now widely adopted 'Mass 
Spectrometry/Mass Spectrometry' (MS/MS) techniques, 
greatly increased the specificity of the detection of 
target compounds. Warfarin from human blood and N-hydroxy 
phenacetin from human urine were quantified by this 
technique. These two examples were among the first to use 
a conventional geometry mass spectrometer in this way for 
the simultaneous monitoring of daughter ions from 
different parents from the first field-free region of the 
spectrometer. 
Conventional low and high resolution MS and GC-MS were 
applied to the analysis of essential oils, wasp 
secretions and plant gums and waxes. The essential oils 
of six hop cultivars were analysed in detail, 
particularly with respect to the levels of selinene 
isomers. Commercial extracts of Boronia megastigma 
flowers were analysed by GC-MS; (Z)-heptadec-8-ene and 
dodecyl acetate were identified as major components, 
together with the new oxygenated sesquiterpene 
'sesquicineole' in some clones, and some fifty other 
volatile components. 
A library of several hundred reference mass spectra was 
compiled to enable analyses on a range of essential oils 
to be undertaken. This was made available to the MS 
community via the U.S. National Institutes of Standards 
and Technology (NIST) database. A collection of 'Kovats' 
GC retention indices, important corroborative evidence 
for the MS identification of essential oil related 
compounds, was obtained from a diverse range of 
literature sources for 400 mono- and sesquiterpenes. This 
collection of data was published as a review article. 
Based on MS evidence in conjunction with microchemical 
reactions and subsequent comparison with authentic 
standards, 	(E,E)-2,8-dimethy1-1,7-dioxaspiro[5.5]- 
undecane, (E,E)-2-ethy1-7-methy1-1,6-dioxaspiro[4.5]- 
decane, 	(Z,E)-2,8-dimethy1-1,7-dioxaspiro[5.5]undecane 
and 2-methyl-6-penty1-3,4-dihydro-2H-pyran were 
identified in the mandibular gland secretions of 
parasitic wasps. The structures of three new 
cycloartenone related triterpenes from Gardenia species 
were determined primarily by MS from first principles; 
these were 9,19-cyclolanostan-3,24-dione, 9,19- 
cyclolanost-24-en-3,23-dione, 	and 	9,19-cyclolanostan- 
3,23-dione. 
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CONTRIBUTIONS TO JOINT PUBLICATIONS BY THE CANDIDATE 
Eight of the fourteen publications used as the basis of 
this thesis involved joint authorship. In almost all of 
these cases the candidate was the senior and 
corresponding author. The following section outlines the 
various contributions of the candidate and others to 
these publications. 
An automated screening procedure (Neill et al., 1991) was 
the result of an Australian Research Council Grant of 
$37,000 to Associate Professor Stuart McLean (School of 
Pharmacy, University of Tasmania) and the candidate. The 
grant provided funds for the purchase of the necessary 
equipment (GC autosampler), and a part-time graduate 
assistant, Mr. Glen Neill, who worked under the joint 
supervision of the candidate and Associate Professor 
McLean. 
The candidate wrote the flow-chart and subsequent Pascal 
macro that enabled the procedure to function, chose the 
diagnostic target ions, determined the empirical formulae 
of target ions, and was responsible for the overall 
supervision of all GC and MS aspects of the project, and 
the writing of a substantial portion of the submitted 
manuscript. Mr. Neill was responsible for the day to day 
preparation, extraction, derivatization and injection of 
samples, and the building of the database of mass spectra 
and retention times. Associate Professor McLean also 
wrote a substantial portion of the manuscript. The 
candidate was the author for correspondence. 
The first application from the selected reaction 
monitoring procedure (Davies, Bignall and Roberts, 1983), 
involving the quantitative determination of warfarin from 
crude plasma extracts by a direct insertion probe 
technique. This project resulted from a request to the 
candidate from Dr. Mike Roberts of the School of Pharmacy 
at the University of Tasmania for the development of a 
quantitative assay for this drug. The blood samples were 
provided by Dr. Roberts, who wrote the clinical aspects 
in the introduction. 
This request came at a time when the candidate had been 
working as a Research Fellow towards using the selected 
reaction monitoring technique for a range of 
applications, in consultation with Mr. John Bignall, the 
officer-in-charge of the MS facility. Useful discussions 
were held with Mr. Bignall throughout this work. For the 
warfarin paper, the candidate undertook all the 
experimental work, did the literature review, prepared 
the figures, wrote the majority of the manuscript, and 
was the corresponding author. 
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For the determination of N-hydroxy phenacetin (NHP) by 
selected reaction monitoring (Davies, Veronese and 
McLean, 1984) the candidate was responsible for all mass 
spectrometry aspects of this project, including the 
writing of those sections for the manuscript. Dr. Maurice 
Veronese, who was at the time a Ph.D. student of 
Associate Professor Stuart McLean, was investigating the 
differences in drug metabolism and response between 
individuals for a range of drugs (Veronese, 1988). Part 
of this work was the investigation of phenacetin 
metabolism; the determination of NHP in clinical samples 
formed part of a detailed pharmacological study of 
several metabolites by Dr. Veronese. 
The candidate developed the NHP assay and used it on 
samples supplied by Dr. Veronese. These had been taken 
from thin layer plates after it was determined that 
analyses on crude extracts could not be adequately 
undertaken; sample extractions, enzyme hydrolyses and 
purifications were undertaken by Dr. Veronese. While the 
clinical results of this assay were part of Dr. 
Veronese's thesis, the candidate suggested, developed and 
undertook the assay when it was determined that thermal 
instability rendered N-methoxyphenacetin (NMP) (the 
derivative of NHP used for analysis) unsuitable for 
conventional capillary GC-MS analysis. The synthesis of 
both the standard and deuterated NMP was undertaken by 
Associate Professor McLean, and the article was jointly 
written by Associate Professor McLean and the candidate. 
The short note outlining the advantages of accelerating 
voltage adjustments to obtain spectra of the daughter 
ions of several parent ions via linked scans using the 
same magnetic field to electric sector voltage ratio 
(Davies et al., 1982a) resulted from discussions between 
the candidate, Mr. John Bignall and Mr. Ross Lincolne. 
The candidate wrote the manuscript for this note and was 
the corresponding author. 
Dr. John Madden, of the Department of Agricultural 
Science, and the candidate worked together on the 
determination of the chemistry and biological 
significance of mandibular gland secretions of parasitic 
wasps (Davies and Madden, 1985). The candidate undertook 
all aspects of the chemical analysis, the literature 
review pertaining to the chemistry of wasp secretions and 
any other insects in which the detected compounds had 
been found, and the writing up of all matters relating to 
the chemistry of the secretions. Dr. Madden provided the 
samples and undertook all experimental work on insect 
behaviour as well as the writing up of all the biological 
and behavioural aspects. 
7 
The analysis by GC-MS of essential oils derived from hops 
grown in Tasmania (Davies and Menary, 1982) was 
undertaken with Professor Bob Menary of the Department of 
Agricultural Science, as part of a wider program looking 
at a range of commercial essential oils by GC-MS. The 
candidate was responsible for all analytical aspects of 
this paper, and much of the literature search. Pure a-
and p-selinene were isolated by preparative GC from 
rosewood and celery oils respectively. Professor Menary 
provided the hop oil samples, much of the background 
information on hop varieties and origins of aroma 
compounds, and the discussion of 'aroma' type hops. The 
candidate wrote the majority of the manuscript and was 
the corresponding author. 
The analysis of Boronia megastigma (Davies and Menary, 
1983b) was also undertaken in collaboration with 
Professor Menary. Apart from the original isolation of 
the extract, the candidate undertook all the experimental 
aspects outlined in the paper, including the 
identification of all the listed components by GC-MS and 
ancillary techniques, was responsible for the majority of 
the literature survey and most of the text of the 
manuscript, and was the corresponding author. 
The characterization of gums obtained from the various 
Gardenia 	species 	(Davies 	et 	al., 	1992) 	was 	a 
collaborative 	project 	between 	the 	candidate 	and 
colleagues at the University of the South Pacific in 
Fiji. 	Partially purified samples were provided by the 
group in Fiji, 	and the candidate undertook the 
identification of new and known triterpenes based on 
interpretation of GC-MS and MS data from first principles 
and comparison with reference spectra. The candidate 
undertook the literature review for known work in the 
area of triterpene and steroid fragmentation mechanisms. 
In correspondence with Professor Subranamiam Sotheeswaran 
the candidate indicated the structures and devised the MS 
fragmentation schemes. For 9,19-cyclolanost-24-en-3,23- 
dione, UMR data from a partially purified fraction was 
used to assign the double bond position in the side 
chain. Professor Sotheeswaran provided a first draft of 
the manuscript, which was substantially modified and 
corrected by the candidate, and for which the candidate 
provided the structural and MS fragmentation diagrams. 
Almost all of the references are the result of the 
candidate's own literature searches at the time of the 
original research, or subsequently for this thesis. Some 
of the references on phenacetin metabolism were obtained 
from Associate Professor Stuart McLean, and the 
reference to earlier German work on characterization of 
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hop varieties from their essential oils was obtained from 
Professor Bob Menary. 
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1 . INTRODUCTION 
Scope and Limitations 
This thesis is based on research undertaken at the 
University of Tasmania over thirteen years prior to 
enrolment. The majority of this work has been published 
in the refereed scientific literature, and has been 
submitted under the University of Tasmania rules for 
Research Higher Degrees based on published work. 
The text of the thesis summarizes the work in each 
section, and refers the reader to the relevant 
publications; it does not attempt to present the work in 
each section in full detail where this is present in the 
published work. The principal publications have been 
incorporated in full into an appendix, which nevertheless 
constitutes an important part of the thesis. 
Significant advances in organic mass spectrometers have 
occurred since much of the work described was carried 
out. Applications of mass spectrometry/mass spectrometry 
(MS/MS) using 'selected reaction monitoring' in 
conjunction with stable isotope labelled internal 
standards have become relatively commonplace, and modern 
instrument hardware and software accommodate this mode; 
the examples described here, dating back some ten years, 
were among the first to illustrate the utility of this 
technique on a conventional geometry mass spectrometer, 
and predated the commercial availability of the 
technique. 
General Background 
MS has traditionally provided a high degree of 
specificity and sensitivity to the detection and 
determination of known compounds. Information provided by 
empirical formulae of molecular and fragment ions via 
accurate mass measurement, and the study of specific 
fragmentation pathways yields a wealth of structural 
information for unknown organic compounds (Beynon, 1960; 
Budzikiewicz et al., 1964; Beynon et al., 1968; Waller, 
1972; McLafferty, 1980a; McLafferty and Turecek, 1993). 
The coupling of mass spectrometry with gas chromatography 
(GC-MS) provided the ability to integrate the excellent 
separation capabilities of GC with the powerful 
identification capacity of MS, enabling the direct 
analyses of complex mixtures. Numerous books and reviews 
have been written in this area, both on general and 
specific applications (e.g. Junk, 1972; McFadden, 1973; 
Karasek and Clement, 1988). The introduction of capillary 
GC-MS, beginning in the 1960's (McFadden et a/., 1963; 
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Teranishi et al., 1963), had a major impact on the amount 
of information that could be obtained from a single 
analysis, due to the improved chromatographic separations 
provided by capillary columns. GC-MS has subsequently had 
an enormous impact as an analytical technique in 
clinical, environmental, forensic and natural product 
chemistry. 
The applications of MS as an analytical technique for 
organic compounds have continued to expand; benchtop 
quadrupole and ion trap instruments now make the 
technique available to a much wider range of institutions 
and researchers than was previously possible. Advances in 
ionization modes and chromatographic coupling such as 
Fast Atom Bombardment, Liquid Secondary Ion MS, 
Thermospray and Electrospray liquid chromatography 
interfaces have enabled the analysis of a range of 
biochemicals and macromolecules that were previously not 
suited to MS. Numerous reviews have been written on these 
developments (e.g. Burlingame et al., 1990; 1992), and a 
recent overview of the practical techniques used in 
organic MS has been published (Chapman, 1991), including 
reference to some of the original work described in this 
thesis. 
Research areas 
The overall theme of the individual and collaborative 
research undertaken since 1979 has been the development 
of a number of theoretical and practical aspects of MS 
and GC as techniques for the determination and analysis 
of organic compounds, in both chromatographically coupled 
(GC-MS) and MS only modes, and the application of these 
techniques and conventional MS and GC-MS to the analysis 
of organic samples in several disciplines. The work 
described in this thesis has been divided into three 
major subheadings; the development of certain theoretical 
and practical considerations in gas chromatography 
relevant to the coupling of this technique with MS; the 
development of specific GC-MS and mass spectrometry/mass 
spectrometry (MS/MS) techniques of relevance to a wide 
range of analyses; and the specific applications of these 
developments and conventional MS and GC-MS to specific 
analytical problems. 
Under theoretical considerations has been included the 
chromatographic optimization of GC-MS systems based on 
carrier gas flow rate and GC oven temperature programming 
parameters. The determination of analyte yield using the 
'open-split' interface in capillary GC-MS and the 
quantitative implications of this have also been included 
under theoretical development. 
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The analytical technique development category includes 
the development of an automated screening procedure for a 
complex range of target compounds using GC-MS, and the 
use of 'selected reaction monitoring' methods (MS/MS) for 
enhanced specificity in the determination of target 
compounds from relatively crude matrices. The 
applications of the latter technique to the analysis of 
warfarin in human blood plasma and N-hydroxy phenacetin 
in human urine have also been included in this section. 
Other applications discussed relate to the use of MS in 
the analysis of a range of known and new natural 
products. These include; secretions involved in 
communication in parasitic wasps; the general application 
to essential oils and other plant extracts; essential 
oils from hops (Humulus lupulus); solvent extracts of 
Boronia megastigma flowers; and bud exudates from several 
Fijian Gardenia species. The development of relevant mass 
spectral and Kovdts' retention index databases has been 
included under the general application of these 
techniques to essential oils and other plant extracts. 
Background to Research Undertaken 
During a five year Research Fellowship in Mass 
Spectrometry in the Central Science Laboratory (CSL) at 
the University of Tasmania, MS and GC-MS were introduced 
as analytical methods to a number of academic departments 
and projects, and basic research was undertaken in 
several areas. Existing research projects from within 
academic departments at the University were also 
supported, and the full potential of the then recently 
acquired Vacuum Generators (VG) 7070F double focussing 
mass spectrometer was developed. The application of GC-MS 
to the analysis of essential oils and related products 
commenced during this period, and the characterization of 
parasitic wasp secretions also formed part of the 
Research Fellowship. 
Although the general technique of capillary GC-MS was 
well established by 1979, a number of contributions to 
the literature towards achieving optimum chromatographic 
performance were made during the period of the Research 
Fellowship. In particular, relationships between carrier 
gas flow rate, carrier gas linear velocity, oven 
temperature programming and type of capillary GC-MS 
interface were quantified. This in turn enabled optimum 
separations to be obtained under a variety of widely 
differing conditions. 
Development 	of the then new technique of 'selected 
reaction 	monitoring' 	on 	mass 	spectrometers 	of 
conventional Nier-Johnson geometry was also undertaken, 
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using fragmentations occurring in the first field-free 
region of the spectrometer. This work included some of 
the first applications of this technique in conjunction 
with stable isotope dilution for quantitative 
determinations. 
Appointment in 1984 as Officer-in-Charge of the MS 
facility in the CSL at the University of Tasmania saw the 
continued participation in collaborative research with 
colleagues from several disciplines in which MS was used 
to solve specific analytical problems, as well as further 
independent research relating to the techniques of gas 
chromatography and mass spectrometry. This period 
included the development of the automated GC-MS drug 
screening procedure. The principal areas of collaborative 
applications were in the disciplines of Agricultural 
Science, Pharmacy, Plant Science and Chemistry. 
Publications 
The individual and collaborative work outlined above on 
the development and analytical applications of MS and GC 
led to 36 publications in 	refereed 	international 
journals, and 32 presentations at national and 
international conferences. This thesis is based on 
fourteen articles directly relevant to the central theme, 
which in most cases involved sole or senior authorship. 
These publications are included in full in Appendix B. 
A further 18 collaborative publications relating to the 
application of MS and GC to the analysis of a range of 
natural products and xenobiotics have been listed in 
Appendix A. 
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2 . THEORETICAL CONSIDERATIONS IN GAS CHROMATOGRAPHY-
MASS SPECTROMETRY 
i• Chromatographic Optimization 
a) Carrier Gas Flow Rate Determination in Directly 
Coupled GC-MS  
Capillary GC-MS as a tool for organic analysis was first 
introduced in the 1960's (McFadden et al., 1963; 
Teranishi et al., 1963) using a time-of-flight mass 
spectrometer, and was subsequently used with quadrupole 
and magnetic sector mass spectrometers. Capillary GC-MS 
subsequently became a much more widespread technique 
during the late 1970's and early 1980's after the 
introduction of benchtop quadrupole and ion trap 
instruments made it affordable by many laboratories. 
Obtaining 	and 	maintaining 	the 	best 	possible 
chromatographic separation of components for a given 
column remained of fundamental importance in the analysis 
of complex mixtures by capillary GC-MS; failure to do 
this can easily result in the mass spectra of unresolved 
components being recorded, complicating the 
interpretation of the data. 
During this period there were substantial improvements 
made in the manufacture and performance of capillary GC 
columns in terms of the maximum resolution, including the 
introduction of fused silica capillary column technology 
(Dandenau and Zerenner, 1979; Dandenau et al. 1979; 
Lipsky et al., 1980). One of the limitations of magnetic 
sector mass spectrometers for capillary GC-MS had been 
their inability to scan fast enough to keep pace with the 
narrow peak width of high resolution capillary columns, 
resulting in distorted spectra and effectively degraded 
chromatographic resolution. 
Laminated magnet technology was introduced commercially 
during this same period, making magnetic sector mass 
spectrometers capable of scanning fast enough to cope 
with high resolution capillary chromatography peak 
widths. Various MS modes could be used in conjunction 
with the capillary GC separations, such as low and high 
mass resolution scanning, low and high mass resolution 
selected ion monitoring (SIM) and, for double focussing 
spectrometers, linked scans of magnetic field and 
electric sector to probe fragmentation pathways (Boyd and 
Beynon, 1977). 
However, the introduction of the mass spectrometer to the 
chromatographic system has the potential to significantly 
degrade the chromatographic resolution, due to possible 
diffusion of separated components along the length of any 
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transfer lines, and the inherent operating pressure 
difference between the gas chromatograph and the mass 
spectrometer (McFadden, 1979, p.5). 
Some commercial GC-MS capillary column interface designs 
of the mid to late 1970's, including that on the VG 7070F 
in the CSL, resulted in a substantial loss of 
chromatographic resolution. Some, including that on the 
VG 7070F, also resulted in a significant degree of 
discrimination against relatively non-volatile material 
that could otherwise pass through a GC column. For 
example, the heavier petroleum hydrocarbons in oil and 
sediment samples could not be adequately transmitted 
through the manufacturer's interface on the VG 7070F, 
with significant peak broadening and reduction in peak 
area occurring before n-triacontane. Modified interfaces 
were reported for some commercial instruments (e.g. 
Rose, 1983) that overcame some of these deficiencies. 
One of the first priorities as Research Fellow in the CSL 
at the University of Tasmania in 1979 was the improvement 
in the chromatographic resolution in the capillary GC-MS 
mode of the then recently acquired VG 7070F double-
focussing mass spectrometer. This instrument was supplied 
with a capillary column interface containing a glass 
lined tubing connection from the end of the capillary 
column to a 0.15mm diameter 'jet' situated just before 
the ion source, and remote from the end of the glass 
capillary column. The jet offered a fine restriction into 
the mass spectrometer, providing a large pressure drop 
across its length. 
This maintained the pressure at the end of the capillary 
column at or near one atmosphere, such that the 
chromatographic separation was theoretically the same as 
when connected to a conventional GC detector. However, in 
practice this arrangement resulted in a considerable 
'unswept' dead volume between the end of the column and 
the jet, which led to a significant loss of 
chromatographic resolution. By replacing this jet with 
one of wider bore (1mm), and thereby directly exposing 
the capillary column to the MS vacuum, maximum resolution 
could be achieved without substantial band broadening in 
the interface. This results from the effective 'sweeping' 
of the dead volume by the relatively high vacuum 
extending back to the end of column; as the pressure in 
the column approaches zero, linear gas velocities 
approach or exceed supersonic speeds. 
Under these conditions, residence time in the transfer 
line is minimized by increasing the diameter (and 
therefore also the conductance) of the tubing; the 
traditional chromatographic approach of minimizing 'dead 
volume' in the connecting plumbing becomes 
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counterproductive. In the original modification to the 
VG7070, prior to the advent of fused silica columns, the 
glass capillary column terminated in the GC oven and was 
connected by a piece of 3mm internal diameter glass-lined 
steel tubing to the lmm diameter ion source re-entrant. 
Subsequently fused silica capillary columns were threaded 
directly into the ion source. 
The direct coupling of capillary columns to mass 
spectrometers, without the use of some device to provide 
a pressure drop from one atmosphere to ion source 
pressure at the end of the column, was not in widespread 
use in 1979. 
Early research (Sellier and Guiochon, 1970) on direct 
coupling of capillary GC to mass spectrometers, in which 
the GC column was exposed to the vacuum of the mass 
spectrometer, concluded that the optimum average carrier 
gas velocity, as determined from 'van Deemter' plots of 
the Height Equivalent to a Theoretical Plate (HETP) 
versus average velocity (Giddings, 1965), was the same as 
the optimum value with the end of the column at or near 
atmospheric pressure. The latter situation occurs in 
normal GC and also in coupled GC-MS where there is a 
restriction with the appropriate conductance prior to the 
mass spectrometer. 
Subsequently it was shown that this work had reached the 
incorrect conclusion due to the limited pumping capacity 
of the authors' mass spectrometer and their use of 
relatively long capillary columns, which substantially 
reduced the observable difference in effect between 
having atmospheric pressure or a vacuum at the end of the 
column (see discussion below, and Figure 2). It was 
determined (Hatch and Parrish, 1978; Cramers et al., 
1981) that it was in fact the volumetric flow of gas, as 
measured at atmospheric pressure, that needed to be held 
constant between the two modes of operation to maintain 
the highest possible number of theoretical plates. 
Directly coupled capillary GC-MS therefore inevitably 
requires higher average carrier gas velocities than 
normal GC, the extent of the difference depending on the 
column's length and diameter (Hatch and Parrish, 1978). 
These higher optimum gas velocities result in 
correspondingly shorter analysis times, and this fact was 
one of the driving forces behind some of these early 
developments; the work of Hatch and Parrish was not 
specifically aimed at GC-MS coupling, but rather at the 
advantages in speed of analysis of running any capillary 
GC column with the outlet held at very low pressure. 
However, directly coupled capillary GC-MS may result in a 
theoretically larger HETP than is achievable with 
atmospheric outlet pressure, and hence lower efficiency 
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per unit length and lower total plate count. Expressed in 
terms of the total number of theoretical plates, Cramers 
et al. (1981) calculated that it was possible under 
vacuum GC conditions to obtain 87.5% of the resolution 
achieved with atmospheric outlet pressure. In practice 
they found no measurable decrease in performance. 
From this work it was shown that there was no 'universal' 
optimum average velocity for any particular carrier gas 
as was originally thought, but rather a volumetric flow 
rate optimum for a given column and carrier gas 
regardless of the method of GC-MS interfacing. 'Flow 
rate' in this context refers to the actual flux of gas 
(e.g. in mL min -1 measured at atmospheric pressure), and 
not the 'average' flow rate, which is simply the volume 
of the column divided by the retention time of an 
unretained peak. Since optimum flow rates for various 
carrier gases and column types were known (e.g. Grob and 
Grob, 1981), the simplest solution for setting flow rates 
in directly coupled capillary GC-MS would be to measure 
the volumetric flow and adjust it till the correct value 
is reached. An added advantage of being able to determine 
flow rates in directly coupled capillary GC-MS is the 
ability to readily stay within the pumping capacity of 
the system. 
However, this parameter can not be measured easily by the 
traditional methods, such as using some form of flow-
meter, since the only access to the effluent is from the 
rotary pump, which gives a very erratic flow resulting in 
both very imprecise and inaccurate measurements. A 
relationship for directly coupled GC-MS between various 
more easily measured parameters and the volumetric flow 
rate was therefore sought. 
The starting point for this relationship was Poiseuille's 
equation for 'viscous' flow in long, open cylindrical 
tubes (Dushman, 1962), and the fact that flow rate of gas 
through a tube is the product of the tube's conductance 
and the pressure drop across it (Holland, 1974, p.26). It 
was well established that the flow in capillary GC 
columns was viscous (McFadden, 1973, p.125). While the 
situation in the last few centimetres of wider bore 
columns approaches molecular flow conditions, this 
contributes a negligible amount to the overall time that 
a component spends in the GC-MS system. 
Poiseuille's equation can be expressed (Cramers et al., 
1981); 
3d2 (P.2 	p2\2 
	
( 1 ) 
12811L(P1 3 - P03 ) 
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where 5 is the average linear velocity, d is column 
diameter, Pi is inlet pressure, P, is outlet pressure, L 
is column length and 1 is the carrier gas viscosity at 
the column temperature. Since ri = L/t a where ta is the 
'hold-up' time (the time taken for an unretarded 
component such as air to pass through the column), 
equation 1 can be rearranged and expressed in terms of ta ; 
t a 	1281L2 (P1 3- P0 3 ) 
	 (2) 
3d2 (P1 2— .1)02 ) 2 
The expression for flow rate (Q) based on the product of 
the conductance of the column (Holland, 1974, p.26) and 
the pressure drop across the column (P i -P,) is; 
7cci4 ( p i 2 —P0 2 ) 	 (3) 
256iL 
Rearrangement of equation 3 allows expression in terms of 
P i 256iLQ 
nc/4 
 
(4) 
 
+ 1,0 2 
 
    
    
Substitution of equation 4 in equation 2, for the 
specific case when P, = 0, resulted in the derivation of 
the expression; 
ta, vac 
	 8 	rm L 3 	 (5) 
3 
where t,,,„ is the hold-up time under directly coupled GC-
MS. This expression enabled ready conversion between 
required flow rates and optimum average linear gas 
velocity for any column and carrier gas in directly 
coupled GC-MS. i.e. for any flow rate 0 —vac the average 
velocity under directly coupled GC-MS (a„) will be; 
i5 vac 
	 3 	QVaC 	 (6) 
8 	ruriL 
Rearrangement of equation 5 also allows expression of the 
flow rate in directly coupled capillary GC-MS (Qvac) in 
terms of the length of the column, the air peak time and 
the carrier gas viscosity, without any reference to 
column diameter or inlet pressure; 
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Qvac 
	 64nriL3 	(7) 
9 	2 (ta,vac)  
The removal of all reference to the column internal 
diameter and inlet pressure in equations 5 and 7 was not 
expected; a previous published relationship (Sellier and 
Guiochon, 1970) had incorporated both inlet pressure and 
column diameter terms. This relationship of flow rate 
being proportional to the cube of the column length 
divided by the square of the 'dead time' enabled the 
volumetric flow rate as measured at atmospheric pressure 
to be readily determined from accessible parameters, with 
no reference to the column's internal diameter or inlet 
pressure as was previously required. 
The relationship further simplified to; 
Qvac 
	 kL3 	(8) 
t 	2 a,vac)  
where k is a constant for any particular carrier gas at a 
given temperature. For helium, k - 0.2568 at 20 °C for the 
answer to be expressed directly in the convenient units 
of mL atm minute -1 . For example, the flow rate through a 
directly coupled 30m column of any diameter using helium 
as carrier gas, with the column held at 20°C, and with 
an experimentally determined hold-up time of 70 seconds, 
is (0.2568 x (30 3 /70 2 )) = 1.41 mL atm minute -1 . 
The hold-up time for air was plotted against flow rate 
for vacuum GC for representative column lengths and 
carrier gases (Figure 1). 
Plots showing the additional velocity required under 
direct coupling to correspond to the same flow rate as 
average velocities measured with the column outlet at 
atmospheric pressure were also generated for a range of 
representative column lengths, diameters and carrier 
gases (Figure 2). These enabled simple prediction of the 
optimum average velocity for a number of common 
situations. 
To convert directly from a known optimum average carrier 
gas velocity with atmospheric outlet pressure to the 
corresponding optimum average velocity under conditions 
of direct coupling requires an iterative solution to a 
polynomial function. Rearrangement of equation 2, using 
the optimum value for 15 with atmospheric outlet pressure 
(.opt,atrn)l and substituting t a = ii/L, gives: 
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1281L5op t,atm 	= 	( Pi, opt, a tm2 — Pa tm2 ) 2 
	 (9) 
3ci2 	Pi, opt , atm3 	Patm3 
where P,opt,atill is the inlet pressure required to give the 
optimum velocity with atmospheric outlet pressure, and P atm 
is atmospheric pressure. An iterative solution to this 
equation yields a value for P i ,opt,atrn- The optimum hold-up 
time under directly coupled conditions, t a,opt,vacr can be 
found directly from this via substitution in the 
expression (Cramers et al., 1981); 
ta, opt, vac 	= 	( Pi, opt, atm2 	patm2 ) 3/2 
	
(10) 
13opt, atm ( Pi, opt, atm3 	Pato3 
The subsequent commercial introduction of flexible fused 
silica capillary columns enabled columns to be threaded 
right into the ion source of the mass spectrometer, and 
direct coupling became and remains one of the most common 
methods of interfacing GC with MS. 
This work was published in Analytical Chemistry (Davies, 
1984a) 1 . It presented a simple solution to the otherwise 
difficult task of experimentally determining carrier gas 
flow rates in directly coupled capillary GC-MS, and 
enabled conditions to be chosen so that near to optimum 
flow rates could be employed for any given analysis. This 
then ensured the best possible chromatographic resolution 
of closely eluting components for a particular carrier 
gas for any given set of GC oven temperature parameters. 
While the known optimum average linear velocity could be 
used under atmospheric outlet pressure to set appropriate 
conditions for analysis, this was not true for directly 
coupled GC-MS. In this case optimum values varied widely 
depending on the length and diameter of the column, and 
had not been established for many cases. 
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Figure 1 
Plots of the air peak 'hold-up' time, t,,,, for directly coupled 
. capillary GC-MS that will result in the given flow rates for 25m 
and 50m columns of any diameter consistent with viscous flow, 
with hydrogen and helium carrier gases, based on equation 5 
derived above. 
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Figure 2 
Plots of the additional average velocity required under directly 
coupled GC-MS to maintain the same flow rate relative to normal 
atmospheric outlet pressure GC for the specific column lengths, 
diameters and carrier gases indicated. 
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b) Temperature Programming and Carrier Gas Flow Rates in 
Gas Chromatography  
A further fundamental aspect affecting the separation of 
individual components in any particular analysis is the 
rate at which the GC oven temperature is ramped. Until 
the relatively recent commercial introduction of 
electronic inlet pressure programming (Hermann et al., 
1990; Wylie et al., 1991), most commercial gas 
chromatographs employed a constant head pressure to 
regulate carrier gas flow through capillary columns. 
Where a mass flow controller existed in the line, it was 
generally employed to control the total gas flow (i.e. 
including the 'split vent' portion of flow through a 
split/splitless injector), and not the actual column 
flow. A direct consequence of temperature programming 
under circumstances where the column head pressure is 
constant is that the flow rate and average linear 
velocity will fall as the column temperature rises, due 
to the increased viscosity of the gas with rising 
temperature (Ettre, 1984). 
An article in Analytical Chemistry (Jones et al., 1983) 
attempted to determine the best theoretical combination 
of flow rate and temperature program rate to yield 
optimized chromatographic resolution. This article 
plotted the separation number ('TZ') (Kaiser, 1961), a 
measure of a column's separating efficiency, against both 
temperature program rate and carrier gas flow rate in 
three dimensions, in an attempt to find the optimum 
combination of conditions. 
However, there were a number of misconceptions in this 
article, and correspondence with the journal was entered 
into on the matter by the candidate. One of the major 
problems associated with the article by Jones et al. was 
that the authors failed to recognize the fact that the 
flow rate and average linear velocity were varying during 
any temperature programmed part of the analysis, and that 
this introduced an extra degree of complication in any 
procedure designed to optimize performance for a wide 
range of compounds of different retention times. 
Specifically, their attempt to specify a flow rate (in 
reality an initial flow rate) and temperature program 
rate combination that was ideal for all compounds made no 
sense in the light of the fact that compounds eluting at 
higher temperatures will experience overall lower flow 
rates. Moreover, the rate of temperature programming also 
influences the column temperature at which a given 
component will elute, and hence the range of flow rates 
that the sample has been exposed to. 
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Jones et al. were invited by the editor of Analytical 
Chemistry to respond to these comments prior to their 
publication, and the original draft by the candidate was 
modified slightly based on the information contained in 
their reply. This article appeared soon after in 
Analytical Chemistry (Davies, 1984b) 2 . 
Further complications in the article by Jones and 
coworkers arose from the possible confusion between the 
concept of 'average flow rate' and 'measured flow rate'. 
The former is defined simply as the volume of the column 
divided by the retention time of an air peak, and does 
not represent a quantity of gas per unit of time, while 
the latter is the flow rate that can be measured at the 
end of the column at atmospheric pressure. If the 
temperature at which the measurement is made is known, 
then this defines the actual quantity of gas flowing per 
unit of time. The use of the term 'flow rate' without 
further definition implies the measured flow rate to most 
chromatographers; Jones et al. were talking about 
'average flow rate', which will be substantially 
different from measured flow rate for all columns that 
have any appreciable pressure drop across their length. 
Jones et al. (1987) subsequently published a second 
article investigating the effects on separation number 
of starting temperatures in association with temperature 
and pressure programming, in which these factors were 
more fully addressed. 
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c) General Effects of Interface, Method of Flow Control  
and Temperature Programming on Capillary GC-MS  
A more detailed study of the effect of GC-MS interface 
type, the type of flow control and the effects of 
temperature programming on carrier gas flow rates was 
undertaken. The effects and implications of various 
combinations of these for optimizing chromatographic 
resolution were examined in some detail. 
This work, published in Journal of Chromatography 
(Davies, l985) 3 , summarized a number of theoretical 
considerations which had not been addressed in the 
literature up to that point relevant to both GC and GC-
MS, and presented detailed practical information to 
enable optimized performance to be achieved under a 
variety of differing conditions. 
The article specifically addressed two areas; the effects 
that the type of GC-MS interface (such as direct 
coupling, capillary leak and open-split) would have on 
optimum average gas velocities and flow rates, and the 
effect that temperature programming of the GC oven, in 
combination with different types of flow control and GC-
MS interface, would have on flow rate and average 
velocity parameters. The possible consequences of these 
effects on separation efficiency were also addressed. The 
points at which sub-atmospheric inlet pressure would be 
required to deliver desired flow rates were set out for a 
broad range of columns and carrier gases, enabling any 
potential problems to be avoided by suitable choice of 
column lengths and diameters. 
The flow rates required to correspond to a particular 
optimum average carrier gas velocity with atmospheric 
outlet pressure were calculated, using the iterative 
solution to equation 9 to calculate Pi, opt,atm and 
substituting this value in equation 3. The results of 
this procedure are shown in Figure 3, and illustrate the 
slight increase in flow rate required to deliver the same 
average velocity for increasing column lengths. The hold-
up times, inlet pressures required with atmospheric 
pressure outlet pressure and with direct coupling were 
also plotted for the same range of columns. 
Figure 4 shows the average velocities required for 
directly coupled columns of the stated diameters to 
correspond to the flow rates generated by the average 
velocity 25cm s -1 for helium and 50 cm s -1 for hydrogen. 
Dotted regions in these graphs represent column lengths 
that would require sub-atmospheric inlet pressure. Where 
such control is available, wide bore columns clearly 
provide the potential for very rapid analyses. 
29 
The effect of temperature programming on flow rates was 
investigated in some detail, including the different 
effects caused by the method of flow control and the type 
of GC-MS interface. While the theoretical optimum average 
velocity does actually increase very slightly with 
increasing column temperature (Guiochon, 1966), due to 
the dependence of the diffusion coefficient in the gas on 
temperature, the following discussion only looks at 
actual trends caused by temperature programming. 
From equation 1, i3 will fall in an inversely proportional 
manner to the increase in carrier gas viscosity with 
temperature if the inlet pressure is held constant. This 
'isobaric' governing of the flow through capillary 
columns remains one of the most common methods of flow 
control. Similarly, from equation 3, Q will also fall in 
an inverse proportional manner with increased gas 
viscosity. This effect is illustrated in Figure 5(a). The 
flow rate as measured after cooling to room temperature 
(Qend) will be lower still by the ratio of the two absolute 
temperatures, due to the contraction of the gas (Charles' 
law). This is illustrated in Figure 5(b). 
Where the column flow rate is regulated by a mass flow 
controller, or as is now possible by electronic pressure 
programming to maintain constant flow (Hermann et al., 
1990; Wylie et al., 1991), an entirely different set of 
conditions prevail. A point that was perhaps not well 
appreciated is that under these operating conditions 
average carrier gas velocity i will not be constant but 
will increase, sometimes substantially, depending on the 
length and diameter of the column. If constant flow is 
maintained through a thermally isolated device, then from 
consideration of Charles' law, the flow rate (but not the 
average velocity or average flow rate) through the column 
will be greater by the ratio of the absolute temperature 
change of the GC oven, as illustrated in Figure 5(d). 
When columns are directly coupled to a mass spectrometer, 
a constant relationship for the change in average 
velocity exists for all cases, as is shown in Figure 
5(e). This follows from equation 7. Substituting K = 
64nL/9 and t = L/ta gives; 
Q1 	/011012 
and 
Q2 	Kil 2 2 2 
	 (12) 
where Q1 is the flow rate at some initial temperature T 1 
with carrier gas viscosity Tb  and average velocity 171 , and 
Q2 is the flow rate at a higher temperature 7?2 with 
carrier gas viscosity 1 2 and average velocity ;2 . Since Q2 
= Q1.(T2/T1) when 0 —end is held constant (from Charles' law), 
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substitution and expressing in terms of -6.1 and 1-)2 and 
taking the ratio gives; 
-62/ 6-1 111 T2 (13) 
   
n2T, 
The change in average velocity and average flow rate with 
increased column temperature under conditions of mass 
flow control (0 .-end held constant) and atmospheric outlet 
pressure needs independent consideration. When the column 
outlet is at atmospheric pressure, the situation is more 
complex, and the increase in velocity with temperature 
depends on column length, diameter and initial velocity. 
From equation 1, where 02, P2 and 1 2 are the average 
carrier gas velocity, inlet pressure and viscosity at a 
temperature T" and 13 1 , P1 and ii are the corresponding 
values for an initial temperature T1 ; 
l52/ 5 1 
	= 711 (p2 2 _ 
P0 2 ) 2 (P1 3 - P0 3 ) (14) 
112(P1 2 P0 2 ) 2 (P2 3 - P0 3 ) 
P1 and P2 can be calculated from equation 4; 
= !25611 1 1,(2 1 	+ 	P02 
	 (15) 
and, since Q2 = (T2/ 	Qi when Qend is constant; 
P2 	= 1-25 6112LQiT2 + Pc  i i 	 1 	ncl4T3 
.--- 
To illustrate this effect, the following describes the 
specific case of a 25m, 0.32mm internal diameter column 
with a flow rate of helium at 20 °C of 3 mL atm minute - I, 
programmed with mass flow control to 200 °C and with 
atmospheric outlet pressure. 
Working in SI units; 
11 = 1.941.10 -5 kg m-is-i 
1 2 = 2.672.10 -5 kg m- ls - I 
= 293 
T2 = 473 
co l = 3 x 1.6885.10 -3 = 5.065 m 3 Pa S -1 
Q2 = 3 x (473/293) x 1.6885.10 -3 = 8.177 m3 Pa s -1 
P, = 1.013.10 5 Pa 
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L = 25 m 
d = 0.00032 m 
From equation 15, P1 = 171,300 Pa absolute (70 kPa above 
atmospheric pressure). 
From equation 16, P2 = 229,600 	Pa absolute (128.3 kPa 
above atmospheric pressure). 
Substitution of these values in equation 14 gives; 
u2lui 	 1.29 
The same answer can be achieved working from 
consideration of expressions for 'average' flow rates 
(James and Martin, 1952). In this case the ratio of the 
average flow rates 0 and a„ is given by; 
Qav, 2 
	= 	T2 ( p2 2 - P.2 ) ( P1 3 - P. 3 ) 
	(17) 
Qav, 1 
	 p2 3 _ 1,0 3 	p1 2 	p02 ) 
Since -6 = WA where A is the cross sectional area of the 
column, the ratio of the average velocities is the same 
as the ratio of the average flow rates. Substitution of 
the specific values for P1 and P2 derived for the above 
example yields a calculated ratio for average flow rates 
of 1.29. 
With electronic pressure control, the rate of pressure 
increase can be set such that either Q or '6 is held 
constant after appropriate calculations are made, 
although pre-programmed 'constant flow' conditions result 
in constant Qericir giving mass flow control. The specific 
values for P1 and P2 calculated for the example above are 
precisely the values calculated and set by the electronic 
pressure control module on a HP 5890 series II 
split/splitless injector when 'constant flow' of 3mL atm 
minute-1 was requested for a column of the stated 
dimensions, and the oven was ramped from 20°C to 200 °C. 
To achieve constant velocity in this case, substituting 
in equation 1 and setting = '62 and solving for P2 
results in a value of only 98kPa above atmospheric 
pressure (rather than the 128kPa required for constant 
flow), corresponding in a fall in 0 —end to 2.1 mL atm 
minute-1 . While a modest rise in average carrier gas 
velocity with temperature as a result of 'constant flow' 
conditions may help to offset the rise required in 
optimum average velocities by higher temperatures 
(Guiochon, 1966), in most cases the actual rise will 
greatly exceed any required increase. 
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The lower the initial inlet pressure, the larger the 
relative increase in velocity will be. Figure 6 shows 
this effect for a range of columns and conditions. 
From Figure 5a, 5d and Figure 6 it can be seen that 
average velocities and flow rates can be either doubled 
or halved in extreme cases, result ing in inevitable 
deterioration in GC resolution as val ues move away from 
optimum. 
A rearrangement of equations derived in the course of 
this work enabled the calculation of the precise length 
of a piece of tubing of given internal diameter necessary 
to give atmospheric pressure at the end of the column for 
a given flow rate; this is the case in the 'capillary 
leak' interface. 
nd4 Patm2 
 
(18) 
2 5 611Qopt 
 
where d is the tubing internal diameter, is Patm 
atmospheric pressure and Qopt the optimum flow rate. 
These equations and figures resulted in a clarification 
of the relationships between flow rate, average linear 
velocity and temperature programming for a range of 
possible situations, for both conventional capillary GC 
and capillary GC-MS with various types of interface and 
carrier gas flow control. A quick consultation of the 
resulting figures enabled the choice of appropriate 
starting conditions for optimum separations to be readily 
made when installing a column for an analysis. In cases 
where average linear velocity varies substantially during 
the course of oven temperature programming, the 
appropriate parameters can be set at the midpoint of the 
temperature range to minimize degradation of 
chromatographic performance. 
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Figure 3 
Flow rates required to deliver average velocities of 25cm s -1 for 
helium and 50 cm s -1 for hydrogen for the column internal 
diameters, lengths and carrier gases indicated with atmospheric 
pressure at the column outlet. When these same flow rates are 
applied to directly coupled GC-MS, the dotted regions represent 
situations which would require a column inlet pressure of less 
than one atmosphere. 
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Figure 4 
Average linear carrier gas velocities required for different 
column lengths, diameters and carrier gases to provide flow 
rates under directly coupled GC-MS corresponding to average 
velocities of 25 cm s -1 for helium and 50 cm s -1 for hydrogen 
under atmospheric outlet pressure. Dotted regions represent 
column lengths that would require sub-atmospheric inlet 
pressure. 
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Figure 5 
Effects of temperature programming on various parameters after 
flow-rate has been set, for different flow control and GC-MS 
interface combinations. The vertical axis shows the values as a 
percentage of any initial value at 20 °C. 
(a) flow rate as measured at atmospheric pressure and column 
temperature, average flow rate and average linear velocity with 
isobaric pressure control and any interface. 
(b) flow rate as measured at atmospheric pressure and room 
temperature with isobaric pressure control and any interface. 
(c) flow rate as measured at atmospheric pressure and room 
temperature with mass flow control and any interface. 
(d) flow rate as measured at column temperature and atmospheric 
pressure with mass flow control and any interface. 
(e) average flow rate and average linear velocity with mass flow 
control and direct coupling. 
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Figure 6 
Increase in average carrier gas velocity (5) and average flow 
rate (Q) under conditions of mass flow control and atmospheric 
outlet pressure for the range of columns and starting conditions 
indicated. 
a) 50m x 0.2mm, initial 5 = 
mL atm min" 
b) 25m x 0.2mm, initial 5= 
mL atm min" 
c) 25m x 0.3mm, initial 5 = 
mL atm min' 
d) 25m x 0.5mm, initial 5 = 
mL atm min' 
50 cm s" hydrogen, initial Q = 0.94 
50 cm s" hydrogen, initial Q , = 0.94 
50 cm 	s --1 hydrogen, initial Q, = 2.12 
30 cm s' helium, initial (2,-, = 3.53 
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ii) Yield and Quantitative Considerations for the Open-
Split Interface 
A further aspect of coupled GC-MS that was investigated 
was the performance of the 'open-split' interface, which 
had been in commercial use for more than a decade after 
its first description (Henneberg et al., 1975). A 
schematic diagram of an open-split interface is shown in 
Figure 7. Maximizing the yield of analyte to the mass 
spectrometer and also the quantitative performance in 
temperature programmed GC were investigated by both 
theory and experiment, and published in the Journal of 
Chromatography (Davies, 1988) 4 . 
Equations were derived to enable compensation for the 
change in yield of analyte to either the mass 
spectrometer or a second detector run in parallel with 
the mass spectrometer when the carrier gas inlet pressure 
was isobaric and the interface was held at constant 
temperature. The changes in the flow rate through the 
column at different oven temperatures were used as the 
starting point for these relationships. 
The flow rate Fb through the column at some elution 
temperature Tb (in Kelvin), as measured after cooling to 
room temperature, and representing the actual flux of 
gas, will be (Davies, 1985); 
Fb 1 a Ta Fa (19) 
   
lb Tb 
where F„ is the flow rate through the column at 
temperature T, and l a and /lb are the carrier gas 
viscosities at Ta and Tb respectively. When T, equals room 
temperature, Fa can be measured by disconnecting the 
column, and hence the flow to the mass spectrometer (1-;,) 
can be determined from Fa - Fs, where Fs, is the flow rate 
from the vent at the column temperature Ta . The various 
flow rates discussed are illustrated in Figure 7. 
The percentage yield of effluent to the mass spectrometer 
(Ya) at temperature T, can then be calculated as; 
Ya 	= 	100F, 	(20) 
Fp + Fa 
where Fp is the flow rate of any added purge or make-up 
gas. 
Gas viscosities can be calculated to within 1% of their 
experimentally determined values (Weast, 1984, p. F-43) 
38 
for the normal GC temperature range from the relationship 
1 = kr- 7 where 	is viscosity, k a different constant for 
each gas and T the absolute temperature. 	This 
relationship is in close agreement with previously 
published data (Ettre, 1984). Substituting in equation 19 
the appropriate value of T for each viscosity value, and 
substituting the result in the expression to calculate Y1, 
the percentage yield of effluent to the mass spectrometer 
at temperature Tb gives; 
Yb 100Fm (21) 
   
Fp + Fa (Li Tb) 1 • 7 
The yield ratio at the different temperatures is 
therefore; 
Yb/Ya 	 Fp + Fa 	(22) 
Fp + Fa ( Ta Tb ) 1 * 7 
Yield was determined experimentally by physically 
measuring the only readily accessible parameters; Fa , Fsa , 
Fab and F. This results in an agreement of better than 3% 
between theoretical and measured yields. If greater 
accuracy is required, then a better approximation of the 
relationship between temperature and the viscosity of a 
specific gas can be used (Ettre, 1984). 
A calculated yield of more than 100% from this equation 
indicated that the mass spectrometer will be drawing in 
some air rather than venting excess helium, a situation 
which should naturally be avoided by the addition of some 
'purge' or make-up gas. 
The second equation, derived along similar lines, enables 
correction for changes in peak areas on a second detector 
such as a Flame Ionization Detector run in parallel from 
the effluent split away from the mass spectrometer; 
KsblYsa (Fp + Fa ) [Fa (Ta /Tb ) 1 • 7 	 - Fa ] 	(23) 
   
Faa [Fp + Fa (TaiT0 1.7 ) 
where Yab and I's, are the percentage of total flow going to 
the second detector at temperatures Tb and Ta 
respectively, and Fa, is the absolute flow rate to the 
second detector at temperature Ta. 
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Figure 7 
Schematic diagram of an open-split interface, indicating the gas 
flows referred to at the oven temperatures defined in the text. 
This trend towards higher yields of analyte to the mass 
spectrometer with increasing column temperature can mask 
potential problems of injector discrimination against 
higher-boiling materials which can Occur using 
traditional split/splitless injectors. This can have 
Serious effects on quantitative GC-MS analysis. Some 
publications in this area (e.g. Wetzel and Kuster, 1983) 
have neglected this aspect of yield variation when 
looking at discrimination against higher boilers. The 
effect due to the increase in yield in the high 
temperature end of the analysis compensating for possible 
losses in sample transfer caused by condensation may have 
caused a significant underestimation of discrimination in 
these cases. 
Since the response of a mass spectrometer for n-alkanes 
in the relevant boiling range (approximately C10 to C50), 
based on ionization cross sections and electron 
multiplier responses, is essentially proportional to the 
total mass of hydrocarbon and independent of molecular 
weight (Beynon, 1960, p.240), the true level of 
discrimination can be established by applying the 
appropriate correction factor based on equation 22 to 
each alkane in a standard solution. 
Figure 8 illustrates the close agreement between 
experimental and calculated yield changes with GC oven 
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temperature for open-split interfaces in which the GC has 
isobaric pressure control. The yields were determined 
experimentally by measuring F„, F, and Fp for a given T, 
and Est, for a range of values of 7,,; F„, was determined from 
the difference between Fa and F„. 
Where the open-split interface, including the restrictor 
to the mass spectrometer, is incorporated into the GC 
oven there will be no change in yield with temperature 
programming and isobaric pressure control. Under these 
circumstances, the flow through the column and restrictor 
will be equally affected by temperature changes. 
With mass flow control or electronic pressure programming 
to provide constant flow, the flux of gas is constant at 
different oven temperatures, and the yield to the mass 
spectrometer will not vary regardless of the position of 
the interface. Under these circumstances the 
considerations outlined above do not apply. 
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Figure 8 
Calculated (circles and dotted lines) and experimental (crosses 
and solid lines) yield changes that occur during temperature 
programming with an open-split interface held at constant 
temperature with isobaric control of flow rates. 
(a) the relative increase in yield of effluent to the mass 
spectrometer with no added purge gas. 
(b) the relative increase in yield of effluent to the mass 
spectrometer with a purge gas set at 1.3 mL atm minute', 
an initial column flow rate of 2.83 mL atm minute -1 and an 
initial yield of 12.4%. 
(c) the relative decrease in yield to a second detector for the 
conditions given in b. 
(d) the relative decrease in yield to a second detector for all 
cases where no added purge gas is used. 
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3 . DEVELOPMENT OF ANALYTICAL TECHNIQUES 
1) Development of an Automated ScreeningProcedure 
As part of a research project aimed at identifying drugs 
other than alcohol that might be a contributory cause to 
road accidents, in collaboration with Associate Professor 
Stuart McLean of the School of Pharmacy at the University 
of Tasmania, the development of an automated screening 
protocol for human blood and tissue extracts based on 
capillary GC-MS on a Hewlett-Packard 5970B benchtop mass 
spectrometer was undertaken. 
Preliminary research on the potential relationship 
between drugs (other than alcohol) and road accidents 
had been undertaken by a collaborative team at the 
University of Tasmania. This study, which was reported in 
The Medical Journal of Australia (McLean et al., 1987), 
relied on a nitrogen specific Flame Thermionic GC 
detector for preliminary screening, followed by GC-MS 
analysis of all samples showing potential positives for 
drugs. 
There were, however, some disadvantages using this 
preliminary screening method, including many apparent 
false positive drug findings. In addition, non-
nitrogenous drugs such as A-9 tetrahydrocannabinol (THC), 
the active constituent of Cannabis sativa, and non-
steroidal anti-inflammatory agents such as ibuprofen, 
ketoprofen and naproxen could not be detected. THC was 
determined in this preliminary study by a separate 
immunological screening procedure. 
• It was therefore decided to develop an automated GC-MS 
analysis and reporting protocol enabling a reasonably 
large number of samples to be screened directly for a 
large number of target substances by this relatively 
specific and sensitive method. The development was not 
only aimed towards the Drugs and •Driving project, but had 
widespread relevance. Many forensic laboratories lack the 
equipment and/or staff resources for carrying out full 
toxicological screens targeting individual drugs or 
classes of drugs based on the traditional range of tests 
such as HPLC, TLC, radioimmunoassay and other 
immunological tests. 
While never intended to be a panacea for drug analyses at 
trace levels, the automated GC-MS screen nevertheless 
suited the requirements and resources of the Drugs and 
Driving project. The results of this study were reported 
in an article in journal of Chromatography (Biomedical 
Applications) (Neill et al., 1991) 5 . 
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The first stage of the project was to fully develop all 
aspects relating to the acquisition and processing of 
data by the benchtop GC-MS system. This initially 
required the acquisition of reference mass spectra and GC 
retention data for some 120 drug standards. Appropriate 
derivatives were selected where necessary to improve 
chromatographic performance. Derivatization procedures 
used, based on work undertaken at the University of 
Sydney (Vine and Watson, 1983), included methylation of 
carboxylic acid groups and trifluoroacetylation of 
alcohols and amines. The chromatographic performance of 
each drug was also carefully monitored, due to the 
potential for irreversible adsorption and/or thermal 
degradation of various polar drugs. 
The second stage was the development of a data editing 
procedure to enable positive drug findings to be 
automatically detected and the results directly reported 
from the analysis of relatively crude body fluid and 
tissue extracts. In conjunction with this, data 
acquisition programs for trace drug analysis by selected 
ion monitoring (SIM) were also developed, based on 
standard retention times and choosing two diagnostic ions 
per target drug. 
A procedure for automatically correcting retention times 
for any drift was also employed, by incorporating n-
decane (C10) and n-triacontane (C30) in each sample vial 
and comparing the retention times of these peaks against 
the 'standard' retention times obtained at the beginning 
of the project. 
While automation was a standard feature of the 
quantitative software supplied with the Hewlett-Packard 
59703 GC-MS system used in this study, it was not capable 
of doing the job required. The quantitative software was 
geared towards expecting to find target compounds, 
whereas in any screening procedure, the majority of 
target substances tested for will inevitably be absent. 
It was imperative that the screening method be capable of 
detecting genuine drugs without numerous false positive 
reports. Most false positives equally had to be able to 
be eliminated by visual inspection of the chromatograms. 
Figure 9 shows the flow chart devised to carry out the 
automated drug identification procedure, which was based 
on searching for the appearance of two diagnostic ions at 
the right retention time, after adjustment of the time 
scale based on the two hydrocarbon markers. The peak area 
ratios for the two diagnostic ions also had to fall 
between predetermined limits. A Pascal 'macro' was then 
written to enable chromatograms to be generated and 
searched for the presence of each target drug based on 
this flow chart. 
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Figure 10 shows the portion of the macro that was 
replicated for each drug with appropriate values for the 
variables in each case. A brief preliminary section 
automatically identifies the retention times of n-decane 
and n-triacontane, used to correct for any drift in 
retention times. 
Figures 11 and 12 show the results of a typical automated 
analysis and data editing session on a forensic blood 
sample. This sample had previously been examined for the 
presence of any drugs by normal GC-MS with manual editing 
of peaks by an experienced chemist, and had come up with 
a negative result, based on the inspection of the mass 
spectra of all the major and obvious minor peaks. Figure 
11 shows the Total Ion Chromatogram (TIC), with the inset 
diagram displaying an expansion of the relevant region 
where diazepam was subsequently detected at 23.84 minutes 
by the automated editing protocol, as shown in Figure 12. 
In this example Figure 12 was the entire report. 
The work was extended to include a series of selected ion 
time windows, with up to 20 ions per window, to enable 
the maximum possible sensitivity for up to 80 target 
drugs in the data acquisition phase of the work. Figures 
13 and 14 show the results of the analysis of a liver 
extract from a different subject in which both diazepam 
and nordiazepam were detected. The TIC in this case is 
simply the summation of the ions monitored in each 
window, and not the total ions in the spectrometer. A 
false 'probable' positive for the drug haloperidol ('H' 
on the chromatogram) was also reported, but visual 
inspection of the resulting chromatograms in the report 
indicated this could not be genuine, since the 
chromatograms for the two diagnostic ions did not quite 
match. 
This whole procedure could be readily applied to screen 
for target substance from a variety of sample matrices. 
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Figure 9 
Flow chart showing the scheme for automated drug identification. 
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TD=DRUGTME 
TDCOR= (A+ ((T D-TC10)/(TC30-TC10))*(B-A)) 
CH TDCOR-0/TDCOR +0.2, IONI 
THRESH TBMWSHII:np-1 
INT 
THRESH THRESH!, -(IT1-1) 
N = NPEAICS 
IF NPEAKS >0 
CH TDCOR-0/TDCOR+0.2, I0N2 
THRESH THRFSH2, TD-1 
INT 
THRESH THRESH2, -(TD-1) 
NB= NPEAKS 
IF NPEAKS >0 
EX 
Z = I 
WHILE N >0 
PE Z 
RO 4 
PI =PEAK AREA 
RT=RET TIME 
EX 
Y=1 
M= NB 
WHILE IM >0 
PE Y 
RO 4 
IF RT-RET TIME <0.02 
IF RT-RE? TIME > -0.02 
P2= PEAK AREA 
ARATI0=-PI/P2 
IF ARATIO < MAXRATIO 
IF ARATIO > MINRATIO 
WRITELN 701,"PROBARLE DRUGNAME FOUND" 
WRffELN 701,#10,#10,#10 
N=0 
P=2 
ENDIF 
ENDM 
IF P=1 
wRITELN 701 , -********** ******** **** ****** **** ****** 
WRITELN 701,"IONS FOR DRUGNAME FOUND, RATIO SUSPECT" 
WRffELN 701," 	  
WRITELN 701,#10,#10,#10,#10 
ENDM 
MERGE 
CLEAR 3 
CLEAR Y 
CLEAR Z 
DR 3,X 
SCR 
WRITELN 701,in0,#10 
IF P=2 
TAB RESULTS, PRINTER: 
WRITELN 701,#10,#10,#10 
WRITELN 701," 	  
WRITELN 701,#10,#10 9 #10,#10 
P= I 
ENDW 
ENDW 
M=0 
ELSE 
Y= Y +1 
M = M-1 
ENDM 
ENDWHILE 
Z=Z+I 
N = N4 
EX 
END WHILE 
ENDM 
ENDIF 
Figure 10 
Drug Editing 'Macro'. The macro is replicated for each drug with 
the following variables substituted: 
DRUGTIME 	the standard drug retention time, based on the 
specific retention times 6.06 minutes and 27.65 
minutes for decane and triacontane respectively. 
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ION1 	- the m/z value of the principal diagnostic ion 
THRESH1 	- the integration threshold to use for ION1 
I0N2 	- the m/z value of the second diagnostic ion 
THRESH2 	- the integration threshold to use for I0N2 
MAXRATIO 	- the maximum allowable ratio for the peak areas of 
ION1/ION2 
MINRATIO 	- the minimum allowable ratio for the peak areas of 
ION 1/10N2 
DRUGNAME 	- the name of the target drug 
48 
Figure 11 
Portion of the Total Ion 	Chromatogram of an extract of a 
forensic blood sample. The inset diagram shows the expansion of 
the region where diazepam was subsequently detected by the 
automated editing protocol. 'D' indicates diazepam, 'C30' the 
triacontane time reference peak and 'CH' cholesterol. 
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Figure 12 
The entire report of the automated editing protocol for the same 
sample, showing the probable detection of diazepam and the 
relevant ion chromatograms. 
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Figure 13 
Portion of the 'Total Ion Chromatogram' of an extract of a• 
forensic liver extract acquired in the selected ion monitoring 
screening mode, indicating the probable drugs detected; diazepam 
(D), nordiazepam (N) and the false positive report for 
haloperidol (H) (see text). C10 and C30 are the time reference 
peaks n-decane and n-triacontane respectively. 
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Figure 14 
Portion of the report of the automated editing protocol from the 
selected ion monitoring acquisition mode, showing the detection 
of nordiazepam and the two relevant ion chromatograms giving 
good visual confirmation. 
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ii) MS/MS Techniques 
a) Background 
Research was undertaken in the area of analytical 
applications of metastable or collisionally induced 
fragmentations in the first field-free region of double-
focussing mass spectrometers of conventional Nier-
Johnson geometry. Double focussing mass spectrometers 
with this geometry, in which the electric sector (E) 
preceded the magnetic sector (B) (Figure 15), represent 
the majority of high resolution instruments sold. 
The monitoring of daughter ions formed by fragmentations 
after the ion source was first applied to instruments of 
reverse geometry, in which the magnetic sector precedes 
the electric sector, by groups led by McLafferty 
(McLafferty and Bockhoff, 1978) and Cooks (Kondrat et 
al., 1978). In these cases the aim was to provide greater 
specificity for both the detection and quantitative 
determination of target compounds. There are numerous 
examples in the literature beginning in the late 1970's 
and early 1980's of the application of this technique to 
the direct analysis of crude biological extracts or even 
intact tissue samples on instruments of reversed geometry 
(e.g. McClusky et al., 1978; Youssefi et al., 1979; 
McLafferty, 1980b; Glish et al., 1980), and an early 
overview of the subject was published (Cooks, 1979). 
The greater specificity is gained from the fact that ions 
formed in this way will be transmitted at a lower energy 
from the 'main beam' daughter ions formed in the ion 
source, and the amount of kinetic energy lost 
specifically relates the daughter ion m/z value back to 
its parent ion (e.g. Beynon et al., 1968, p58); 
KEd = (md /rap ) . KEp 
where KEd is the kinetic energy of the daughter ion, KEp 
the kinetic energy of the parent ion and md and mp the m/z 
values of the daughter and parent ions respectively. 
The use of tandem mass spectrometers for 	the 
determination of fragmentation pathways and/or the 
structural analysis of individual ions in the scanning 
mode, as well as the analytical application of detecting 
and quantifying target substances by focussing on 
specific parent ion-daughter ion fragmentations became 
known as 'MS/MS' (Kondrat and Cooks, 1978). 
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Figure 15 
Schematic Diagram of a Nier-Johnson Mass Spectrometer 
In reversed geometry instruments, this was accomplished 
by choosing a suitable parent ion using the magnetic 
sector, and either acquiring a full 'Mass-analysed Ion 
Kinetic Energy Spectroscopy' (MIKES) (Beynon and Cooks, 
1971) spectrum by scanning the electric sector voltage, 
or more typically for target compound detection by 
switching to one or more voltages to focus known daughter 
ions. The parent ion in these cases could itself have 
arisen by one or more previous fragmentations, while the 
daughter ions are formed in the second field-free region 
of the spectrometer. 
In instruments of conventional Nier-Johnson geometry, 
second field-free region daughter ions resulting from the 
fragmentation of metastable precursors cannot be focussed 
independently of the main beam, but rather give rise to 
the classic broad 'metastable' peaks in analogue spectra; 
these are usually intentionally filtered out in digitized 
spectra by parameters associated with peak width. 
However, fragmentations that occur in the first field-
free region, immediately following the ion source, can be 
focussed away from the main beam either by scanning the 
accelerating voltage (V) alone to produce spectra of 
parent ions of given daughters, or by the various 'linked 
scans' of the magnetic and electric sectors to produce 
spectra of parent ions of given daughters or daughter 
ions of given parents (Boyd and Beynon, 1977; Millington 
and Smith, 1977), and constant neutral losses (Zackett et 
al., 1979; Lacey and McDonald, 1979). 
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To focus individual fragmentations within the first 
field-free region there are in fact an infinite number of 
combinations of B, E and V that can be used (e.g. Lacey 
and McDonald, 1977). Only by scanning B or by holding the 
ratio VIE constant while scanning V can the 'main beam' 
ions formed within the ion source be focussed. 
It was realized in the late 1970's and early 1980's that 
monitoring ions derived from fragmentations within the 
first field-free region of conventional geometry 
instruments would provide an extra dimension of 
specificity in the determination of target compounds by 
both GC-MS and direct insertion probe MS (Gaskell et al., 
1978, 1979, 1980b; Harvey et al., 1980; Chess and Gross, 
1980). In these publications single decompositions or 
decompositions to more than one daughter ion derived from 
the same parent were monitored, or else the same daughter 
ion from different parent ions was monitored. 
The ions were focussed either by accelerating voltage 
'defocusing' or by switching both the magnetic and 
electric sectors together such that there was no change 
in the ratio of their field values (the 'B/E' scan). The 
technique has been variously named 'metastable 
decomposition monitoring', 'metastable peak monitoring', 
'metastable ion detection', 'selected reaction 
monitoring' and 'selected decomposition monitoring'. The 
last two can apply to either unimolecular or collision 
induced fragmentations, while the others can strictly 
only be applied to unimolecular fragmentations. 
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b) Quantitative Selected Reaction Monitoring (SRM)  
In work carried out in 1981, this technique was applied•
to a range of experimental qualitative and quantitative 
determinations. The starting point for each case was the 
acquisition of B/E scans from the molecular ion and high 
mass daughter ions from reference standards of the 
substances under investigation, and of prospective 
substances for use as internal standards. 
For the initial unpublished quantitative analyses, an 
internal standard having an ion at the same m/z value as 
the chosen parent ion of the target substance was used, 
which did not have any interference at the daughter ion 
m/z value(s) chosen for monitoring. 
A series of compounds was investigated, including an 
unpublished homoerythrina alkaloid in crude solvent 
extracts of Athrotaxis selaginoides (King Billy Pine). 
The new alkaloid was subsequently determined to have 
structure (I) (Panichanun and Bick, 1984), and was named 
selaginoidine. The work on quantitative analysis of this 
alkaloid was presented at the 1981 conference of the 
Australian and New Zealand Society for Mass Spectrometry 
(Davies and Bignall, 1981). 
Me00C 
The normal mass spectrum of selaginoidine had a molecular 
ion at m/z 317 (10%), and prominent ions at m/z 286 (18), 
259 (100), 258 (90) and 244 (10). B/E linked scan from 
the molecular ion at m/z 317 showed a single prominent 
first field-free region fragmentation for the loss of 58 
(COOCH 2 ) to 259, and this was chosen as the target 
reaction from the alkaloid for monitoring. 
As an internal standard, a substance with a different and 
characteristic fragmentation from m/z 317 was required. 
It was found that the pesticide Dicophane (DDT) had a 
small but significant ion at m/z 317 [M-Cl]t, and a B/E 
linked scan from this ion indicated a daughter ion at m/z 
282 NM-C1)-C1T.. 
The alkaloid was then quantified in a series of crude 
extracts from a number of genotypes. A small amount of 
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purified material was available, and so a standard curve 
was constructed over the range 2ng ---> 2Ong alkaloid per 
microlitre. Linear regression gave the relationship y = 
0.014 + 0.033x (correlation coefficient 0.995) where y 
was the concentration of alkaloid in ng 111 -1 , and x the 
ratio of the m/z 259 to m/z 282 daughter ions from m/z 
317. 
A 5111 aliquot a solution containing lmg m1 -1- of crude 
extract and lmg mL-1 of DDT was loaded onto the direct 
insertion probe, and the daughter ions at m/z 282 
(internal standard) and m/z 259 were alternately 
monitored with a 300ms dwell time per channel. Standard 
deviation over 20 replicates was 8%, within the 
requirements of a rapid screening technique. 
Additional qualitative confirmation of compound identity 
in this technique is contained in the distillation 
profile of the sample off the direct insertion probe, 
which must closely match that of a reference sample of 
the target substance. 
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c) Selected Reaction Monitoring Using Stable Isotope  
Labelled Internal Standards 
The use of stable isotope labelled internal standards for 
quantitative determination by GC-MS had become a routine 
procedure by 1980. The advantages that these bring to GC-
MS analyses are equally valid to selected reaction 
monitoring. In work presented as a poster at the 8th 
International Mass Spectrometry Conference, Gaskell and 
coworkers discussed the advantages of multiple metastable 
peak monitoring with the use of stable isotope labelled 
internal standards, using the measurement of testosterone 
in human plasma as an example (Gaskell et al., 1980a). 
In almost all cases, the use of isotope labelled internal 
standards will require the monitoring of two or more 
parent ion/daughter ion decompositions; only in cases 
where the label is lost will the daughter ions be the 
same. The spectrometer therefore has to be controlled in 
such a way as to alternately bring these different 
fragmentations to focus. 
The information inherent in tracking ion intensity versus 
the values of B, E and V can be represented in a three 
dimensional ion 'surface' by appropriate choice of axes, 
such as those proposed by Lacey and McDonald (1977). In 
this representation, intensity is plotted as contour 
lines versus p and p where p = (V0/V)(E/E0 ) 	and p 
(Eo/E)m8 where V, and E0 are values of V and E at which the 
main beam of ions formed within the ion source is 
transmitted, and rti, is the mass of singly charged ions 
transmitted when V=Vo and E=E0 . Figure 16 schematically 
illustrates this approach using a portion of the ion 
'surface' 	for a mixture of warfarin (II) 	and its 
pentadeuterated analogue (III). 
HR=H 
HI R=D 
Other approaches have also been used for the three 
dimensional representation of ion current surfaces (Kiser 
et al., 1969; Farncombe et al., 1982). These approaches 
show that there are an infinite number of combinations of 
E, B and V that can be used to focus these independent 
first field-free region fragmentations; synchronized 
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switching of any two of the three variables to 
appropriate values will allow the required first field-
free region fragmentations to be focussed. 
The normal advantages and disadvantages of changing 
particular variables apply. Switching V can result in 
significant loss of sensitivity if relatively large 
changes are made. However, the difference required to 
focus stable isotope labelled ions and the corresponding 
unlabelled ions is minimal. Switching of the magnetic 
field suffers from the limitation of how quickly the 
field will stabilize at the new value, and can be 
limiting for capillary column peak widths. Again, the 
change in the field required to alternately focus 
labelled and unlabelled ions is minimal. 
Importantly, complete mapping of ion current surfaces in 
this way enables various artifact peaks found in normal 
linked scans to be recognized for what they are; e.g. 
intersection of 'ridges' caused by fragmentations 
occurring within the electric sector, or detection of 
daughter ions from parent ions near to the target parent 
ion in mass, but not resolved because of the relatively 
poor energy discrimination of the technique (Lacey and 
McDonald, 1977, 1978, 1980). The dotted lines in Figure 
16 show where constant parent ion scans (B/E constant) 
from the molecular ions m/z 308 and m/z 313 respectively 
intersect features on the ion current surface. 
Commercial instruments prior to the early 1980's did not 
have the capability of synchronizing the switching of 
more than one independent variable from among E, B and V, 
since the analytical applications were not foreseen when 
the instruments were designed. In the published abstract 
of the work described by Gaskell and coworkers discussed 
above (Gaskell et al., 1980a), no experimental details 
were presented other than the statement that switching 
between the separate metastables was under computer 
control. 
The ability to independently control more than one 
variable at a time was not a standard feature of the 
instrument and the software described, and yet 
synchronized switching of at least two of the three 
variables among B, E and V is required to alternately 
focus . two unrelated fragmentations. The VG 7070 with VG 
2035 datasystem mentioned was the same configuration as 
used in the CSL. Even with the optional feature of a 
digital scan control system, only one independent 
variable at a time could be controlled. It was therefore 
not clear how the independent control had been achieved 
by Gaskell's group; it had presumably involved 
significant electronic and software modifications. 
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Gaskell subsequently published a technique for dual 
metastable peak monitoring by switching E and V (Thorne 
and Gaskell, 1985), which allows rapid switching between 
target daughter ions as no change in magnetic field is 
required. 
Figure 16 
Portion of the ion current surface for a mixture of the drug 
warfarin (II) and its pentadeuterated analogue (III). The major 
ions present are from the metastable decompositions m/z 308 -4 
m/z 265 and m/z 313 --> m/z 267, plus fragmentations from the 
natural isotopic parent ions at m/z 309, 310, 314 and 315. p = 
(V0/V)(E/E0 ) and p = (E0 /E)mB where 14 and E0 are values of V and 
E at which main beam ions are transmitted, and ma is the mass of 
singly charged ions transmitted when V=Vc and E=E0 . 
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d) Warfarin Determination in Crude Plasma Extracts by SRM 
While the VG7070 was not initially designed to undertake 
multiple reaction monitoring, the considerations outlined 
above meant that it was possible provided two independent 
variables from E, B and V could be controlled. 
An assay was developed for the direct quantitative 
determination of the anticoagulant drug warfarin (II) in 
crude extracts of human blood plasma. Warfarin is used in 
the clinical management of thromboembolic disorders such 
as strokes and heart attacks. This assay utilized the 
metastable losses of CH 3C0 and CD3C0 from the molecular 
ions of warfarin and its deuterated analogue (III) 
respectively, and represented one of the first 
applications of direct quantitative determinations using 
unrelated parent-daughter fragmentations on a normal 
geometry instrument. A cycle of 2 seconds was achieved on 
a standard instrument with no modifications. This work 
was published in Biomedical Mass Spectrometry (Davies et 
al., 1983) 6 . 
The synchronization in this case was accomplished by 
having two 'blank' channels in the magnet switching mode 
between the two analytical channels, during which the 
accelerating voltage was switched to the appropriate 
preset values. The fragmentations chosen for monitoring 
were m/z 308 --> m/z 265 ((M - CH 3C0]+•) for warfarin and 
the corresponding m/z 313 —> m/z 267 for the internal 
standard D5-warfarin, based on a full B/E scan from the 
warfarin molecular ion. The deuterated warfarin was 
prepared directly from warfarin by isotope exchange using 
a previously published method (Duffield et al., 1979). 
(An editorial change altered the submitted figures 
substantially, resulting in erroneous linked scan data 
being published for warfarin. A spectrum showing full 
peak profiles had been submitted, partly since that was 
the manner in which the data had been acquired, and 
partly to illustrate the good daughter ion resolution. 
The sides of the peaks at m/z 265 and m/z 266 were 
redrawn by the journal as four individual centroided 
peaks, implying the presence of significant daughter ions 
from m/z 308 at m/z 267 and m/z 268, which did not exist. 
This was noted in the returned proofs, and a request was 
made that the correct original figure be restored, but 
this was not carried out.) 
It was first necessary to confirm that extracts of plasma 
from subjects not on warfarin therapy contained minimal 
interference at these positions on the ion current 
surface - i.e. whether the signal was due to the 
specified fragmentations or to fragmentations within the 
electric sector or during acceleration which might 
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contribute to the ion current at these points (Lacey and 
McDonald, 1977). 
Human plasma samples (1 mL) were acidified to pH 3, 2Rg 
(nominal) of internal standard was added, and the sample 
was extracted with 250 RL of chloroform. A one p1 aliquot 
of the organic layer was loaded onto the direct insertion 
probe, and the solvent allowed to evaporate before 
analysis. 
Figure 17 shows the ion current profiles for the target 
fragmentation in a blank plasma extract, as well as 
individual plasma extracts that had been spiked with only 
labelled warfarin (looking for potential interferences in 
the m/z 308 —> m/z 265 channel), only unlabelled 
warfarin, and a patient sample showing both the labelled 
and unlabelled warfarin. The observable response in the 
m/z 308 —> m/z 265 channel in the sample that had only 
been spiked with labelled warfarin is mainly 
attributable to the m/z 313 ---> m/z 267 fragmentation 
within the electric sector from the labelled warfarin. 
This effectively placed a lower limit of detection on the 
assay of 0.2Rg mL -1 . 
A standard curve was constructed using plasma samples 
spiked with between 0.5Rg and 5Rg of warfarin, and 
(nominally) 2Rg of D5-warfarin. A linear regression on 
this data gave the relationship y = 0.11 + 0.63x 
(correlation coefficient 0.998), where y is the 
concentration of warfarin plasma in Rg mL -1 , and x is the 
ratio of peak areas of the m/z 308 —> m/z 265 channel to 
the m/z 313 —> m/z 267 channel. The coefficient of 
variation on replicate analyses of the same extract was 
7.2% (n=5). 
This method was then applied to a number of clinical 
plasma samples, where levels of between 0.5Rg and 1Rg mL-1 
were recorded. 
Great caution is required in using direct insertion probe 
MS/MS for quantitative work in pharmacology; not only 
must blank samples be free of any appreciable signal at 
the relevant points on the ion current surface, but also 
care must be taken that no metabolite of the target 
compound could give rise to a measurable signal at these 
points. In the case of warfarin, it was established that 
no known metabolite would produce the fragmentation m/z 
308 --> m/z 265. It was noted that the fragmentation m/z 
310 --> m/z 265 was known for the two diastereomers 
produced by biological reduction of the ketone group to 
the corresponding alcohol (Trager et al., 1970), and that 
due to the inherent energy spread of the ions, resulting 
in relatively poor parent ion specificity, that a very 
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small contribution to the nominal m/z 308 —* m/z 265 
fragmentation would occur from this source. 
The first draft of this paper was received by the editors 
in November 1982, just prior to the publication of plans 
for an electronic device that had been designed to allow 
switching to unrelated first field free region daughter 
ions on a similar instrument (Durden, 1982), and after a 
presentation at the 1981 American Society for Mass 
Spectrometry conference in Minneapolis (Durden, 1981). 
This device enabled isotope labelled internal standards 
to be employed for quantitative determinations by MS/MS, 
with full automation of the peak switching. 
This approach then enabled the direct quantitative 
determination of specific target substances in relatively 
crude matrices with stable isotope labelled internal 
standards, either by combined GC/MS/MS or direct 
insertion probe MS/MS. For best results the former 
required fast scanning magnets (not present on the 7070F) 
and electronic synchronization of the switching of two 
voltage sources; the latter was possible with a degree of 
manual initialization and no modifications to the 
instrument or software. The technique proved invaluable 
in the solution of specific problems. 
The ability to carry out selected reaction monitoring is 
now a routine feature of most commercial instruments. 
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Figure 17 
Ion profiles 	and areas for the indicated decompositions for 
warfarin in blood plasma extracts; 
a) warfarin channel, blank plasma only 
b) warfarin channel, plasma spiked with 1 Ilg/mL of 
warfarin 
c) warfarin channel, blank plasma spiked with deuterated 
warfarin only 
d) warfarin channel, plasma from a patient on warfarin 
therapy 
e) deuterated warfarin channel, from the same direct probe 
insertion experiment as 
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e) N-Hydroxyphenacetin Determination in Urine Extracts  
A subsequent application of selected reaction monitoring 
included the quantitative determination of the thermally 
sensitive N-hydroxyl metabolite of phenacetin 	in 
enzymically hydrolysed urine extracts, 	which was 
published in Journal of Chromatography (Biomedical 
Applications) (Davies et al., 1984) 7 . 
Phenacetin had already been largely discontinued as a 
clinical analgesic due to the known or suspected toxic 
side-effects (Gillette et al., 1982). However, the 
proposed mechanism of toxicity, via N-hydroxylation, had 
never been conclusively demonstrated in vivo in any 
mammal prior to work undertaken with Associate Professor 
Stuart McLean, in which the occurrence of N- 
hydroxyphenacetin (NHP) (IV) was demonstrated 
conclusively for the first time in vivo in rats (McLean et 
al., 1981). This reactive metabolite was thought to be 
responsible for carcinogenic, mutagenic and hepatic 
toxicity effects, but had only been positively identified 
previously from in vitro studies. 
Earlier publications had reported the presence of NHP as 
an in vivo metabolite of phenacetin in man (Belman et 
al., 1968; Klutch and Bordun, 1968), but this work was 
subsequently criticized for the lack of specificity in 
the assays used (Weisburger and Weisburger, 1973; Macklin 
and Welch, 1980). 
However, variable decomposition in the GC injection port 
of the methylated derivative, N-methoxyphenacetin (NMP) 
(V), to phenacetin (VI) and 2-methoxyphenacetin (2MP) 
(VII) was noted in the original study (McLean et al., 
1981), making quantitative work via GC-MS difficult. 
Selected reaction monitoring from the direct insertion 
probe overcame the problems associated with decomposition 
on GC analysis, and for the human urine was used to 
conclusively prove the presence of this metabolite, and 
subsequently to quantify it (Davies et al., 1984) 7 . 
While the most intense ion in the full B/E scan from the 
molecular ion of NMP corresponded to the loss of ketene 
after hydrogen transfer, this fragmentation was also 
observed to be strong in standard samples of both the 2- 
and 3-methoxy isomers from which it had to be 
distinguished. The proposed mechanism for this process 
for acetanilide (Tomer et al., 1973) is a direct transfer 
of an acetyl hydrogen to the nitrogen, followed by 
breaking of the N-C bond. 
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However, there was a relatively intense ion at m/z 135 in 
the B/E scan from the molecular ion at m/z 209 in NMP 
(18% intensity relative to the daughter ion at m/z 167) 
that was not present in the other two isomers. High 
resolution mass measurement indicated that the loss of 74 
mass units corresponded to the loss of both the methoxy 
and acetyl moieties. It clearly required the very rapid 
consecutive loss of the two groups within the first field 
free region of the spectrometer, a phenomenon that is 
known to produce daughter ions of the correct 'apparent' 
m/z value and energy (Jennings, 1966). 
Under these circumstances the 	'grand-daughter' 	ion 
behaves for the purposes of detection as though it was a 
single fragmentation, even in cases where neither of the 
individual losses is observed in the B/E scan. In the 
case of NMP, small daughter ions corresponding to the 
individual losses of the acetyl and methoxy groups were 
observed in the B/E scan from the molecular ion. 
As part of the preliminary work on this metabolite, the 
mass spectrum of NMP was characterized in detail using 
high resolution mass spectrometry and a series of B/E 
linked scans to assign fragmentation pathways, since any 
characteristic daughter ion could be used for the assay, 
not just those from the molecular ion. Major differences 
in the B/E linked scans from the NMP daughter ion at m/z 
1-79 and the-phenacetin molecular ion at m/z 179 indicated 
these ions to be of different structures. Daughter ions 
from adjacent parents (particularly m/z 135, 136, 137 and 
138) were subsequently assigned unequivocally from a 
series of 32/E scans from the respective daughter ions. 
Figure 18 shows the principal fragmentation pathway of 
NMP based on this work, with some possible ion 
structures. 
A comparison with similar work undertaken on the isomeric 
2- and 3-methoxy phenacetin resulted in the choice of the 
daughter ion at m/z 135, as discussed above, to be the 
most useful diagnostic ion. 
Preliminary trials of enzymically hydrolysed blank urine 
extracts indicated there was some interference for the 
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m/z 209 ----> m/z 135 fragmentation. Although this 
interference had a significantly higher boiling point 
than NMP and hence a much slower distillation profile 
from the direct insertion probe, it would have made 
accurate quantitation difficult. A preliminary 
purification by thin-layer chromatography subsequently 
eliminated this interference. 
Initially 	N-butyry1-4-aminobenzoic acid (4-BABA) was 
used as an internal standard, with the fragmentation 
m/z 221 —> m/z 151 ([M - C 4 H 601+•) from the methylated 
derivative (4-BAMB) being monitored along with the NMP 
fragmentation m/z 209 —> m/z 135. Good linearity was 
achieved for a standard curve of NMP in urine with 4-BABA 
added as internal standard (correlation coefficient = 
0.9993). However, the distillation profiles of the two 
compounds off the direct insertion probe were 
significantly different. An ion source temperature of 
120°C was necessary to maintain a minimum peak width of 
about 20 seconds and hence an adequate sampling rate on 
the relatively volatile NMP peak. Under these conditions 
the 4-BAMB took several minutes to completely evaporate 
from the probe tip without supplementary heating, which 
was undesirable in that it would introduce a much greater 
fraction of other urine components into the ion source, 
and also increase the time between analyses. 
Tetra-deuterated 	NMP 	(DNMP, 	98% 	2H4) 	(VIII) 	was 
subsequently made available as the internal standard, 
following its synthesis by Associate Professor Stuart 
McLean. This resulted in a significant improvement in the 
precision and accuracy of the assay. This improvement 
was a result of the essentially identical distillation 
profiles of the analyte and internal standard, and the 
better compensation for losses and variability during 
workup and sampling for MS/MS analysis. Figure 19 shows 
the normal mass spectrum of NMP and DNMP, and the 
metastable loss employed for quantitative monitoring. 
A standard curve was generated by the addition of between 
1 and 20 pg of NMP and 5 lig of DNMP to 2 mL of blank 
urine. Linear regression on peak areas gave a slope of 
0.191, a y-intercept of 0.03 and a correlation 
coefficient of 0.9983. The coefficient of variation 
(C.V.) on repeated analysis of the same extract was 1.94% 
(n=8), while the C.V. on extracts of eight replicate 2 mL 
aliquots of the same urine sample was 9.2%. 
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Figure 18 
Mass spectral fragmentation scheme for NMP as determined from 
high resolution MS and a series of B/E and B2/E linked scans. 
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Figure 19 
Mass spectra of NMP (V) and tetradeuterated NMP (VIII), 
illustrating the two metastable fragmentations used for the 
assay. 
Figure 20 
GC/MS/MS chromatograms for the fragmentations m/z 386 ---> 
371 for THC (IX) and 389 ---> 374 for 2H 3THC (X) from a 
crude plasma extract. 
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f) Flexible Control of B, E and V 
The MS/MS work was subsequently extended to enable 
switching to any point on the three dimensional 'ion 
surface' on an ageing conventional instrument with a 
minimum of modification by independent control of B, E 
and V. This work was presented as a poster at the 11th 
International Mass Spectrometry Conference in Bordeaux in 
1988 (Davies, 1988) 8 . Examples used in this work included 
the quantitative determination of A-9 
tetrahydrocannabinol (THC) (IX), the active constituent 
of cannabis, from human blood extracts by isotope 
dilution GC/MS/MS. 
Metastable mapping of the mass spectrum of camphor was 
also illustrated, by acquiring a series of magnet scans 
with the value of E stepped down by 0.05% between 
successive scans. Each scan taken in this manner is a 
slice through the ion current surface (as illustrated and 
defined in Figure 16 for warfarin), parallel to the p. 
axis. 
Figure 20 shows the chromatograms for the fragmentations 
m/z 386 ---> m/z 371 from the molecular ion of the 
trimethylsilyl derivative of THC, and the corresponding 
fragmentation for the trideuterated internal standard 
(X), from an unpurified whole blood extract. The levels 
were 2.5ng mL -1 blood for THC and (nominally) 'Ong mL -1 of 
internal standard. This monitoring was achieved by 
independent control of V and E, with no magnetic field 
switching, so that cycle times were compatible with GC 
peak widths. Low resolution normal selected ion 
monitoring for this compound frequently has numerous 
interfering substances at the same or similar retention 
time for the main beam ions m/z 386, 371, 343 and 303 
normally monitored. 
TX R=CH3 
X R=CD3 
While analysis of crude mixtures by MS/MS via the direct 
insertion probe (as distinct from GC/MS/MS) has fallen 
into some disfavour, due to the relatively high load of 
organic matter that is vaporized into the spectrometer 
resulting in potential problems with ion source and 
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flight tube contamination, it nevertheless has a place 
for some samples. 
A recent book (Busch et al., 1988) presents an overview 
of the many diverse aspects of MS/MS, including the 
various other instrument types that are also capable of 
this technique. These include triple quadrupole, multi-
sector and hybrid instruments that provide separation of 
generations of ions in space, and ion cyclotron resonance 
and quadrupole ion trap instruments that provide the 
separation in time. 
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g) Accelerating Voltage Adjustments in B/E Scans  
A short note published in Organic Mass Spectrometry 
(Davies et al., 1982a) 9 was also relevant to the 
monitoring of metastable or collisionally induced 
fragmentations in the first field-free region of a Nier-
Johnson double-focussing mass spectrometer. This note 
pointed out the advantages of using a single B/E ratio 
and small accelerating voltage adjustments to focus new 
parent ions for the generation of multiple linked scans 
from different parent ions from the same compound without 
tedious refocussing, resetting of a new B/E ratio and 
recalibration of the mass scale. This accelerating 
voltage adjustment was in fact the mechanism that was 
employed for the multiple reaction monitoring assay for 
warfarin discussed above. 
The principal application of the voltage adjustment 
technique was to the acquisition of a number of full B/E 
linked scans from different parent ions over a period of 
only a few seconds. This was important where as much 
structural information as possible was required on very 
limited amounts of sample. Appropriate voltages to select 
different parent ions could be pre-set, for example, into 
separate channels of a Multiple Ion Detection (MID) unit 
or other multichannel device, and then selected by push-
button operation during the magnet reset time. 
A range of B/E scans could then be acquired with 
absolutely no delay between them other than the normal 
magnet reset time. This naturally required that the 
normal linkage of E with V was removed (Davies, 1989) 8 
such that the MID system controlled only V, while the 
single B/E ratio was controlled in the normal manner by 
the linked scan unit of the spectrometer. 
Working with a scan rate of 1 second per decade, linked 
scans acquiring the daughters of eight different parent 
ions could be achieved in a total of ten to fifteen 
seconds, which was well within the normal distillation 
profile of a single loading of the direct insertion 
probe. The technique is naturally limited to parent ions 
that are not grossly different in m/z value, to minimize 
losses in sensitivity caused by ion source defocussing 
effects of the lower accelerating voltage. 
In practice parent ions could differ in m/z value by a 
ratio of 40% and still achieve acceptable results. 
Defocussing caused by changes in accelerating voltage 
could be minimized by tuning the ion source with the 
accelerating voltage set to the middle of the range to be 
used. The technique was particularly useful where only a 
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very small quantity of sample was available, and the 
maximum amount of linked scan data was required. 
While mass spectrometers at the time were heading toward 
full digital control enabling loading of different B/E 
ratios for successive constant parent ion scans with 
different parents selected, the software and hardware 
capability of the VG 7070F resulted in delays of up to 
one minute while each change in ratio was downloaded, 
making it an impractical technique. 
Current generation double-focussing mass spectrometers, 
with the associated advances in computer technology, 
generally enable totally flexible control of B, E and V, 
and also have the capacity for the necessary parameters 
for different B/E ratios to be rapidly loaded, obviating 
the need for the voltage adjustment technique. 
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h) Instrumentation and Techniques Used for MS/MS Work 
Preliminary work on selected reaction monitoring was 
carried out on a VG 7070F mass spectrometer with 2035 
datasystem, a Linked Scan control unit and Multiple Ion 
Detection (MID) unit. A Digital Scan control unit was 
subsequently installed on this instrument in 1982. 
In initial experiments on multiple reaction monitoring 
from the same precursor, the B/E scan was selected in the 
normal manner, focussing the chosen main beam ion, and 
channels in the MID unit were set for the apparent m/z 
values of the daughter ions (i.e. at md2 /mp where md is the 
m/z value of the daughter ion and mp the m/z value of the 
precursor ion). Standard magnet switching selected ion 
monitoring (SIM) was employed. A minimum dwell time of 
300ms per channel was chosen, due to the relatively long 
'settling' time required by the older style, solid core 
magnet. This was sufficient to adequately switch the 
magnetic field over the very small range required to 
alternately focus ions differing only by the replacement 
of several hydrogens with deuterium. 
In subsequent experiments looking at daughters from 
unrelated precursors, the ions were focussed by one of 
the following methods. In the first method, the linked 
scan unit was employed as described above, in addition to 
the use of two separate accelerating voltage channels 
(unlinked from E) switched in synchronization with the 
MID unit control of the relevant B/E channels. The use of 
accelerating voltage adjustments enabled different 
precursors to be selected, while maintaining the same 
mass axis (Davies et al., 1982a), precluding the need to 
download different calibration files. 
The accelerating voltage for the second precursor MN was 
set to (mp2 /mp1 )V1 where mo was the m/z value of the first 
precursor, and V1 the accelerating voltage at which this 
main beam ion was focussed. Two extra channels were 
incorporated into the magnet SIM mode, during which the 
accelerating voltage was alternated. This avoided the 
need for precise synchronization of the V and B/E 
switching. This technique was used for the warfarin assay 
(Davies et al., 1983). 
In the second method, a Digital Scan control unit was 
used to control the switching of B/E, and the MID unit 
was used to set up independent channels for V. This was 
the method used for the NMP assay (Davies et al., 1984). 
Alternatively, to avoid any switching of the magnetic 
field (Thorne and Gaskell, 1985), the Digital Scan unit 
was used to control E, and the MID unit was used to 
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control V. This was the method used for GC/MS/MS, such as 
for THC in human blood plasma discussed above. 
73 
4 . APPLICATIONS 
i) Parasitic Wasp Secretions 
The specificity and sensitivity of GC-MS as an analytical 
technique makes it the method of first choice for the 
characterization of the secretions used by insects in 
behavioural control. These include sex pheromones, trail 
pheromones, alarm substances, defensive secretions and 
other behaviour modifying chemicals. They often occur at 
only trace levels, and in many cases exhibit extreme 
biologically activity at these levels. Several reviews of 
the area have been published (Silverstein, 1982; Baker 
and Herbert, 1984). 
Research was commenced in 1981 aimed at identifying the 
chemistry of the mandibular gland secretions of two 
species of introduced parasitic wasps, which are 
important in the biological control of the Sirex wood 
wasp, a serious pest of Pinus radiata plantations. These 
secretions, obtained experimentally by 'milking' the 
fluid exuded from disturbed insects into glass micro 
capillaries, are implicated in the courtship and mating 
behaviour of the insects (Madden, personal 
communication). The chemical and behavioural results of 
this research were presented in an article in Journal of 
Chemical Ecology (Davies and Madden, 1985) 10 . 
One of the species, Rhyssa persuasoria, produced a 
secretion in which there were two principal volatile 
components. The first of these gave a mass spectrum with 
base peak m/z 59, and ions at m/z 31(42%), 39(17), 
41(28), 43(49) and 87(5). This was identified as 3- 
hydroxy-3-methylbutan-2-one by comparison with reference 
spectra (Stenhagen et al., 1974) and subsequently with an 
authentic sample (a gift from Prof. W. Francke). The 
second compound had a base peak at m/z 43, and ions at 
m/z 41(60), 55(30), 58(15), 69(26), 108(19), 111(15) and 
126(7). This was identified from reference spectra and an 
authentic sample (a gift from Prof. G.W.K. Cavill) as 6- 
methylhept-5-en-2-one. After its first identification as 
a natural product in the defensive secretion of ants 
(Cavill and Ford, 1953), this ketone has been associated 
with the alarm and defensive secretions of numerous 
insects. 
The second species, Megarhyssa nortoni, also produced 6- 
methylhept-5-en-2-one, as well as pentan-2-one and a 
series of compounds which could not be readily identified 
form reference data or from first principles. Three of 
these had similar mass spectra, with prominent ions at 
m/z 112 and m/z 115 and apparent molecular ions at m/z 
184 (Figures 21, 22 and 23). A fourth compound, which 
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appeared to be unstable and diminished fairly rapidly 
upon storage, had a related but significantly different 
spectrum (Figure 24). 
Accurate mass measurements on the molecular ion at m/z 
184 of the first three compounds gave the empirical 
formulae C 11 H200" while the fourth compound had an 
apparent molecular ion at m/z 168 with the formula C 11 H200. 
The prominent fragment ions at m/z 112 and 115 were found 
to be C7H 120 and C6H 1102 respectively. 
The first three of these compounds all failed to form any 
ester, methoxime or trimethylsilyl derivatives, or to 
change upon hydrogenation or saponification. Bicyclic 
acetals or ethers were therefore suggested as possible 
candidates. Consultation with colleagues involved in 
insect chemistry (Brophy, personal communication) 
confirmed that a number of bicyclic acetals had recently 
been identified in insect secretions, and an examination 
of the literature (Francke et al., 1978, 1979, 1980) 
showed that these compounds did in fact match closely the 
reported mass spectra of (E,E)-2,8-dimethy1-1,7- 
dioxaspiro[5.5]undecane (XI), (E,E)-2-ethyl-7-methyl-1,6- 
dioxaspiro[4.5]decane (XII) and (Z,E)-2,8-dimethy1-1,7- 
dioxaspiro[5.5]undecane (XIII) respectively. Comparison 
of GC and MS data with authentic standards provided by 
Professor Francke of the University of Hamburg confirmed 
these three identifications. 
The fragmentation under electron impact of alkyl 
spiroacetals was studied by Francke et al. (1979). The 
diagnostic ion at m/z 112 in these three isomers is due 
to the extrusion of acetaldehyde and ethylene via 
electron transfer around the 6-membered ring. The ion at 
m/z 115 results from elimination of C 5H 9 after hydrogen 
transfer. 
The fourth, unstable compound appeared to be related to 
an unknown isolated with these same spiroacetals 
(Bergstrom et al., 1982). The identification of this 
compound had not been published prior to the dispatch of 
the original manuscript; however, the structure had just 
been determined to be 2-methy1-6-penty1-3,4-dihydro-2H-
pyran (XIV) (Francke, personal communication). 
The unknown from Megarhyssa was confirmed to be identical 
by GC and MS by comparison with a synthetic sample of 
this enolether. Professor Francke generously let the 
identification of this pyran in Megarhyssa nortoni be 
published simultaneously with his report on cyclic 
enolethers from insects (Francke et al., 1985) in which 
the identification of the pyran as a new natural product 
first appeared. 
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Other compounds identified in Megarhyssa were undecan-2- 
one and undecan-2-ol, which are biogenetically related to 
the spiroacetals. 
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Figure 21 
Mass 	spectrum 	of 	M. 	nortoni 	compound 
identified 	as 	(E,E)-2,8-dimethy1-1,7-dioxaspiro[5.5]undecane 
(XI) 
Figure 22 
Mass spectrum of M. nortoni compound identified as (E,E)-2- 
ethy1-7-methy1-1,6-dioxaspiro[4.5]decane (XII) 
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Figure 23 
Mass spectrum of M. nortoni compound identified as (Z,E)-2,8- 
dimethy1-1,7-dioxaspiro(5.51undecane (XIII) 
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Figure 24 
Mass spectrum of FL nortoni compound identified as 2-methy1-6- 
penty1-3,4-dihydro-2H-pyran (XIV) 
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ii) Essential Oils and Related Plant Extracts 
The detailed chemical characterization of essential oils 
and volatile plant extracts formed an important part of 
research activities during the period of the Research 
Fellowship. This work was principally done in 
collaboration with Professor R. Menary of the Department 
of Agricultural Science at the University of Tasmania, 
who provided most of the samples. 
The characterization of essential oils forms an area of 
specialization within the field of GC-MS analysis. The 
requirement for this degree of specialization is in part 
due to the enormous range of potential terpenoid and 
other compounds likely to be found in essential oils and 
related products, and the relatively poor range of 
commercially available reference mass spectral data for 
these compounds. Furthermore, the mass spectra of 
terpenes are in many cases very similar, due both to the 
minor structural differences between some isomers, and to 
intramolecular rearrangements after ionization resulting 
in bond migration, yielding in some cases identical ion 
structures. Many terpenes exist in several diastereomeric 
forms with almost identical mass spectra (e.g. the 
sesquiterpene alcohols globulol, ledol, viridiflorol and 
epiglobulol; the monoterpene alcohols menthol, 
neomenthol, isomenthol and neoisomenthol). 
There are also potential problems with artifacts caused 
by thermal rearrangements within the GC injection port or 
the GC-MS interface, such as the Cope rearrangement of 
Germacrene A, Germacrene B and bicyclogermacrene to p-
elemene, 7-elemene and bicycloelemene respectively (Clark 
et al., 1987; LeQuere and Latrasse, 1990). 
The number of biogenetically feasible ,monoterpenes and 
sesquiterpenes is very large; there are over 100 reported 
carbon skeletons for sesquiterpenes. Even considering 
only hydrocarbons, alcohols and ketones, there are many 
thousand possible structures; mass spectral and GC data 
have only been reported in the general literature for a 
very small fraction of these. (Some of the large 
international flavour and fragrance companies have 
developed extensive libraries of both mass spectral and 
GC data for terpenes and other volatile compounds likely 
to be found in essential oils and related plant extracts, 
but due to commercial considerations do not release this 
information.) 
Correct identification of known essential oil components 
therefore requires great care, often requiring the use of 
Kovats' retention indices (Kovats, 1958) in conjunction 
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with mass spectral data, and possibly direct comparison 
with authentic standards. 
The difficulties of structural assignment of novel 
terpenes based on MS evidence alone have been outlined by 
Enzell et al. 	(1972). In general, monoterpenes and 
sesquiterpenes 	lack 	strong 	fragmentation-directing 
groups. 
A considerable amount of development was therefore 
required to build up a suitable database of reference 
data on known terpenoids and other essential oil 
compounds either from the literature, or by acquiring 
data from pure samples or essential oils of known 
composition. This was done for both GC data, using 
KovAts' retention indices, and mass spectra. The former 
was ultimately published in 1990 as a review of 900 
indices of 400 different terpenes in Journal of 
Chromatography (Davies, 1990) 11 , to facilitate analytical 
work in this area. This review was based on a personal 
database of literature values for retention indices built 
up over the preceding ten years. The mass spectral data 
was developed as a database acquired from literature 
sources, colleagues, individual reference compounds and 
commercial essential oils of known composition, against 
which unknown compounds could be searched using 
commercial software (VG 2035 datasytem). 
Apart from data generated on the VG 7070F (see Appendix 
C), the major sources for the mass spectral database were 
Brophy (personal communication), Hirose (1967), Moshonas 
and Lund (1970), Stenhagen et al. (1974), Heller and 
Milne (1978, 1980), Kennett et al. (1977a, 1977b, 1980, 
1982), ten Noever de Brauw et al. (1979, 1982, 1986), 
Jennings and Shibamoto (1980), Swigar and Silverstein 
(1981), Ramaswami et al. (1986) and Adams (1989). Some 
sixty other literature references to mass spectra of 
individual terpenes or groups of terpenes and other 
essential oil compounds were used in the compilation of 
this database. This data has since been made available to 
other researchers in the area of essential oil analysis, 
and is incorporated into the database of the Laboratory 
for Aroma Research of the French National Institute for 
Agronomic Research (INRA) in Dijon, France. 
Novel terpenes, which are often encountered in studies of 
essential oils from Australian native species (e.g. 
Southwell, 1978, 1987; Lassak and Southwell, 1977), will 
generally require classical isolation and structural 
elucidation by MS, IR and NMR for unequivocal structural 
assignments; this is seldom possible by MS alone from 
first principles. 
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Table 1 summarizes the range of commercial and 
experimental oils that were analysed during the period 
1979-1992 using a combination of the mass spectral and 
KovAts' index databases described above. 
During the course of this research on essential oils, a 
considerable number of errors in reference mass spectra 
in the EPA/NIH Mass Spectral Database (Heller and Milne, 
1978, 1980) (subsequently incorporated into the 
NIST/EPA/MSDC Mass Spectral Database) and the Wiley 
Registry of Mass Spectral Data (Stenhagen et al., 1974) 
were identified and noted in correspondence to the 
editors. 
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Acradenia frankliniae 
Artemisia afra 
Athrotaxus cuppressoides 
Athrotaxus selaginoides 
Bedfordia salicina 
Beyeria viscosa 
bitter fennel 
blackcurrant buds 
Boronia megastigma 
Boronia pilosa 
buchu 
bush basil 
Callitris rhomboidea 
Calotis 
caraway 
celery herb 
celery seed 
chamomille 
clary sage 
coriander 
cornmint (Mentha arvensis) 
Dalmatian sage 
Drimys lanceolata 
Eucalyptus citriodora 
Eucalyptus delegatensis 
Eucalyptus globulus 
Eucalyptus macarthuri 
Eucalyptus nitens 
Eucalyptus ovata 
Eucalyptus polybractea 
Eucalyptus pulchella 
Eucalyptus radiata 
Eucalyptus regnans 
Eucalyptus smithii 
Eucalyptus tenuiramis 
Eucalyptus viminalis 
ginger 
hops 
Huon Pine 
hyssop 
jasmine 
kaprao 
lemon 
Leptospermum lanigerum 
Leptospermum sericea 
lime 
marjoram 
Melaleuca dissitiflora 
Melaleuca uncinata 
onion 
orange 
Osman thus 
palmerosa 
parsley herb 
parsley seed 
peppermint 
Phebalium squameum 
pine-needle 
Podocarpus lawrencii 
Prostanthera lasianthos 
rosemary 
sage 
spearmint 
summer savory 
sweet basil 
sweet fennel 
sweet marjoram 
tarragon 
thryptomene 
thyme 
ti-tree (Melaleuca alternifolia) 
verticordia 
vetiver 
wormwood (Artemisia absinthium) 
Zieria arborescens 
Table 1 
Commercial and experimental essential oils analysed 
during the period 1980-1992 using the mass spectral and 
Kovats' index databases described. 
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a) Essential Oils from Hops  
The first specific oils for which the results were 
published were distilled from commercially grown hops 
(Plumulus lupulus) (Davies and Menary, 1982) 12 . 
Clarification of the composition of hop essential oils 
from various cultivars grown in Tasmania was undertaken, 
particularly with respect to the level of selinene 
isomers. The levels of a- and P-selinenes (XV and XVI) 
were of particular interest from the point of view of 
'aroma' characteristics of the hops (Menary, personal 
communication), and ultimately of the beer brewed using 
particular hop cultivars. Other selinenes that were also 
of interest with respect to 'aroma' character were 
selina-4(14),7(11)-diene and selina-3,7(11)-diene. 
XV 
	
XVI 
What appeared to be the same compounds had been 
ambiguously identified in Europe as 'posthumulenes' 
(Maier, 1978), and it was determined from reference 
standards that there were serious errors in much of the 
readily available published reference spectra for both a-
selinene (Moshonas and Lund, 1970) and P-selinene (Heller 
and Milne, 1978,1980; Stenhagen et al., 1974), although 
summarized spectra had been published that were 
substantially correct for a-selinene (Hirose, 1967) and 
P-selinene (e.g. Schreier et a/., 1976; Moshonas and 
Lund, 1970). 
The correct mass spectra, obtained from pure samples of 
a- and P-selinene isolated by preparative GC from 
rosewood and celery oils respectively, are shown in 
Figures 25 and 26. The incorrect published spectra for 
these two sesquiteroenes were possibly based on erroneous 
identifications or thermal degradation within the MS. 
Reference mass spectra for selina-4(14),7(11)-diene and 
selina-3,7(11)-diene were obtained from a sample of oil 
from the hop variety 'Sunshine'. 
Approximately fifty other volatile compounds in the hop 
oils were fully or partially characterized on the basis 
of GC and MS evidence. 
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Some published correspondence was entered into as a 
result of this work, regarding the possible role of 
sesquiterpenes as constituents of the hop 'aroma' 
character of certain beers (Clarke, 1982; Davies and 
Menary, 1983a). 
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Mass spectrum of a-selinene (XV) 
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Figure 26 
Mass spectrum of P-selinene (XVI) 
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b) Boronia megastigma Floral Concretes  
The 'concrete' obtained by the solvent extraction of 
Boronia megastigma flowers is of interest to perfumers 
and flavorists due to its intense aroma and flavour 
enhancing characteristics. From pioneering studies done 
in the 1920's (Penfold, 1927) it was known to be the 
first natural source of P-ionone, but very little other 
chemistry had ever been carried out on this product. As 
part of the ongoing development of an essential oils 
industry in Tasmania, the Boronia concrete was 
characterized in some detail (Davies and Menary, 1983b) 13 . 
The organoleptic quality of the concrete, which is used 
as a flavour enhancer in foods and beverages, and to a 
lesser extent in perfumery products (Menary, personal 
communication) was of great importance from a marketing 
point of view. It was quickly established by GC analyses 
that there was a great deal of chemical diversity among 
the trial populations of Boronia megastigma, and detailed 
chemical investigations were undertaken with a view to 
correlating chemical composition with organoleptic 
properties. 
Among the major components in all clones examined was the 
simple alkene (Z)-heptadec-8-ene. The double bond 
position of this compound was determined by the technique 
of methoxymercuration-demercuration (Blomquist et al., 
1980), followed by GC-MS analysis of the products. 
A single, substantial GC peak was obtained following the 
methoxymercuration-demercuration of the heptadecene peak 
isolated by preparative GC, with prominent ions at m/z 
143 (39%), 157(60%) and 171 (35%). The strong ion at 157 
could be best interpreted as arriving from alpha cleavage 
to the methoxy group (on both sides) from 9- 
methoxyheptadecane, whereas the ions at m/z 143 and 171 
could be interpreted as alpha-cleavage on both sides to 
the methoxy group in 8-methoxyheptadecane. The mixed 
product of 8- and 9-methoxyheptadecanes was consistent 
with a heptadec-8-ene. 
The cis double bond geometry was determined by the 
characteristic band in the Raman spectrum at 1657 cm -1 , 
and the absence of trans absorptions between 1665 and 
1676 cm-1 , in a sample purified by micro-preparative GC. 
While this compound could be readily obtained 
biosynthetically from the decarboxylation of oleic acid, 
it had only been reported twice before in plants. 
Among the compounds identified as a major component in 
one particular chemotype was a new sesquiterpene (XVII) 
which was given the trivial name 'sesquicineole', due to 
its close structural relationship to the common 
86 
monoterpene 1,8-cineole (XVIII). This structure was not 
confirmed by any independent spectroscopic means. 
The mass spectrum of the parent compound is given in 
Figure 27. The empirical formula C 15 1-1 260 was determined by 
accurate mass measurement. Upon hydrogenation in the GC 
injection port (80% Chromosorb W, 20% (5% Pd on carbon), 
200°C, hydrogen carrier gas) a dihydro derivative was 
obtained (M+ 224, m/z 43, 95, 139, 209), indicating a 
single double bond, with no effect on the major ion at 
139, which was found to be C 9H 150. A mixture of trans- and 
cis- bisabolane (XIX, XX) was obtained upon pre-column 
hydrogenolysis (80% Chromosorb W, 20% (5% Pd on carbon), 
300°C, hydrogen carrier gas). 
Precolumn hydrogenations and hydrogenolyses were based on 
the work of Beroza and Sarmiento (1963; 1966), with some 
modifications to the catalyst. These reactions were 
carried out using the packed column injection port of a 
Pye 204 GC, with a 1.8 metre packed (3% SE30 on 
Chromosorb W) stainless steel column (one eighth inch 
outside diameter) coupled to a VG 7070F mass spectrometer 
via a glass jet separator, using hydrogen as carrier gas. 
Model compounds were tested prior to analysis of the 
unknowns to ensure that adequate conversions were 
occurring. 
Attempted 	formation 	of 	oxime 	and 	trimethylsilyl 
derivatives resulted in no change, indicating the oxygen 
function was not present as a carbonyl or alcohol. This 
evidence indicated the compound to be a cyclic ether with 
a 0 6 1-1 11 side chain, and a bisabolane skeleton. The strength 
of the ion at m/z 139 indicated that the ether function 
was likely to join to carbon 8. Biosynthetic 
considerations indicated the 1,8 cyclic ether as 
described. Subsequent trials with 1,8-cineole as a model 
confirmed the behaviour of this compound under the 
hydrogenolysis conditions employed, yielding a mixture of 
cis- and trans- p-menthane. 
Other compounds found included methyl jasmonate (XXI) and 
a previously undescribed isomer of methyl jasmonate. 
Again the structural assignment for methyl jasmonate was 
based primarily on mass spectral evidence from first 
principles, since no reference spectra were available 
until after the preliminary structural assignment. Due to 
the occurrence of only a single peak in the hydrogenated 
product, the minor isomer most likely contained a trans 
double bond, rather than being a stereoisomer on the 
cyclopentanone ring. 
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The molecular formula (C 13 H 200 3 ) was determined by accurate 
mass measurement, as were the formulae of key fragment 
ions at m/z 83 (0 5 H 70), m/z 151 (C 10 1-1 150) and m/z 156 
(C 6 H 120 3 ). The prominent ion at m/z 83 suggested the 
compounds could be substituted cyclopentanones. A 0 5H 9 
side chain adjacent to the carbonyl could be responsible 
for a McLafferty rearrangement peak at m/z 156. The 
additional subunit present (C 3H SO2 ), as shown by the losses 
from the molecular ion and the ion at m/z 156, and 
presence of diagnostic peaks at m/z 59 and m/z 74, 
suggested a methyl ester function. Hydrogenation (5% Pd 
on carbon, in solution) of the concrete and subsequent 
GC-MS analysis confirmed the presence of a double bond in 
the C 5H 9 portion of the molecule. Methyl jasmonate was 
found to be the only known natural product satisfying 
these criteria, and the identification was confirmed from 
GC retention data and mass spectra of methyl jasmonate 
from a sample of Egyptian jasmine 'absolute'. 
Two other volatile components could not be characterized 
by comparison with readily available reference data. 
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These 	showed m/z 82(100%), 	71(77), 	43(58), 	67(42), 
55(16), 59(8) and m/z 71(100%), 82(77), 43(86), 67(59), 
55(14), 119(19), 134(9) and 152(trace) respectively. Both 
of these had no apparent molecular ion, and had strong 
similarities to the mass spectrum of 'hotrienol' (3,7- 
dimethy1-1,5,7-octatriene-3-01). 
However, the Kovats' index of hotrienol was much lower 
than either unknown. Subsequent comparison with authentic 
hotrienol confirmed that both eluted well after this 
compound. There were two known hydrated forms of 
hotrienol; 2,6-dimethy1-3,7-octadiene-2,6-diol and 3,7- 
dimethy1-1,7-octadiene-3,6-diol, that had been first 
reported from ho-leaf oil (Cinnamomum camphora) (Takaoka 
and Hiroi, 1976), and subsequently in Muscat of 
Alexandria grapes and wine (Williams et al., 1980). Due 
to the ready dehydration of alcohols to alkenes on 
electron impact ionization, it was probable that the mass 
spectra of these diols would not be dissimilar to that 
of hotrienol, although no reference MS data were 
available. They would also be expected to elute 
considerably later than hotrienol on both polar and non-
polar columns, consistent with the observed unknowns. 
Synthetic samples of these two diols and hotrienol were 
obtained from Dr. Pat Williams of the Australian Wine 
Research Institute. The first unknown from Boronia was 
found to match exactly by GC and MS to 3,7-dimethy1-1,7- 
octadiene-3,6-diol. The second unknown eluted well after 
both diols on a non-polar methyl silicone GC phase, but 
before the 3,7-dimethy1-1,7-octadiene-3,6-diol on a 
Carbowax 20M column, indicating it to be less polar than 
the diol, but with a higher boiling point. A mono- or di-
acetate of 3,7-dimethy1-1,7-octadiene-3,6-diol was a 
possible inference from this data. 
Other major components present in all clones included the 
simple esters dodecyl acetate and tetradecyl acetate. 
Since it is known that in its native Western Australia 
Boronia megastigma is only pollinated by a single species 
of night-flying moth (Menary, personal communication), it 
is possible that these esters are present as specific sex 
pheromone mimics to attract the moth. Long chain 
saturated and unsaturated acetates are commonly found as 
Lepidopteran sex pheromones (Tumlinson, 1988). 
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Figure 27 
Mass spectrum of sesquicineole (XVII) 
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c) Gardenia Exudates  
Collaborative natural product research with Professor 
Subranamiam Sotheeswaran from the University of the South 
Pacific in Fiji, including the provision and 
interpretation from first principles of mass spectral 
data, was undertaken over a number of years. As part of 
this work, extracts from a number of plants indigenous to 
Fiji were analysed by capillary GC-MS and direct 
insertion probe MS for known and new natural products. 
Structures of known and new triterpenes were assigned 
primarily on the basis of mass spectral information. 
While NMR data has also been used, the samples were not 
always pure enough for direct structural assignments by 
this method; it was used rather to back up the 
assignments based on the MS data. The first of this work 
to be published was the identification of cycloartenone 
(XXII) and three new related triterpenes in the bud 
exudates of six Gardenia species (Davies et a/., 1992) 14 . 
Cycloartenone was characterized by a molecular ion at m/z 
424.370 (C 30H00 requires 424.3705), and ions at 340.278 
(C 24 H 360), 313.250 (C 22H 330), 311.235 (C 22H 310) and 286.265 
(C21 11 34 ). The fragmentation under electron impact 
conditions of the cycloartane skeleton has been studied 
extensively (Audier et al., 1966; Aplin and Hornby, 
1966). The effect on fragmentation of double bond 
position in attached side-chains at C-17 in related 
sterols has also been studied in detail (Wyllie and 
Djerassi, 1968). Figure 28 summarizes some of the 
characteristic fragment ions for cycloartenone and 
related triterpenes. One ion in particular, designated as 
ion 'a' (m/z 286 for cycloartenone), is known to be 
formed as a result of the cyclopropane bridge. Ion 'b' 
(m/z 313 for cycloartenone) results from the loss of the 
side chain at C-17, while ion 'c' arises from the A24 
double bond in cycloartenone. The equivalent ions arise 
in other 6,24 triterpenes and sterols (Wyllie and Djerassi, 
1968). 
Three unknown compounds designated here as A, B and C 
(mass spectra Figures 29, 30 and 31) had the empirical 
formulae of their molecular and major diagnostic fragment 
ions determined by high resolution MS. The characteristic 
cycloartane fragmentation ion 'a', in which the A ring 
is completely lost, was found in each case. Compounds A 
and C were unaffected by catalytic hydrogenation, while 
compound B was converted to compound C. A literature 
search revealed no known cycloartane related triterpenes 
with the relevant formulae for the side chains at C-17 
for compounds A and C. A cycloartane triterpene assigned 
the trivial name 'schizandraflorin' had been identified 
in Schizandra grandiflora (Talapatra et al., 1982), with 
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XXII R= 
XXIII R 
XXIV R = 
XXV R = 
a A 0(20, 24-one cycloartane structure (XXIII). However, the 
published mass spectrum of this compound was 
significantly different from that of compound B. 
The structures of compounds A, B and C were determined by 
mass spectrometry from first principles, based on the 
characteristic fragmentations discussed above, and 
further fragment ions resulting from simple cleavage and 
McLafferty rearrangement ions (McLafferty, 1962, p. 93). 
The structure of compound A was determined to be the new 
natural product 9,19-cyclolanostan-3,24-dione (XXIV). 
Accurate mass data indicated the molecular ion to be m/z 
440.363, indicating C 30H 4602 (requires 440.3654). Standing 
out from the general triterpene skeleton hydrocarbon ions 
were ions at m/z 43.055 (C 3 H 7 ), 71.051 (C 4 H,0), 127.112 
(C 8 H 150), 302.262 (C2 0-1 340), 313.249 (C22 1-1 330) and 354.290 
(C25H 380). 	Figure 	32 	summarizes 	the 	case 	for 	the 
identification of this compound. 
R' = Me 	XXVI R 
R' = Me 
R' = Me 
XXVIII R = 
R' = Me  
R' = Me 
R' = H 
R'= Me 
XXVII R= 
Figure 33 summarizes the case for compound B to be 9,19- 
cyclolanost-24-en-3,23-dione (XXV), another new natural 
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product. The position of the double bond assignment in 
the side chain was confirmed by proton NMR (o / 6.07 for the 
olefinic proton adjacent to the carbonyl group). 
Accurate mass data for this compound indicated M 438.351 
(C 99 11 4600 and significant ions at m/z 83.050 (C 5H 70), 
98.073 (C 6 1-1 100), 125.098 (C 9 1-1 130), 300.244 ( •C2i H .920) and 
340.275 (C 24 1-1 360). 
Figure 34 shows the case for compound C, which was found 
to be the new triterpene 9,19-cyclolanostan-3,23-dione 
(XXVI). Accurate mass data indicated NI" 440.364 (C 30H002 
requires 440.3654), and significant ions at m/z 85.067 
(C 5H 90), 127.112 (C 9H 150), 302.263 (C 21H .940), 313.247 
(C 22 1-1 990) and 340.278 (C 24 1-1 360). 
Further new triterpenes characterized as minor components 
in the exudates by mass spectra from first principles 
were C-4 nor-9,19-cyclolanost-24-en-3,23-dione (XXVII) 
and cycloartdienone (XXVIII). 
In the published paper, an editorial decision was made 
not to include the MS fragmentation schemes or any 
discussion of the key ions; this left no explanation in 
the text as to the relevance of the indicated ions. 
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Figure 28 
Key Fragment Ions for cycloartenone and related compounds 
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Figure 29 
Mass spectrum of compound A (9,19-cyclolanostan-3,24-dione) 
(XXIV) 
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Figure 30 
Mass spectrum of compound B (9,19-cyclolanost-24-en-3,23-dione) 
(XXIV) 
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Mass spectrum of compound C (9,19-cyclolanostan-3,23-dione) 
(XXV) 
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Figure 32 
Mass Spectral Fragmentation Scheme for (9,19-cyclolanostan-
3,24-dione) 
Figure 33 
Mass Spectral Fragmentation Scheme for (9,19-cyclolanost-24- 
en-3,23-dione) 
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Figure 34 
Mass Spectral Fragmentation Scheme for (9,19-cyclolanostan-
3,23-dione) 
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iii) Contributions to the NIST/EPA/MSDC Mass Spectral 
Database 
Several hundred full mass spectra acquired on the VG7070F 
in the CSL were incorporated into the database discussed 
above in section 4(ii). These spectra, obtained either 
from certified reference standards or from compounds 
otherwise unambiguously identified, were acquired during 
work on essential oil compositions, the potential 
involvement of drugs other than alcohol in road traffic 
accidents (McLean et al., 1987; Neill et al., 1991), the 
metabolic fate of phenacetin (McLean et al., 1981) and 
related drugs, and forensic drug analyses. 
Approximately three hundred mass spectra, predominately 
of natural products, drugs and drug metabolites, were 
submitted to the NIST/EPA/MSDC mass spectral database 
(Lias and Stein, 1990, 1992). 
An eight peak version of these spectra (as distinct from 
spectra entered from literature sources and acquired from 
colleagues) is presented in Appendix C, indexed by name, 
major ions and molecular weight. A significant proportion 
were not present in the published mass spectral databases 
(Stenhagen et al., 1974; Heller and Milne, 1978, 1980, 
1982; Mass Spectrometry Data Centre, 1983; ten Noever de 
Brauw et al., 1979, 1982, 1986; Kennett et al., 1977a, 
1977b, 1980, 1982), and so formed an integral part of the 
analytical strategy for essential oils and drugs. 
The mass spectra of a series of N-arylacetylhydroxamic 
acids, acetamidophenols and their methyl derivatives, 
which formed part of the contributed data, were published 
separately together with a discussion of diagnostic 
fragment ions and their implications in drug metabolism 
studies (Davies et al., 1982b). 
Table 2 lists those compounds for which spectra were 
incorporated into the released versions of the 
NIST/EPA/MSDC database. 
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Table 2 
acetanilide, 2,4-dihydroxy-
acetanilide, 2,4-dimethoxy-
acetanilide, 2-hydroxy-4- 
chloro- 
acetanilide, 2-methoxy-4- 
chloro- 
acetanilide, 3,4-dihydroxy-
acetanilide, 3,4-dimethoxy-
acetanilide, 3-methylthio-4- 
methoxy 
acetanilide, N-hydroxy-3,4- 
dichloro- 
acetanilide, N-hydroxy-4- 
chloro 
allopurinol 
benezene, 2,3,4,5- 
tetramethoxy allyl-
benzenesulfonamide, 2- 
hydroxy-4-acetylamino-
benzenesulfonamide, 2- 
methoxy-4-acetylamino-
benzenesulfonamide, N- 
hydroxy-4-acetylamino-
benzenesulfonamide, N- 
methoxy-4-acetylamino-
benzofuran, 3,6-dimethyl-, 
2,3,3a,4,5,7a-hexahydro-
benzoic acid, 4-acetylamino-, 
methyl ester 
biphenyl, N-hydroxy-4- 
acetylamino- 
biphenyl, N-methoxy-4- 
acetylamino 
bisabolol oxide A 
bisabolol oxide B 
bisabolol, a-
bisabolone oxide 
bourbonene, p- 
brefeldin A 
camphene hydrate 
campholene aldehyde, a-
capillin 
carbimazole 
carveol, cis-
carveol, trans- 
carvone 
chamazulene 
chlorpheniramine 
cineole, exo-2-hydroxy-
citric acid, acetyl-, tri-n-
butyl ester 
clonazepam 
clonidine 
cuminic aldehyde, p- 
cymen-7-ol, p- 
cymen-8-ol, p- 
damascenone 
dec-4-enoic acid, methyl 
ester 
dihydrocarvone 
dihydrocodeine 
dillapiole 
diosphenol 
diosphenol, psi- 
elemicin 
ephedrine 
ethylmorphine 
eudesman-11-ol, 413,5a-
eudesmane, 4aH- 
eudesmol, a- 
eudesmol, y- 
fluorene, N-hydroxy-2- 
acetylamino- 
fluorene, N-hydroxy-3- 
acetylamino- 
fluorene, N-mehtoxy-2- 
acetylamino-
fluorene-9-ol, 2-acetylamino-
Germacrene D 
glibenclamide 
guaifenesin 
hotrienol 
hydralazine 
ibuprofen 
indoleacetic acid, 4-chloro-, 
methyl ester 
indomethacin 
MDMA (ecstasy) 
menth-2-en-l-ol, cis-p-
menth-2-en-l-ol, trans-p-
menthan-4-ol, p- 
menthan-8-ol, p- 
menthatriene, 1,3,8-p-
menthon-8-thiol, p-
methyl eugenol 
methyprylone 
miconazole 
myrtanol 
myrtanyl acetate 
naphthalene, N-hydroxy-2- 
acetylamino- 
naproxen 
octadecyl acetate 
octadiene-2,6-diol, 2,6- 
dimethyl-, 3,7- 
octadiene-3,6-diol, 3,7- 
dimethyl-, 1,7- 
phenacetin 
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Table 2 (continued) 
phenacetin, 2-methoxy-
phenacetin, 3-methoxy-
phenacetin, N-hydroxy-
phenacetin, N-methoxy-
phenetidine, 2-hydroxy-
phenetidine, N-butyryl-
phenetidine, N-propiony1-2- 
methoxy- 
pheniramine 
phenyl-l-hexanone, 1- 
phenylpropanolamine 
pholcodine 
pinocarveol 
piperitol, cis- 
piperitol, trans- 
prazosin 
propanamide, N-(4- 
chloropheny1)- 
propanamide, N-(4- 
methoxypheny1)- 
propiophenone, N-hydroxy-4- 
acetylamino- 
quinine 
radicicol 
sabibene hydrate, trans-
selinene, a- 
selinene, p- 
selinene, 8- 
seselin 
spathulenol 
sulindac 
sulphanilamide, N1,N4- 
diacetyl- 
sulphanilamide, N1-acetyl-
theophylline 
thuj one 
verbenol 
verbenone 
viridiflorol 
warfarin 
zeatin 
zierone 
zingiberene 
Table 2 
Entries from the mass spectral library subsequently 
incorporated into the NIST/EPA/MSDC PC database. 
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Determination and Optimization of Flow Rates in Vacuum Capillary Gas 
Chromatography 
Noel W. Davies 
Central Science Laboratory, University of Tasmania, G.P.O. Box 252C, Hobart, Tasmania, Australia 7001 
The direct insertion of capillary gas chromatography col-
umns into mass spectrometer ion sources is a common method 
of coupling these instruments (1-6). This results in the 
pressure at the column outlet being effectively zero and the 
advantages of this such as increased speed of analysis over 
atmospheric outlet operation, total transfer of effluent to the 
ion source, and the relative ease of transfer of labile com-
pounds have been well publicized. Cramers et al. (7) presented 
a detailed analysis of the various factors involved, including 
the gain in speed of analysis over atmospheric outlet for a 
given system and the potential loss in efficiency with vacuum 
outlet pressure. 
In any capillary gas chromatographic analysis, the flow rate 
of carrier gas is a critical parameter for optimized performance. 
Average linear velocity (0) is often the form in which this is 
expressed and relates to a particular carrier gas diameter, and 
outlet pressure. An increased average velocity will be required 
for optimum performance if outlet pressure is lowered (6, 7). 
However, the optimum volume flow rate, reduced to atmos-
pheric pressure, remains independent of outlet pressure (7). 
Optimum average carrier gas velocity at atmospheric outlet 
pressure (Vopt,strn)  can be found from literature values, while  
in many situations the corresponding volume flow rate is also 
known. To obtain the optimum performance with vacuum 
outlet, 0  must be adjusted to the correct value for vacuum 
outlet (0) or the volume flow must be measured. It is 
generally impracticable to measure flow in directly coupled 
gas chromatography/mass spectrometry, since the outlet of 
the source pump is the only available point for measurement, 
after isolation of all other pumps to ensure passage of total 
effluent. The erratic liberation of gas makes accurate mea-
surement difficult, particularly for very low flow rates. 
The discussion below shows how flow rate can be simply 
measured from readily accessible parameters, the air peak 
retention time (t.,,,„c), the length of the column (L), and the 
carrier gas viscosity (11), without requiring column diameter 
or inlet pressure terms. Conversely, the air peak retention 
time required to give a particular flow rate can be predicted. 
Alternatively, 0,,c and hence the optimum air 
peak time with zero outlet pressure, can be calculated from 
D after calculation or accurate measurement of the inlet 
pressure required for the latter. 
Calculation of Flow Rates. Poiseuille's equation for 
viscous flow in long cylindrical columns can be written (7) 
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3r2P0(P2 - 1) 2 
=  	 (1) 
32nL(P1 - 1) 
where r is the column radius, Po is the outlet pressure, and 
P= (Pi/Pa)where P 1 is inlet pressure. Since = Llt„, where 
t a is air peak retention time, rearrangement gives 
32nL2(P3 - 1) 
3d2(pi2 _ po2)2 
where d is column diameter. 
Now the flow rate as measured at the column outlet (Q), 
which unlike average flow rate (as defined by the ratio of the 
volume of the column to the air peak time t a ) incorporates 
a pressure term, can be determined from the product of the 
pressure drop across the column and the conductance (C,) of 
the column (8). 
Substituting eq 4 in eq 2, for vacuum outlet pressure (Po 
= 0), the time for the air peak (t a.„,) can be found. 
t •,Vat = 
12817L2( ircts  ) 112 
3d2 256nLQ 
= §( 771L3 1 
3 Q 
Thus t a.„., can be predicted from a knowledge of Q, n, and 
L, is independent of d, and requires no knowledge of inlet 
pressure. Equation 5 also follows from Sellier and Guiochon 
(3) who found 
4nL2 
= 3kpi 	 (6) 
where k is the "column permeability" defined as r2/8. When 
eq 4 is substituted in eq 6, eq 5 results. 
Rearrangement of eq 5 gives the expression enabling direct 
calculation of flow rate 
64TnL3 
9tc 2 
For a given gas at a fixed temperature this can be expressed 
as 
Q = k-L3 mL atm min' 	(8) 
tc,w2 
where k is a constant. If L is in meters and t a.„, in seconds, 
some values for k allowing direct expression of the results in 
mL atm min-1 are as follows: helium, 20 °C, k = 0.2568; 
250 
200 
t a,vac 
(secs) 
50m, He 
50m H 
25m, Ne 
25m. H 2 
3 	4 	5 
• 	 0 (mis /m.r.) 
Figure 1. Plot of the air peak time required at vacuum outlet pressure 
(t...,) to produce a given flow rate (0), as would be measured at the 
column outlet at atmospheric pressure (i.e., milliliters at atmospheric 
pressure per minute), for 25-m and 50-rn columns with hydrogen and 
helium at 20 °C. Column diameter has no bearing on this relationship. 
60 
so 
9vac -Yatm 
(cm 
leo 0 2crum, Ne 
Om 0 2 rnm,Ne 
10 20 30 40 50 60 70 
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Figure 2. Plot of the additional average carrier gas velocity required 
at vacuurn outlet pressure - 9 ) to maintain the same flow rate. 
In atmospheric milliliters per minute, as a green average velocity at 
atmospheric outlet pressure (P aa„). The results are for the column 
lengths, diameters, and carrier gases Indicated at 20 ° C. 
helium, 100 °C, k = 0.3017; hydrogen, 20 °C, k = 0.1156; 
hydrogen, 100 °C, k = 0.1360; nitrogen, 20 °C, k = 0.2311; 
nitrogen, 100 °C, k = 0.2752. 
Prediction of t 	from e,,,„„a . If the required flow 
is not known, but 0 0,„„„ for a similar diameter is known, from 
eq 2 
Patm2)2 
(9) 
3d2 	Pi.optat= 3 P 3 at. 
where n, and L I are the viscosity of the gas and length of the 
column for which 0, 1  is known, is the inlet pressure 
employed, and Pa., is atmospheric pressure. 
From this, 	can be found by iteration, as the zero 
of the function of the form x' - ax 3 - bx 2 + c = 0. 
From Cramers et al. (7), if Po ,,„, for a given column is 
known 
L i 	 pitm2) 3/ 2 
(10) 
A 
t
L°P"Ic 
- 
D°Pi ir° (Pi.opt.At.3 Pat. 3) 
To transfer to a more general situation with a column with 
length 1.2 at a different temperature (I/ = 712.), substituting eq 
3 in eq 5 gives 
(2) 
/2 
(5) 
Om 05mm, He 
25m 0 2 mm, h12 
50m 0 0 5mm, N2 
25m 0 5mm, He 
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Figure 1 shows the relationship between flow rate and 
for 25-rn and 50-m columns with both hydrogen and helium. 
enabling ready estimation of one parameter from the other 
for these typical columns. Figure 2 illustrates the effect of 
column diameter, length, and carrier gas on the additional 
average velocity necessary to maintain the same flow rate at 
vacuum outlet pressure as that produced by a particular av-
erage velocity at atmospheric outlet (C1.(m )• 	 for each 
situation can thus be found readily from knowledge of 
Taking the case of a 25 m x 0.5 mm column using helium, 
if 	= 30 cm/s, the additional velocity required is 47 cm/s 
for a total of 77 cm/s. Hence 	= (25/0.771 = 32 s. 
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Temperature Programming and Flow Rates in Capillary Gas 
Chromatography 
Sir: In a recent article in this journal, Jones et al. (1) 
discussed the combined effect of temperature program rate 
and carrier gas flow rate on the efficiency of capillary gas 
chromatographic separations. They employed a mathematical 
approach to infer optimum combination of flow rate and 
program rate values from a series of collected data from 
0003-2700/04/0356-2600601.50/0 
different compound classes at different temperature program 
and flow rates. There are several aspects of this article that 
require some comment. 
In the first instance, the overall impression created by the 
article is that within each temperature-programmed run the 
carrier gas flow rate was held constant, due to the repeated 
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reference to a "flow rate", quoted to three decimal places, being 
used with a particular program rate. In their aim to find the 
best combination of the two for a particular column for a range 
of compound classes, there is no reference to the fact that the 
flow rate was itself dependent on temperature and subject to 
the normal variation associated with isobaric pressure-con-
trolled columns. That this was so can be ascertained from 
the instrument described, a Hewlett-Packard 5880A, which 
has a flow controller situated upstream of the inlet splitter, 
while the column flow is controlled by a back-pressure regu-
lator. While some hint of this may be gained from the ref-
erence in the Experimental Section to the value of -column-
head pressures", if the authors were aware that flow rate was 
constantly falling with increased temperature, and falling more 
rapidly with faster program rates, it seems an oversight not 
to have included the effect of this in their mathematical 
treatment and discussion. 
Assuming the quoted flow rates were measured at the initial 
temperature of 50 °C (viscosity of helium, 2.07 x 10 -5 N s 
from Poiseuille's law the flow rate at the final temperature 
of 250 °C (viscosity of helium, 2.85 x 104 N s to -2) would be 
reduced, from the ratio of the viscosities, to some 72% of the 
initial value. Chromatographers generally do not find that 
this causes any practical difficulty in obtaining good resolution, 
since a range of the flow rates can be tolerated with only a 
small loss in efficiency, particularly on the high side of op-
timum. However, not only will there be an elution temper-
ature for a given compound, increasing with increased program 
rate, but also an "elution flow rate", decreasing correspondingly 
with increased program rate. For the expression TZ = a(CH 
+ b), where TZ is the separation number and CH the average 
carbon number of a pair of homologues (/), the actual data 
obtained from the regression equations for the series of ho-
mologues can still be plotted in three dimensions (TZ vs. 
program rate and flow rate), provided the flow rate axis is 
clearly marked as "initial flow rate". However, when a gen-
eralized relationship aimed at optimizing TZ in terms of both 
parameters is derived, account must be taken of the depen-
dency of flow rate on temperature. There can be no theoretical 
combination of program rate and initial flow rate that will be 
an optimum for all compounds, since compounds eluting at 
higher temperatures will experience overall lower flow rates 
than those eluting at lower temperatures. Thus, an idestized 
flow rate/program rate combination that produces optimum 
performance under constant flow conditions for a specified 
compound will not necessarily be the same (based on initial 
flow rate) as when the column has isobaric pressure control 
and is subject to a gradual reduction in flow rate. These 
differences may or may not be significant, depending on the 
elution temperatures of the test compounds. The range of 
compounds used by Jones et al. may not show this effect to 
a significant degree, since flow rates may not have altered 
greatly during the analysis. From Table I in their article, 
elution temperatures of 118 and 172 °C for the C12 and C16 
alkanes, respectively, are found (initial flow rate, 0.812 
mL/min; program rate, 10 °C/min). These correspond to 
elution flow rates of 0.69 and 0.65 mL/min, respectively, a 
drop of some 8%, while the potential reduction between initial 
and final temperatures is 28%. The reduction in elution flow 
rates in the other compound classes is 12-14%. The gradual 
increase in peak widths at half height observed with increasing 
carbon number in this work may be due in part to the re-
duction in flow rate, in addition to any effect directly related 
to temperature. 
A second important point is raised by the method of de-
termining flow rates. Although not stated in the article, these 
were measured by dividing the volume of the column by the 
time taken for an unretarded component to elute (2), pro- 
Table I. Variation in Flow Rates with Temperature and 
Differences between Average and Column Outlet Flow 
Rates 
Q., e Q•, Q• Q,,, 
(50 °C/° (50 °Cl ° (250 'Cl' (250 °C)a (50 °C)' (20 °C)I 
0.649 22.0 0.47 16.0 0.74 0.79 
0.812 27.6 0.59 20.0 0.96 1.02 
0.982 33.3 0.71 24.1 1.20 1.28 
'Flow rates as quoted in ref 1, equal to average flow rate at the 
initial column temperature, 50 °C. °Average velocity at initial 
column temperature. 'Average flow rate at the final temperature, 
250 °C. °Average velocity at the final temperature. 'Column 
outlet flow rate at the initial temperature. 'Column outlet flow 
rate at 20 °C necessary to approximately reproduce the described 
flow rates. Units for Q„ are mL/min, for mL atm/min, for 
average velocity (0) cm/s. 
ducing the "average flow rate". While there is argument in 
favor of this method, or of quoting average linear velocity, 
when column efficiency calculations are used (3, 4), the method 
employed should be clearly stated. To many chromatogra-
phers "flow rate", when not further defined, means the flow 
rate at the column outlet that can be measured with a soap-
bubble flow meter or similar device. Since the pressure in this 
context is constant, and usually atmospheric pressure, column 
outlet flow rate incorporates a pressure term, as flow rate also 
does in a strict physical sense. The units for average flow rate 
and column outlet flow rate are often both quoted as "mL/ 
min", which strictly only applies to the former. Column outlet 
flow rate can be set experimentally to the appropriate value 
when installing a capillary column, while average flow rate 
cannot be used directly in this sense. Grob et al. (5), in their 
article on standardized quality tests for capillary columns, and 
on TZ numbers in particular, make no reference to flow rates 
as such but report the retention time of an unretarded com-
ponent, enabling calculation of average velocity, average flow 
rate, or column outlet flow rate as required. Average flow rate 
is defined as 
Qend 	Qev  	 (2) 3(P,2 - 1) 
where P, is the inlet pressure in atmospheres. 
Thus, for the column quoted (12 m x 0.25 mm), the ap-
propriate conversion can be made if P i is known. The 
"column-head pressures" quoted (1) of 60, 70, and 80 kPa 
above atmospheric pressure, respectively, are in fact upstream 
of a trap and therefore are considerably higher than the actual 
column inlet pressure. P i can be calculated from a rear-
rangement of Poiseuille's equation 
(P13 - P.3) 	3r2 
(P12 _ p02)2 — 32,2LE, 
where 13,, is the column outlet pressure, r the radius, 17 the 
viscosity of the carrier gas, and 0 the average linear gas ve-
locity. This can be solved by iteration for P, after determining 
D from Q55/A. For the 0.649 mL/min average flow rate, 0 = 
22 cm/s and Pi (total inlet pressure) is found to be 129.3 kPa, 
or some 28 kPa above atmospheric pressure. Prom eq 2, Q.,, d 
if found to be 0.74 mL atm/min at 50°C. Table I summarizes 
the actual flow rates (Q..) at the initial and final column 
temperatures and gives the corresponding Q values at the 
Q„. = (AL)/ t 	 (1) 
where A is the cross-sectional area of the column, L is the 
length, and t is the retention time of an unretarded compo-
nent. To obtain the flow rate at the column outlet at at-
mospheric pressure (Q.d), rearranging from Zlatkis et al. (3) 
2(Pi 3 - 1) 
(3) 
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initial temperature, as well as the (tend at 20 °C which will 
approximate the required Q, values when the column reaches 
the initial analytical temperature of 50°C. Average velocities 
at both the initial and final temperatures for the three flow 
rates quoted are also included. 
While in this case the difference between Qv and Qend is 
not substantial, for longer columns or higher flow rates where 
higher inlet pressure is employed, the difference can easily 
reach a factor of 2 or more, making it important that the type 
of flow rate is fully defined. The quoting of flow rates to three 
decimal places enables the average velocity and "dead time" 
to be calculated precisely where these are not given in the text, 
but it is unlikely that the actual column volume is known with 
this precision. A variation of only 1 pm between the quoted 
diameter of 0.25 mm and the actual effective diameter will 
make a difference of almost 1% in the average flow rate. 
The conclusions reached by Jones et al. of flow rates of 
about 1 mL/min of helium (Q.a  of 1.2 mL/min) and 2.5 
deg/min program rate as being a general optimum are in 
agreement with our observations. It is somewhat misleading 
to refer to these as "high flow rates", however, particularly  
when they represent initial values that fall by 28% during the 
run. For the test column the initial average velocity corre-
sponding to a 1 mL/min average flow rate is 34 cm/s, falling 
to 25 cm/s at 250 °C, which is within the range that might 
be expected from van Deemter plots at various isothermal 
temperatures. 
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SUMMARY 
The effects of the type of gas chromatograph—mass spectrometer interface and 
the type of flow regulation on flow-rate requirements for optimum efficiency for both 
isothermal and temperature programmed analyses on capillary columns are exam-
ined. Equations and figures are presented which enable rapid selection of optimum 
parameters such as inlet pressure, average velocity and flow-rate for various situa-
tions. 
INTRODUCTION 
The flow-rate of carrier gas is an important parameter in obtaining the max-
imum separation efficiency in capillary gas chromatographic (GC) analyses. Column 
efficiency is generally measured in terms of either the number of effective theoretical 
plates or the Trenzzahl, number, a measure of the degree of separation 'of a pair of - 
homologues' ,2 . A general review of gas flow in GC was presented by Guiochon 3 , 
and aspects relating to programmed temperature GC were discussed by Harris and 
Habgood4 . 
While the measured flow-rate at the column outlet can be used as a guide when _ 
installing capillary columns, the average carrier gas velocity is the parameter more 
directly related to column performance. For operation with atmospheric outlet pres- • 
sure, such as is the case in most capillary GC, the optimum'average velocity is rel-
atively constant for different column lengths and internal diameters, depending prin-
cipally on the type of carrier gas used. For columns between 0.2 and 0.5 mm I.D., 
typical quoted values are 25-30 cm/sec for helium and 45-50 cm/sec for hydro-
gen 2 .' ,9 . 
Jennings and Adam' discussed the effects of the rate of temperature program-
ming and carrier gas velocity on the speed of analysis and separation efficiency in 
capillary gas chromatography. Jones et al. 8 discussed an approach to optimizing 
performance in temperature programmed analyses in terms of both flow-rate and 
program rate. This article, however, did not note the direct relationship between 
column temperature and flow-rate that comes as a consequence of the type of flow 
regulation employed 9 . 
0021-9673/85/S03.30 	© 1985 Elsevier Science Publishers B.V. 
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Sellier and Guiochon" discussed the influence of the type of gas 
chromatography—mass spectrometry (GC—MS) coupling on column performance. 
Due to a limited pumping capacity they were not able to operate at the optimum 
flow-rate when using direct coupling, and this combined with the use of a very long 
capillary column led them to erroneously infer that column efficiency at a given 
average velocity was not affected by the column outlet pressure. Hatch and Parrish° 
subsequently showed that significantly higher average velocities were required when 
using direct coupling with its associated zero effective outlet pressure, and Cramers 
et al.' in a detailed analysis proved that it is the volume flow-rate that needs to 
remain the same for a given column to maintain optimum efficiency with variations 
in outlet pressure. 
The following discussion reviews the effects on flow-rate requirements of the 
three principal forms of capillary GC—MS interface: direct coupling, open split and 
capillary leak. Equations and figures are presented enabling rapid determination of 
parameters such as optimum average velocity, dead time, flow-rate and inlet pressure 
for various situations. The effects on actual flow-rates of changes in column temper-
ature with the two principal forms of flow regulation are examined in conjunction 
with the type of GC—MS interface employed. 
EFFECT OF INTERFACE TYPE 
Direct coupling 
Cramers et al.' showed that column length and diameter had a very significant 
effect on the optimum average velocity when using directly coupled columns. Direct 
coupling in this context refers to situations in which the column is inserted right into 
the ion source, as well as when it is connected via a section of relatively high con-
ductance tubing such that the column outlet pressure is still effectively zero. They 
showed that the optimum flow-rate from atmospheric outlet pressure studies can be 
used directly with vacuum outlet pressure to obtain the optimum efficiency. Optimum 
flow-rate for a particular temperature can be found from the following expression: 
mc14 (P? — Pa') 
Q = 	  256/L 	 (1) 
using the optimum value for P i = Pj,opt,alM, which in turn can be found from an 
iterative solution to Poiseuille's equation": 
_ 11 ) 2 _ 128„Lv 
(P? _ n) 
using 	= f'opt.atm. Fig. I shows the result of this calculation for different column 
lengths for hydrogen (using 17opt.atm = 50 cm/sec) and helium (using 17opt,atrn = 25 
cm/sec) for three different diameter columns at 20°C. Where Qv, is known, the flow- 
rate for directly coupled columns can be simply measured using the expression": 
64irti.L 3 
Q 	 (3) 
(2) 
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The conversion factor for ml atm/min to S.I. units of m 3 Pa/sec is 1.6885 • 10. 
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Fig. I. Optimum flow-rates in ml/min at atmospheric pressure against column length for the internal 
column diameters and carrier gases indicated at 20°C. Dotted regions represent column lengths that will 
require sub-atmospheric inlet pressure when direct coupling is used. Values of 25 cm/sec for helium and 
50 cm/sec for hydrogen as being the optimum average velocities with atmospheric outlet pressure operation 
have been used as the basis for calculations. 
or alternatively, simply predict the optimum dead time, 'a = ta.opt,vac from the rear- 
rangement of eqn. 3: 
25 	20 
	
25 	30 	35 	40 	45 	50 	55 	63 
L (m) 
Fig. 2. Column inlet pressures required with atmospheric outlet pressure to generate the optimum flow-
rates at 20°C in Fig. 1 for the lengths, internal diameters and carrier gases indicated. 
The average velocity required with directly coupled columns is related to the 
optimum average velocity at atmospheric outlet pressure by the expressions: 
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' 	
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m 
t at — ntrn)  
'opt,vac = 17opt.atm • P 	(5) 
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Figs. 3-5 illustrate the various parameters relating specifically to directly 
coupled columns versus column length for 3 different diameters and hydrogen and 
helium carrier gases at 20°C. Figs. 1 and 2 were obtained from eqns. 1 and 2 using 
ten different values for column length and constructing a curve of best fit. Fig. 4 was 
obtained from eqn. 5 for the same points, and Fig. 5 was obtained from t a = Lif. 
Fig. 3 was obtained from a rearrangement of eqn. 1, substituting P0 = 0 and Q = 
QOpl: 
(6) 
30 	35 
L (m) 
Fig. 3. Column inlet pressures required with vacuum outlet pressure (direct coupling) to generate the 
optimum flow-rates at 20°C in Fig. 1 for the lengths, internal diameters and carrier gases indicated. Dotted 
regions represent column lengths that will require sub-atmospheric inlet pressure. 
150 
O. 4mm, H2 
0.3nm, H2 
0.2m, H2 
_ 0.4mm, He 
0.3m., He 
0.2ee, He 
4C, 
20 
10 	15 	20 	25 	30 	35 	4.0 	45 	50 	55 	53 
L (m) 
Fig. 4. Average carrier gas velocities required with vacuum outlet pressure (direct coupling) to generate 
the optimum flow-rates at 20°C in Fig. 1 for the lengths, diameters and carrier gases indicated. Dotted 
regions represent column lengths that will require sub-atmospheric inlet pressure. . 
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Fig. 5. Dead time required with vacuum outlet pressure (direct coupling) to generate the optimum flow-
rates at 20°C in Fig. 1 for the lengths, internal diameters and carrier gases indicated. Dotted regions 
represent column lengths that will require sub-atmospheric inlet pressure. 
The dotted region in each figure represents the column lengths for which sub-
atmospheric inlet pressures would be required. Figs. 3-5 relate only to directly 
coupled columns with zero effective outlet pressure, while the dotted region in Fig. 
1 refers to directly coupled columns as well, although the values for Q„, are inde-
pendent of the type of interface. While sub-atmospheric inlet pressures can be 
achieved readily enough, this naturally precludes the use of inlet splitting for injec-
tion. Column lengths and diameters can thus be quickly chosen by refering to the 
figures such that this situation does not arise. 
Open split 
In this interface, the pressure at the column outlet is maintained near 1 at-
mosphere, and hence the optimum average velocity will not differ from the values 
quoted for atmospheric outlet pressure. 
Capillary leak 
A third common type of interface incorporates a length of fine capillary tubing 
or other form of constriction between the end of the column and the mass spectrom-
eter. This provides a substantial pressure drop so that a column is not exposed di-
rectly to the vacuum of the mass spectrometer, and yet all the sample is delivered to 
the ion source. This will result in atmospheric pressure at the column outlet for a 
specific flow-rate for each carrier gas, such that no change from normal atmospheric 
outlet operation is required. Even over the relatively wide range of flow-rates required 
to accommodate short, narrow bore columns up to long, wide bore columns, such 
as 0.5 to 3.0 ml atm/min for helium (Fig. 1), the difference in column outlet pressure 
remains less than a factor of 2 and the theoretical increase required in average velocity 
to maintain flow-rates is less than 30%. 
For example an interface constructed of a I2-cm length of 0.1 mm internal 
diameter fused-silica tubing results in approximately 1 atmosphere outlet pressure 
when the optimum flow-rate (based on c,o,„,„,„, = 25 cm/sec) of 2.5 ml atm/min of 
r 
Si 
161; 
V) 
> ILL — 
4— 	a. .- 
20 
10 
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helium is used for a 60 m x 0.4 mm column. A 20 m x 0.2 mm column with the 
optimum flow-rate of 0.7 ml atm/min of helium results in a calculated outlet pressure 
of around 400 Torr when used with same interface. The required inlet pressure can 
be found from eqn. 6, and from eqn. 2 the average velocity will need to be 31 cm/sec. 
This is an increase of only 25% over the atmospheric outlet pressure value, and 
almost within the normal quoted range. 
Generally the differences in column outlet pressure in these cases can be ig-
nored, and the normal atmospheric outlet pressure optimum average velocities can 
be used with little or no observable change in separation efficiency. 
To calculate the length of a piece of capillary necessary to give atmospheric 
outlet pressure when constructing a capillary leak interface the following expression 
can be used: 
nd4Patm 2 
L = 	 
256tiQop , 
where L and d are the length and diameter of the interface tubing. 
EFFECT OF TEMPERATURE PROGRAMMING 
The following discussion points out the various changes that occur in flow-
rates and average velocities as a consequence of changing column temperature after 
a flow-rate has been set with either constant pressure drop or "flow control". The 
influence that the type of GC—MS interface has on these changes is examined. 
The theoretical optimum average velocity, f o,„ increases slightly as tempera-
ture rises, due to the dependence, in the Van Deemter equation, of Popi on the dif-
fusion coefficient in the gas, and to some extent, liquid phases 3 . For the purposes of 
this discussion fop, is not considered as varying with temperature, and also any 
changes in the column dimensions with increased temperature are ignored. 
Isobaric pressure control 
"Isobaric" refers to those systems in which the inlet pressure is set to a fixed 
value and hence a constant pressure drop is maintained throughout a temperature 
programmed analysis' 2 . In these cases, the average carrier gas velocity and flow-rate 
at the column outlet, Q, will fall such that a value at a higher temperature will be 
related to a value at a lower temperature by the factor ?i 1 k/ 2 , where n, and ri 2 are 
carrier gas viscosities at the lower and higher temperatures respectively. This follows 
directly from Poiseuille's equation for average carrier gas velocity: 
(p? 	/1)23d2 
V = 
(P? — n) 1280. (8) 
and from eqn. 1 describing flow-rate. This effect is illustrated in Fig. 6a. The flow-
rate that would be measured at room temperature outside the column oven must be 
adjusted for the temperature difference: 
(7) 
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ni 
gend = 	Q ?72 T2  
(9) 
where Q 1 is the flow-rate at the temperature corresponding to ni , and Q end is the 
measured flow-rate at room temperature corresponding to a column temperature T2 
with a carrier gas viscosity ri 2 . 
Fig. 6b shows the effect of column temperature on 0 relative to the value 
at 20°C. 
With isobaric pressure control, there is no difference in the relative effects of 
direct coupling or open split interfaces, and the column length, diameter, flow-rate 
and carrier gas also have no effect on these relationships. 
22 
20 l b 
60 	100 	140 	152 	322 	260 	300 	342 	350 
Temperature 1 ° C 
Fig. 6. Effects of temperature programming on various parameters after flow-rate has been set for different 
flow control and GC-MS interface combinations. The vertical axis shows the values as a percentage of 
any initial value at 20°C. (a) Q,Q., and f, with isobaric pressure control and any interface. (b) Q,„d with 
isobaric pressure control and any interface. (c) Q,„ d with mass flow control and any interface. (d) Q with 
mass flow control and any interface. (e) Q.  and C with mass flow control and direct coupling. 
For example a 25 m x 0.2 mm column programmed from 20°C to 200°C with 
an initial average velocity of 25 cm/sec using helium has Q = 0 = 0.73 ml atm/min ..—end • 
at 20°C from eqns. 1 and 2. The average flow-rate, as defined by the ratio of column 
volume to dead time is 0.47 ml/min. At 200°C the average velocity will be: 
(1.941 • 10 -5 ) 
— 	  • 25 cm/sec 
(2.672 • 10 -5 ) 
= 18.2 cm/sec 
Q = 0.53 ml atm/min, Qend  = (293/473) • 0.53 = 0.33 ml atm/min, Q., = 0.34 
ml/min. 
Flow controller 
When flow-rate is regulated by a flow controller, a constant rate is maintained 
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through the controller regardless of any changes downstream such as in temperature 
or by installing a different column (Fig. 6c). However, the parameter that remains 
constant is Q e „d . and hence changes to the actual flow-rate through the column occur 
whenever there is a change in temperature 3 . The flow-rate through the column will 
be: 
Tc 
Q = 	Qend 
Tr 
(10) 
Thus in the example above the 0.73 ml atm/min becomes 1.00 ml atm/min at 200°C. 
Fig. 6d illustrates the effect on Q of changing column temperature with a flow con-
troller in the line. 
More relevant to the column performance, however, is the average velocity or 
average flow-rate. This effect will depend on the type of interface employed. 
Atmospheric outlet pressure (open split, capillary leak interfaces). Average 
flow-rate, Q av, can be found from Q from the following expression' 3 : 
Qa, = Q 
 
   
3(P? — PO) Po 
= Q 2(/) — /1) 
At a flow-rate Q i at room temperature with P i = P 1 , the average flow-rate Q„ v ,, will 
be 
3(Pi — PLm)Pat. 
Qai — 
2(Pi — PLO 
At a column temperature T, the flow-rate will be Q2 = Q i • Tell', with an inlet 
pressure P2 when a flow controller exists in the line. The new average flow-rate 0 
is now 
= Qi Tr 	2(P3 — 
and the ratio is therefore 
Qav.2 = Te(P3 — PLO (Pi — PLO 
Qav, 	Tr(Pi — PLO (Pi — PLO 
P 1 and P2 can be calculated from eqn. 6 using the appropriate values for flow-rate 
and viscosity. Taking the example of the 25 m x 0.2 mm column using helium as 
3(11 — Lm) P mm 
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the carrier gas, programming from 20°C to 200°C with an initial average velocity of 
25 cm/sec, corresponding to an initial flow-rate of 0.73 ml atm/min, from eqn. 6, P 1 
= 1514 Torr, and P2 at 200°C = 3319 Torr. From eqn. 12 
Qa, 2 	473 = 	 • 0.769 
Q.,.1 	293 
= 1.24 
The factor increase in average velocity will be the same as this, since i = Qa„I A . The 
percentage increases thus clearly depends on the actual flow-rate, the column length 
and column diameter, as P i is related to all these. The lower the initial inlet pressure, 
the larger the percentage increase in average velocity with increasing temperature. 
Fig. 7 shows the percentage increase in fi and Qa , with temperature for several 
situations relative to an initial value at 20°C. These are all much larger increases than 
the theoretical increase in fop , with increasing temperature. 
60 	103 	143 	180 	220 	260 
	
330 	340 	38: , 
Temperature 1 ° C) 
Fig. 7. Effects of temperature programming on Q„ and i after flow-rate has been set with a mass flow 
controller and with atmospheric outlet pressure. The vertical axis shows the values as a percentage of the 
specific initial values at 20°C for the columns indicated. (a) 50 m x 0.2 mm with hydrogen as carrier gas, 
initial = 50 cm/sec, initial Q., = 0.94 ml/min. Q.„ a = 2.0 ml atm/min. (b) 25 m x 0.2 mm with 
hydrogen as carrier gas, initial = 50 cm/sec, initial Q., = 0.94 ml/min, Q d = 1.4 ml atm/min. (c) 25 
m x 0.3 mm with hydrogen as carrier gas, initial i = 50 cm/sec, initial Q., = 2.12 ml/min. Qend = 2.5 
ml atm/min. (d) 25 m x 0.5 mm with helium as carrier gas. initial C = 30 cm/sec, initial Q. = 3.53 
ml/min, Q,„d = 4.0 ml atm/min. 
Vacuum outlet pressure (direct coupling). As P0 approaches zero in eqns. 11 
and 12, the increase in average flow-rate can be seen to approach 
Q.v.' 	11)2 
TcP1 	 (13) 
However, this ratio can be found more simply without the use of inlet pressure terms. 
Since I,- = Lila , substituting this and K = 647rL/9 in eqn. 3 gives 
Q i = Kthq 
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and 
Q2 = 
where 	and 172 are the average velocities corresponding to Q, and Qz, 
Since Q2 = Q1 TcITr 
= Q'  
respectively. 
(  Q 1 74 
.101 2 Tr) 
Hence 
fi 2 	(1 I/ 7.4 
171 	/12 Tr) 
(14) 
In the example from above, a 25 m x 0.2 mm column programmed from 20°C to 
200°C with helium directly coupled to a mass spectrometer will have an increase in 
velocity of 
(1.941 • 10 -5 • 473) 1 
= 1.083 
Pi 	2.672 • 10 -5 293 
This figure is again independent of flow-rate, column length, diameter and carrier 
gas. Fig. 6e illustrates the percentage increase in average velocity and average flow-
rate when using directly coupled columns and a flow controller. It can be seen that 
only slight increases are encountered in this situation. 
It should be noted that the changes in flow-rates with column temperature 
described represent the equilibrium state. This is approximated by relatively slow 
program rates, but at faster program rates the changes will be somewhat less than 
those specified due to the time taken for equilibrium to be reached. 
EFFECTS OF HIGHER ISOTHERMAL TEMPERATURES 
Figs. 1-5 presented optimum values of various parameters that correspond to 
flow-rates at 20°C that yield average velocities of 25 cm/sec and 50 cm/sec, respec-
tively for helium and hydrogen with atmospheric outlet pressure. Higher temperature 
operation will change all these to some extent, with the degree of change depending 
on column length, diameter and carrier gas. Fig. 8 illustrates the changes for the 
specific example of a 25 m x 0.2 mm internal diameter column with helium as carrier 
gas. Higher values of Q will be necessary to maintain the same average velocities 
(Fig. 8a), which requires higher inlet pressures (Fig. 8b). The optimum flow-rate 
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Temperature rc) 
Fig. 8. Effects of increased isothermal temperature operation on optimum parameters for the specific case 
of a 25 m x 0.2 mm internal diameter column with helium as carrier gas. 25 cm/sec was used as the 
optimum average velocity for all temperatures with atmospheric outlet pressure. The vertical axis shows 
the values as a percentage of the specific initial values at 20°C. (a) 	initial value 0.73 ml atmlmin: (b) 
Pi.opt.alm. initial value 1515 Torr: (c) Q.d.",. initial value 0.73 ml atm/min: (d) 	V.c. initial value 33.7 
cm/sec: (e) 	initial value 74.2 sec: (0 Q,nd set at 20°C and isobaric pressure control to give the 
optimum flow-rate at higher temperature. initial value 0.73 ml atm/min. 
measured at room temperature (e.g. via a calibrated vacuum gauge) will fall (Fig. 
8c). The optimum average velocity and dead time with vacuum outlet pressure will 
be the least affected (Fig. 8d and e). Fig. 8f illustrates the necessary increase in 0 end 
where this is set at room temperature with isobaric pressure control prior to estab-
lishing the column temperature. 
PRACTICAL CONSIDERATIONS 
The reduction in flow-rate and average velocity with rising temperature and 
isobaric flow control is a well known phenomenon. This can generally be compen-
sated for in practice by setting flow-rates such that the optimum average velocity is 
achieved near the middle of the temperature range. i.e. set initial average velocity to 
opi (q m/qs) where qm and II, are the carrier gas viscosities at the middle and start of 
the temperature range, respectively. This then maintains the flow-rate closer to the 
optimum value at all times. 
With flow control and vacuum outlet pressure, average velocity is maintained 
very close to the starting value. Where flow control is used with atmospheric outlet 
pressure operation, significant increases in average velocity can occur with increases 
in temperature, particularly where wider bore columns are used. 
From Fig. 7d, a 25 m x 0.5 mm column with an initial average velocity of 30 
cm/sec at 20°C with atmospheric outlet pressure results in 50 cm/sec at 300°C. In 
these cases close to optimum average velocities would be maintained again if the 
middle of the temperature range was chosen to set flow-rates. In the above example, 
30 cm/sec is required at 160°C. From eqn. 2, Pi =- 942 Tom from eqn. 1 Q = 3.97 
ml atm/min; Qend = 2.68 ml atm/min. Since a flow controller is employed, the latter 
is the value that will remain constant throughout the run. Since Q at 20°C is 2.68 ml 
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atm/min, from eqn. 6 P i at this temperature is 859 Torr, and the average velocity at 
20°C will be, from eqn. 8, 21 cm/sec. A similar method yields an average velocity at 
300°C of 43 cm/sec. 
It can be seen from the above discussion the potential for significant discrep-
ancy between actual and optimum flow-rates at higher temperatures during temper-
ature programming unless the correct compromise flow-rate is set. 
While average velocity can be determined and set accurately by the measure-
ment of dead times, this can be time consuming where they are of the order of two 
or three minutes. The simplest method of assuring close to optimum flow-rates in 
capillary GC-MS systems which incorporate a backing pressure gauge is to calibrate 
the gauge against actual flow-rates at room temperature (in directly coupled systems 
eqn. 3 enables this to be simply done). The gauge is a measure of 0 and so actual 
flow-rates at the column temperature can be found by multiplying by Tc1Tr . Calcu- 
TABLE I 
FLOW-RATES CORRESPONDING TO AVERAGE VELOCITIES 25 cm/sec (FOR HELIUM) AND 
50 cm/sec (FOR HYDROGEN). RESPECTIVELY. WITH AN OUTLET PRESSURE OF 
I atm FOR THE COLUMNS AND TEMPERATURES INDICATED 
The optimum flow-rate values are independent of the type of interface used. A calibrated vacuum gauge 
should correspond approximately to Q,„ d ,op , at the midpoint of a temperature programmed analysis. With 
mass flow control this will be the value of Q,„d for the whole analysis. while with isobaric pressure control 
the value of Q end in the last column (i.e. set to this value with the column at room temperature) will result 
in the appropriate Q,nd..,,, at the desired temperature. 
Cohan,' Carrier gas Temperature Qom Qend.opi Qend.20°C 
( S C) (ml atrultnin) (nil aim/min) (nil atm/min) 
25m x 0.2 mm H2 100 1.50 1.18 1.76 
H 2 200 1.61 1.00 2.22 
H2 300 1.72 0.88 2.71 
He 100 0.78 0.62 0.92 
He 200 0.84 0.52 1.16 
He 300 0.91 0.46 1.43 
25 m x 0.3 ITIM H2 100 2.59 2.03 3.05 
H2 200 2.67 1.66 3.69 
H2 300 2.77 1.43 4.37 
He 100 1.35 1.06 1.59 
He 200 1.40 0.87 1.93 
He 300 1.46 .0.75 2.30 
50 m x 0.2 MM H2 100 2.17 1.70 2.55 
H2 200 2.42 1.50 3.33 
H2 300 2.68 1.37 4.23 
He 100 1.13 0.88 1.33 
He 200 1.27 0.79 1.74 
He 300 1.41 0.72 2.23 
50 m x 0.3 !MT H2 100 3.21 2.52 3.77 
H2 200 3.43 2.12 4.73 
H2 300 3.65 1.87 5.76 
He 100 1.67 1.31 1.96 
He 200 1.80 1.12 2.48 
He 300 1.92 0.98 3.03 
• 
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lation of Q.„„ at the midpoint of a temperature program, and hence 0 ,_end,opt, enables 
flow-rates to be set correctly by the use of the backing pressure gauge. In the case of 
isobaric pressure control, the value of Q end  with the column at room temperature 
that will yield the appropriate 0 at the midpoint of the temperature program 
is the relevant parameter when installing a column. 
Table I summarizes some typical values of 0 z_optt Qend.opt and Q en d set at 20°C 
with isobaric pressure control to yield the optimum flow-rate at the specified tem-
peratures. 
SYMBOLS 
P i 
Po 
r a 
ta.opt,vac 
Qopt 
'opt vac 
opt.atm 
Pi.opt.atm 
Pi.opt,vac 
Patm 
Tr 
Qend 
A 
Qav 
Qend,opt 
"opt 
flow-rate measured at atmospheric pressure and column temperature 
internal column diameter 
column inlet pressure 
column outlet pressure 
carrier gas viscosity 
column length 
average carrier gas velocity 
dead time, the retention time of an unretarded peak 
optimum value of t a with zero outlet pressure 
optimum value of Q 
optimum value of with zero outlet pressure 
optimum value of with atmospheric outlet pressure 
optimum value of P i with atmospheric outlet pressure 
optimum value of P i with zero outlet pressure 
atmospheric pressure 
room temperature in Kelvin 
column temperature in Kelvin 
flow-rate measured at atmospheric pressure and room temperature 
internal cross-sectional area of the column 
average flow-rate (= ALIta ) 
optimum value of 0 0d 
optimum value of i
e 
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Note 
Open split interfaces in capillary gas chromatography—mass spectrom-
etry 
Yield and quantitative aspects 
N. W. DAVIES 
Central Science Laboratory. University of Tasmania, P.O. Bo.v 252C. Hobart, Tasmania 7001 (Australia) 
(First received December 14th. 1987: revised manucript received June 9th, 1988) 
One of the most common methods of coupling capillary gas chromatography 
(GC) columns to mass spectrometers is the open split interface first described by 
Henneberg et al. 1 . These devices usually employ a capillary restrictor tube which 
governs the amount of gas allowed into the mass spectrometer, with provision for 
venting any excess gas to atmosphere or a second detector. There is also usually 
provision for one or two "make-up - or "purge" gas lines to supplement column flow 
where necessary, to sweep dead volumes within the interface and to enable "cutting" of 
large GC peaks away from the mass spectrometer to avoid contamination'. Under 
these conditions the column exit is at atmospheric pressure and hence combined 
GC—mass spectrometry (MS) results can be directly compared with those from normal 
GC, since no change in retention times or resolution will have occurred for the same 
flow-rates. These interfaces also facilitate the rapid exchange of columns as the mass 
spectrometer is not directly exposed to atmospheric pressure, and enable columns 
requiring relatively high flow-rates to be used in conjunction with mass spectrometers 
of limited pumping capacity. 
However, there are two related potential problems when open split interfaces are 
used in conjunction with isobaric pressure control of the GC column flow-rate and 
temperature programming, a combination found on several commercial instruments. 
The first is that if the interface is independently heated at a constant temperature. the 
"yield", defined as the proportion of any given compound that enters the mass 
spectrometer, depends on the elution temperature of the compound. This is evident 
since while the total flow-rate through the column will fall substantially as column 
temperature rises', the flow to the mass spectrometer will be fixed. As a consequence of 
this, it is possible for there to be insufficient gas at higher column temperatures if 
flow-rates are not established at the maximum operating column temperature, or 
appropriate allowances are not made. This results in an influx of air into the interface, 
which will be potentialy damaging to both the interface and the mass spectrometer. 
Quantitative work based on standard curves of the analytes is not affected by the 
variation in yield provided the same temperature profile is used for-standards and 
samples. Direct quantitative or semiquantitative comparisons of different peaks 
0021-9673/88503.50 	0 1988 Elsevier Science Publishers WV. 
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within a temperature programmed analysis will however require appropriate correc-
tion factors to be applied. Direct semiquantitative analysis of different compounds in 
a mixture by comparison of total ion currents is of course complicated by the different 
ionization cross sections of each compound. Nevertheless compounds in a homol-
ogous series such as alkanes will have a total ion current proportional to the total 
weight of sample and independent of the molecular weight of the individual species'. 
Useful semiquantitative data are then available from the mass spectrometer provided 
corrections for interface yield are made. If total ion current is indirectly determined by 
software from the summation of electron multiplier response for all ions in a given 
compound, then the dependence of the multiplier gain on ion size and structure further 
complicates direct comparisons. Notwithstanding the complications of total ion 
current, quantitative comparisons can be readily made using another detector 
monitoring the flow from the open split vent after appropriate corrections. 
Operation in this mode also means that the yield to the mass spectrometer can 
only be maximized at the high temperature end of the analysis, causing losses in 
sensitivity by up to a factor of three for the earlier eluting components. 
The following discussion presents the appropriate correction factors required to 
compensate for change in yield, and describes different methods for obtaining constant 
and maximum yield from an open split interface. 
EXPERIMENTAL 
The experimental results were obtained on an HP 5890A gas chromatograph 
with a 25 m x 0.32 mm I.D. fused-silica column installed, coupled loan HP 5970 mass 
selective detector with an open split interface. The interface was held at 270°C and the 
initial oven temperature (7' a) was 27'C. Flow-rates were measured at room tem-
perature with a 1-ml soap bubble flow meter (Alltech) after the GC oven had 
equilibrated at the individual temperatures, with the average of three separate 
measurements being used in each case. The column flow-rate was measured only at 
27°C (i.e. Fa), and the split vent flow-rate (Fsa and Fsb) at all indicated temperatures. Fm 
was determined from the difference between Fa and Fsa with no purge gas. Fp was 
determined from the difference between values of Fsa with the purge on and purge off. 
RESULTS AND DISCUSSION 
The schematic diagram shown in Fig. I illustrates an open split interface of the 
configuration described, with the flows used in the expressions below indicated. All 
flow-rates discussed are measured after equilibration with room temperature, so that 
the flux of gas can be compared fordifferent temperatures. Ignoring the very minor 
changes in column dimensions with increased temperature, the flow-rate Fb through 
the column at some elution temperature Tb (in Kelvin) will be': 
qaTaFa 
b — 
b Tb 
( 1 ) 
where Fa is the original flow-rate at some temperature Ta , as measured after 
equilibration to room temperature, and qa and b are the gas viscosities at Ta and Tb 
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Fb (TzT b ) 
Fig. I. Schematic diagram illustrating an independently heated open split interface with flows indicated. 
respectively. The change in yield can be calculated from the following general case. 
If the flow-rate going to the mass spectrometer is defined as Fin and the purge gas 
flow-rate is Fp , the initial percentage yield at Ta is 
Ya Fp + Fa 
At temperature Tb the percentage yield becomes: 
Yb = 
Fp + 	 
100F,, 
qa Ta Fa 
rib Tb 
Carrier gas viscosities can be calculated to within I °A) for the normal temperature range 
of gas chromatography from the following relationship derived from empirical date: 
= kr' • 10-7 kg m"-- ' 
where T is the temperature in Kelvin and k is 3.60 for helium, 1.63 for hydrogen and 
3.29 for nitrogen. Substitution in eqn. 3 gives: 
Yb = Fp + Fa(TalT0 1.7 
The ratio of the yields at Tb and T., which is the correction factor that integration 
results at each value of elution temperature Tb will have to be divided by for 
quantitative comparisons, is therefore: 
1 00 Fa, (2) 
(3) 
100Fn, (4) 
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Yb/Y. = Fp + Fa(Ta lTb ) 1. ' 
With no purge gas this reduces to: 
Yb/ Ya = ( Tb/ Ta)1 • 
As an illustration of the above effects, a change in temperature from 100 to 300°C 
results in slightly more than a doubling of the yield if no purge gas is employed. The 
same temperature change results in a 35% relative increase in yield when half the initial 
flow is from the purge line. The larger the proportion that the purge gas is of the total, 
the smaller the increase in yield. 
Naturally if quantitative comparisons are made using a second detector 
monitoring the flow from the open split vent the correction will be opposite in 
direction. The ratio will be: 
Ysbl Y 3  = 
100 — Yb 
100 — Y a 
where )7, b and Ysa are the percentage of total flow going to the split vent at 
temperatures Tb and Ta respectively. Substitution of eqns. 2 and 4 and simplifying 
based on the fact that Fp + Fa = Fsa Fm where Fsa is the split vent flow-rate at oven 
temperature Ta , results in: 
(Fp + Fa )[Fa(TalTb) 1 • 7 + Fs, — Fa ] 
Ysb/ Ysa = 	Fsa [Fp 	Fa(TalTb) 1 7 ] 
(7) 
Integration results for each elution temperature Th will need to be divided by this value 
for direct quantitative comparisons on a second detector. 
Arithmetical yields of more than 100% in eqn. 4 correspond to an influx of air 
into the mass spectrometer. This situation is reached when 
Fp + (Ta/Tb) 1 • 7 Fa < Fr,, 	 (8) 
Fig. 2 shows the comparison of calculated and experimental values for the yield ratios 
Yb/ Ya and /1st,/ Ysa for the examples listed. The discrepancy between experimental and 
calculated data ranged from —2.5 to + 3.0% of the calculated yield ratio. During 
relatively rapid temperature programming the column may not be at equilibrium with 
the GC oven. Under these conditions there may be a somewhat greater discrepancy 
from calculated data than indicated here. 
The yield will remain constant throughout a temperature programmed analysis 
only if the carrier gas is controlled by a mass flow controller, or if the interface is heated 
at the same rate as the GC column. The former method results in significant increases 
in average carrier gas velocity with increasing temperature', but would be suitable in 
many cases where it is desirable to maintain a constant and maximum yield. The latter 
method can be achieved either by independently heating the interface at the same rate 
Fp + Fa (5) 
(6) 
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Fig. 2. Calculated data (0 — — — 0) and experimental data ( x — — — x) for yield ratios from an open split 
interface held at constant temperature during temperature programming of the GC oven, with isobaric 
control of flow-rates. (a) Ybi Y. no purge gas, all values of Y. For experimental points F, = 2.88 ml min, Y. 
= 18.4%. (b) Yb/ Y. Fp = 1.30 ml/min, F = 2.83 ml/min. Y. = 12.4%. (c) Y. same conditions as for 
(b), Y, = 87.6%. (d) )10,11,.. no purge gas, same conditions as for (a), Y, = 81.6%. 
as the GC oven, or by incorporating the interface in the GC oven. The yield will be 
maintaned at a constant value in the absence of purge gas since both the column and 
restrictor flows will be reduced by the same factor. Provided that any purge gas added 
is also isobarically controlled original yields will still be maintained across a tem-
perature range. If only the purge gas is controlled by a mass flow controller there will 
be a decrease in yield with rising temperature. 
Incorporating the interface in the GC oven is the simpler alternative, but 
increases the dead volume of the system and goes against the normal practice of placing 
the interface as close as possible to the mass spectrometer. However, since the dead 
volume is all on the high vacuum side it is rapidly swept out and should not result in any 
detectable broadening due to diffusion. A piece of deactivated fused-silica or 
glass-lined tubing (50 cm in length) as the final connection to the mass spectrometer 
will take less than 0.2 s to sweep out with a flow of 1.5 ml/min of helium'. 
A second advantage of incorporating the interface in the GC oven is that it can 
be removed simply and rapidly, allowing the option of direct coupling if required. 
A disadvantage of having the open split interface remote from the mass 
spectrometer could be in the transfer of relatively involatile compounds, such as those 
boiling above about 500°C. The best results for these appear to be when the column or 
the restrictor tube go directly into the ion source' l . This is despite the fact that vapour 
pressure in equilibrium with a glass wall is higher than that with a liquid phase, and 
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hence interface temperatures can in theory be lower than the column temperatue 2 . The 
"Joule-Thompson" cooling effect upon expansion of gas from the restrictor tube does 
not explain this provided either helium or hydrogen are used as carrier gases, since 
both have a negative Joule-Thompson coefficient resulting in heating of the gas upon 
expansion. 
The combination of type of flow control and method of interface heating 
therefore depends on the analytical requirements. If maximum yield is not essential 
and quantitative comparisons are not important, or the appropriate correction factors 
are applied, then isobaric pressure control of column flow and an open split interface 
that is held at constant temperature in association with temperature programmed 
analyses presents no problems. If it is desired to yield almost 100% of the GC effluent 
to the mass spectrometer over a wide temperature range, or to maintain a constant 
yield of effluent to the mass spectrometer, then the method of flow control or the 
method of heating the interface is relevant when an open split interface is employed. 
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ABSTRACT 
A novel analytical screening procedure has been developed, using computer-controlled gas chromato-
graphy-mass spectrometry (GC-MS), to detect 120 drugs of interest to road safety. This paper describes 
GC-MS methodology suitable for use on extracts of biological origin, while extraction procedures will be 
the subject of a future communication. The method was devised . to identify drugs in extracts of blood 
samples, as part of an investigation into the involvement of drugs, other than alcohol, in road accidents. 
The method could be adapted to screen for other substances. The method depends on a "macro - program 
which was written to automate the search of GC-MS data for target drugs. The strategy used was to 
initially search for each drug in the database by monitoring for a single characteristic ion at the expected 
retention time. If a peak is found in this first mass chromatogram, a peak for a second characteristic ion is 
sought within 0.02 min of the first and, if found, the ratio of peak areas calculated. Probable drug identifi-
cation is based on the simultaneous appearance of peaks for both characteristic ions at the expected 
retention time and in the correct ratio. If the ratio is outside acceptable limits, a suspected drug (requiring 
further investigation) is reported. The search macro can use either full mass spectra or, for enhanced 
sensitivity, data from selected ion monitoring (which requires switching between groups of ions during data 
acquisition). Quantitative data can be obtained in the usual way by the addition of internal standards. 
INTRODUCTION 
While the relationship between alcohol and road accidents has been well docu-
mented, little is known of the contribution of other drugs to road safety. A major 
difficulty has been the need to analyse a large number of blood samples, taken 
from road users involved in accidents, for the presence of drugs which could 
impair driving performance. A great variety of chemically dissimilar substances 
are used as medicines and social drugs and have the capacity to impair driving 
performance and the potential, therefore, to contribute to road accidents. This 
presents a considerable analytical challenge, which has been managed in previous 
studies by restricting the analytical screen to a relatively small number of drugs 
which are considered most likely to be involved in road accidents. Even so, bat-
teries of analytical methods (radioimmunoassay, thin-layer chromatography, gas 
0378-4347/91503.50 	C) 1991 Elsevier Science Publishers B.V. 
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chromatography, high-performance liquid chromatography) have been used to 
screen for drugs in blood samples taken in road accident studies [1-4]. as in many 
toxicological screens. These methods are often time-consuming and generally 
lack specificity, although drug findings can be confirmed by subsequent gas chro-
matography—mass spectrometry (GC—MS) [1.4]. 
Since many drugs contain nitrogen, GC with nitrogen—phosphorus detection 
(GC—NPD) can be used for initial screening [5], an approach taken in some 
previous road accident studies [6-8] and in other drug screening procedures [9— 
11]. GC—NPD provides a single analytical procedure which is sufficiently sensitive 
and selective to detect a large number of drugs. However, as drug detection is 
based only on retention time, searching complex chromatograms is laborious, 
and possible drug findings need to be confirmed by an additional analysis, such as 
GC—MS. Another problem, which we found in a previous study [8], was that even 
GC—NPD chromatograms of extracts of blood samples contained large numbers 
of extraneous peaks which eluted close to the retention times of drugs: these all 
required subsequent analysis by GC—MS although most proved negative. In addi-
tion, important non-nitrogenous drugs, especially tetrahydrocannabinol and its 
metabolites and anti-inflammatory agents, cannot be detected by NPD. 
This report describes a GC—MS method of screening for 120 drugs of possible 
concern to road safety. Compared with previous methods, it has better specificity 
and sensitivity, and is faster in searching for the targeted drugs. In cases where the 
identification of a drug is critical, such as in forensic work and in analysis by 
selected ion monitoring (SIM), it may be necessary to confirm the drug finding by 
appropriate re-analysis to increase the number of ions used. Sample extraction 
procedures have not been investigated in this study, which instead focuses on the 
problem of the efficient identification of drugs in complex chromatograms, where 
there are many possible drugs present. The biomedical application of this method 
will be the subject of a separate paper. 
EXPERIMENTAL 
Materials 
Water was purified by the Millipore-Q decontamination system (Millipore, 
Sydney, Australia). Organic solvent were HPLC grade (Waters Assoc., Division 
of Millipore, Sydney, Australia) except chloroform (nanograde, Mallinckrodt, 
Melbourne, Australia). Al! were found to be free from contaminants by GC 
analysis of a thousand-fold concentrated sample. Glassware was washed using 
Extran 300 detergent (BDH Chemicals, Melbourne, Australia), followed by a 
Milli-Q water wash and a methanol wash. After drying, all glassware was rinsed 
in dichloromethane prior to use. A list of drugs of interest to road safety was 
prepared, based on the drugs reported most frequently in road accident studies in 
Australia and other commonly used drugs with the potential to impair driving 
performance. Most reference drug standards were obtained from pharmaceutical 
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companies (see Acknowledgements). Benzoylecognine, 3,4-methylenedioxymeth-
ylamphetamine (MDMA) and 9-carboxy-11-nor-4 9 -tetrahydrocannabinol were 
obtained from Alltech Assoc. (Deerfield. IL, U.S.A.) and tetrahydrocannabinol 
(THC) was a gift of the Research Triangle Institute (Research Triangle Park, NC, 
U.S.A.). n-Decane and n-triacontane were obtained from Sigma (St. Louis, MO, 
U.S.A.). Other chemicals were of analytical reagent grade. 
Equipment 
Samples for GC analysis (usually 1 ml) were placed in 1.5-ml crimp-top glass 
autosampler vials (Sun Brokers, Wilmington, NC, U.S.A.). Small volumes (less 
than 200 pl) were contained in smaller conical glass inserts (Microsun Insert, Sun 
Brokers). GC—MS analysis was performed on a Hewlett-Packard 5890 gas chro-
matograph and 5970 series mass-selective detector (Hewlett-Packard Australia, 
Melbourne, Australia). Automated injections were made with a Hewlett-Packard 
7673A autosampler. Programming and data processing were carried out using a 
Hewlett-Packard 59970A workstation and Version 3.1.1 Pascal software. The 
injector was fitted with a wide-bore (4 mm) quartz liner, which contained a small 
plug of quartz wool in the centre. Free drugs and methylated derivatives were 
analysed on a 22 m x 0.32 mm I.D. fused-silica capillary column, coated with 
0.52-pm cross-linked 5% phenyl methyl silicone gum (HP-5, Hewlett-Packard). 
Samples which had been treated with N-methyl-bis(trifluoroacetamide) 
(MBTFA; Pierce, Rockford, IL, U.S.A.) as a derivatising agent caused a loss of 
column performance when underivatised samples were analysed. Therefore, a 
separate column was used exclusively for analysis of samples treated with trifluo-
roacetylating reagent: this was a 12 m x 0.32 mm I.D. fused-silica column coated 
with 0.25-pm SE-30 gum (Econo-Cap, Alltech Assoc.). Each column was protect-
ed by a 20 cm length of the same type of column which was fitted as a pre-column, 
and changed when there was evidence of column activation. Separate analyses 
were performed for underivatised, methylated and trifluoroacetylated drugs. This 
reduced the total number of ions being monitored each time to a manageable size, 
as well as being consistent with conventional extraction procedures. 
The following GC—MS conditions were used: injector temperature, 260°C; 
open-split interface temperature, 290°C; oven program, 40°C for 1 min, then 
increasing at 10°C/min to 290°C; carrier gas, helium, column head pressure, 105 
kPa (22-m column) or 70 kPa (12-m column); column flow-rate at 40°C, 2.5 
ml/min; sample size, 5p1; split ratio, 10:1. 
Reference samples 
To obtain reference GC and MS data, drug solutions (concentration 100 ng/ 
pl) were prepared in chloroform and 1 ml was placed in a crimp-top autosampler 
vial. Hydrocarbon standards in chloroform (decane, 54 pg in 50 pl; triacontane, 
26 pg in 100 pl) were added to the 1-ml sample to enable standardisation of GC 
retention times. Drugs which were obtained as salts were first dissolved in water 
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(1-2 me in 1 ml), then the pH of the solution was adjusted with either 2 ml of 0.05 
Al sodium borate, pH 9.2 (for basic drugs) or 1 ml of 15% hydrochloric acid, pH 
3 (for acidic drugs). The free drug was extracied with 1 ml of a mixture of dichlo-
romethane—hexane—ethyl acetate (6:3:1) by vortex-mixing for 5 min and, after 
separation by centrifugation, the organic phase was transferred to a sample vial 
and concentrated to about 50 pl under nitrogen, then made to 1 ml with chloro-
form. An aliquot (usually 100 pl) was placed in a GC vial and made to 1 ml with 
chloroform, giving a final concentration of about 100 ng/pl. Drug solutions were 
stored at 4°C until analysed. 
Derivatisation 
Trifluoroacetyl derivatives were made of drugs with free hydroxyl, primary or 
secondary amino groups. This improved their chromatographic properties and 
enabled better resolution of peaks. The 1-ml drug solution in chloroform in the 
GC autosampler vial was concentrated to about 20 pl. 50 pl of MBTFA (Pierce) 
were added, and the vial was heated at 60°C for 30 min. Care was taken to keep 
the solvent dry and free from protic solvents to prevent cleavage of the trifluoro-
acetate derivatives. Then the sample was concentrated to about 20 pl under nitro-
gen and made to 1 ml with chloroform. Acidic drugs were similarly methylated 
with freshly prepared ethereal diazomethane (200 pl), except that the reaction was 
carried out at room temperature. 
Extracts from tissue 
Forensic samples were obtained from the Government Analyst (Hobart, Aus-
tralia) as extracts of blood, urine or liver (TOXI-LAB Analytical Systems, Kan-
sas City, MO, U.S.A.). This is similar to the extraction method described for 
reference samples. Extracts of biological samples were concentrated to 20-50 pl 
and placed in the small-volume inserts in the autosampler vials before GC—MS 
analysis. Blank plasma samples were similarly extracted to check on extraneous 
peaks and possible false positives. 
GC—MS analysis 
Database. Mass spectra and retention times of drugs were generated from the 
reference drug samples, which were analysed either individually or in simple mix-
tures. The "standard" retention times for decane (TC I 0 = 6.06 min) and triacon-
tane (TC30 = 27.65 min) were chosen arbitrarily from an initial GC—MS run. 
Retention times from subsequent GC—MS analyses of reference drugs were cor-
rected (TD, Table I), where necessary, by a transformation of the retention times 
of the two hydrocarbons to the standard times. 
GC—MS. Full mass spectra were acquired by scanning over the mass range m/z 
500 to 40 approximately once per second. For maximum sensitivity in analysing 
unknown samples, however, SIM is required. Because only twenty ions could be 
monitored at one time while there were 120 drugs to be searched for, the follow- 
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TABLE 1 
GC-MS DATA USED BY THE MACRO TO SCREEN FOR EACH DRUG 
Compound' Retention time 
TD (min) 
ION l b 
(ni/z) 
ION2 
(m1.-_-) 
Peak ratio 
(I ON1/10N2) 
Free drugs 
Benzaldehyde (d)° 5.42 105.05 77.05 1:1 
C!0 6.07 71.05 - - 
Valproic acid 8.15 73.10 102.05 2:1 
Amphetamine 8.17 91.05 65.05 2:1 
Methylamphetamine 9.08 58.05 91.05 15:1 
Tranylcypromine 9.58 132.10 115.05 5:3 
Ethosuximide 9.88 55.05 113.05 1:1 
Ephedrine 12.12 58.05 77.05 10:1 
MDMA 14.00 58.05 135.05 20:1 
Clofibrate 14.25 128.00 169.05 5:1 
Metronidazole 15.55 81.05 124.05 5:4 
Tolbutamide (d) 15.61 91.05 171.00 5:2 
Carbimazole 15.79 186.05 114.05 2:1 
Paracetamol 16.15 109.05 151.05 5:2 
Methyl phenidate 16.58 84.10 91.05 10:1 
Pethidine 16.82 177.10f 247.15 1:1 
Pheniramine 17.60 169.10 58.05 5:3 
Caffeine 17.70 194.10 109.05 7:5 
Alprenolol 17.78 72.10 249.15 20:1 
Ketamine 18.00 180.05 209.10 5:1 
Methylphenobarbitone 18.58 218.10 246.10 15:1 
Captopril 18.82 70.05 198.10 10:1 
Phenyltoloxamine 19.02 58.05 255.15 20:1 
Phenobarbitone 19.21 204.10 232.10 10:1 
Theophylline 19.23 180.05 95.00 2:1 
Fenoprofen 19.30 242.10 197.10 1:1 
Dexchlorpheniramine 19.68 203.05 58.05 1:1 
Clonidine 20.52 229.00 171.95 2:1 
Raniiidine 20.65 137.10 94.05 5:4 
Diphenylpyraline 20.70 99.05 114.10 2:1 
Diclofenac 20.90 214.05 242.05 5:4 
Dextromethorphan 21.03 59,05 271.20 1:1 
Methadone 21.10 72.10 294.20 50:1 
Dextropropoxyphene 21.24 58.05 208.10 5:1 
Procyclidine 21.41 84.10 204.15 20:1 
Amitriptyline 21.59 58.05 275.20 50:1 
Hyoscyamine 21.68 124.10 289.20 4:1 
Cocaine • 21.69 82.05 182.10 3:2 
Mianserin 21.72 193.10 264.15 5:4 
Procainamide 21.73 86.10 120.05 5:1 
Nortriptyline 21.81 44.00 202.10 10:1 
Trimipramine 21.82 58.05 249.15 5:1 
Imipramine 21.88 234.15 280.20 5:2 
(Continued on p. 212) 
149 
'11 
TABLE 1 (cominued) 
G. P. NEILL et al. 
Compound' Retention time 
TD (min) 
ION l b 
(ni;:) 
10N2 
(m1.7) 
Peak ratio 
(ION! 110N2) 
Doxepin 7 1.9 7 58.05 277.15 50:1 
Primidone 77 .00 190.10 146.05 5:4 
Desipramine 72.10 234.15 195.10 1:1 
Benzhexol 22.13 98.10 218.15 20:1 
Triprolidene 22.20 208.10 278.20 10:3 
Promethazine 7 7 .41 72.05 284.15 20:1 
Trimeprazine 77 .6 7 58.05 298.15 10:3 
Benztropine 22.81 83.05 140.10 5:4 
Carbamazepine 22.85 193.10 236.10 5:2 
Phenytoin 22.86 180.05 252.10 5:3 
Oxazepam 22.95 268.05 239.05 10:7 
Hyoscine 23.09 94.05 138.10 3:1 
Cyproheptadine 23.14 287.15 215.10 5:3 
Pizotifen 23.23 295.15 96.00 5:4 
Azatidine 23.36 246.15 290.20 6:5 
Dothiepin 23.39 . 58.05 202.10 50:1 
Codeine 7 3.45 299.15 162.10 2:1 
Sulphamethoxazole 23.64 92.05 253.05 10:1 
Dihydrocodeine 23.65 301.20 244.10 7:1 
Lorazepam 7 3.69 239.05 274.00 1:1 
Morphine 23.88 285.15 162.10 3:1 
Diazepam 23.89 256.10 283.05 I:I 
4 9 -THC 7 3.95 299.20 314.20 5:4 
Methdilazine 24.19 296.15 199.05 1:1 
Disopyramide 24.31 195.05 212.05 5:3 
Chlorpromazine 24.38 58.05 318.10 5:1 
Desmethyldiazepam 24.47 242.05 269.05 1:1 
Chlordiazepoxide 24.61 282.10 247.10 5:1 
Oxycodone 24.93 315.15 230.10 5:2 
Trimethoprim 25.00 290.15 259.10 5:2 
Chloroquine 25.11 86.10 319.20 10:1 
Haloperidol 25.29 224.10 237.10 5:4 
Flunitrazepam 7 5.4 7 285.10 312.10 1:1 
Metoclopramide 25.43 86.10 184.00 10:1 
Trifluoperazine 25.49 407.15 267.05 1:1 
Diamorphine 25.56 327.15 369.15 3:2 
Nifedipine 25.82 329.10 284.15 1:1 
Hydrochlorothiazide 25.94 268.95 228.00 4:1 
Temazepam 26.00 271.05 300.05 10:1 
Fentanyl 26.05 245.15 146.05 3:1 
Nitrazepam 26.70 280.05 253.10 5:4 
Sulindac 27.17 296.05 239.05 5:3 
Quinine 27.20 136.10 189.10 13:1 
Clonazepam 27.34 314.05 280.05 1:1 
C30 	. 27.65 71.05 
Clomiphene 27.82 86.10 405.20 50:1 
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Compound° Retention time 
TD (min) 
ION 1 10N2 
(nil:) 
Peak ratio 
(ION 1 /10N2) 
Dextromoramide 27.97 100.10 265.15 5:4 
Miconazole 28.23 159.00 334.95 5:1 
Diltiazem 28.26 58.05 121.10 20:1 
Prochlorperazine 28.38 373.15 272.05 3:1 
Thioridazine 29.95 98.10 378.15 10:3 
Verapamil 30.46 303.20 151.10 10:1 
Pholcodine 30.92 114.10 100.10 10:7 
Glibenclamide 35.17 169.05 287.10 5:1 
Methylated drugs 
Valproic acid 6.65 87.10 116.10 10:3 
Salicylic acid 9.98 120.05 92.05 10:7 
Allopurinol (I)g 11.39 164.05 80.05 1:1 
Ibuprofen 14.07 161.15 220.15 4:1 
Allopurinol (2)g 15.06 164.05 136.05 10:1 
Tolbutamide (d) 15.74 91.05 185.00 ", :l 
Captopril 16.86 70.05 231.10 10:1 
Captopril (Me,) 17.80 70.05 128.05 5:3 
Diflunisal 17.97 232.05 264.05 2:1 
Methylphenobarbitone 18.00 232.10 175.05 10:1 
Phenobarbitone (Me 2 ) 18.00 232.10 175.05 10:1 
Fenoprofen 18.36 197.10 256.10 5:4 
Phenobarbitone 18.58 218.10 246.10 20:1 
Naproxen 19.56 185.05 244.10 1 :1 
Chlorpropamide 19.73 111.00 175.00 1:1 
Mefenamic acid 20.43 223.10 255.15 10:9 
Tolbutamide (d) 20.51 91.05 155.00 5:4 
Ketoprofen 20.74 209.10 105.05 5:4 
Probenecid 21.16 270.10 135.05 5:3 
Diclofenac 21.55 214.05 242.05 2:1 
Benzoylecgonine 21.69 82.05 182.10 5:4 
Phenytoin 21.87 180.05 266.10 10:9 
Tolbutamide 22.09 91.05 129.00 10:9 
Nitrazepam 24.32 294.10 248.10 5:4 
Bendrofluazide (Me 2 ) 24.86 254.00 347.00 10:7 
Clonazepam 25.11 329.05 294.10 10:7 
Warfarin 25.14 279.10 322.10 5:1 
Bendrofluazide 25.31 240.00 333.00 2:1 
Enalaprilat 25.35 220.15 317.15 10:1 
Enalaprilat (Me,) 25.73 234.10 331.15 10:1 
Nitrazepam (Me,) 25.98 267.10 294.10 10:9 
Chlorothiazide (Me,) 26.47 323.95 245.00 3:2 
Clonazepam 26.67 328.05 294.10 1:1 
Frusemide (Me,) 27.13 81.05 358.05 5:2 
Chlorothiazide (Me 3 ) 27.13 308.95 337.00 5:4 
4 9 -THC acid metabolite 27.21 343.20 299.20 5:4 
Indomethacin 27.40 139.00 371.10 5:2 
(Continued on p. 214 ) 
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Compound" Retention time ION I" I0N2 Peak ratio 
TD (min) (n11.7) (ntj.:) (10N 1/10N2) 
Bumetanide (Me,) 28.54 392.15 349.10 1:1 
Bumetanide 29.23 3.18.10 378.15 1:1 
Sulindac 30.70 233.05 354.10 5:3 
Trifluoroacetylated drugs 
Amphetamine 7.54 140.05 118.05 5:4 
Methylamphetamine 8.93 154.05 110.05 7 :1 
Tranylcypromine 9.48 116.05 69.00 10:3 
Ephedrine 9.61 154.04 110.05 5:1 
Metronidazole 10.81 141.00 221.05 5:4 
Methoxyphenamine 11.00 154.05 148.05 2:1 
Paracetamol 11.04 108.00 205.05 5:3 
MDMA 12.97 154.10 289.10 5:3 
Alprenolol (TFA 2 ) 14.50 266.05 308.05 10:7 
Methylphenidate 14.65 180.05 150.05 10:1 
Hydralazine (TFA 2 or TFA,) 14.84 281.00 295.00 5:1 
Oxprenolol (TFA 2 ) 15.25 266.05 308.05 10:7 
Clonidine 15.50 290.05 199.00 5:1 
Hyoscyamine 16.20 124.10 271.20 5:2 
MetoProlol (TFA 2 ) 16.39 266.05 308.05 5:3 
Propranolol (TFA 2 ) 17.24 266.05 308.05 10:7 
t1 9-THC 17.41 410.20 339.10 1:1 
Hyoscine 17.52 94.05 399.15 5:1 
Morphine (TFA 2 ) 18.29 364.10 477.10 5:2 
Codeine 18.68 282.15 395.15 2:1 
Metoclopramide 19.42 86.10 280.00 15:1 
Nortriptyline 19.47 232.15 290.15 20:1 
Desipramine 19.78 208.10 362.10 10:3 
Dihydrocodeine 22.61 397.15 284.15 2:1 
Pholcodine 24.35 100.10 114.10 10:9 
Terfenadine (TFA, or TFA 2 ) 27.85 262.15 433.20 10:1 
o Abbreviations: MDMA = 3,4-Methylenedioxymethylamphetamine; z1 9-THC = 4 9-tetrahydrocannabi-
nol; J 9-THC acid metabolite = 9-carboxy-l1-nor-4 9 -tetrahydrocannabinol; Me 2 = dimethylated; Me, 
= trimethylated; TFA 2 = di(trifluoroacetylated); TFA, = tri(trifluoroacetylated). 
ION1 was the base peak. unless otherwise specified. 
• Benzaldehyde was a decomposition product of ephedrine. 
• (d) indicates a drug decomposition product. 
e Base peak of amphetamine was m/z 44. 
f Base peak of pethidine was m/z 71. 
° Different positional isomers. 
ing approach was taken. Two diagnostic ions (usually including the base peak) 
were chosen for each drug. An acquisition method file was created in which up to 
twenty ions were monitored during each of ten time periods (the maximum avail-
able with this instrument). Groups of ions were monitored during appropriate 
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A 
NAME DRUGS 
WRITELN 701, •10,410,410,410 
TAB HEADER, PRINTER 
WRITELN 701, •••• 	.44 
WFJTELN 701, •10,410,410,410 
CH 4E71 
GETS 
AX 
IF Y4.50000 
WRITELN701,•••••••••••••••••••••••• 	 •••••••••■•••••••••••••••••••••••••■••••••■•••• 
W MEL": 701, •C10 AREA VERY LAW, CHECK THAT IDENTITY IS CORRECT' 
WRITELN 701,•••••••••••••••*"••••••• 
WRITELN: 701, 410,010,410,010 
Es:DIF 
CH 2530,71 
GETS 
E6X 
IF Y4.50000 
W MEL,: 71:11, 	++. 	 
WRITELN 701, *C30 AREA VERY LOW, CHECK THAT IDENTITY IS CORRECT' 
WFUTELN 701, 
WRITELN 701, 010,010,410,410 
ENDIF 
TC10a).06 
TC30.271.5 
P=1 
(START OF REPEATING SECTION OF MACRO) 
TD=DRUCTIME 
TDCOR=4A+ICID-TC10)/ (TC30-TC10)) • (11-A)) 
CH TDCOR-02:1DCOR+02, ION1 
THRESH THRESH/ TDCOR-1 
INT 
THRESH THRESH; -CIDCOR-1) 
N=NPEAKS 
IF NPEAKS>0 
CH TDCOR-0.2: TDCOR+0/, IONS 
THRESH THRESH; TDCOR-1 
INT 
THRESH THRESH2, -(TDCOR-1) 
NB=NPEAKS 
IF INPEAKS>0 
Z=1 
WHILE N>0 
PE Z 
RO -1 
P1=PEAK_AREA 
RT=RET_TIME 
134 
Y=1 
M=NB 
WHILE Mal 
FEY 
RO -1 
IF RT-RET_TIME<0.02 
IF RTEET_TIME....,-0.02 
P2=PEAK_AREA 
ARATICP1/11 
IF ARATIO 4 MA XR ATI 0 
IF ARATIO > M I NRATIO 
WRITELN 701, 'PROBABLE DRUG NAM E FOUND' 
WRJTELN 701, •104)104010,410 
N4 
P-4 
ENDIF 
ENDIF 
IF P=1 
WR1TELN 701, •••••  
WRITELN 701, 'IONS FOR D RUC NAME FOUND, RATIO SUSPECT' 
WRITELN 701, •••••• 	• 
WRITELN 701, 1110,1110,410,410 
ENDIF 
MERGE 
CLEAR 3 
CLEAR Y 
CLEAR Z 
DR 3,X 
SCR 
WRIFELIN 701, 410,410 
IF P=2 
TAB RESULTS, PRINTER: 
WRITEIN 701,1110,410,410 
WRITELN 701, ••••••••••••••••••••••••••••••••• 	• 	 
WRITELN 701, 410510,410,010 
P=1 
ENDIF 
ENDIF 
Ma) 
ELSE 
Y=Y+1 
M=M-1 
ENDIF 
ENDWHILE 
Z=Z+1 
N=N-1 
EX 
END WHILE 
EsIDIF 
LNDIF 
....(END OF REPEATING SECTION OF MACRO) 
• QUIT 
C. 
Fig. I. (Continued on p. 216) 
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calculate corrected drug retention time. TDCOR 
generate IONI chromatogram (7DCOR 1.0.2 min) 
set threshold 
Integrate 
delete threshold 
NO 	are there any peaks? 
• YES 
generate I0N2 chromatogram (7DCOR 0.2 min) 
set threshold 
Integrate 
delete threshold 
• 
NO 
NO 
are there any peaks? 
recall first peak of ION1 chromatogram 
recall next peak of 	 store retention time and peak area 	 recall next peak of 
ION1 chromatogram-• recall first peak of I0N2 chromatogram 	ION2 chromatogram 
Is ION2 peak more 
than ION1 peak?  	 I YES 
 than 0.02 min 
Is ION2 peak more than 0.02 min 
later than ION1 peak? 
NO 
NO 
calculate ratio ION1/10N2 peak areas 
NO Is ratio < max allowed? 
  
are there more peaks 
In the I0N1 
chromatogram? 
YES 
YES 
NO are there more peaks 
In the I0N2 
chromatogram? 
NO 
print message: -IONS FOR 'DRUGNAME 4 
FOUND, RATIO SUSPECT' 
w print chromatograms  
YES 
Is ratio > min. allowed? 
YES 
print message: -PROBABLE 'DRUGNAME' FOUND" 
print ckiromatograms 
tabula( l peak areas 
	to. go to next drug 4 	 
Fig. 1. (A) Listing of the macro program used to search the GC—MS acquisition file for drugs in the data 
base. The section between the two markers is repeated for each drug with appropriate names and values for 
the following variables: DRUGTIME, the standard drug retention time, based on retention times of 6.06 
min for decane and 27.65 min for triacontane; IONI, the m/z value of the principal diagnostic ion: 
THRESH I, the integration threshold to use for ION 1; I0N2, the m/z value of the second diagnostic ion: 
THRESH2, the integration threshold to use for I0N2; MAXRATIO, the maximum allowable ratio for the 
peak areas of ION1/10N2; MINRATIO, the minimum allowable ratio for the peak areas of ION1/10N2: 
DRUGNAME, the name of the target drug. (B) Flow diagram of the repeating section of the macro 
program. 
time windows, based on the retention times of drugs of interest (Table I). This 
procedure enabled the maximum possible number of drugs to be included in the 
analytical screening procedure. Drugs which eluted close to the time When a 
different group of ions was monitored had to be included in both groups, to allow 
for changes in retention time. On the other hand, some ions were common to 
more than one drug, which improved efficiency (eleven drugs were monitored in 
one group). 
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Dwell time per ion was 30 ms. Masses of diagnostic ions were calculated to the 
nearest 0.05 mass units, based on ion structures. Where the empirical formula of 
the ion was not obvious, an estimate to the nearest 0.05 mass units was made. 
This level of accuracy was to enable interference from endogenous substances to 
be kept to a minimum, provided the maximum resolution of the mass spectrom-
eter was used. For example, halogenated ions from drug molecules could be 
partially resolved from ions derived from lipids which had the same nominal 
mass, because of the lower mass defect of the halogenated ions. 
Macro. Editing was automated by means of a "macro" built into the data 
editing portion of the sequencing software (Fig. IA and B). This operated by 
checking a small time window ( ± 0.2 min) about the expected retention time of 
each drug for the principal diagnostic ion (ION I) and then, if successful, for the 
second ion (10N2). The macro program calculated the expected retention time 
(TDCOR) for each drug in the individual GC run based on a correction for any 
change in the retention times of decane and triacontane from the standard times. 
If both the primary (ION 1) and secondary (10N2) ions for a drug were detected 
at the same time (within 0.02 min), the ratio of their peak areas (10N 1/10N2) was 
compared with the expected ratio. Generous limits were allowed, because of the 
possible variability in relative ion abundances and the potential for interference 
from other substances in biological samples which could produce interfering ions 
at the same retention time. Thus if the expected ratio was 2, the limits could be > 
1 to <4, although this must be decided for each drug and biological matrix 
depending on interferences. 
In those cases when more than one peak was detected at the mass of ION1 or 
ION2 within the defined 0.4-min time window about the expected drug retention 
time, the macro checked all peaks until either a drug was found or all possibilities 
had been examined. Thus the retention time of the first possible ION1 peak was 
noted and the ION2 channel examined for the occurrence of a peak within 0.02 
min of the retention time of the ION1 peak. If none was found, the next possible 
ION 1 peak was considered and the I0N2 channel again examined for a peak 
within 0.02 min of this second ION I peak. This process continued until either a 
suitable pair of peaks was found or all options were exhausted. Results were only 
reported if there was a probable drug finding. 
The macro consists principally of a repeating unit containing information on 
each drug: name, retention time, the two diagnostic ions with their thresholds for 
integration and the permissable range of ion ratios (Fig. IA and B). The software 
does not allow this to be written as a single subroutine in which variables are 
substituted. The full macro for a hundred or so drugs is therefore quite long (160 
KBytes), although each new drug can be readily added to it from a template of 
the repeating unit in which only the variables need to be changed. 
Separate SIM data acquisition methods and macros were created for un-
derivatised drugs, methylated drugs and trifluoroacetylated drugs. In practice, 
each biological sample would need to be split and subjected to three different 
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work-ups (for underivatised, methylated and trifluoroacetylated drugs), and 
these would then be analysed separately. 
RESULTS AND DISCUSSION 
The value of the macro is in the relatively rapid, automated searching of the 
acquisition file for a large number of possible drugs: while this can be done 
manually, it would be very time-consuming. The macro took about 5 s to check 
for each drug, provided that it found no peaks within the time window for the 
PROBABLE DIAZEPAM FOUND 
Fig. 2. (A) Portion of TIC chromatogram of an extract of a forensic blood sample. Arrow marks the 
position of diazepam peak, found in Fig. 2B. Inset: expansion of region from 23 to 25 min. CH is choles-
terol. (B) Text and mass chromatograms for diagnostic ions for diazepam generated by the macro from the 
full scan acquisition data in (A), as part of a report of a probable diazepam finding (see text for details). 
The macro also tabulated retention times and peak areas for all integrated peaks. * = subthreshold peaks 
(not integrated). 
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principal diagnostic ion. Complex chromatograms with peaks for both ions pres-
ent within the time window could take considerably longer. Automated editing 
time for biological samples could be up to 30 min per run, depending on the 
nature of the sample and the integration threshold levels used. 
Fig. 2 illustrates the use of the macro in searching a complex chromatogram 
for target drugs. Fig. 2A shows a portion of a total ion current (TIC) chroma-
togram obtained by GC—MS analysis of a basic (pH 9) TOXI-LAB solvent ex-
tract of a forensic blood sample. Diazepam was present, but at a level giving only 
a very small peak, even when that region of the chromatogram was expanded 
PROBABLE DIAZEPAM FOUND 
Fig. 3. (A) Portion of TIC chromatogram obtained by SIM re-analysis of the sample used in Fig. 2. The 
groups of ions monitored at different times are given in Table I. Arrow marks the position of diazepam 
peak, which is quite small even in SIM mode. (B) Text and mass fragmentograms generated by the macro 
from the SIM acquisition data in (A). Note that more accurate mass values were used for monitoring the 
diagnostic ions compared to full scan acquisition (Fig. 2B), and that there was less noise and smoother 
peak shapes. 
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(Fig. 2A insert). Fig. 2B shows the mass chromatograms generated by the macro 
from the full scan data in Fig. 2A. To search for diazepam, the macro first 
calculated the expected retention time of diazepam (TDCOR = 23.80 min in this 
run) by correcting for any changes in the retention times of CI 0 and C30, then 
examined the chromatogram of the first diagnostic ion for diazepam (ION1 = 
m/z 256) over the time interval within 0.2 min of TDCOR (i.e. 23.60-24.00 min). 
The first ION1 peak was below threshold, but the second (at 23.775 min) was not 
and this initiated a search in the 10N2 (m/z 283) chromatogram for a peak 
occurring within 0.02 min of 23.775 min. No match was found, the second ION I 
peak (23.839 min) was located, and this time paired with the I0N2 peak at 23.842 
min. The ratio of peak areas (ION I /10N2) was 1.39, within the set limits (0.5— 
2.0), and a report of a probable diazepam finding was printed, with the ION1 and 
ION2 chromatograms and a table of the areas of all integrated peaks. In this case, 
confirmation was obtained from a recognizable full spectrum of diazepam at the 
appropriate retention time, after careful background subtraction. 
Fig. 3 shows the results from analysis of the same sample by SIM mode GC—
MS. The TIC chromatogram (Fig. 3A) was produced by monitoring the ions 
listed in Table I for free drugs, sequentially in groups of up to twenty ions at a 
time. The diazepam peak was still quite small. Fig. 3B shows the mass frag-
mentograms generated by the macro as in Fig. 2B, except that in this case more 
accurate values for ION I (m/z 256.10) and I0N2 (m/z 283.05) were monitored 
during the SIM acquisition. Due to the inherently longer dwell times of SIM, and 
the more rapid sampling, there was less noise and smoother peak shapes than 
when the same nominal masses were acquired from full scans (Fig. 2B). 
False positive findings could often be rejected by visual inspection of the mass 
chromatograms, as illustrated in Fig. 4. The SIM chromatogram of a basic ex-
tract (TOXI-LAB) of liver (a forensic sample) shows peaks near the retention 
times of diazepam and nordiazepam (Fig. 4A), and these drug findings were 
confirmed by the macro report. A probable finding of haloperidol was also re-
ported by the macro, but inspection of the mass fragmentograms in Fig. 4C 
shows this to have been an error due to the threshold values having been set too 
low. The macro integrated an ION1 peak at 25.084 min and paired it with an 
I0N2 peak at 25.075 min (peak ratio 0.54, limits 0.5-2.0), but inspection of the 
chromatogram (Fig. 4C) shows that neither was a real peak (compare Fig. 4B). 
The only possible ION1 and I0N2 peaks in Fig. 4C did not occur within 0.02 min 
of each other and would not have led to a report of haloperidol. 
It was more important to avoid false negative findings, which would result in 
drugs being missed altogether, than false positives, which could be detected by 
examination of the macro report or an additional GC—MS analysis. Interferences 
in one or both ion channels could cause the ION 1 /ION2 ratio to be outside the 
set limits, and this was reported as "IONS FOR DRUGNAME FOUND, 
RATIO SUSPECT", indicating the need for further investigation. This could be 
readily done for drugs which chromatographed in both free and derivatised forms 
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Fig. 4. (A) Portion of a SIM chromatogram of a chloroform extract of liver found to contain diazepam (D) 
and nordiazepam (ND). H indicates the retention time of haloperidol (see C). (B) Text and mass frag-
mentograms generated by the macro from the SIM data in (A), showing the identification of probable 
nordiazepam. (C) Text and mass fragmentogram generated by the macro from the SIM data in (A), 
showing identification of probable haloperidol. Visual inspection shows this to have been an error, due to 
integration of noise caused by thresholds being set too low. See text for discussion. 
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(Table 1) by comparison with the macro report on the other analysis. Otherwise 
re-analysis was required, using specific acquisition methods to identify the partic-
ular drug. 
Drugs could also be undetected because of deterioration of the chromato-
graphic system, and this was avoided by routine monitoring of GC performance 
with a mixture of some of the drugs in the search database which were very 
sensitive to column activity (methylamphetamine, oxazepam and oxycodone). If 
peak shape indicated activity, the injection port accessories (quartz insert and 
quartz wool packing, septum and 0-ring) were changed. If necessary, a new 
precolumn was fitted. 
Some variability was found even in the corrected drug retention times. Note 
that the actual retention time of nordiazepam in Fig. 4B (24.42 min) was slightly 
later than the expected time (TDCOR = 24.35 min, at the centre of the mass 
chromatogram). The longer retention time was presumably due to the presence of 
biological molecules which modify the polarity of the liquid phase. This shows 
the need for the relatively wide limits (TDCOR ± 0.2 min) which were allowed 
on the search window used by the macro. For the same reason, drugs which 
eluted near the beginning or (more particularly) the end of a SIM ion group were 
also included in the adjacent group's acquisition file. 
Warnings were also given if the areas of either of the hydrocarbon peaks were 
low (Fig. 1). This was to avoid the possibility of the wrong peak being assigned as 
the reference hydrocarbon. In addition, a small C10 peak could indicate a general 
loss of volatile substances, perhaps during a concentration step. 
Caffeine was the only drug reported in blank plasma extracts since, although 
the SIM chromatogram contained many peaks (as in Fig. 3A), the other criteria 
in the macro prevented false drug identifications. The method has not yet been 
evaluated on plasma samples, but the simple solvent extraction procedure de-
scribed in Experimental was successfully tested on a group of eighteen drugs 
added to blank plasma. The drugs found in spiked plasma samples included 
amphetamines, opiates, benzodiazepines, an antihistamine (azatedine), A 9 - tetra-
hydrocannabinol and anticonvulsants. The concentrations added to plasma were 
relatively high (10 pg/ml) as the intention was to test the capacity of the macro to 
search complex chromatograms rather than the extraction procedure. Success in 
screening for drugs in biological samples is critically dependent on the efficiency 
of extraction procedures, and several methods have been described [1-12]. The 
signal-to-noise ratio is also of decisive importance in analysis of biological sam-
ples and becomes more of a problem with the low drug concentrations likely to be 
seen in practice. The measurement of low levels of drugs in biological samples 
may require changes to thresholds and even selection of different diagnostic ions, 
and this will be the subject of future work. 
We were unable to analyse some drugs by GC, even as derivatives. Important-
ly, these included some of the )6-blocking drugs: atenolol, labetalol, pindolol and 
timolol. However, alprenolol, metroprolol, oxprenolol and propranolol were 
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chromatographed as trifluoroacetyl derivatives (Table I). Leloux et al. [13] suc-
cessfully analysed fl-blockers by GC with on-column injection after double deriv-
atisation (trimethylsilylation and trifluoroacetylation), but this was not used in 
our study. 
This method was developed to provide a preliminary screen to detect drugs 
which could contribute to road accidents, using extracts of plasma suitable for 
GC analysis. In many cases the evidence of two diagnostic ions, in the correct 
ratio and occurring at the expected retention time of the drug, would be sufficient 
evidence for drug identification. Positive drug findings can be confirmed, when 
necessary, by additional analyses with specific acquisition methods designed to 
identify the particular drug. In SIM mode, up to twenty ions can be monitored 
per drug. The macro could be written to use a larger number of co-eluting charac-
teristic ions for fewer target substances, which would increase certainty of identi-
fications. 
The Hewlett-Packard GC—MSD system is a widely used instrument, and the 
screening method described here could be readily adopted by other MSD users. It 
was not practical to use the quantitative report software supplied with the MSD 
for drug screening, because it gives full reports on peaks not found. This results in 
a very lengthy report when screening for over a hundred drugs. The method 
described in this article only reports on drug findings and is suitable for screening 
when most samples contain few, if any, of the target drugs. The macro could be 
applied to screening for other substances, such as metabolites used in clinical 
diagnosis [14,15], anabolic steroids and other doping agents [16,17] and possibly 
for pesticides or environmental pollutants. 
Copies of the macro containing data on the drugs listed in Table I are available 
from the authors. 
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Direct Quantitative Determinations by Multiple 
Metastable Peak Monitoring 
1—Warfarin in Plasma 
Noel W. Davies,t John C. Bignall and Michael S. Roberts 
Central Science Laboratory and School of Pharmacy. University of Tasmania. PO Box 252C, Hobart, Tasmania, Australia 
A technique for the direct quantitathe determination of plasma warfarin concentrations has been developed 
using multiple metastable peak monitoring on a double focusing mass spectrometer of normal geometry. The 
method uses a direct insertion probe and requires no sample purification or derh atization. Deuterated warfarin 
was added as an internal standard, and the first field free region metastable fragmentations for the loss of an 
acetyl radical from the molecular ion of both warfarin and internal standard were monitored. These independent 
daughter ions were focused by a simple combination of linking the magnetic and electric sectors, accelerating 
voltage switching and selected ion monitoring using standard instrumentation. Results were acquired and 
processed by normal selected ion monitoring software. Repeated determinations of plasma warfarin concentra-
tions were made with plasma extracts representing approximately 4 p1 of plasma, each sample taking two 
minutes to process by this technique. 
INTRODUCTION 
The anticoagulant drug warfarin (1) is used in the clinical 
management of thromboembolic disorders. Techniques 
such as spectrophotometry,' thin-layer chromatography 
(TLC), 2 high-performance liquid chromatography 
(HPLC), 3 gas chromatography 4 and gas chromatogra-
phy chemical ionization (Cl) mass spectrometry 5 have 
been used for the quantitative determination of warfarin. 
The therapeutic effect of warfarin and other coumarin 
anticoagulants is usually monitored from prothrombin 
times. 6 However, plasma warfarin assays are occasion-
ally required to check patient compliance to therapy, to 
quantify covert anticoagulant ingestion, to monitor war-
farin resistance and to study warfarin drug interactions. 6 
This paper reports the rapid and direct assay of war-
farin from plasma extracts by the technique of multiple 
metastable peak monitoring. This involves the monitor-
ing of specific metastable ion fragmentations in the first 
field free region of a normal geometry double focusing 
mass spectrometer, and is analogous to the monitoring 
of specific reactions in the second field free region of a 
reversed geometry instrument by the mass-analysed ion 
kinetic energy technique.' The focusing of first field free 
region metastable peaks for individual monitoring is 
normally achieved using accelerating voltage (V) adjust-
ments, or the linked sector scan in which the ratio of 
magnetic field (B) to electric sector voltage (E) is held 
constant. 8 This technique has been applied to the 
determination of hormones and drugs in body fluids, in 
conjunction with gas chromatography, to provide better 
specificity over normal selected ion monitoring. 9-11 In 
these cases the internal standard undergoes the same 
reaction as the compound being determined, and is 
separated by gas chromatography. One report discusses 
the application of selected metastable peak monitoring 
t Author to whom correspondence should be addressed.  
to determinations directly from crude matrices, using a 
narrow sweep of metastable ions for better specificity 
as the sample contained chlorine, but without the use 
of an internal standard." To quantify compounds by 
direct insertion with the use of an internal standard, it 
is clearly necessary to monitor more than one reaction. 
Different daughters from the same precursor can be 
readily focused by the B/E scan, but this does not allow 
much scope for the selection of internal standards. If 
deuterated internal standards are to be used, daughters 
from different precursors must be focused. This can be 
done by altering both B and E to appropriate values. 
and an instrumental modification to achieve this has 
been described.' 3 This involves the use of a commercial 
linked scan unit and a 'metastable ratio amplifier' allow-
ing the alternate selection of two B/E ratios, thus allow-
ing sample and internal standard constant parent ion 
scans to be focused, respectively. Switching B to the 
appropriate value with the respective B/E ratio selected 
thus allows focusing of parents and first field-free region 
daughter ions from both the sample and internal stan-
dard. Another way in which independent reaction prod-
ucts can be focused is by combining a single B/E ratio 
and magnetic field switching with small accelerating 
voltage adjustments to change the precursors," and this 
is the technique described in this paper. This involved 
no modifications to a standard commercial instrument. 
The number of independent reactions that can be 
monitored by this method depends on the number of 
channels in the selected ion monitoring mode and the 
number of preset accelerating voltage positions 
available. 
Thus, while single or multiple metastable peak 
monitoring may be used in conjunction with gas 
chromatography or HPLC to provide a higher degree 
of specificity, multiple metastable peak monitoring may 
also be used with varying degrees of sample purification 
to the direct probe determination of compounds in mix-
tures. In this example no purification was required, and 
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MULTIPLE METASTABLE PEAK MONITORING 
this factor coupled with the absence of any chromato-
graphic system enabled very rapid determinations. The 
multiple metastable peak mode can be selected and 
calibrated rapidly, making it well suited to an assay that 
is only infrequently required. 
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Instrumentation 
The instrument used was a Vacuum Generators 70/70F 
double focusing mass spectrometer, fitted with a multiple 
ion detection (MID) unit or a digital scan controller, a 
linked scan unit, three independent manually set 
accelerating voltage positions and a mode selection 
switch. The instrument was coupled to a Vacuum Gen-
erators 2235 Datasystem with selected ion recording 
software. No modifications to this standard instrumenta-
tion were required. The system was operated with the 
linked scan unit and selected ion facility (whether MID 
or digital scan controller) both switched in. The ion 
source was maintained at 180-220 °C, and was operated 
at 70 eV in the electron impact mode with a trap current 
of 200 p.A. Accelerating voltage was nominally 4 kV for 
main beam ions, and was adjusted to appropriate values 
for desired precursors by reference to a four figure digital 
panel meter. The electric sector voltage was adjusted to 
transmit main beam ions at 4 kV accelerating voltage. 
Resolution was set to 1000 with 50% transmission on 
the slit preceding the electric sector. The datasystem 
was used to control magnetic field switching, and thus 
switched electric sector voltage as this was coupled via 
the linked scan unit. 
Metastable peaks 
The reaction chosen for monitoring was the loss of an 
acetyl radical from the molecular ion of warfarin i.e. 
m/z 308-* m/z 265. which from the full B/E scan was 
shown to produce the strongest daughter ion. m/z 265 
is also the base peak in the normal electron impact (El) 
mass spectrum of warfarin (see Fig. 1). In the case of 
the internal standard (2) this becomes m/z 313-p 
m/z 267, as two of the deuterium atoms remain after 
the loss of the acetyl group. 
Setting up 
The ion at rn/z 314 in the mass spectrum of the standard 
reference compound perfluorotributylamine was used 
for initial determination of the B/E ratio, removing the 
need for the introduction of warfarin. This ion was 
selected with magnetic field controls, at a nominal 
150 
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250 
m/r 
Figure 1. (a) Normal 70 eV electron impact mass spectrum of war-
farin. (b) B/E Linked scan of warfarin from the molecular ion at 
m/z 308. The mass scale shows actual m/z values rather than 
apparent m/z values. The molecular ion is off scale, and is thirteen 
times the height of the first field free region m/z 265 daughter ion. 
accelerating voltage of 4 kV (V1), and this magnetic 
field was then linked to the electric sector voltage so 
that when B was scanned the B/E ratio remained con-
stant. This created a constant parent ion scan from 
m/z 314, transmitting only daughter ions formed in the 
first field free region. Using two of the independent 
potentiometers and switch positions on the accelerating 
voltage control unit, voltages V2= (308/314) x VI = 
0.981 VI and V3= (313/314) x VI °°0.997V1 were 
accurately selected. This has the effect of bringing to 
focus at these positions the constant parent ion scans 
from m/z 308 and m/ z 313, respectively, without the 
need to change the B/E ratio. The daughter ions formed 
at these voltages are nevertheless on the mass scale as 
initially determined by the selection of m/z 314. Hence 
these daughters follow the equation m* = daughter 
mass 2/parent mass where m * is the apparent m/z value 
of the daughter ions and parent mass is 314." Thus the 
two channels requested were 265 2/314 = 223.6 and 
267 2/314 = 227.0. On the 70/70F in the linked scan 
mode the mass marker shows the actual mass of the 
daughter ions, so that these requested channels resulted 
in indicated values of 265 and 267, respectively. Two 
extra channels, at apparent m/z values 225.0 and 229.0 
were also included to allow time for the accelerating 
voltage to be switched to the appropriate constant parent 
scan position. Dwell time per channel was 500 ms, which 
gave sufficient time to switch between the two preset 
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voltages in synchronization with the B/E switching to 
the genuine daughter channels. Although this may sound 
daunting, it was relatively simple as switching was 
required only every second. and the 500 ms dwell time 
in the extra channels meant that no great precision in 
timing was necessary. Clearly the automatic switching 
of the accelerating voltage in synchronization with the 
B/E switching would simplify the technique. 
In this way the distillation off the direct insertion 
probe of compounds undergoing the unimolecular meta-
stable fragmentations m/z 308 -■ m/z 265 and 
m/z 313 -■ m/z 267 could be monitored, and sub-
sequently quantified by measurement of area of the ion 
current against time. The total time required for this 
setting-up procedure was approximately 5 min. Small 
quantities of both warfarin and internal standard were 
introduced prior to the acquisition of data to ensure the 
accurate centering of the respective channels. 
Internal standard 
The internal standard (2) was prepared by a previously 
described method,' using 50 mg warfarin sodium salt 
and 5 ml 2 H 20. The product had an isotopic composi-
tion, as determined by direct insertion at an ion source 
temperature of 180°C and corrected for ' 3C isotope 
effects, of 0.4% 2 H 1 , 0.6% 2H 2 , 4.6% 2 H 3 , 22.6% 2H4, 
53.9% 2 E1 5 (2) and 17.9% 2H 6 (3). A 2 p.gp.1 -1 solution 
of the mixed isotope product in acetonitrile was prepared 
and stored at —20 °C. The isotopic composition of this 
solution was checked before each use to guard against 
back exchange. 
The ion source temperature was maintained at a con-
stant level throughout the acquisition of data from the 
samples and standard curve solutions, to ensure constant 
isotopic composition of the internal standard.' 
In general, the number of deuterium atoms that should 
be present in the daughter ion to be monitored depends 
on the mass of the compound, the energy resolution of 
the instrument and the number of deuterium atoms in 
the parent compound. Thus for the Vacuum Generators 
70/70F around mass 300 at least two deuteriums should 
remain in the daughter if the parent contains two or 
three deuteriums. This avoids interference from the 13C 
sample daughter ion, which may be partially transmitted 
even when parents with two or three deuteriums atoms 
are requested for the reasons outlined below. For inter-
nal standards with four or more deuterium atoms, it 
should be possible to monitor daughters with only one 
deuterium. 
Additional peaks 
The 2H4 product in the mixed isotopes will also con-
tribute to some extent to the daughter at m/z 267, due 
to the relatively poor precursor resolution of the tech-
nique. The energy discrimination of the B/E scan results 
in the complete resolution of daughters of adjacent mass, 
but some ambiguity of assignment of precursors to 
daughters exists. This arises since daughters from adja-
cent precursors will be partially transmitted due to the 
energy spread of the daughter ions.' ' A consequence of 
the energy spread of the main beam is the inclusion of 
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adjacent main beam peaks, as shown in Fig. 1(b) where 
m/z 307 and 309 are present in the spectrum. Instru-
ments with higher energy resolution will have propor-
tionally fewer of these main beam and first field free 
region additional peaks, and those transmitted will be 
of smaller relative intensity. 
Sample preparation 
Plasma samples (1 ml) from patients on regular but 
different warfarin regimes were acidified to pH 3.0 with 
INI HCI. Internal standard solution (1 lir) was added 
and the plasma was extracted with 250 u.lof chloroform. 
This was then centrifuged if necessary to separate the 
two phases. Aliquots (1 ill) of this extract were loaded 
onto the direct insertion probe for the monitoring of 
the two first field free region daughter ions. 
Standard curve 
To 1 ml aliquots of blank plasma, 0.5, 1, 2, 3 and 5 u.g 
amounts of warfarin in acetone were added. Internal 
standard (10) was added and extraction proceeded as 
for normal samples. A blank (internal standard only) 
was also included. 
RESULTS 
Figure 2(a) shows the result of monitoring the reaction 
m/z 308 -) m/z 265 from a blank plasma extract (no 
internal standard), and clearly indicates the presence of 
this reaction to some extent in compounds other than 
warfarin. This could arise from molecular or fragment 
ions undergoing the identical reaction, or could arise 
from reactions from adjacent precursors giving rise to 
a daughter at m/z 265 for the reasons outlined above. 
Furthermore, metastable fragmentations from non field-
free regions can also be detected by this procedure, as 
shown by a three dimensional approach to the rep-
resentation of metastable peaks from a double focusing 
mass spectrometer: 6 Thus, daughter ions of m/z 265 
arising from parents greater than m/z 308 during 
acceleration will create a ridge which will be a potential 
small source of background. Similarly, the ridge due to 
fragmentations within the electric sector from reactions 
where the ratio of (daughter mass) 2/(parent mass) is 
approximately the same as this ratio for the reaction 
under consideration will contribute to the background. 
when both parent and daughter masses are greater than 
those of the sample. For warfarin the ratio is 
265 2/308 = 228.0. The endogenous background can 
therefore be viewed as the sum of these various factors. 
Figure 2(b) shows the result of monitorin,g the same 
reaction from plasma which had I u.g of added 
warfarin, representing typical therapeutic levels." 7 This 
is over 13 times the size of the blank, and clearly shows 
a distinct distillation profile off the probe. A pure war-
farin sample exhibited the same profile. 
Figure 2(c) shows the profile for the same reaction 
from a plasma sample which had internal standard added 
only. This also shows the warfarin profile, and arises 
from any 2H, and 2H 2 warfarin present in the internal 
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Figure 2. Each trace shows the metastable ion current versus time 
for the reaction indicated, with area in arbitrary units. The traces 
are drawn to the same scale and represent the material from 4 (11 
of plasma: (a) blank plasma; (b) plasma +1 Rg warfarin ml - '; (c) 
plasma +internal standard only; (d) and (e) plasma from patient 
At, simultaneously acquired traces showing endogenous warfarin 
and internal standard. 
standard, which will produce a proportion of daughters 
at m/z 265 partially transmitted at accelerating voltage 
V2. However, it would appear to have its main origin 
from fragmentations within the electric sector from the 
fully labelled ( 2H 5) internal standard for the reasons 
outlined above, i.e. 267 2/313 = 227.8 which is almost 
the same ratio as for normal warfarin, and hence frag-
mentations within the electric sector will be detected 
when monitoring the 308 -*265 reaction in the first field 
free region. This situation only arises due to the relative 
number of deuterium atoms in the parent and daughter 
ions, so that an internal standard can be_clesigned so 
that the electric sector ridge from the internal standard 
does not intersect the sample first field free region 
daughter ion. The possibility of back exchange of the 
deuterium label also exists in this case where it has been 
synthesized by exchange, but a time course study of 
plasma with only deuterated warfarin added showed 
no measurable amount of ( 2 1-10)warfarin formed over 
1 h. 
For each determination it was not necessary to acquire 
the entire warfarin profile, as the internal standard  
would compensate for any material remaininc on the 
probe. Therefore, to further speed up the assay data 
were normally only acquired until the levels had fall-:n 
to approximately 25% of the maximum value. The ptobe 
was then removed and the quartz tip flamed ready for 
the next sample. 
Least squares linear regression analysis on the metast-
able peak ratios ((area m/z 380 mlz265)l(area 
m/z 313 m/z 267)) obtained for the standard curve 
points versus warfarin concentration gave a line defined 
by y = 0.11 +0.63x, with a correlation coefficient of 
0.998. Repetitive determinations on the same plasma 
sample (1 pi.g m1 -1 ) gave an average ratio of 0.75, with 
a standard deviation of 0.05 (coefficient of variation 
7.2%, n = 5). 
Figure 2(d) shows the profile for the m/z 308 
m/z 265 reaction from the plasma of patient A.L., who 
was receiving a 7 mg oral dose of warfarin daily as part 
of normal therapy. Figure 2(e) shows the results from 
the internal standard channel for the same sample. Peak 
area ratio was therefore 3706/ 4914 = 0.75, which gave 
a value of 1.02 p.g warfarin m1 -I plasma from the 
regression equation. 
The results for patients on different warfarin regimes 
are summarized in Table 1, together with the prothrom-
bin times for the same samples. Each concentration is 
the average of two determinations. The daily dose rates 
for each patient had been determined from previous 
prothrombin time data. 
At the 0.5 1.i.g m1 -1 of plasma level, the amount of 
material loaded onto the probe corresponds to 2 ng 
warfarin. This gave a signal to noise ratio of 20 :1, so 
that at normal levels sensitivity was more than adequate. 
However, the limitation to sensitivity is the background 
in the warfarin channel from the plasma and the internal 
standard for the reascins described, so that at a level of 
0.2 1.i.g m1 -1 of warfarin in plasma, the signal is only twice 
that of a blank plasma with internal standard only. This 
then represents the approximate sensitivity limit of the 
assay. If the internal standard was changed by substitut-
ing deuterium at different sites (e.g. five deuterium 
atoms on the phenyl ring) then this background would 
be considerably lower, and hence the sensitivity of the 
assay will be increased. 
The amount of plasma equivalent loaded onto the 
probe for each determination was 4 ILI, and the amount 
of chloroform soluble (pH = 3) 'volatile' material (i.e. 
Table 1. This shows the warfarin concentration in the plasma 
of five patients on continual warfarin therapy. Daily 
dose rates had been determined by monitoring of 
prothrombin time results. The natural differences in 
metabolic rate are reflected in the four-fold range 
of doses with less than two-fold range in warfarin 
concentrations 
Concentrations at 
warterin in plasma erotnrombin time 
Patient Iwo rril - ') Dose (mg) (min) 
P.E. 0.55 5 2.2 
M.A. 0.71 2 2.9 
M.T. 0.59 2 3.5 
S.E. 0.57 8 2.2 
At. 1.02 7 1.7 
(c) 
308-•-265 653 
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with a boiling point less than or equal to 180°C at 
10 -7 Torr such that it will vaporize in the ion source of 
the mass spectrometer) can be calculated from composi-
tion tables"- to be on average about 20 p.g. Since the 
majority of this is lipid material, an initial extraction at 
alkaline pH could be carried out if desired to remove 
this materia1, 5 and so reduce the quantity used to the 
order of single micrograms. Thus the amount of sample 
used in terms of ion source contamination likely to result 
is no more than would be used for normal probe spectra 
or individual gas chromatography mass spectrometry 
(GC/MS) runs, a factor which was critical to the success 
of the assay. Clearly if large quantities of plasma 
equivalent are used for each determination, this places 
an excessive amount of material into the ion source with 
subsequent increase in background levels. This generally 
will not interfere with the assay, but would prohibit 
subsequent acquisition of normal spectra and degrade 
instrument resolution. Where large quantities of plasma 
equivalent are required for sufficient sensitivity, some 
form of sample purification to reduce the amount of 
material being vaporized into the ion source would 
be required. Similarly where blank plasma shows an 
unacceptable degree of background for the reaction of 
interest, this may be overcome by selective purification 
of the sample prior to insertion. 
DISCUSSION 
The strength of the unimolecular first field free region 
metastable decompositions initially determines whether 
this technique can be used, and the ratio of the back-
ground for the chosen reaction to .the endogenous level 
of the drug or metabolite in question ultimately decides 
the suitability of the assay. Collisional activation of ions 
in the first field free region to promote fragmentation. 
by the introduction of a collision gas, will generally 
increase the number and size of daughter ions. However, 
this will not necessarily result in any increase in specific-
ity, as background from the plasma will also be 
increased. 
It should be noted that several compounds could be 
monitored simultaneously by this method. The small 
changes in accelerating voltage used in any isotope dilu-
tion assay will not measurably decrease ion transmission. 
Nevertheless the same constraints applying to normal 
voltage switched selected ion monitoring exist, so that 
precursors covering a wide mass range cannot be covered 
by a single B/E ratio without a decrease in transmission. 
Very volatile compounds that have normally evaporated 
completely in a few seconds will require either faster 
magnet and accelerating voltage switching or a cooled 
probe to obtain sufficient 'sampling points for accurate 
quantification. 
It is also necessary to guard against the possibility of 
interference from metabolites of the drug in question. 
If a metabolite is capable of producing an ion at the 
same mass as the parent drug, this fragment ion is likely 
to produce interfering daughters. This happens, for 
example, in the case of hydroxylated metabolites that 
lose an oxygen atom from their molecular ion, yielding 
an ion of the same mass as the parent drug. The analgesic 
phenacetin is an example in this class, so that to monitor 
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the loss of ketene from the molecular ion at m/z 179 
would also include the N-hydroxylated metabolite which 
yields a daughter at m/z 179 and a subsequent loss of 
ketene. 19 The various hydroxylated metabolites of war-
farin do not produce an ion at m/z 308. 2" The ion at 
m/z 265 in these spectra comes from the ion at 
m/ z 267, which in turn is derived from the molecular 
ion m/z 324, as well as m/z 306 and 281, 2" none of 
which interfere with either channel being monitored. 
The warfarin alcohol diastereoisomers resulting from 
the reduction of the ketone group produce the reaction 
m/z 310-s m/z 265,20 which could produce a very 
minor interference peak when monitoring rnlz 308 
m/z 265. 
For the application to warfarin, this assay compares 
favorably with the gas chromatographic Cl mass spec-
trometric assay 5 in sensitivity (similar values), time 
required per sample (2 mm against 6 min) and specificity 
as judged by blank plasma traces. In addition, it avoids 
chromatographic 'active site' effects and loss of 
deuterium from the labelled compound. The main 
requirement for this type of assay is a double focusing 
mass spectrometer. While the method has been 
described for a magnetic/electric sector instrument of 
conventional geometry, it could be readily adapted to 
an instrument of reversed geometry using either first or 
second field free region metastable transitions, or to a 
multi-sector instrument of any type. 
The major advantage of the method we describe over 
a previously published method of multiple metastable 
peak monitoring' 3 is that no modifications to a standard 
commercial instrument were required. This does, 
however, involve a degree of manual operation not 
necessary in the other method. Furthermore, it is the 
application of a stable isotope dilution assay to the direct 
determination of a specific compound that is somewhat 
novel. While second field-free region metastable transi-
tions in tandem mass spectrometers have been used for 
the direct determination of compounds in crude mix-
tures, using either full scans or selected reaction 
monitoring,''' the use of first field-free region metast-
able transitions in conventional geometry double-
focusing mass spectrometers has been largely 
applied to gas chromatographic mass spectrometric 
assays. 
Providing the limitations of precursor resolution and 
'ridge' effects from non field-free region transitions are 
recognized, this technique should be able to be applied 
to the qualitative and quantitative determinations of 
specific drugs and metabolites in body fluids. It is of 
particular value where conventional separation tech-
niques are time consuming or the sample is labile. In 
the present study the technique provides a rapid method 
for the determination of plasma warfarin levels without 
the need for derivatization or chromatography of any 
form. 
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SUMMARY 
This work describes a method for the quantitative determination of the labile, toxic 
N-hydroxy metabolite of phenacetin in urine. A thin-layer chromatography step was used 
for the preliminary purification of extracts, and the specificity of the assay was based on the 
monitoring of specific metastable decompositions in a forward geometry double-focussing 
mass spectrometer, in a manner analogous to conventional tandem mass spectrometry. This 
precluded the need for a gas chromatographic separation, thus minimizing thermal decom-
position which can occur with these compounds, as well as enabling very rapid analyses. 
INTRODUCTION 
The toxicity of the antipyretic—analgesic drug, phenacetin, is considered to 
be at least partly mediated by its N-hydroxy metabolite [1] . The formation of 
N-hydroxyphenacetin (NHP), and its biochemical reactivity, have been studied 
extensively in vitro, but little is known of the extent of N-hydroxylation of 
phenacetin in vivo. The problem has been to measure NHP, which is only 
formed in small amounts from phenacetin, in the presence of other phenacetin 
metabolites and endogenous interfering substances in urine. A variety of assays 
have been reported for NHP and similar N-arylacetylhydroxamic acids. At first, 
colorimetric methods were used for urinary analysis [2] , but these lack 
specificity [3] . NHP and other N-arylacetylhydroxamic acids formed in 
biochemical reactions in vitro have been assayed by high-performance liquid 
chromatography (HPLC) [4, 5] , gas chromatography—mass spectrometry 
(GC—MS) [6] , and thin-layer chromatography (TLC) using radiolabelled 
phenacetin [7] . We have previously reported the assay of urinary NHP by GC 
0378-4347/84/$03.00 © 1984 Elsevier Science Publishers B.V. 
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of its methylated derivative, N-methoxyphenacetin (NMP), using flame-ioniza-
tion detection [8] . However, as mentioned in that report [8] , NNW can 
undergo decomposition under GC conditions, so we sought a more reliable 
assay of NHP. 
This paper describes the determination of NHP, as NMP, using TLC to 
se.parate NMP from most interfering substances, followed by specific detection 
by MS using metastable peak monitoring. This MS technique deserves some 
introductory remarks. 
Increasing use is being made of mass spectrometers with more than one 
analysing region to act as specific and sensitive detectors for target compounds 
in relatively impure samples. Much of this work has been carried out with 
reversed geometry [9, 10] or tandem quadrupole [11, 12] instruments. In 
these cases, the two sectors are used sequentially, the first to isolate an ion 
of interest and the second to examine its metastable or collisionally induced de-
composition products (MS—MS). Full daughter ion spectra [13, 14] or selected 
daughter ion monitoring [15-17] have been used. Double-focussing mass 
spectrometers of normal geometry have also been used, in which the metastable 
or collisionally induced decompositions occur in the first field-free region, just 
after the ion source. This was used originally to increase the specificity of 
GC—MS [18, 19] , and more recently has been applied to direct probe analyses 
[20, 21] . Although the sectors are not used sequentially in normal geometry 
instruments, since the products of specific decompositions are being 
monitored, it nevertheless constitutes a form of MS—MS. 
EXPERIMENTAL 
Materials 
NHP was prepared and characterised as previously described [8] . As internal 
standard, the deuterated analogue of N-hydroxyphenacetin was synthesized 
from 4-nitro[2,3,5,6-2 1-14 ] phenol (KOR Isotopes, Cambridge, MA, U.S.A.). The 
deuterated 4-nitrophenol was first ethylated, using ethyl iodide—potassium 
carbonate in acetone, after the method of Vogel [22]. The resulting 4-nitro-
[ 2 H4 ] phenetole was reduced and selectively acetylated to give N-hydroxy-
[2,3,5,6-2 114 ]phenacetin (DNHP), by the method used for the synthesis of 
unlabelled NHP [8] . DNHP was identical to NHP in m.p. (104 ° C) and TLC 
mobility, and on reduction with titanous chloride it yielded a single product 
which co-chromatographed with phenacetin on TLC [8] . The mass spectrum of 
DNHP was similar to that of NHP [23] except the major fragments were four 
a.m.u. higher. The isotopic purity was 98% 2 I14 . 
N-Butyry1-4-aminobenzoic acid (4-BABA) was prepared by reacting 4-amino-
benzoic acid with butyric anhydride, and was recrystallized from 95% ethanol, 
m.p. 228-231 ° C. 4-BABA ran as a single substance on TLC, and its methylated 
derivative, N-butyry1-4-aminomethyl benzoate (4-BAMB), behaved as one 
compound on TLC and GC. The mass spectrum of 4-BAMB was consistent with 
its structure. 
Diazomethane was made in small quantities, fresh as required, from p-tosyl-
sulphonylmethylnitrosamide [22], and was used as the ethereal solution. Other 
chemicals and solvents were of analytical grade. 
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Extract of Helix pomatia (13-glucuronidase plus arylsulphatase) was obtained 
from Boehringer (Mannheim, F.R.G.). 
Apparatus 
Glass TLC plates (20 X 20 cm) were coated with silica gel (0.25-mm thick) 
containing a fluorescent marker (Sigma type GF, size 10-40 pm; St. Louis, 
MO, U.S.A.). The mass spectrometer was a Vacuum Generators (U.K.) 70/70F 
double-focussing instrument, with a digital scan controller, linked-scan unit, 
mode switch, 8-channel M.I.D. unit and 2035 data system with magnet 
switching selected ion software. The instrument was operated in the electron 
impact mode at 70 eV and 4 kV main beam accelerating voltage. 
Extraction and methylation 
Urine was collected from subjects who had taken a dose of phenacetin 
(10 mg/kg in two gelatin capsules), and samples were kept at —20 ° C until 
analysed. The analysis was commenced on the day of collection, since the 
glucuronide conjugate of NHP is known to be unstable in aqueous solution 
[24] . 
Calibration curves were obtained by addition of known amounts of NHP (in 
methanol) to urine from an undosed subject. 
A 2-ml aliquot of urine was placed in a 30-ml stoppered centrifuge tube, 200 
pl of 1.10 M acetate buffer, pH 5.2 were added and the final solution was ad-
justed to pH 5.2, if necessary, with 5 M hydrochloric acid. To this were added 
100 pl extract of Helix pomatia and 25 pl of methanol containing the internal 
standard. The internal standard was originally 25 pg of 4-BABA, but eventually 
5 pg of DNHP were used when DNHP became available. The mixture was in-
cubated overnight (17 h) at 37 ° C to hydrolyse conjugated NHP. 
The tubes were then cooled in ice, the hydrolysate adjusted to pH 1.0 with 
5 M hydrochloric acid (200 pl) and extracted with 15 ml methylene chloride 
by vortexing for 30 sec. The phases were separated by centrifugation (1200 
g, 5 min), and freezing (dry ice—acetone), and the methylene chloride decanted 
into a 50-ml round bottomed flask. The extract was taken to dryness on a 
rotary evaporator (40 ° C), the residue redissolved in 2 ml methanol, and cooled 
in ice. Methylation was achieved with 2 ml ethereal diazomethane (1 h, on ice) 
and the reaction mixture again evaporated to dryness. 
Thin -layer chromatography 
The residue in the flask was redissolved in 200 pl methylene chloride and 
applied as a 5-cm strip to a silica gel TLC plate, which was developed twice 
with chloroform. A band which moved with reference NMP (RF 0.26) was 
scraped off and eluted by vortexing for 30 sec with 10 ml methanol. After 
sedimenting the silica gel by centrifugation (1200 g, 5 min) the methanol was 
transferred by Pasteur pipette to a 50-ml round bottom flask, and the solvent 
removed with a rotary evaporator. The residue was redissolved in 200 pl 
methylene chloride and transferred to a conical-tipped tube ready for analysis. 
Mass spectrometry 
The daughter ions chosen for monitoring NMP and DNMP were m/z 135 
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and 139, respectively (see Results). The two metastable peaks were alter-
nately brought to focus by a combination of linked magnetic field/electric 
sector (B/E) and accelerating voltage switching, through a modification of a 
previously described method [21] . 
At a resolution of 1000, the ion at m/z 214 in the mass spectrum of 
perfluorotributylamine was selected as the starting point of a theoretical B/E 
linked scan (i.e. the magnetic field which transmitted m/z 214 was linked to 
the electric sector voltage). B/E scans from m/z 209 and 213 could then be 
easily focussed by small accelerating voltage adjustments [25]. Accelerating 
voltages V 1 = (209/214) X Vc, and V2 = (213/214) X Vo , where 170 was the 
accelerating voltage at which the main beam was being transmitted, were 
entered into two channels of the M.I.D. unit, the output of which was routed 
directly to the accelerating voltage programmed power supply, bypassing the 
normal electric sector coupling. The appropriate constant parent ion scans were 
then focussed when the respective channel was selected. 
Two genuine daughter ion channels were entered, at m/z 85.16 (= 135 2 /214) 
(channel 2), and m/z 90.28 (= 139 2 /214) (channel 4) into the magnetic selected 
ion software, along with two additional channels at m/z 82.66 (= 133 2 /214) 
(channel 1) and m/z 87.70 (= 137 2 /214) (channel 3), with the linked scan unit 
remaining on. These channels resulted in m/z 133, 135, 137 and 139 daughter 
ions being selected, and to be shown as such on the mass indicator of the 
70/70. 
A small sample of standard NMP and DNMP was loaded onto the direct 
insertion probe, and using a small sweep of the B/E scan over 1 mass unit each 
genuine daughter channel was accurately centred with the appropriate M.I.D. 
channel selected. The collector slit was then opened to give flat topped peaks. 
The accelerating voltage was cycled to switch during daughter channels 1 and 
3 so that the appropriate voltage was selected when genuine daughter channels 
2 and 4 were selected. Dwell time was 1 sec for each accelerating voltage 
channel, and 500 msec, including reset time, for each daughter ion channel, 
with a full cycle resulting every 2 sec. For synchronization, the accelerating 
voltage cycle was started and the magnet switching was then initiated at the 
appropriate instant to result in V 1 being selected during channel 1 and V2 
during channel 3. 
To avoid a very rapid distillation of NMP from the probe, a relatively cool 
(120 ° C) source temperature was used. This resulted in the distillation 
maximizing at about 20 sec after insertion of the probe, providing 20 sampling 
points. 
A 1-pi aliquot of the sample was loaded on to the direct insertion probe and 
the results of the 209 -4- 135 and 213 -* 139 decompositions were acquired in 
the manner described, being displayed as intensity versus time. The area of each 
was measured on the data system and the ratio calculated for determination of 
unknown concentrations. 
RESULTS AND DISCUSSION 
Thin-layer chromatography 
Preliminary experiments showed that the extracted hydrolysate contained 
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too many interfering substances for NHP to be determined by direct insertion 
MS—MS, as we had previously found it to be too impure for GC analysis [8] . 
TLC was used to separate NHP from most of these interfering compounds. 
Methylation of NHP gave a stable derivative for TLC. NHP itself tails badly 
on silica gel 18], possibly because of chelation to trace metals [4] . Hinson and 
Mitchell [7] found it necessary to add non-radioactive NHP to minimize 
adsorption losses of [ 3 H1NHP during their TLC assay. 
Recovery from urine 
Blank urine was spiked with NHP to examine the effect of pH on the extrac-
tion of NHP into methylene chloride. In this experiment 4-methylacetanilide 
was used to standardize the GC assay [8] . Recovery of NHP was better at pH 1 
(95%) than at pH 3 or 5 (65%). 
The methylation reaction mixture was analysed at various times up to 24 h 
to check on the completeness of NHP conversion to NMP. The reaction was 
90% complete in 30 min, and no further NMP was formed after 1 h. 
Optimal conditions for hydrolysis of conjugated NHP were found by treating 
urine from a subject dosed with phenacetin with different amounts of enzyme 
and various incubation times. It was found that 0.1 ml extract Helix pomatia 
per 2 ml urine gave the highest recovery of NHP, as well as most phenolic 
metabolites of phenacetin (to be reported elsewhere). An exception was 2- 
hydroxyphenacetin (2HP), whose recovery, and therefore hydrolysis, was 
maximal with 0.04 ml enzyme mixture. Incremental additions of enzyme 
(0.02 ml) resulted in a progressive decline in 2HP recovery, and a 
concomittant increase in NHP found. It seems likely that this reciprocal 
relationship is due to two competing reactions: the rearrangement of NHP-
glucuronide to 2HP-glucuronide [24] and the enzymatic hydrolysis of the 
NHP-glucuronide. More enzyme, and therefore a faster hydrolysis, leaves less 
time for the rearrangement to occur. Lacking an NHP-glucuronide standard, we 
were unable to check on the extent of residual isomerization under conditions 
giving maximum recovery of NHP. 
Using 0.1 ml enzyme, hydrolysis was found to be complete after incubation 
for 17 h (overnight). 
Mean overall recovery was 63%, estimated from the NMP/DNMP ratio found 
when 5 pg NHP were added to urine and 5 pg DNHP added at the methylation 
step 
Mass spectrometry 
Fig. 1 shows the normal 70-eV mass spectrum of NMP, with that of DNMP, 
in which all the major ions are shifted by 4 a.m.u. A full B/E linked scan from 
the molecular ion (m/z 209) of NMP, to find the direct daughter ions from the 
first field-free region, gave a spectrum with m/z 179 (2.5%), 178 (5%), 167 
(100%), 166 (10%), and 135 (18%) as the only significant peaks. The ions at 
m/z 167 and 166 corresponded to the loss of ketene and an acetyl radical 
respectively, and were also found to occur in the normal and B/E spectra of 
the isomeric ring methoxylated compounds, 2- and 3-methoxyphenacetin 
[23]. Therefore these daughter ions were not suitable for monitoring NMP in 
the presence of isomeric phenolic metabolites of phenacetin. However, the 
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Fig. 1. Electron impact mass spectra of NMP and DNMP, with arrows showing the meta-
stable reactions monitored for quantitative analysis. Broken lines show the sites of cleavage 
in these reactions. 
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Fig. 2. Ion traces obtained during metastable peak monitoring of NMP and DNMP. The left 
side shows a calibration standard, in which 10 pg NHP was added to 2 ml blank urine. The 
right side shows analysis of urine following a dose of phenacetin; 6.7 pg NHP was found 
per 2 ml urine. 
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daughter ions at m/z 179, 178 and 135 were not found to be present in the 
normal or B/E spectra of the ring-substituted compounds, making them 
suitable candidates for a specific assay. Due to the relative size, and specificity 
of the loss, the ion at m/z 135 was chosen as being the most suitable. This ion 
was found from the high-resolution studies of the main beam m/z 135 ion to be 
C 8 H 9NO, corresponding to the loss of the elements of the acetyl and methoxy 
groups by an undetermined mechanism. Thus the decompositions monitored 
were 209 -> 135 for NMP, and 213 -> 139 for DNMP, as indicated in Figs. 1 
and 2. 
An extract of hydrolysed urine from an undosed subject, without any 
preliminary purification, was monitored for these decompositions to deter-
mine the extent, if any, of interference from compounds other than NMP. This 
indicated there was some interference from other 209 -> 135 decompositions, 
or additional reactions which could be focussed under the conditions employed 
[21] . Although the interference did not display the distillation profile of NMP 
from the direct insertion probe, it would nevertheless have made accurate 
quantification difficult. Hence a preliminary purification was necessary, and 
the TLC procedure was employed. An examination of the extract of a TLC 
scrape at the RF of NMP from an undosed subject indicated virtually no 
detectable signal in either channel being monitored. 
Calibration curve 
Addition of NHP (1-20 pg) and DNHP (5 pg) to 2 ml blank urine gave a 
good linear relationship using either peak heights or peak areas (ratio 
NMP/DNMP versus amount NHP added). Peak areas gave a slope of 0.191, 
y-intercept 0.03, and correlation coefficient 0.9983. Peak heights gave a slope 
of 0.186, y-intercept 0.055, and correlation coefficient 0.9994. Repeated 
measurements on the same sample gave an instrumental coefficient of variation 
(C.V.) of 1.94% (n = 8). Replicate assays using eight lots of 2 ml urine from 
one urine collection sample from a subject who had taken phenacetin gave a 
C.V. of 9.2% (by peak area) and 7.2% (by peak height). 
The selectivity of the assay depends on two separation steps: (1) TLC and 
(2) the selection of specific daughter ions produced from the molecular ions of 
NMP and DNMP in the first field-free region of the mass spectrometer. Thus 
NHP can be assayed in the presence of many other metabolites of phenacetin 
which are mostly formed in far greater amounts. 
In early experiments, before DNHP was available, 4-BABA was used success-
fully as an internal standard. In this case the metastable reaction monitored was 
221 -9. 151 (the molecular ion losing C 4H60). There was no interference from 
blank urine, and the calibration curve was linear (slope 0.0098, y-intercept 
0.0018, correlation coefficient 0.9993). The only unsatisfactory aspect of 
4-BAMB was that it distilled off the probe much more slowly than NMP, 
which considerably prolonged the MS analysis time. DNMP, having the same 
distillation profile as NMP, enabled much faster analyses, and is the ideal 
internal standard. 
Formation of NHP from phenacetin in man 
Fig. 3 shows the urinary excretion of NHP by a male subject following a 
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Fig. 3. Cumulative urinary excretion of NHP and some other phenacetin metabolites, 
following an oral dose of 10 mg/kg phenacetin in a male subject. APAP-gluc (*) is 
paracetamol glucuronide and APAP-sulph (•) is paracetamol sulphate. These two major 
metabolites of phenacetin are included for comparison with NHP (•) and 2HP (• ), and their 
HPLC determination will be described in a separate communication. 
dose of phenacetin (10 mg/kg, orally in two gelatin capsules). The presence of 
NHP in urine was separately confirmed by GC—MS, as previously described 
[8] . The total amount of NHP excreted in 24 h corresponded to 0.40% of the 
dose of phenacetin. This is comparable with the finding of 0.28% NHP after 
900 mg phenacetin, in which NHP was determined by its ability to chelate 
copper and extract it into water [2] . However, in view of the complex metab-
olism of phenacetin, we believe that our structurally specific assay is preferable. 
The assay is sensitive to less than 0.5 pg NHP per ml urine, which appears 
quite adequate for metabolic studies involving urine analysis. 
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Updating Instrument Control Modes on a VG 7070F 
N W Davis 
Central Science Laboratory, University of Tasmania, PO Box 252C, Hobart, Tasmania, 
Australia 
INTRODUCTION  
The normal operational modes on a VG 7070F double focussing mass spectrometer 
can be updated by relatively simple modifications to allow independent control of the 
magnetic sector field (B), the electric sector field (B)  and the accelerating voltage (V). 
This enables multiple reaction monitoring of metastable or collisionally induced 
decompositions in the first field free region (1st FFR) for added specificity when 
targeting specific compounds by qualitative or quantitative mass spectrometry or gas 
chromatography-mass spectrometry (GCMS). The acquisition of data for ion current 
surfaces (Lacey and McDonald, 1977) is also made simpler and more flexible. 
METHODS  
Where a "DIGMID" unit is present, this makes an ideal source of accurately 
controlled 0 to 10V input for stepping either E or V between magnetic sector scans 
for mapping ion current surfaces. The only modification required is to the cable 
connections. Use of 'continuum' mode during data acquisition gives up to 4000 
data points per scan. Where a DIGMED and digital scan controller are both present 
then multiple reaction monitoring is also possible simply with changes to cable 
connections. If only one multichannel variable voltage supply is present, an 
independent unit will be required. Due to the relatively slow magnet response, rapid 
cycling between different decompositions can best be achieved by synchronized 
independent control of E and V, with fixed B. For this case, with any main beam 
ion ma focussed with B = B cp  E = E0 and V = V0, a 1st 1-1-4( decomposition mb --> 
mc can be focussed with B = Bo, E = (mairndEo and V = (mamb /mc2 )Vo. Figure la 
illustrates the normal mode of operation for an instrument equipped with a digital 
scan controller. Figure lb shows the necessary modifications to enable steps of V 
between scans of B for mapping of ion current surfaces. This same configuration, 
using two or more channels on the independent voltage source (in this case the 
DIGMLD) and on the normal selected ion mode, enables multiple reaction monitoring 
with changes to B and V or E and V.Suitable choice of dwell times enables 
synchronization to be maintained for the length of GCMS analyses. Mapping by 
control of E and B is possible by connecting the independent input to the electric 
sector power supply, while providing fixed accelerating voltage from the decoupled 
('manual') position of the accelerating voltage power supply. 
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Instrumentation and novel techniques 
RESULTS  
Figure 2 shows a portion of the cross section through the ion current surface for 
camphor, obtained at p = 0.722, where p = (V0/V)(E/E0), with the configuration 
shown in Figure lb. This is the result of five averaged scans at 10 s/decade. Figure 
3 shows the results of GCMS multiple reaction monitoring for the 1st FFR 
metastable decompositions 386 --> 371 for the trimethylsilyl (TMS) derivative of 
Al-tetrahydrocannabinol (THC) (Harvey et al 1980), the active constituent of 
cannabis, and 389 --> 374 for 5'- 2H 3 - THC (internal standard) for a blood sample 
containing 2.5 ng/ml of THC and (nominally) 10 ng/ml of the internal standard. 
This was achieved by independent control of E and V with a cycle time of 1 second. 
Chromatography was on a 25m x 0.32mm x 0.52p HP- 1 column directly coupled to 
the ion source and temperature programmed from 60° to 280° at 30°/minute. 
Figure la 	 Figure lb 
Figure 1. Schematic diagram of normal and modified connections 
Figure 2 Cross section of the ion current surface for 
camphor. jr. = (Eo /E)mg where mg is the mass 
of a singly charged main beam ion transmitted 
with V = Vo and E = Eo. This corresponds to 
the normal calibrated mass scale with 
accelerating voltage adjustments to P. 
Figure 3. Multiple reaction monitoring 
GCMS for THC and deuterated 
internal standard from blood. 
D.J. Harvey, J.T.A. Leuschner and W.D.M. Paton. J. Chromatogr. 202, 83 (1980). 
M.J. Lacey and C.G. McDonald. Org . Mass Spectrom..12, 587 (1977) 
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Dear Sir 
A Rapid Method for the Generation of 
Multiple Constant Parent Ion Spectra 
Linked scans of the magnetic field (Et( 
and the electric sector voltage (El at con-
stant accelerating voltage (V1 to produce 
spectra containing onl .s ions originating in 
the 1st field free region IFFR) of double 
focusing mass spectrometers are well 
known," Three-dimensional representation 
by various techniques using more than one 
scanning mode has been shown to provide 
the maximum amount of information about 
metastable peaks for cases where sample 
size is not limiting.' Computer techniques 
now also allow for automatic switching to 
linked scans during normal magnet scans, 
using previously entered calibration files for 
each desired daughter or precursor.' 
We would like to point out a simplified 
procedure for the acquisition of all desired 
constant parent ion spectra for a given sam-
ple, based on the linked scan at constant 
B/E. Normally, individual scans would be 
carried out for each parent ion using differ-
ent DIE ratios for each, at constant ac-
celerating voltage. This necessitates changes 
in the initial magnetic field and electric sec-
tor voltage to be selected manually, and also 
results in a new mass scale. This can be 
time-consuming and wasteful where sample 
size is limited. A much faster way of 
generating constant parent ion spectra for 
all required parents is to set up on the initial 
precursor (P 1 ). at 13 1 , E, and V, in the 
normal manner, and then for each subse-
quent precursor I', change the accelerating 
voltage to P,V,IP, and scan at constant BIE 
using the same ratio as set up for P, 
(=B,/E,). This generates a BIE scan from 
each precursor without the need to change 
the DIE ratio, and at the same time main-
tains the correct mass scale for all scans.' 
This mass scale is normally already adjusted 
for the apparent mass of the 1st FFR daugh-
ters (=D 2IP where D is the ml: value of 
the daughters formed in the ion source). so 
that ions appear at their actual ml: values. 
While it is not desirable to lower ac-
celerating voltage in general, in practice a 
moderate lowering of voltage results in an 
acceptable loss in transmission. If parents 
less than 0.8 P, are required, then V may 
need to be changed back to V, and a new 
B/E ratio entered. 
LETTERS TO THE EDITOR 
A justification of the above considerations 
can be seen from the following. If two par-
ents P, fat B,, E, and Vd and P, give rise 
to daughters D, and D, respectively, since 
ml: =13 2W/2V where R is the radius of 
curvature of the magnet, main beam daugh-
ters are transmitted at magnetic fields of 
B 1 (D 1 IP 1 ) 112 and B,(D,IP,) 1 b. while 1st 
FFR daughters will be transmitted at 
D,B,IP, and D2 13 1 1(P,P2 )"2 respectively. 
In the normal linked scan at constant B/E 
from P, at constant V. 1st FFR D, ions 
would require an electric sector voltage of 
D,E,/P, and all daughters would be trans-
mitted at a B/E ratio of B,IE,. Similarly, a 
normal linked scan at constant B/E from P, 
at V, would produce 1st FFR D, ions at 
B = D2 B 1 I(P 1 P2)"2 and E = D 2 E 1 /P2 . and 
a B/E ratio of P2 B 1 IE 1 (P 1 P2 ) 112 . 
The same 1st FFR ions will be transmit-
ted at different accelerating voltage, pro-
vided the ratios E/ V and 13 2IV remain con-
stant, as nil:. is proportional to both. Hence, 
the new values are x 112 B„, xE, and xV„. 
where B„. E, and V„ are the original values 
for D2, and x is the factor by which V is to 
be changed. If the DIE ratio is to be the 
same as for P, daughters, substitution gives 
x 1/2 D2BtP2  =B,IE, 
x(P,P2)"2D2 E, 
x 1 '2 = P2I(P 1 P2 ) 112 
The new values then 'become 1, 2 13 1 1P 1 , 
D,E,IP, and P2 V 1 /P 1 . Thus, all. constant 
parent scans can be generated at the same 
DIE ratio. The mass scale as set up for P, is 
still correct since D2 13 1 1P 1 is the magnetic 
field required, before accelerating voltage 
was changed, to focus any 122 ions arising 
from P,. Similarly, main beam P2 ions are 
also placed on the correct mass scale. 
This procedure facilitates the rapid ac-
quisition of all constant parent scans for a 
given sample, with only a few seconds re-
quired to manually adjust the accelerating 
voltage to the calculated positions between 
successive scans. A further advantage is that 
an ion from a reference compound such as 
heptacosatributylamine, slightly lower than 
the highest precursor required, can be used 
for the initial setting up of the BIE ratio, 
and the accelerating voltage increased to bring 
in P, before successive reduction for subse-
quent precursors. Thus, any valuable sample  
is not required prior to the actual acquisi-
tion of the data. 
There are also analytical applications for 
this method using selected metastable ion 
monitoring for the analysis of mixtures. 
either in conjunction with gas chromatog-
raphy mass spectrometry or as direct mix-
ture analysis.'-' In this case an internal 
standard could be employed with rapid 
switching between daughters from the sam-
ple and the standard. The linked scan at 
constant DIE would be linked to accelerat-
ing voltage as well as to a peak switching 
unit, thus enabling any daughter from any 
parent to be readily focused. Furthermore, 
computer acquisition of normal linked scan 
data would be facilitated by using the same 
mass scale for different constant parent 
scans, thus requiring at most only a few 
calibration files to cover the entire mass 
range. 
Yours 
NOEL W. DAVIES, JOHN C BIGNALL 
and ROSS W. LINCOLNE 
Central Science Laboratory, 
University of Tasmania, 
P.O. Box 252C, 
Hobart, 
Tasmania, 
Australia 7001 
November 1981 
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Dear Sir 
Distinction Between Epinseric 3-Hydroxy 
Steroids by Mass Analysed Ion Kinetic 
Energy Spectrometry 
Steroids have been extensively studied by 
conventional mass spectrometry.' and it is 
known that the stereochemistry of the A/B 
ring junction and the orientation of a hyd-
roxy substituent at the ring system may in- 
fluence the peak pattern of the mass 
spectra. = Recently. Larka et al. have shown 
that epimers of certain steroidal hydrocar-
bons and ketones can be distinguished by 
differences in the kinetic energy released 
during CH 3 ' loss from the molecular ions. 
Usually, the value of T0.5 is larger for the 
50-isomer. During the course of an ex-
tended study of steric effects in the mass 
analysed ion kinetic energy (MIKE) spectra 
of stereoisomeric cyclic alcohols' we also 
investigated the fragmentations of metasta-
ble molecular ions of some stereoisomeric 
3-hydroxy steroids after 70 eV electron im-
pact ionization in the 2nd field free region 
of a VG ZAB 2F mass spectrometer. For all 
the compounds investigated loss of CH,' 
and H 2O, respectively, from metastable 
molecular ions was observed. The values of 
the kinetic energy T released during these 
fragmentations are given in Table 1. It is 
clearly seen that the correlation observed by 
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MANDIBULAR GLAND SECRETIONS OF TWO 
PARASITOID WASPS 
(HYMENOPTERA: ICHNEUMONIDAE) 
N. W. DAVIES' and J. L. MADDEN 2 
'Central Science Laboratory 
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University of Tasmania 
PO. Box 252C 
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Abstract—Males of Rhyssa persuasoria and Megarhyssa nortoni nortoni ex-
hibit marked aggregation behavior prior to and during the emergence of fe-
males from host trees, and this has been linked with the secretion of an odor-
ous liquid from the mandibular glands. The volatile components of these se-
cretions were examined by combined gas chromatography-mass spectrom-
etry. While both species contained 6-methylhept-5-en-2-one, M. nortoni nor-
toni was characterized by a series of alkyl spiroacetals and R. persuasoria 
contained 3-hydroxy-3-methylbutan-2-one. The same spiroacetals have pre-
viously been isolated from the mandibular glands of other Hymenoptera and 
have been directly associated with aggregation behavior in some species. The 
chemical and behavioral aspects of the two species are discussed. 
Key Words—Mandibular secretions, parasitoids. aggregation pheromones, 
spiroacetals, 6-methylhept-5-en-2-one. 3-hydroxy-3-methylbutan-2-one, 
Rhyssa, Megarhyssa, Hymenoptera, Ichneumonidae. 
INTRODUCTION 
The parasitoids Megarhyssa nortoni nortoni Cresson (hereafter referred to as 
M. nortoni) and Rhyssa persuasoria L. (Hymenoptera: Ichneumonidae) were 
introduced into Australia as natural enemies of the wood wasp, Sirex noctilio 
F., an exotic pest of radiata pine (Pinus radiata D Don) (Taylor, 1967). Both 
species attack mature larvae of S. noctilio within the wood of infested trees to 
emerge, in general, 12 months later. 
Males of both species aggregate at sites of potential emergence or at sites 
1115 
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which are otherwise attractive. The aggregation response is initiated by volatiles 
produced by the symbiotic fungus of S. noctilio, Amylosterum areola-
tum , (Madden, 1968). Localized generation of fungal volatiles is presumably 
stimulated by moisture changes associated with adult eclosion, since injection 
of water into fine drill holes made in dry, fungus-infested logs will promote 
aggregation at such sites after 24-48 hr (Madden, unpublished results). 
The aggregation behavior of male M. nortoni is similar to that described 
for several 'other Megarhyssa species (Heatwole et al., 1963; Crankshaw and 
Matthews, 1981), and the group is typically compact with arching of the abdo-
men so that the distal abdominal segments make contact with the bark substrate 
at the point of interest discerned by the antennae. Aggregations of R. persua-
soria are less compact and males are incapable of arching their abdomens, al-
though curvature of the abdomen may be observed. 
In laboratory studies with M. nortoni males, presentation of the fungus on 
agar or water extracts of insect frass is sufficient to initiate individual interest 
followed by, through 4-min exposure periods, accelerated recruitment of males 
to the sites. This second response is a function of the number of males making 
contact with each other (Madden, unpublished results). In this situation mutual 
antagonism occurs between individuals, in which opening of the mandibles is 
observed. Furthermore, the rapid drumming of the antennae at the sites of 
emerging insects elicits a like response in the emergent. In the majority of cases, 
the space between the mandibles is observed to be occupied by a liquid. 
Depending on the species of the emergent, a number of outcomes may 
occur: (1) If the emergent is a nonparasitoid, e.g., S. noctilio, the male aggre-
gation of either parasitoid is retained and males will mount the emergent and 
display precopulatory movements. (2) If the emergent parasitoid species is a 
conspecific, of either sex, precopulatory activity is enhanced and mounting oc-
curs. (3) If the emergent parasitoid species is dissimilar, the males' precopula-
tory activity, which may include males mounting males, will subside and the 
aggregation will disperse. 
The odor of each species is characteristically different and, in preliminary 
experiments, it was found that it could be released if the insects were grasped 
or shaken. In addition, mandibular opening with the appearance of liquid could 
be elicited by swift decapitation. The odor source was clearly localized in the 
head, as crop and stomach contents and thorax and abdomen possessed no such 
odor. 
It would appear that this secretion plays an important role in the complex 
species recognition, aggregation formation, and defensive behavior of the two 
species. This paper reports the chemical identity of the major volatile com-
pounds occurring in the mandibular secretion of male and female R. persuasoria 
and M. nortoni. Compound classes encountered include spiroacetals, ketones, 
alcohols, and esters. 
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METHODS AND MATERIALS 
Insect Material. Insects were collected as they emerged from infested logs 
in an insectary, were kept in polystyrene pots, provided with water and honey, 
and held at 10°C between tests. They were then available for bioassy or chemical 
examinations as required. 
Three main approaches were used in the study of the volatiles. These were 
the direct collection of the secretions from stimulated individuals, examination 
of extracts of dissected mandibular glands to confirm the origin of the secretion, 
and the examination of extracts of excised heads. Males and females were treated 
separately. 
Collection of Secretions. The mandibular secretions were collected in the 
following manner. Individual insects were grasped at the thorax between thumb 
and forefinger, an action which resulted in the opening of the mandibles and the 
appearance of the secretion in variable amounts. The tip of a 1-p.1 microcapillary 
tube (Microcaps, Drummond Scientific Co., Broomall, Pa.) was placed between 
the extended mandibles resulting in the uptake of the liquid. The microcap was 
either immediately dropped into, or its contents flushed into, a vial of pentane. 
Maximum yield per collection ranged from 0.25 ul to 0.80 Al for R. persuasoria 
and M. nortoni, respectively. In general greater quantities were obtained from 
females and M. nortoni. Insects were returned to a new container, stored at 
10°C, and could be processed daily for up to 14 days. 
Gland Material. Mandibles and associated glands, gland reservoirs, and 
muscles were dissected from parasitoids that had been killed by short exposure 
to —20°C prior to analysis. Ten to fourteen mandibles for each species and sex 
were prepared. In another approach, insects were decapitated, antennae re-
moved, and the heads stored in pentane. 
Extraction. The frozen gland material and heads were crushed and left in 
pentane overnight. The gland extract was filtered and used without further work-
up after evaporation to minimum volume. The head extracts were washed with 
5% sodium bicarbonate solution to remove fatty acids, dried over MgSO 4 , and 
evaporated to a minimum volume prior to injection. 
Bioassay. The response of male parasitoids to live females contained in 
perforated vials, excised female heads, and mandibular secretion was evaluated. 
In paired comparisons, presentation of a test subject to 25 males of one species 
was alternated with a similar presentation to 25 males of the second species 
through 10 presentations for each of the three species treatments. The number 
of males that visited or revisited and drummed the test site with their antennae 
during a 2-min exposure was recorded to evaluate the response to each treat-
ment. 
Gas Chromatography-Mass Spectrometry. A Pye 204 gas chromatograph 
was employed, directly coupled to a VG 70/70F mass spectrometer with 2035 
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data system. The mass spectrometer was normally operated in the electron im-
pact mode at 70 eV, 4 KV accelerating volts, and a source temperature of 200°C. 
Scans from m/z 350-20 were stored every 1.6 sec. Chemical ionization analyses 
were carried out with isobutane as the reagent gas at a pressure of approximately 
1 torr in the ion chamber. Accurate masses were determined at a resolution of 
1000 by means of perfluorokerosene as an internal reference with peak times 
relative to the reference peak times being used. The gas chromatography was 
carried out on 50-m x 0.2-mm fused silica OV-101 or 25-m x 0.2-mm BP1 
(bonded-phase equivalent of OV-101, SGE Pty. Ltd) with the column passing 
through into the ion source. The carrier gas was hydrogen, with a flow rate at 
70°C of 1.8 ml atm/min (Davies, 1984). Injections were splitless at 250°C, and 
a typical column temperature program was 70-250° at 4°/min. 
The mandibular secretions inside microcapillaries were sealed inside larger 
capillaries (2 cm x 1 mm) and injected with a capillary crusher, a modification 
of a previously described device (Stanley and Kennett, 1973). 
Hydrogenations were carried out in sealed Reacti-vials (Pierce) using 
Adams catalyst. Methylations were carried out with ethereal diazomethane. Tri-
methylsilylation was carried out with BSTFA (Pierce), and methoxime deriva-
tives were prepared with methoxylamine hydrochloride (2% in pyridine). 
Identifications were based on GC retention indices, mass spectra, chemical 
modification of functional groups and, where possible, by comparison with au-
thentic standards. 
RESULTS 
The mandibular gland secretion is presumably produced by the glandular 
mass of cells that envelop the mandibular gland reservoir (Figure 1). The volu-
metric capacity per reservoir was approximately 2.0 and 1.4 Al for average-size 
female and male M. nortoni, respectively, and 1.5 and 1.0 /21 for average-size 
female and male R. persuasoria. The ducts from the reservoir pass through the 
mandible to open on the inner margin at the base of the mandible. 
The secretions showed the presence of several volatile components, with 
that of M. nortoni being considerably more complex than that of R. persuasoria. 
Figure 2 shows the chromatogram obtained from the secretion of a single M. 
nortoni female. Peak 1 was found to be pentan-2-one, and peak 2 to be 6- 
methylhept-5-en-2-one. This latter compound was also readily identified in the 
secretion of R. persuasoria. M. nortoni, however, also produced a series of 
compounds (peaks 3-6, Figure 2), the mass spectra of which did not match any 
compound in the available mass spectral data bases. 
Three of these compounds (peaks 3, 4, and 6) were found to have a molec-
ular weight of 184 and prominent fragment ions at m/z 112 and 115, while the 
molecular weight of the other (peak 5) was 168. Peak 5 was not consistently 
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FIG. 1. Excised mandibles and associated glands and tissue from a M. nor-toni male. 
Photographed in 70% ethanol. Scale represents 1 mm. 
found and appeared to diminish rapidly on storage, indicating an unstable struc-
ture. The molecular weight 184 compounds were found from accurate mass 
determinations to be C 11 I-1 2002 (found, 184.149; calculated for C 11 1-1 2002 , 
184.146). Using bulked material from whole heads, compounds 3, 4, and 6 failed 
to hydrogenate or form any methyl ester, methoxime, or trimethylsilyl deriva- 
6 
5 	 10 	 15 
Time (minutes) . 
FIG. 2. Chromatogram of the volatile components in the mandibular gland secretion of 
a single M. nortoni female. GC column was 50 m OV-101, fused silica, programed from 
70° to 200°C at 4°/min. Peak numbers are referred to in the text and Table I. 
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FIG. 3. Structures of characteristic M. nortoni compounds, with numerals corresponding 
to peak numbers in Figure 2. III: E, E-2,8-dimethy1-1,7-dioxaspiro[5.5jundecane; IV: 
E,E-2-ethyl-7-methyl-1,6-dioxaspiro[4.5]decane; V: 2-methy1-6-penty1-3,4-dihydro-2H-
pyran; VI: Z,E-2,8-dimethy1-1,7-dioxaspiro[5.51undecane. 
tive, indicating that there were no double bonds present and that the oxygens 
were not present as acid, ketone, or alcohol groups. Saponification with etha-
nolic potassium hydroxide also effected no change, indicating that no ester func-
tion was present. 
The two degrees of unsaturation, therefore, had to be accounted for by ring 
systems, with the oxygens in the ring, suggesting a cyclic acetal could account 
for the structure. An examination of the literature for known acetals of the same 
formula showed that the mass spectra of compounds 3, 4 and 6 did in fact match 
closely a series of previously reported spiroacetals (Francke et al., 1978, 1979, 
1980a) from the mandibular glands of bees and wasps. Close comparison of 
mass spectra and gas chromatographic retention indices with those of authentic 
samples run under identical conditions confirmed the identities, and enabled 
stereoisomers to be assigned. Peak 3 was shown to be E,E-2,8-dimethy1-1,7- 
dioxaspiro[5.5Jundecane, peak 4 to be E,E-2-ethy1-7-methyl-1,6-dioxaspiro-
[4.5]decane, and peak 6 to be Z,E-2,8-dimethy1-1,7-dioxaspiro[5.5]undecane. 
(Figure 3) 
The two stereoisomers of the synthetic dimethy1-1,7-dioxaspiro[5.5]- 
undecanes are well separated on nonpolar stationary phases and can be distin-
guished as well by their mass spectra which show significant differences (Francke 
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et al., 1980a). The two synthetic dimethy1-1,6-dioxaspiro[4.5] decanes (E,E and 
Z,E isomers) were much closer in relative retention time and had virtually iden-
tical mass spectra. Only the E,E and Z,E steroisomers of the 1,7-dioxas-
piro[5.5]undecanes would appear to be thermodynamically stable (Francke et 
al., 1980b; Mori and Tanida, 1981). The chirality of the spiroacetals was not 
determined. 
Peak 5 was shown to correspond to C II I-1 200 (found, 168.147; calculated 
for C II H200, 168.151), and it appeared that it could be related to an unknown 
previously reported in association with the same spiroacetals (Bergstr6m et al., 
1982) which was subsequently shown to be the biogenetically related 2-methyl-
6-penty1-3,4-dihydro-2H-pyran (Francke, 1984; Francke et al., 1985). Peak 5 
had a mass spectrum with m/z 168(23%), 125 (42), 112 (100), 97(30), 84(16), 
83 (31), 70 (25), 58 (15), 55 (61), and 41(36). Comparison of this spectrum 
with that of the above dihydropyran (Francke, personal communication) con-
firmed that the spectra were very similar, and an authentic sample run under the 
same conditions confirmed the assignment based on an identical retention index 
and mass spectrum. 
Peaks 7 and 8 in Figure 2 were found to be undecan-2-one and undecan-2- 
ol, respectively. Methyl oleate was observed as a major component in the M. 
nortoni secretion. A major peak in the R. persuasoria secretion gave a mass 
spectrum with m/z 31(42%), 39 (17), 41(28), 43 (49), 59 (100) and 87 (5). 
After chemical ionization mass spectrometry to obtain a molecular weight, and 
subsequent comparison of GC and MS data with an authentic sample, this was 
found to be 3-hydroxy-3-methylbutan-2-one. 
The components identified in the two secretions are summarized in Table 
1. Analysis of excised mandibular gland extracts confirmed that the volatiles in 
the secretion did in fact originate from this gland. In addition to the compounds 
listed, several other peaks were observed at longer retention times in M. nortoni 
which have yet to be identified. The gland and head extracts of M. nortoni were 
also found to contain normal fatty acids such as palmitoleic, palmitic, oleic, 
linoleic, and stearic acids and a range of cuticle wax hydrocarbons including n-
heneicosane, n-tricosane, n-pentacosane, n-heptacosane, as well as a C-25 al-
kene, while R. persuasoria contained the same range of fatty acids with a num-
ber of branched-chain alkanes in addition to the n-alkanes. 
Whole females, excised female heads, and female secretions were used in 
bioassays to determine the degree of attraction to conspecific males and the 
degree of interspecific attraction. Table 2 summarizes these results. In each 
comparison, a significant preference for males to respond to females of the same 
species, their excised heads, and in particular their mandibular secretions was 
apparent. Excised heads were the least effective in eliciting activity by males, 
followed by live females, and then mandibular secretion which was the most 
active and specific. 
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TABLE I. PRINCIPAL COMPONENTS FOUND IN MANDIBULAR SECRETIONS a 
e--■ 
co 
Peak no. Compound 
M. nortoni R. persuasoria 
Male Female Male Female 
1 
2 
Pentan-2-one 
3-Hydroxy-3-methylbutan-2-one 
6-Methylhept-5-en-2-one 
+ 
+ 
+ 
+ 
++ 
++ 
++ 
++ 
co 3 E, E-2,8-Dimethy1-1,7-dioxaspiror5.51undecane + + 
4 E, E-2-Ethyl-7-methyl-1,6-dictxaspiro14.51 decane ++ ++ 
5 2-Methyl-6-penty1-3,4-dihydro-2H-pyran ++ 
6 Z, E-2, 8- dimethyl-1, 7-d ioxaspiro [ 5.5 ] undecane +++ +++ 
7 Undecan-2-one + + 
8 Undecan-2-ol + + 
Methyl oleate +++ +++ 
aKey: + = minor component, ++ = medium component, +++ = major component. 
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TABLE 2. RESPONSE OF MALE PARASITOIDS TO LIVE FEMALES, EXCISED HEADS, AND 
MANDIBULAR SECRETIONS OF FEMALE PARASITOIDS ° 
Treatment 
Excised heads Live females 	 Mandibular secretion 
R. persuasoria 	M. nortoni 
 
R. persuasoria 	M. nortoni 
 
R. persuasoria 	M. 'tortoni 
Male R. persuasoria 	 14 	 1 
1—, co 	 Male M. nortoni 1 9 
to X2 	 15.4 
Significance 	 P < 0.001 
39 
25 
34.16 
P < 0.001 
	
8 	 78 	 16 
59 50 156 
89.77 
P < 0.001 
'Key response was the number of visits made by males, from 25 of each species, to the presentation point over two minutes. 
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DISCUSSION 
Males of both parasitoid species aggregate at potential emergence sites by 
a common stimulus of fungal origin (Madden, 1968; Madden and Coutts, 1979). 
Male M. nortoni, the larger of the two species, excludes R. persuasoria where 
they compete for a common site, and this exclusion is complemented by the 
release of repellent mandibular secretions from a compact aggregation. R. per-
suasoria males will then stand outside the aggregation and may reform if the 
emerging insect results in the dispersal of M. nortoni. 
It has been demonstrated that the mandibular glands produce distinctly dif-
ferent compounds which confer species identification. In M. nortoni these com-
pounds include a number of closely related spiroacetals, while in R. persuasoria 
the species-specific compound would appear to be 3-hydroxy-3-methylbutan-2- 
one. 6-Methylhept-5-en-2-one may act as a repellent and alarm pheromone. After 
the first report of this compound in ants (Cavill and Ford, 1953), it has been 
confirmed to be associated with alarm and defense in numerous species of ants 
(Regnier and Law, 1968; Blum, 1978), as well as in secretions of Andrena bees 
(Tengo and Bergstrom, 1976), other parasitic bees (Hefetz et al., 1982) and 
some beetles, such as the Douglas-fir beetle (Dendroctonus pseudotsugae Hop-
kins) (Ryker et al., 1979). The species-specific compounds may act to synergize 
the repellent effect of the secretion while masking or potentiating its effect on 
the precopulatory activity of conspecifics. 
Compound 4 was first found together with the Z,E isomer in three vespine 
wasp species (Francke et al., 1978), while compounds 3 and 6 were first re-
ported in the mandibular secretions of Andrena bees (Francke et al., 1980a) 
together with the two former spiroacetals. The spiroacetals represent a class of 
compounds increasingly being identified as having pheromone activity. The first 
isolation of them from insects would appear to be `chalcogran' (2-ethy1-1,6-dioxa-
spiro[4.4]nonane), an aggregation pheromone of the beetle, Pityogenes chalco-
graphus (Francke et al., 1977). Cyclic acetals such as brevicomin (Silverstein 
et al., 1968) have, of course, been known for some time as insect pheromones, 
again principally as attraction or aggregation pheromones. Since 
the first reported spiroacetal, a range of these compounds has been found in 
bees (Francke et al., 1981; Tengo et al., 1982; Bergstrom et al., 1982), wasps 
(Francke et al., 1979) and the olive fly (Baker et al., 1980). The ring systems 
include dioxaspiro[4.4]nonanes, 44.51decanes, -[5.5]undecanes, 44.6Jun-
decanes, and 45.6]dodecanes. The alkyl substituents range from methyl to butyl, 
with over 20 skeletons identified, excluding stereoisomers. These are almost 
always based on an odd carbon number and unbranched skeletons, as are the 
three found in M. nortoni. In these reports and the other references to spiro-
acetals, the function assigned has generally been that of attraction to members 
of the same species. 
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Undecan-2-one and undecan-2-ol, which are biosynthetically related to the 
spiroacetals found in M. nortoni were also found in association with the spiro-
acetals in Andrena bees (Bergstrom et al., 1982). These two compounds are 
widespread among the Hymenoptera. There appear to be few reports of normal 
fatty acid methyl esters appearing in insects generally. Methyl oleate was found 
along with the methyl esters of other fatty acids in extracts of the Argentine ant, 
Iridomyrmex humilis (Cavill et al., 1980). 3-Hydroxy-3-methylbutan-2-one has 
only been isolated once before from an insect source (Francke et al., 1974), as 
an attractant for the ambrosia beetle, Xyloterus domesticus. Pentan-2-one has 
not been commonly found in insects, but has been detected in cockroach secre-
tions (Brossut, 1978), beetles (Moore and Brown, 1979), and bumblebees (Ceder-
berg, 1977), again in mandibular secretions. 
Although no mixed species aggregations were observed in the present study, 
the phenomenon is common among Megarhyssa species (Heatwole et al., 1963; 
Crankshaw and Matthews, 1981) and could be due to the presence of similar 
spiroacetals in other members of the genus, with final recognition only occurring 
when the emergent insect releases its secretion. In contrast, R. persuasoria is 
predominantly allopatric with respect to other Rhyssa species (Kirk, 1975). 
Male aggregations have also been observed in the ichneumonid Certonotus 
tasmaniensis (Turner) which is an indigenous species which has adapted to at-
tack S. noctilio in radiata pine. This species also has a characteristic odor. Ce-
phalic secretions are not confined solely to the Ichneumonidae, as myrtenol and 
methyl oleate were found to be the major volatiles in the mandibular secretion 
of Schletterarius cinctipes (Cresson) of the family Stephanidae. (Davies and 
Madden, unpublished results). 
It is, therefore, apparent that mandibular secretions occur within the par-
asitic Hymenoptera, acting to facilitate species recognition in mating behavior 
and the possible exclusion of competing species during oviposition. 
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INTRODUCTION 
The separation and identification of monoterpenes and sesquiterpenes in plant 
essential oils and other natural and synthetic sources relies heavily on gas chromato-
graphy. In some cases gas chromatography may be the sole means of identification, in 
which case at least two columns of substantially different polarity are required for any 
confidence in assignments based on direct comparison of retention times with 
standards or precise knowledge of Kovats retention indices'. Even where combined 
gas chromatography—mass spectrometry is used for the analysis. assignments often 
cannot be made on the basis of mass spectrometric data only. As has been noted by 
Jennings and Shibamoto 2 . many terpenes have essentially identical mass spectra. This 
can be due to the initial similarity of structures. or due to various fragmentations and 
rearrangements after ionization. Hence some knowledge of retention characteristics is 
often required to complement mass spectral data. 
Much of the relevant literature is concerned with retention data on the many 
different types of stationary phase that have been used for terpene separations. 
However, most work now is carried out on capillary columns with "standard" 
dimethyl polysiloxane (methyl silicone) non-polar and Carbowax 20M polar phases. 
Indices on these phases have been reported in the literature over many years, but no 
single source to data has provided a comprehensive summary. Jennings and 
Shibamoto 2 have published a substantial set of retention indices for flavour and 
fragrance compounds on these phases, including some 150 terpenes. Andersen and 
0021-9673/90/503.50 	C) 1990 Elsevier Science Publishers B.V. 
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co-workers' have provided a significant amount of information on sesquiterpene 
hydrocarbons. A ueneral discussion on the use of retention indices in essential oil 
analyses has been presented by Shibamoto". 
.The following tables list K mats retention indices for some 400 monoterpenes 
and sesquiterpenes (including some hydrogenation products) on either or both of these 
two types of stationary phase from various literature sources. Carbowax 20M 
(CW2OM ) phases include DB-Wax, BP20, PEG 20M and 1-1 P20. while methyl silicone 
phases include SE-30, SF-96, OV-1,0V-101, BPI, CPSIL5C13, SP2 I 00. DB1 and HP1. 
There will be slight differences between the McReynolds constants on these various 
"equivalent'S phases. The age of a column and amount of use it has had also have 
a slight influence on polarity of the liquid phase. 
The dependence of retention index on temperature has been extensively 
described, including specific reference to terpenes' 13 . In the temperature pro-
grammed mode variables such as carrier gas flow-rate and programme rate affect the 
measurement, since they determine the temperature range that the sample is exposed to 
prior to elution. Several articles have described the relationships between isothermal 
and temperature programmed retention indices"- ". 
Temperature has .a relatively small effect on Kovats' indices of terpenes on 
methyl silicone phases, but can have quite marked effects on the indices on CW20M. 
Differences of over 50 units can readily occur in indices determined under widely 
different conditions on CW20M. Multiple entries occur in the tables for many 
compounds to enable comparisons between different references and to give an 
indication of the dependence of the retention index on temperature. Some indices have 
been specifically excluded from the tables where there is a clear discrepancy between 
different sources. 
This summary is primarily intended as a guide to aid the analysis of essential oils 
and related natural and synthetic products by gas chromatography combined with 
mass spectrometry or other spectroscopic detection. Data on the majority of 
commonly occurring monoterpenes and sesquiterpenes are listed here, as well as data 
on some that are relatively obscure. The tables are listed in alphabetical order, and also 
in order of reported Kovats" indices on CW2OM and methyl silicone phases. These 
naturally do not represent elution sequences since the data include indices obtained 
under various isothermal and temperature programmed conditions, as well as multiple 
entries. Where possible generally accepted common names have been used. Isomer 
identification symbols (a, [I, )', 6, E, cis, trans, p, epi, etc.) have been added at the end of 
the parent compound name. 
2. KOVATS' RETENTION INDICES 
The Kovats* retention indices are listed in Tables 1-3. 
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TABLE 1 
ALPHABETICAL LIST OF REPORTED KOVATS' INDICES OF MONOTERPENES AND SES-
QUITERPENES ON CW2OM AND METHYL SILICONE PHASES 
/ = Kovits' index: T = isothermal temperature ( C) at which the index was determined. or - prou - if the 
index was determined using temperature programming. 
Compound C11/20:11 Alethid silicone 
T Ref I T Ref. 
Aequilobene 1702 150 4 1483 170 4 
Agarofuran Y. - 1907 prog 19 
Alaskene 	- 1763 165 5 
Alaskene ft- 1738 165 5 
Alloaromadendrene 1660 130 20 1475 150 20 
1662 prog 2 1478 prog 2 
1683 prog 21° 
Allo-ocimene 	is 1373 70 13 1132 110 13 
Allo-ocimene trans- 1392 70 13 1120 110 13 
Amorphene 	- 1691 prog 11 1451 prog 22 
1724 165 3 1492 170 3 
Anastreptene 1568 150 4 1391 170 4 
Aromadendrene 1650 prog 
Ascaridole 1278 110 23 
Ascaridole epoxide 1215 110 23 
Barbatene 7 - 1627 150 4 —1440 170 4 
Barbatene 1690 150 4 1473 170 4 
Beraamotene 7. - 1590 prog 24 1436 prog 24 
Beraamotene trans-ft- 1586 prog 21 1427 prog 
Bicycloelemene 1482 prog 
Bicyclogermacrene 1744 prog 2 1 1490 prog 22 
1738 130 20 
1768 prog 21° 
Bisabolane a 1492 130 25 1448 150 25 
Bisabolane b 1510 130 25 1458 150 25 
Bisabolene Y. - 1766 165 3 1505 170 3 
Bisabolene 1740 prog 22 1496 prog 
Bisabolene /I- 1745 165 3 1496 130 3 
Bisabolol 7 - )0)2 160 26 1595 175 26 
Bisabolol 11- 1666 175 27 
Borneo! 1698 prog 2 1164 prog 
1735 prog 21" 1154 110 23 
1177 175 27 
Born)') acetate 1599 135 28 1278 135 28 
1615 150 29 
Bornyl benzoate 1749 prog 
Born)') butyrate 1760 prog / 1473 proa 
Bornyl formate 1610 prog 2 1239 prog 
Bornyl isopentanoate 1774 prog 2 1512 prog 
Bourbonene 1586 165 3 1386 130 3 
1546 prog 2 1406 prog 2 
1526 prog 22 
Bulnesene a- 1729 prog 22 1502 prog 
Cadalene 2203 prog 30 1646 prog 22 
Cadina-1,4-diene 1786 prog 22 1518 prog 
(Continued on p. 4) 
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TABLE I (continued 
Ctaniunind C11 .2(01 ;If e 1101 Ailicane 
Rtl: I T Ref. 
Cathodic ()- 1784 165 3 1504 130 3 
1761 proe _ 1524 prog / 
1785 prog 21" 
Cadincne -,.- 1792 165 3 1507 130 
1766 proe 7 1227 prop 1 _ 
Cadinol 7 - 2714 prog 24 
Cadinol (i- 1 150 prog 31 
Cadinol T- 2136 prog 31 
Calacorene 7. - 1926 165 6 
1916 prog 22 
Calamenene 1837 prog 1 " 150 1 prog 2 1 
1839 150 4 1524 170 4 
1842 prog 1 _ 1518 prog / 
Camphane 1021 65 32 953 100 3 1 
Camphene 1066 75 5 95 1 100 5 
1078 75 28 956 100 28 
1083 proN...! 1 _ 954 prog 1 _ 
Camphor 1518 proe 7 1136 prog 1 _ 
1126 110 1 3 
Canine cis- 1064 65 3 1 986 100 3 1 
Carene 3- 1141 75 5 1009 100 5 
1156 75 1 8 1013 100 18 
Carvacrol 2159 prog 7 1297 prog / 
Carveol cis- 1820 prog 7 1215 120 1 3 
1222 prog 1 _ 
Carveol . mans- 1790 prog 1 _ 1209 prog 1 _ 
1200 120 23 
Carvcyl acetate cis- 1795 150 29 
Carveyl acetate /mos- 1759 150 1 9 
Carvomenthone 1181 110 23 
Carvomenthyl acetate 1641 150 29 
Carvone 1715 prog 2 1 1 28 prog 1 _ 
1 11 3 1 1 5 1 3 
Carvone oxide 1805 prog / 1261 prog / _ 
Carvyl propionate 1833 prog 1 1440 prog 7 
Caryolan- 1 -ol 1019 prog 31 
Caryophyllane a 1 522 130 25 1425 150 1 5 
Caryophyllane b 1533 130 1 5 143' 150 1 5 
Caryophyllane c 1555 130 1 5 1450 150 25 
Caryophyllane d 1562 130 1 5 1450 150 1 5 
Caryophyllene 1617 prog / 1428 prog / 
1618 130 20 1436 150 1 0 
1655 165 3 1417 130 3 
Caryophyllene alcohol 1033 prog 31 1559 prog 14 
Caryophyllene oxide 2000 prog 74 1576 prog 14 
1966 prog 31 
Cedrane 8/1H- 1617 130 25 1458 150 1 5 
Cedrane 87H- 1627 130 25 1465 150 1 5 
Cedrene epoxide I- 1961 prog 2 1585 prog 2 
Cedrene a- 1640 165 3 1414 130 3 
1578 prog 22 1411 prog 2 1 
1600 prog 2 1436 prog 1 :- 
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TABLE I . (continued) 
Compound C11 .7'0111 Methyl ovilicone 
T Ref. I T Ref 
Ced rene 1670 165 3 1421 130 3 
1633 prog 2 1446 proa 
1605 prog 
Cedrol 2100 prog / 1609 prog • 2 
1616 175 27 
Chamigrene 	- 1765 150 4 15 7 3 170 4 
Chamigrene /3- 1737 150 4 1550 170 4 
Chrysanthenone 1100 100 23 
Cineole 1.4- 1185 prog / 1010 prog 
1000 80 /3 
Cineole 1.8- 1 71 3 70 20 1025 100 20 
1228 prog 2 1017 prog 
Citronella! 1465 prog 2 1137 prog 
1491 135 28 1143 135 28 
1146 160 33 
Citronellic acid 1300 125 23 
Citronellol 1722 prog 2 1215 prog 
1765 150 34 1216 100 23 
1224 175 27 
Citronellol 7. - 1760 150 34 
Citronellyl acetate 1645 prog 2 1335 prog 
1662 135 28 1335 135 28 
1671 150 29 1335 140 23 
Citronellyl butyrate 1786 prog 2 1511 prog 
1811 150 19 
Citronellyl ethyl acetal 1626 pros 2 1423 prog 
Citronellyl formate 1600 prog 2 1261 prog 
1638 150 29 
Citronellyl isobutyrate 1705 prog 2 1469 prog 
1739 150 29 
Citronellyl pentanoate 1880 prog 2 1608 prog 
Citronellyl propionate 1700 prog 2 1427 prog 
1738 150 29 
Clovane 1621 175 35 
Clovene 1601 175 35 
Copaene 7- 1551 165 3 1378 130 3 
1493 prog // 1369 prog 27 
1519 prog / 1398 prog 
Copaene 13- 1626 prog / 1445 prog 2 
Cubebene 7 - 1481 130 20 1362 150 20 
1458 prog /) 1381 proa 22 
Cubebene 1560 130 20 1400 150 20 
1541 prog 2 7 1381 prog 22 
Cubenol epi- 2037 prog 30 
Cuparene 1811 130 20 1506 150 20 
1838 150 4 1516 170 4 
1831 prog 2 7 
Curcumene 7- (ar-) 1777 prog 
1787 165 3 1475 130 3 
Curcumene /3- 1756 165 3 1510 170 3 
(Continued on p. 6) 
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TABLE 1 (conlinuedi 
Compound CW20.11 Methyl silicone 
T Rif I T Rel. 
C . vclocitral 1100 110 1 3 
CyCIOCitral 1200 125 23 
Cyclosativene 1549 165 3 1400 170 3 
Cymene p- 1 1 50 75 5 1016 100 5 
1272 prog 2 1020 proe 
1275 70 20 1018 100 20 
Cymene-7-ol p- 1270 115 23 
Cymene-8-ol p- 1846 prog 24 1167 115 23 
Cymenene 1277 100 23 
Cyperene 1606 165 3 1398 130 3 
1535 proe 22 1398 prog 
Damascenone 1801 prog 31 
Dihydrocurcumene 1696 130 25 1448 150 25 
Dihydroagarofuran 1737 prog 19 
Dihydrocarveol 1713 prog 2 1188 prog 
Di hyd rocarvone 1600 prog 2 1183 prog 
Dihydrocarvyl acetate 1670 prog 2 1319 prog 2 
1700 150 29 
Dihydrogeraniol 1759 150 34 
Dihydrohumulene 1655 175 35 
Dihydrolinalool 1.2- 1512 prog 2 1122 prog 
1537 150 34 
Dihydrolinalool 6,7- 1449 150 34 
Dihydromyrcenol 6.10- 1438 prog 2 1063 prog 2 
1473 150 34 1056 80 23 
Dihydromyrcenyl acetate 1431 prog 2 1202 prog 2 
Dihydronerol 1725 150 34 
Dihydroterpinyl acetate 1561 prog 2 1282 prog 
Dimethy1-1.6-octadiene 3.7- 946 90 23 
Dimethyloctane 2.6- 922 65 32 938 100 32 
Dimethy1-2-octene 2.6- 966 80 23 
Drimenol 2525 prog 19 
Elemane 1460 130 25 1403 150 25 
Elemene /3- 1608 130 20 1400 150 20 
1591 prog 22 
Elemene (5- 1469 prog 22 1381 prog 
Elemene 1642 prog 22 1425 prog 21 
Elemol 2078 prog 24 1540 prog 24 
Eudesmane 4xH.5y.H- 1636 130 25 1497 150 25 
Eudesmane 4/3H.57.H- 1582 130 25 1405 150 25 
Eudesmol Y.- 2237 prog 19 
2 149 prog 21" 
Eudesmol /1- 2248 prog 19 
1 258 prog 21" 
Eudesmol 2182 prog 19 
Eudesmol 2244 prog 19 
Eudesmol 10-epi- -,.- 2121 prog 19 
Farnesene cis,cis-y- 1697 prog 22 
Farnesene cis,trans-a- 1727 prog 22 
Farnesene 1722 prog 22 
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TABLE 1 (continued) 
Compound C11 -21).1I 	 silicone 
  
1 . 	R(J. 	i 	i 	Rel. 
Farnesene DWI'S .1 	 1756 	130 	20 	1501 	150 	20 
1735 prog 2 7 	1494 prog 22 
Fa rnesene 	 1636 prog 
Farnesene 1671 	130 	10 	1426 	150 	20 
1668 	165 	3 	1449 	170 	4 
1668 prog 11 	1448 prog 36 
Farnesol trans./runs- 	 1745 	175 	1 7 
Farnesyl acetate 	 1 2 1 5 200 	28 	1787 200 	1 8 
Fenchene 7- 	 1071 	70 	13 	957 	110 	13 
Fenchene /(- 1057 	70 	13 	949 	110 	13 
Fenchol 	 1574 prog 	2 	1110 prog 
1580 	135 	1 8 	11 1 5 	135 	28 
Fenchone 	 1410 prog 	2 	1080 prog 
1077 	105 	23 
Fenchyl acetate 	 1473 prog 	2 	1 110 prog 
Geranial 	 1730 prog 	2 	1 1 5 1 prou 
1260 	120 	1 3 
Geranic acid 	 1347 	140 	1 3 
Geraniol 	 1842 	150 	34 	1 1 34 	175 	1 7 
1797 pros 	2 	1243 prog 
1237 	120 	1 3 
Geranyl acetate 	 1754 	135 	1 8 	1363 	135 	1 8 
Geranyl butyrate 1872 prog 	2 	153 1 prog 
1904 	150 	19 
Geranyl formate 	 1684 prog 	2 	1282 prou 
1717 	150 	1 9 
Geranyl isobutyrate 	 1795 prog 	2 	1493 prog 	1 
1821 	150 	29 
Geranyl isopentanoate 	1895 prog 	2 	1593 prog 
Geranyl pentanoate 1960 prog 	2 	1632 prog 
Geranyl propionate 	 1834 150 	1 9 
Germacrane b 	 1572 130 	1 5 	1477 150 	1 5 
Germacrane e 1585 130 	25 	1482 150 	25 
Germacrane d 	 1593 130 	25 	1489 150 	1 5 
Germacrene D 1712 prog 1 2 	1468 prog 21 
1718 	130 	20 	1488 	150 	20 
Globulol 	 2104 prog 21' 
Grandisol 1200 110 	23 
Guaiene a- 	 1651 prog 22 	1454 prog 
Gudiene ti- 1667 prog 22 	1482 prog 2 1 
Guaiene 	 1729 prog 71 	1502 prog 11 
Gurjunene 7- 	 1591 	165 	3 	1413 	130 	3 
1529 prog // 	1400 prog 
Gurjunene 13- (calarene) 	1656 	165 	3 	1435 	130 	3 
1593 prog 22 
Helmiscapene a- 	 1683 150 	4 	1467 170 	4 
Helmiscapene /1- 1686 150 	4 	1466 170 	4 
Himachalene ar- 	 1873 150 	4 	1542 170 	4 
Himachalene a- 1704 165 	3 	1444 130 	3 
1649 prog 22 	1442 prog 22 
Himachalene /3- 	 1736 150 	4 	1517 170 	4 
1718 prog 22 	1494 prog 22 
(Coniinued on p. 8 ) 
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TABLE 1 (conlinued) 
Compound C11 .2031 Alearyl 
I T Ref I T R(11 
Himachalene -,.- 1723 150 4 1499 .170 4 
Flop ether 1360 prog 31 
H umuladienone 1952 prog 31 
Humulane 1609 175 35 
Humulene 1672 prog // 1437 prog 22 
1707 prog 'I" 1465 prog 2 
1719 165 3 1447 130 3 
H umulene epoxide 1 1972 prog 31 
H umulene epoxide II 2011 prog 31 
Humulenol II 11 34 prog 31 
Humulol 2124 prog 31 
Ipsdienol 1128 100 23 
Ipsenol 1087 90 23 
I ridomyrmecin 1400 135 23 
Isoborneol 1660 prog " 1157 prog 1 _ 
1149 110 23 
Isobornyl acetate 1584 prog 1 1279 prog / _ 
16 1 3 150 29 
Isobornyl formate 1596 prou / 1228 prou 1 
Isobornyl propionate 1676 prog / 1376 prou / 
Isocamphane irons- 1056 65 3' 975 100 3' 
Isocamphane cis- 1065 65 3' 980 100 3' 
Isoueraniol cis- 1812 150 2 
Isogeraniol irons- 1812 150 2 
I sogeraniol -,.- 1800 150 1 _ 
lsogeranyl acetate -,.- 1726 150 29 
Isoiridomyrmecin 14 1 ' 150 23 
Isomenthol 1667 130 20 1182 130 20 
1174 100 23 
Isomenthone 1528 130 20 1156 130 10 
1468 prog 39 1151 prog 39 
Isomentlwl acetate 1579 130 20 1283 130 20 
1599 150 29 
Isopinocampheol 1170 115 23 
Isopinocamphone 1157 110 23 
Isopulegol 1574 prog 2 1145 prog / 
1133 110 23 
Isopulegyl acetate 1585 prog 2 1258 prog ' 
1608 150 29 
Isosativene 1639 165 3 1441 170 3 
Junenol 20 1 8 prog 31 
Karahana ether 1368 prog 31 
Lavandulol 1662 prog 1 1154 prog / 
1707 150 34 1153 110 23 
Lavandulyl acetate 1597 prog 2 1274 prog / 
1609 150 29 
Limonene 1187 75 5 1025 100 5 
1206 prog / 1030 prog 2 
1210 70 20 1024 100 213 
Limonene epoxide cis- 1119 100 23 
Limonene epoxide trans- 1122 100 23 
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TABLE 1 (continu('d) • 
CO 1 Ilptn lini C11 .20.1/ Meihy/ silicone 
/ 7 . kc/. 
Linalool 1506 prog 7 1092 prop 7 
1533 135 7 8 1097 135 7 8 
1555 150 34 1086 90 7 3 
Linalool oxide C I'S - ((until) 14 7 3 prog_ 2 6 1068 prog 71' 
1461 prog 30" 
Linalool oxide trans- (furan) 1451 prog 2 1' 1082 prog -i" 
143 7 prog 30" 
Linalool oxide I (pyran) 1063 100 7 3 
Linalool oxide II (pyran) 1077 100 1 3 
Linalyl acetate 1538 prog 7 1246 prog 2 
1569 150 79 1240 130 23 
Linalyl 'butyrate 1680 prog / 1420 prog / 
1698 150 29 
Linalyl formate 1570 prog 1 1206 prog / 
Linitly1 isohutyrate 1597 prog , 1366 prog 7 
16 77 150 29 
Linalyl isopentanoate 1698 prog ? 1461 prog .) 
Linalyl 2-methylbutyrate 1695 prog , 1450 prog ? 
Linalyi pentanoate 1765 prog , 1500 prog ..) 
Linalyl propionate 1596 prog 7 _ 1324 prog 2 
1624 ISO 7 9 
Longicyclene 1554 165 3 1371 130 3 
Longifolane 77.H- 1627 130 7 5 1460 150 75 
Loneifolane 7/(H- 1633 130 7 5 1467 150 25 
Loneifolcne 1574 proe 7 7 1398 prog 7 2 
1643 165 3 1404 130 3 
Longipinenc 7- 1541 165 37 1359 130 3 
Loneipinene /(- 1612 150 4 1432 170 4 
Men tha-2.8-dien-1-ol cis-p- 1120 95 7 3 
Menthane trans-p- 1022 65 37 981 100 3 7 
Menthanc cis-p 1045 65 3 1 995 100 32 
Men than-1-ol p- 1156 160 33 
Menthan-2-ol p- 1205 160 33 
Menthan-7-ol cis-p- 1823 120 12 
Menthan-7-ol trans-p- 1800 120 1 7 
Menthan-8-ol p- 1162 160 33 
Menthan-9-ol cis-p- 1806 120 1 7 
Menthan-9-ol trans-p- 1777 120 1 7 
Mcnthan-8-y1 acetate cis-p- 1598 150 7 9 
Menthan-8-y1 acetate trans-p- 16 7 3 150 29 
Menth- 1 -ene p- 985 160 33 
Menth-4(8)-ene p- 998 160 33 
Menth-1-en-9-ol p- 1904 120 12 
Menth-1(7)-en-9-ol p- 1881 120 12 
Menth-2-en-l-ol cis-p- 1560 pro2 38' 1111 prog 38' 
1662 prog 21'" 
Menth-2-en-l-ol trans-p- 1628 prog 38 1128 prog 38' 
1597 prog 21° ." 
Menth2-en-7-o1 cis-p- 1839 120 12 
Menth-2-en-7-ol trans-p- 1842 120 12 
Menth-3-en-9-ol p- 1736 120 12 
(Continued on p. 10) 
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TAI3LE 1 ( eowinued) 
COI I Ipo pm C1.1 .20111 
T RI I T R(JI 
Men th-8-en-l-ol p- 1156 160 33 
Menth-8-en-2-ol p- 1208 160 33 
Menthofuran 1503 130 20 1147 130 20 
1460 pro g 39 1155 prog 39 
Menthol 1612 prog 2 1171 prog 
1640 130 20 1168 130 * 20 
1600 prog 39 1171 prog 39 
Menthone 1478 prog 2 1143 proe 
1518 130 20 1158 130 20 
1444 prog 39 1142 prog 39 
Mcnthyl acetate 1600 150 29 
1541 prog 39 1281 prog 39 
M uurolene 1753 165 3 1495 130 3 
1727 prog 11 
1730 prog 2 1500 proe 2 
M uurolene 1695 130 20 1486 150 20 
1725 165 3 1486 150 20 
1692 prog 
Muurolene E- 1714 165 3 1445 130 3 
M yrcene 1156 prog 2 986 prog 
1166 75 28 988 100 28 
1168 70 20 984 100 20 
Myrcene-8-ol 1919 150 34 
Myrcenol 1585 prog 2 1103 prog 
1631 150 34 
M \Teeny' acetate 1574 prog 2 1247 prog 2 
1595 150 29 
M yrcenyl propionate 16 1 5 prog 2 1327 prog 
M yrtanol cis- 1245 120 23 
M yrtenal 1173 120 23 
M yrtenol 1281 120 23 
M yrtenyl acetate 1720 150 29 
Neocarvomenthyl acetate 1604 150 29 
Neoisocarvomenthyl acetate 1672 150 29 
Neoisomenthol 1634 130 20 1180 130 20 
Neoisomenthyl acetate 1602 130 20 1297 130 20 
1623 150 29 
Neomenthol 1559 prog 39 1159 prog 39 
1159 120 23 
Neomenthyl acetate 1569 150 29 
Neral 1680 prog 2 1227 prog 
1220 120 23 
Nerol 1757 prog 2 1218 prog 2 
1808 150 34 1218 120 23 
Nerolic acid 1316 140 23 
Nerolidol cis- 1961 prog 2 1524 prog 2 
1540 175 27 
Nerolidol trans- 2000 prog 2 1553 prog 2 
2044 prog 19 
Neryl acetate 1699 prog 2 1345 prog 2 
1735 150 29 1343 135 23 
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TABLE 1 (co/unwe(I) 
Compound C11/20A1 Aiello -1 silicone 
1 T Ref 1 T Ref 
Neryl butyrate 1868 150 79 
Nervl formate 1663 prog / 1267 prog 7 _
1700 150 79 
Neryl isobutyrate 1764 prog 1 1474 pros 1 _ 
1790 150 79 
Neryl isopentanoate 1864 pros 2 1574 prog 2 
Neryl propionate 1771 prog 2 1436 prog 2 
1794 150 29 
Nootkatone 2250 prog / _ 1802 prou / 
Norbornyl acetate 1476 prog / 1112 prog 1 
Ocimene cis-/3- 1238 70 70 1027 100 20 
1228 prog / 1025 prog 1 
1027 90 7 3 
Ocimene nuns-fl- 1257 70 70 1042 100 70 
1250 prog / 1038 prog 7 
Ocimenol cis- 1660 150 34 
Ocimenol trans- 1685 150 34 
Patchoulene /3- 1488 prog 7 2 1378 prog 22 
PeriIla aldehyde 1253 120 23 
Perillyl acetate 1791 150 29 
Perillyl alcohol 1281 115 7 3 
Phellandrene Y.- 1 177 prog 2 1002 prog / 
1173 70 13 1007 110 13 
1000 90 7 3 
PheIlandrene /1- 1216 prog 2 1025 prog / 
1213 70 13 1032 110 13 
Phellandrol 1896 120 1 7 
Pinane cis- 1075 prog 2 987 prog , 
1061 65 32 977 80 7 3 
1002 160 33 
Pi 11 a ne trans- 1062 prog / 981 prog 2 
1049 65 32 973 100 37 
Pinene.a- 1036 75 28 942 100 1 8 
1038 70 70 939 100 20 
942 prog 2 
Pinene oxide a- 1100 112 23 
Pinene /3- 1120 70 20 978 100 20 
1120 75 28 983 100 28 
1124 prog 2 981 prog ? 
Pinocamphone 1152 1-10 23 
Pinocarveol trans- 1132 110 7 3 
Pinocarveyl acetate trans- 1682 150 29 
Pinonic acid cis- 1427 165 23 
Piperitenone 1315 125 23 
Piperitenone oxide 1997 prog 21° 
Piperitone 1739 prog 2 1247 prog 2 
1231 125 23 
Pulegone 1662 prog 2 1230 prog 2 
Pyrovetivene a- 1817 165 3 1522 170 3 
Rose oxide cis- 1354 prog 2 1087 prog 2 
1100 95 23 
(Continued on p. 12) 
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TABLE I (comintie(I) 
Compound Methyl silicone 
T Rd: I T Ref 
Rose oxide trans- 1370 prop. 1100 prog 7 
1114 95 23 
Sabinene 1130 70 20 972 100 20 
1130 prou 2 976 prog 
Sabinene hydrate cis- 1092 prog 38 
Sabinene hydrate trans- 1463 prog 38 1060 prog 38 
Sabinol (cis-) 1683 prog 2 1135 prog 
1130 115 23 
Sabinyl acetate (cis-) 1651 prog 2 1262 prog 
1677 150 29 
Safranal 1167 120 1 3 
Santalene 1638 prog 22 1437 prog 11 
Santalene 7. - 1574 prog 22 1412 prog 
Saritalene 11- 1653 prog 22 1450 prog 11 
Santalol 7- 1660 175 27 
Sativene 1595 165 3 1421 170 3 
Scapanene 1664 150 4 1465 170 4 
Selina-17( 11)-diene 1791 prog 19 
Selina-4(14). 7(1 I )-diene 1816 165 3 
Selina-4(14), 7-diene 1694 165 3 1476 170 3 
Selina-4,1 I-diene 1702 150 4 
Selinene 7 - 1751 150 4 1513 170 3 
1729 prog 22 1484 prog 22 
1759 prog 21. 
Selinene If- 1767 165 3 1506 170 3 
1727 prog 1 2 1477 prog 22 
1756 prog 
Selinene 1728 165 3 
Selinene 7-epi-y- 1775 prog 19 
Selinene 10-epi-7- 1803 165 37 
Sesquiphellandrene /1- 1776 prog ?") 1512 prog 11 
Seychellene 1669 prog 22 
Shisool 1248 130 23 
Sibirene 1594 150 4 1427 170 4 
Sinuene 1646 150 4 1451 170 4 
Spathulenol 2153 prog 21° 
Tagetone cis- 1136 110 23 
Taeetone trans- 1125 110 23 
Tetpinene 7- 1189 70 20 1016 100 20 
1188 70 13 1018 110 13 
Terpinene 1247 75 28 1056 100 28 
1251 prog 2 1057 prog 2 
Terpinene-1-ol 1576 prog 24 
Terpinene-4-ol 1601 135 28 1129 135 28 
1628 prog 2 1175 prog 2 
1637 prog 21° 1170 115 23 
1160 175 27 
Terpinene-4-y1 acetate 1640 150 29 1282 120 23 
Terpineol a- 1731 prog 21° 1185 prog 2 
1685 135 28 1178 135 28 
1205 160 33 
Terpineol 13- 1616 prog 2 1137 prog 2 
Terpineol (5- 1655 prog 2 1160 prog 2 
NW. DAVIES 
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TABLE 1 (continued) 
13 
Conipottlid C1120111 Aletkil silicate 
T Ref I 	T Ref 
Terpinolene 1279 	75 18 1074 	100 28 
1289 	70 20 1081 	100 20 
1287 	prog 
Terpinyl acetate 1687 	prog 2 1333 	prog 2 
1711 	150 29 1337 	140 23 
Terpinyl acetate cis-13- 162 1 	150 29 
Terpinyl butyrate 1828 	prog 2 1514 	prog 
Terpinyl formate 1666 	prog 2 1333 	prog 2 
Terpinyl isobutyrate 1748 	prog 2 1467 	prog 2 
Terpinyl isopentanoate 1858 	prog 2 1565 	prog 
Terpinyl pentanoate 1928 	prog 2 1614 	prog 2 
Terpinyl propionate 1747 	prog 2 1426 	prog 
Tetrahydrogeraniol 1616 	prog 2 1185 	prog 
1675 	150 34 
Tetra hyd rogeranyl acetate 1581 	150 19 
Tetrahydrohumulene 1653 	175 35 
Tetrahydrolavandulol 1600 	150 34 
Tetrahydrolinalool 1397 	prog 2 1087 	prog 2 
1431 	150 34 1088 	90 23 
Tetrahydrolinalyl acetate 14 11 	150 1 9 
Tetrahydromyrcenol 1414 	prog 2 1090 	prog 34 
1449 	150 34 
Tetrahydrothujopsane a 1668 	130 25 1496 	150 1 5 
Tetrahydrothujopsane h 1678 	130 1 5 1508 	150 25 
Thuj-2-en-4-ol cis- 1551 	100 40 1053 	140 ' 40 
Thuj-2-en-4-ol trans- 1468 	100 40 1035 	140 40 
Thujene 7- 1038 	70 1 0 931 	100 10 
1023 	70 13 935 	110 13 
938 	prog 
Thujone 7.- 1100 	110 1 3 
Thujopsene 1626 	prog 2 1 1425 	prog 22 
1660 	prog 2 1451 	prog 
1684 	165 3 1430 	130 3 
Thujy1 acetate 1626 	150 29 
Thymol 1270 	130 23 
Tricyclene 1009 	75 5 928 	100 5 
Undulatene 1811 	150 4 1557 	170 4 
Valencane (nootkatane) 1624 	130 25 1493 	150 1 5 
Valencenc 1711 	prog 22 1482 	prog 22 
1751 	prog 34 1487 	prog 2 
1760 	165 3 1457 	130 3 
Valerianol 2231 	prog 19 
Verbenol 1165 	100 23 
Verbenol trans- 1140 	120 23 
Verbenone 1733 	prog 2 1195 	prog 2 
1185 	110 23 
Vetivenene /3- 1885 	165 3 1563 	170 3 
1868 	prog 22 1544 	prog 
Viridiflorene 1697 	prog 22 1484 	prog 22 
Viridiflorol 2103 	180 20 1588 	150 • 20 
2112 	prog 21 0  
(Continued on p. 14) 
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TABLE 1 ( continued 
N.W. DAVIES 
Compound 	' CIV201t1 Methyl silicone 
T Ref I T Ref: 
Ylangene 1539 165 3 1396 170 3 
1491 proe 22 1368 prou 22 
Zingiberene 1728 prog 22 1486 prog 
1738 165 3 1480 170 3 
Zizaene 1706 165 3 1482 170 3 
Zonarene 1781 165 8 
° Indices reported from this laboratory were determined on a 50 m x 0.33 mm I.D. BP20 column 
with a 0.5-pm film thickness (S.G.E.), temperature programmed from 100 to 220°C at 3°C/min with helium 
as carrier gas. 
° Refs. 2 and 30 have conflicting orders of elution for cis- and irans-linalool oxides. 
Refs. 21 and 38 have conflicting orders of elution for cis- and pinis-p-menth-2-en- 1 -ols. 
TABLE 2 
KOVATS' INDICES LISTED IN ORDER ON CW20M 
Column headings and footnotes as for Table I. 
Compound T Ref. Compound I T Rrf 
Dimethyloctane 2.6- 922 65 32 Myrcene 1156 prog / 
Tricyclene 1009 75 5 Myrcene 1166 75 28 
Camphane 1021 65 32 Myrcene 1168 70 20 
Menthane trans-p- 1022 65 32 Phellandrene 7- 1173 70 13 
Thujene a- 1023 70 13 Phellandrene 7- 1177 prog _ '
Pinene a- 1036 75 28 Cineole 1.4- 1185 prog 1 _
Pinene a- 1038 70 20 Limonene , 1187 75 5 
Thujene a- 1038 70 20 Terpinene 7- 1188 70 13 
Menthane cis-p- 1045 65 32 Terpinene 7- 1189 70 20 
Pinane franc- 1049 65 32 Limonene 1206 prog 7 
Isocamphane trans- 1056 65 32 Limonene 1210 70 20 
Fenchene 13- 1057 70 13 Phellandrene 13- 1213 70 13 
Pinane cis- 1061 65 32 Phellandrene 13- 1216 prog 1 
Pinane trans- 1062 prog 2 Cineole 1,8- 1223 70 20 
Carane cis- 1064 65 32 Cineole 1.8- 1228 prog 1 _
Isocamphane cis- 1065 65 32 Ocimene cis-13- 1228 prog / 
Camphene 1066 75 5 Ocimene cis-fl- 1238 70 20 
Fenchene 7- 1071 70 13 Terpinene y- 1247 75 28 
Pinane cis- 1075 prog 7 Cymene p- 1250 75 5 
Camphenc 1078 75 28 Ocimene trans-13- 1250 prog 1 _
Camphene 1083 prog 2 Terpinene -i- 1251 prog 7 
Pinene /3- 1120 70 20 Ocimene trans-fl- 1257 70 20 
Pinene [3- 1120 75 28 Cymene p- 1272 prog 7 
Pinene fl- 1124 prog 2 Cymene p- 1275 70 20 
Sabinene 1130 70 20 Terpinolene 1279 75 28 
Sabinene 1130 prog 2 Terpinolene 1287 prog 7 
Carene 3- 1141 75 5 Terpinolene 1289 70 20 
Carene 3- 1156 75 28 Rose oxide cis- 1354 prog 2 
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TABLE 2 rcodrinited) 
C'oriipoand T Ref. Compound T 10. 
Hop ether 1360 prog 31 Linalyl acetate 1538 prog 7 
Karahana ether 1368 prog 31 Ylangene 7. - 1539 165 3 
Rose oxide mars- 1370 prog Cubebene [I- 1541 pro!! 77 
Allo-ocimene cis- 1373 70 13 Longipinene 7 - 1541 165 37 
Allo-ocimene !rims- 1392 70 13 Menthyl acetate 1541 prog 39 
Tetrahydrolinalool 1397 proa Bourbonene 1546 prog 
Fenchone 1410 prog Cyclosativene 1549 165 3 
Tetrahydromyrcenol 1414 prog 7 Copaene 7 - 1551 165 3 
Tetrahydrolinalyl acetate 14// 150 29 Thuj-2-en-4-ol  eis- 1551 100 40 
Linalool oxide cis- (furan) 14/3 prog .7" Longicyclene 1554 165 3 
Dihydromyrcenyl acetate 1431 prog Caryophyllane c 1555 130 15 
Tetrithydrolinalool 1431 150 34 Linalool 1555 150 34 
Linalool oxide Irons- (furan) 143? prog 30" Neomenthol 1559 prog 39 
Dihydromyrcenol 6,10- 1438 prog 2 Cubebene I1- 1560 130 20 
Menthone 1444 prog 39 Menth-2-en-l-ol cis-p-. 1560 prog 38' 
Dihydrolinalool 6,7- 1449 150 34 Dihydroterpinyl acetate 1561 prog 
Tetrahydromyrcenol 1449 150 34 Caryophyllane d 1562 130 25 
Linalool oxide trans- (furan) 1451 prog Anastreptene 1568 150 4 
Cubebene a- 1458 prog 2 1 Linalyl acetate 1569 150 29 
Elemane 1460 130 15 Neomenthyl acetate 1569 150 29 
Menthofuran 1460 prog 39 Linaly1 formate 1570 prog 
Linalool oxide cis- (furan) 1461 prog 30" Germacrane h 1572 130 15 
Sabinene hydrate Irons- 1463 prog 38 Fenchol 1574 prog 
Citronella! 1465 prog 2 lsopulegol 1574 prog 
Isomenthone 1468 prog 39 Longifolene 1574 prog 11 
Thuj-2-en-4-ol trans- 1468 100 40 Myrcenyl acetate 1574 prog 
Elemenc 1469 prog Santalene 7. - 1574 prog 77 
Dihydromyrcenol 6,10- 1473 150 34 Terpinene-l-ol 1576 prog 1 4 
Fenchyl acetate 1473 prog Cedrene 1578 prog 22 
Norbornyl acetate 1476 prog 2 Isomenthyl acetate 1579 130 20 
Menthone 1478 prog 2 Fenchol 1580 135 28 
Cubebene 1481 130 20 Eudesmane 4fiH. 5714- 1582 130 25 
Bicycloelemene 1482 prog 24 Tetrahydrogeranyl acetate 1582 150 29 
Patchoulene /3 - 1488 prog 22 lsobornyl acetate 1584 prog 2 
Citronella! 1491 135 28 Germacrane c 1585 130 25 
Ylangene a- 1491 prog 22 Isopulegyl acetate 1585 prog 2 
Bisabolane a 1492 130 25 Myrcenol 1585 prog 
Copaene a- 1493 prog 22 Bergamotene 1586 prog 22 
Menthofuran 1503 130 20 Bourbonene 11- 1586 165 3 
Linalool 1506 prog 2 Bergamotene 7. - 1590 prog 24 
Bisabolane h 1510 130 25 Elemene /1- 1591 prog 22 
Dihydrolinalool 1.2- 1512 prog 2 Gurjunene a- 1591 165 3 
Camphor 1518 prog 2 Germacrane d 1593 130 25 
Menthone 1518 130 20 Gurjunene 	(calarene) 1593 prog 2/ 
Copaene a- 1519 prog 2 Sibirene 1594 150 4 
Caryophyllane a 1522 130 25 Myrcenyl acetate 1595 150 29 
Bourbonene 1526 prog 22 Sativene 1595 165 3 
Isomenthone 1528 130 20 Isobornyl formate 1596 prog 2 
Gurjunene a- 1529 prog 22 Linalyl propionate 1596 prog 2 
Caryophyllane h 1533 130 25 Lavandulyl acetate 1597 prog 2 
Linalool 1533 135 28 Linalyl isobutyrate 1597 prog 2 
Cyperene 1535 prog 22 Menth-2-en-l-ol trans-p- 1597 prog 21°' 
Dihydrolinalool 1,2- 1537 150 34 Menthan-8-y1 acetate cis-p- 1598 150 29 
(Continued on p. 16) 
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TABLE 2 (conthmed) 
N.W. D.AVIES 
Contprnind T Rif. Compound I T 
Bornyl acetate 1599 135 28 Santalene ern-Il- 1638 prog 
Isomenthyl acetate 1 599 150 29 lsosativene 1639 165 3 
Cedrene 2- 1600 proa 2 Cedrene 7.- 1640 165 3 
Citronelly1 formate 1 600 prog 2 Menthol 1640 130 20. 
Dihydrocarvone 1600 prog 2 Terpinene-4-y1 acetate 1640 150 29 
Menthol 1600 prog 39 Carvomenthyl acetate 1641 150 29 
Menthyl acetate 1600 150 29 Elemene 1642 proa 
Tetrahydrolavandulol 1600 150 34 Longifolene 1643 165 3 
Clovene 1601 175 35 Citronellyl acetate 1645 prog 
Terpinene-4-ol 1601 135 28 Sinuene 1646 150 4 
Neoisomenthyl acetate 1602 130 20 Himachalene 7.- 1649 prog 
Neocarvomenthyl acetate 1604 150 29 Aromadendrene 1650 prog 21" 
Cedrene /1- 1605 prog 22 Guaiene a- 1651 proa 21 
Cyperene 1606 165 3 Sabinyl acetate (cis-) 1651 prog 
Elemene /1- 1608 130 20 Santalene 1653 proa // 
Isopulegyl acetate 1608 150 29 Tetrahydrohumulene 1653 175 35 
Humulane 1609 175 35 Caryophyllene 1655 165 3 
Lavandulyl acetate 1609 150 29 Dihydrohumulene 1655 175 35 
Bornyl formate 1610 prog 2 Terpineol 1655 prou 
Longipinene /3- 1612 150 4 Gurjunene 	(calarene) 1656 165 3 
Menthol 1612 prog 2 Alloaromadendrene 1660 130 20 
Bornyl acetate 1615 150 29 Isoborneol 1660 prog 
Terpineol /3- 1616 prog 2 Ocimenol cis- 1660 150 34 
Caryophyllene 1617 prog 2 Thujopsene 1660 proa 
Cedrane 8/111- 1617 130 25 Alloaromadendrene 1662 prog 
Caryophyllene 1618 130 20 Citronellyl acetate 1662 135 1 8 
Clovane 1621 175 35 Lavandulol 1662 prog 
Linalyl isobutyrate 1622 150 29 Menth-2-en-l-ol 1662 prog 21”. , 
Terpinyl acetate cis-fi- 16 1 2 150 29 Pulegone 1662 prog 
lsobornyl acetate 1623 150 29 Ncryl formate. 1663 prog 
Menthan-8-y1 acetate Scapanene 1664 150 4 
trans-p- 1603 150 29 Terpinyl formate 1666 prog 
Neoisomenthyl acetate 1623 150 29 Guaiene /3 - 1667 prog 
Lina. lyl propionate l624 150 29 Isomenthol 1667 130 20 
Valencane (nootkatane) 1624 130 25 Farnesene irons-/I- 1668 165 3 
Myrcenyl propionate 1625 prog 2 Farnesene trans-11- 1668 prog 
Citronellyl ethyl acetal 1626 prog 2 Tetrahydrothujopsane 1668 130 25 
Copaene 13- 1626 prog 2 Seychellene 1669 prog 21 
Tetrahydrogeraniol 1626 prog 2 Cedrene /I- 1670 165 3 
Thujopsene 1626 prog 22 Dihydrocarvyl acetate 1670 prog 
Thujyl acetate 1626 150 29 Citronellyl acetate 1671 150 29 
Barbatene 1627 150 4 Farnesene trans-f)- 1671 130 20 
Cedrane 82H- 1627 130 25 Humulene 1672 prog 21 
Longifolane 72H- 1627 130 25 Neoisocarvomenthyl acetate 1672 150 29 
Menth-2-en-l-ol trans-p- 1628 prog 38" Tetrahydrogeraniol 1675 150 34 
Terpinene-4-ol 1628 prog 2 Isobornyl propionate 1676 prog 
Mytcenol 1631 150 34 Sabinyl acetate (dc-) 1677 150 29 
Cedrene /3- 1633 prog 2 Tetrahydrothujopsane b 1678 130 25 
Longifolane 7/3H- 1633 130 25 Linalyl butyrate 1680 prog 
Neoisomenthol 1634 130 20 Neral 1680 prog 2 
Eudesmane 42H, 52H- 1636 130 25 Pinocarveyl acetate trans- 1682 150 29 
Farnesene cis-fl- 1636 prog 22 Alloaromadendrene 1683 prog 21° 
Citronelly1 formate 1638 150 29 Helmiscapene a- 1683 150 4 
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TABLE 2 (c('minued) 
Compound. 1 T Ref. Compound 1 T [kr 
Sabinol (cis-) 1683 prog 1 Bulnesene 7. - 1729 prog 21 
Geranyl formate I 68 4 proe 1 Guaiene 6- 17/9 prog 22 
Thujopsene 1684 165 3 Selinene a.- 1729 prog 12 
Ochnenol trans- 1685 150 34 Geranial 1730 proe 2 
Terpincol 1685 135 28 Muurolene 7 - 1730 prog 
Helmiscapene 11- 1 686 150 4 Verbenone 1733 prog 
Terpinyl acetate 1687 prog / Borneo! 1735 prog 21 0 
Barbatene If- 1690 150 4 Farnesene trans,n-ans-x- 1735 prog 
Amorphene a- 1691 prog 2" Neryl acetate 1735 150 29 
Muurolene 1692 prog // Himachalene /S- 1736 150 4 
Selina-4(14). 7-diene 1694 165 3 Menth-3-en-9-ol p- 1736 120 P 
Linalyl 2-methylbutyrate 1695 prog / Charnierene 11- 1737 150 4 
Muurolene y- 1695 130 20 Dihydroagarofuran I1- 1737 prog 19 
Dihydrocurcumene 1696 130 25 Alaskene /1- 1738 165 5 
Fa rnesene eis.cis-a- 1697 prog 2" Bicyclogermacrene 1738 130 20 
Viriditlorene 1697 prog ',/ Citronellyl propionate 1738 150 29 
Borneo! 1698 prog / Zingiberene 1738 165 3 
Linalyl butyrate 1698 150 29 Citronellyl isobutyrate 1739 150 29 
Linalyl isopentanoate 1698 prog 1 Piperitone 1739 prog 
Neryl acetate 1699 prog 2 Bisabolene cis-1- 1740 prog 22 
Citronellyl propionate i 700 prog 2 Bicycloaermacrene 1744 prog 22 
Dihydrocarvyl acetate 1700 150 29 Bisabolene [I- 1745 165 3 
Neryl formate 1700 150 29 Terpinyl propionate 1747 prog 
Aequilobene 1702 150 4 Terpinyl isobutyrate 1748 prog 
Selina-4-.1 I-diene 1702 150 4 Selinene 7. - 1751 150 4 
Himachalene 1704 165 3 Valencene 1751 prog 34 
Citronellyl isobutyrate 1705 proe / Muurolene a- 1753 165 3 
Zizaene 1706 165 3 Geranyl acetate 1754 135 28 
Humulene 1707 prog 21° Curcumene f1- 1756 165 3 
Lavandulol 1707 150 34 Farnesene trans,trans-1- 1756 130 20 
Germacrene D 1712 prog 22 Selinene fi- 1756 prog 21" 
Dihydrocarveol 1713 prog 2 Nero! 1757 proe 
M uurolene 	- 1714 165 3 Carve)] acetate trans- 1759 150 29 
Carvone 1715 prog / Dihydrogeraniol 1759 150 34 
Geranyl formate 1717 150 29 Selinene a- 1759 prog 21 0 
Germacrene D 1718 130 20 Bornyl butyrate 1760 prog 2 
Himachalene [I- 1718 prog 2" Citronellol I- 1760 150 34 
Humulene 1719 165 3 Valencene 1760 165 3 
Myrtenyl acetate 1720 150 29 Cadinene 6- 1761 prog 2 
Citronellol (fi-) 1722 prog 2 Alaskene a- 1763 165 5 
Farnesene trans,eis-z- 1722 prog 1" Neryl isobutyrate 1764 prog 2 
Terpinyl acetate 1722 150 29 Chamigrene a- 1765 150 4 
Valencene I 722 prog 22 Citronellol (fl-) 1765 150 34 
Himachalene y- 1723 150 4 Linalyl pentanoate 1765 prog 2 
Amorphene a- 1724 165 3 Bisabolene 1766 165 3 
Dihydronerol 1725 150 34 Cadinene y- 1766 prog 2 
Muurolene y- 1725 165 3 Selinene 1(- 1767 165 3 
lsogeranyl acetate y- 1726 150 29 Bicyclogermacrene 1768 prog 21° 
Farnesene cis,trans-x- 1727 prog 22 Neryl propionate 1771 prog 2 
Muurolene a- 1727 prog 22 Bornyl isopentanoate 1774 prog 2 
Selinene fl- 1727 prog 22 Selinene 7-epi-1- 1775 prog 19 
Selinene 6- 1728 165 3 Sesquiphellandrene P- 1776 prog 22 
Zingiberene 1728 prog 22 Curcumene a- (ar-) 1777 prog 22 
(Continued on p. 18) 
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TABLE 2 from/wird/ 
NW. DAVIES 
Compound Rc./: Conipatint/ Rtl: 
Menthan-9-ol rrans-p- 1777 1/0 12 Citronellyl pentanoate 1880 prog 
Zona rene 1781 165 8 Menth-1(7)-en-9-ol p- 1881 120 12 
Cadinene 6- 1784 165 3 Vetivenene 13- 1885 165 3 
Cadinene (5- 1785 prog /1" Geranyl isopentanoate 1895 prog 
Cadina-1.4-diene 1786 prog Phellandrol 1896 120' I/ 
Citronellyl butyrate 1786 prog Geranyl butyrate 1904 150 29 
Curcumene 7. - (ar-) 1787 165 3 Menth-l-en-9-ol p- 1904 120 12 
Carveol trans- 1790 prog Agarofuran a- 1907 prog 19 
Neryl isobutyrate 1790 150 29 Calacorene 	- 1916 prog 21 
Perillyl acetate 1791 150 /9 Myrcene-8-ol 1919 150 34 
Selina-3.7( 11 )-diene 1791 prog 19 Calacorene a- 1926 165 6 
Cadinenc 1792 165 3 Terpinyl pentanoate 1928 prog 
Neryl propionate 1794 150 H urn ul ad ienone 1952 proe 31 
Carveyl acetate cis- 1795 150 Geranyl pentanoate 1960 prog 
Geranyl isobutyrate 1795 prog Cedrene epoxide Y. - 1961 prog 
Geraniol 1797 prog Ncrolidol cis- 1961 prog 
Isoeeraniol y- 1800 150 Caryophyllene oxide 1966 prog 31 
Menthan-7-ol trans-p- 1800 1/0 I) Humulcne epoxide 1 1972 prog 31 
Damascenone 1801 prog 31 Caryophyllene oxide 2000 prog 
Selinene 10-epi-a- 1803 165 37 Nerolidol trans- 2000 prog 2 
Carvone oxide 1805 prog Humulene epoxide II 2011 prog 31 
Menthan-9-ol cis-p- 1806 120 1) Ca ryola n- 1 -ol 2019 prog 31 
Nerol 1808 150 34 Bisabolol 202 1 160 26 
Citronellyl butyrate 1811 150 /9 'Junenol prog 31 
Cuparene 1811 130 /0 Caryophyllene alcohol 2033 prog 31 
Isogeraniol  cis- 1812 150 Cuben61 epi- 2037 prog 30 
Isogeranio! trans- 1812 150 Nerolidol trans- 2044 prog 19 
Undulatene 1812 150 4 Elemol 2078 proe 24 
Selina-4(14).7(1 I )-diene 1816 165 3 Cedrol 2100 prog 2 
Pyrovetivene 7 - 1817 165 3 Viridiflorol 2103 180 20 
Carveol cis- 1820 prog Globulol 2104 prog /t" 
Geranyl isobutyrate 1821 150 /9 , IP prog 21" 
Menthan-7-ol cis-p- 18/3 120 1/ Eudesmol 10-epi-y- 2121 prog 19 
Terpinyl butyrate 1828 prog Hurnulol 2124 prog 31 
Cuparene 1831 prog Cadinol T- 2136 prog 31 
Carvyl propionate 1833 prog Cadinol (5- 2150 prog 31 
Geranyl propionate 1834 150 /9 Spathulehol 2153 prog 21° 
Calamenene 1837 prog Carvacrol 2159 prog 2 
Cuparene 1838 150 4 Eudesmol 2182 prog 19 
Calamenene 1839 150 4 Cadalene 2203 prog 30 
Menth-2-en-7-ol cis-p- 1839 1/0 12 Cadinol a- 2224 prog 24 
Calamenene 1842 prog Farnesyl acetate 2225 200 28 
Geraniol 1842 150 34 Valerianol 2231 prog 19 
Menth-2-en-7-ol trans-p- 1842 120 1/ Humulenol II 2234 prog 31 
Cymene-8-ol p- 1846 prog 24 Eudesmol a- 2237 prog 19 
Terpinyl isopentanoate 1858 prog 2 Eudesmol 7-epi-x- 2244 prog 19 
Neryl isopentanoate 1864 prog 2 Eudesmol a- 2248 prog 19 
Neryl butyrate 1868 150 29 Eudesmol a- 2249 prog 21° 
Vetivenene 13- 1868 prog 2 ) Nootkatone 2250 prog 2 
Geranyl butyrate 1872 prog 2 Eudesmol 13- 2258 prog 21° 
Himachalene ar- 1873 150 4 Drimenol 2525 prog 19 
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TABLE 3 
KOVATS INDICES LISTED IN ORDER ON METHYL SILICONE 
Column headings and footnotes as for Table I. 
Compound T Ref Compound I T Ref 
Tricyclene 928 100 5 Cineole L8- 1025 100 20 
Thujene 931 100 Limonene 1025 100 5 
Thujene a- 935 110 13 Ocimene cis-11- 1025 prog 
Dimethyloctane 2,6- 938 100 3/ Phellandrene  fi- 1025 prog 7 
Thujene x- 938 prog 2 Ocimene 1027 100 20 
Pinene a- 939 100 20 Ocimene 1027 90 23 
Pinene a- 94 , 100 Limonene 1030 prog 
Pinene 	- 942 prog 2 Phellandrene [1- 1032 110 13 
Dimethy1-1.6-octadiene 3.7- 946 90 23 Thuj-2-en-4-ol trans- 1035 140 40 
Fenchene fl- 949 110 13 Ocimene trans-fl- 1038 prog 2 
Camphene 952 100 5 Ocimenc trans-fl- 1042 100 20 
Camphane 953 100 32 Thuj-2-en-4-ol cis- 1053 140 40 
Camphene 954 prog 2 Dihydromyrcenol 1056 80 
Camphenc 956 100 Terpinene 1056 100 28 
Fenchene a- 957 110 13 Terpincne 1057 prog 
Dimethy1-2-octene 2,6- 966 80 23 Sabinene hydrate trans - 1060 prog 38 
Sabinene 972 100 20 Dihydromyrcenol 6.10- 1063 prog 2 
Pinane trans- 973 100 32 Linalool oxide 1 (pyran) 1063 100 /3 
Isoeamphane trans- 975 100 32 Linalool oxide cis- (furan) 1068 prog 2b, 
Sabinene 976 prog 2 Terpinolene 1074 100 28 
Pinane 977 80 23 Fenchone 1077 105 23 
Pinene 978 100 20 Linalool oxide 11 (pyran) 1077 100 23 
Isocamphane cis- 980 100 Fenchone 1080 prog 
Menthane trans-p- 981 100 32 Terpinolene 1081 100 20 
Pinane trans- 981 prog Linalool oxide trans- (furan) 1082 prog 
Pinene 11- 981 prog 2 Linalool 1086 90 23 
Pinene 983 100 28 Ipsenol 1087 90 23 
Myrcene 984 100 20 Rose oxide cis- 1087 prof!. 2 
Menth- 1 -ene p- 985 160 33 Tetrahydrolinalool 1087 prog 
Carane cis- 986 100 32 Tetrahydrolinalool 1088 90 /3 
Myreene 986 prog 2 Tetrahydromyrcenol 1090 prog 34 
Pinane cis- 987 prog 2 Linalool 1092 prog 2 
Myrcene 988 100 28 Sabinene hydrate cis- 1092 prog 38 
Menthane cis-p 995 100 32 Linalool 1097 135 28 
Menth-4(8)-ene-p- 998 160 33 Chrysanthenone 1100 100 /3 
Cineole 1,4- 1000 80 23 Cyclocitral a- 1100 110 23 
Phellandrene a- 1000 90 23 Pinene oxide a- 1100 112 23 
Phellandrene a- 1002 prog 2 Rose oxide cis- 1100 95 23 
Pinane cis- 1002 160 33 Rose oxide trans- 1100 prog 2 
Phellandrene 1007 110 13 Thujone I- 1100 110 23 
Carene 3- 1009 100 S Myrcenol 1103 prog 2 
Cineole 1,4- 1010 prog 2 Fenchol 1110 prog 2 
Carene 3- 1013 100 28 Menth-2-en-l-ol cis-p- 1111 prog 38C 
Cymene p- 1016 100 5 Norbornyl acetate 1112 prog 2 
Terpinene a- 1016 100 20 Rose oxide trans- 1114 95 23 
Cineole 1017 prog 2 Limonene epoxide cis- 1119 100 23 
Cymene p- 1018 100 20 Allo-ocimene traits- 1120 110 13 
Terpinene 1018 110 13 Mentha-2,8-dien-1-ol cis-p- 1120 95 23 
Cymene p- 1020 prog 2 Dihydrolinalool 1,2- 1122 prog 2 
Limonene 1024 100 20 Limonene epoxide trans- 1122 100 23 
(Continued on p. 20) 
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TABLE 3 ((millilit('r') 
NAV. DAVI ES 
Contingent/ T Ref: Compound / 1 Ref. 
Fenchol 1125 135 78 Borneo! 1177 175 27 
Tagetone trims- 1125 110 13 Terpineol 7.- 1178 135 28 
Camphor 11/6 110 1 3 Neoisomenthol 1180 130 20 
Ipsdienol 1128 100 7 3 Carvomenthone 1181 110 /3 
Menth-2-en-l-ol trans-p- 1128 prog 38' Isomenthol 1182 130 20 
Terpinene-4-ol 1129 135 /8 . Dihydrocarvone 1183 prog 
Sabinol (cis-) 1130 115 23 Terpineol y.- 1185 prog 
Allo-ocimene eis- 1132 110 13 Tetrahydrogeraniol 1185 prog 
Pinocarveol trans- 1132 110 Verbenone 1185 110 /3 
I sopulegol 1133 110 Dihydrocarveol 1188 prog 
Sabinol (cis-) 1135 prog 2 Verbenone 1195 prog 
Camphor 1136 prog Carveol lams- 1200 1/0 
Tagetone cis- 1136 110 23 Cyclocitral /I- 1200 125 /3 
Citronella! 1137 prog Grandisol 1200 110 /3 
Terpineol tf- 1137 prog 2 Dihydromyrcenyl acetate 120 1 prog 
Verbenol Irons- 1140 120 /3 Menthan-2-ol p- 1205 160 33 
Menthone 1142 prog 39 Terpineol 1205 160 33 
Citronella! 1143 135 Linalyl formate 1206 prog 
Menthone 1143 prog 2 Menth-8-en-2-ol p- 1208 160 33 
Isopule,gol 1145 prog 2 Carveol irons- 1209 prog 
Citronella! 1146 160 33 Ascaridole epoxide 1215 110 
Menthofuran 1147 130 20 Carveol 1215 120 23 
Isoborneol 1149 110 /3 Citronellol (fl-) 1215 prog 
lsomenthone 1151 prog 39 Citronellol (fi-) 1216 100 ,3 
Pinocamphone 115/ 110 .73 Nero! 1218 prog 2 
Lavandulol 1153 110 Nero! 1218 120 
Borneo! 1154 110 /3 Fenchyl acetate 1) 1 0 prog 
Lavandulol 1154 prog Neral 1220 120 /3 
Menthofuran 1155 prog 39 Carveol cis- 122/ prog 
Isomenthone 1156 130 20 Carvone 12/3 1/5 23 
Menth-8-en-1-ol p- 1156 160 33 Citronellol (It-) 1224 175 27 
Menthan-l-ol p- 1156 160 33 Cadinene 1227 prog 2 
Isoborneol 1157 prog 2 Neral 1227 prog 
Isopinocamphone 1157 110 23 Carvone 1228 prog 
Menthone 1158 130 20 Isobornyl formate 1228 prog 2 
Neomenthol 1159 prog 39 Pulegone 1230 prog 2 
Neomenthol 1159 120 23 Piperitone 1231 125 /3 
Terpinene-4-o! . 	1160 175 Geraniol 1234 175 /7 
Terpineol (5- 1160 prog 2 Geraniol 1237 120 /3 
Menthan-8-ol p- 1162 160 33 Born)'! formate 1239 prog 
Borneo! 1164 prog 1 Linalyl acetate 1240 130 13 
Verbenol cis- 1165 100 23 Geraniol 1243 prog 
Cymene-8-ol p- 1167 115 23 Myrtanol 	is- 1245 120 /3 
Safranal 1167 120 23 Linaby! acetate 1246 prog 
Menthol 1168 130 /0 Myrcenyl acetate 1247 prog 2 
Isopinocampheol 1170 115 23 Piperitone 1247 prog 
Terpinene-4-o! 1170 115 23 Shisool 1248 130 /3 
Menthol 1171 prog 2 Geranial 1252 prog 2 
Menthol 1171 prog 39 PeriIla aldehyde 1253 120 23 
Menthol 1173 175 27 Isopulegyl acetate 1258 prog 2 
Myrtenal 1173 120 23 Geranial 1260 120 23 
Isomenthol 1174 100 23 Carvone oxide 1261 prog 2 
Terpinene-4-ol 1175 prog 2 Citronellyl formate 1261 prog 2 
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TABLE 3 (continued) 
Contpound 1 T Ref. Otnipound I T 
Sabinyl acetate (cis-) 1262 prog / Cubebene /1- 1400 150 20 
Neryl formate 1267 prog / Cyclosativene 1400 170 3 
Cymene-7-ol p- 1270 115 23 Elemene /1- 1400 150 20 
Thymol 1270 130 23 Gurjenene 7. - 1400 prog --)-) 
Lavandulyl acetate 1274 prog . 	/ Iridomyrmecin 1400 135 23 
Cymenene 1277 100 23 Elemane 1403 150 25 
Ascaridole 1278 110 23 Longifolene 1404 130 3 
Bornyl acetate 1278 135 28 Eudesmane 4/11-1.57H- 1405 150 25 
IsobornY1 acetate 1279 prog / Bourbonene /1- 1406 prog 2 
Menthyl acetate 1281 prog 39 Cedrene 7- 1411 prog 22 
Myrtenol 1281 120 23 Santalene 7- 1412 prog 22 
Perillyl alcohol 1281 115 23 Gurjunene 7- 1413 130 3 
Dihydroterpinyl acetate 1282 prog / Cedrene 7. - 1414 130 3 
Geranyl formate 1282 prog / Caryophyllene 1417 130 3 
Terpinene-4-y1 acetate 1282 120 23 Linalyl butyrate 1420 prog / 
Isomenthyl acetate 1283 130 20 Cedrene /1- 	. 1421 130 3 
Carvacrol 1297 proe / Sativene 1421 170 3 
Neoisomenthyl acetate 1297 130 20 lsoiridomyrmecin 1422 150 23 
Citronellic acid 1300 125 23 Citronellyl ethyl acetal 1423 prog 2 
Piperitenone 1315 125 23 Carvophyllane a 1425 150 25 
Nerolic acid 1316 140 23 Elemene -;.- 1425 prog 22 
Dihydroearvyl acetate 1319 prog 2 Thujopsene 1425 prog /, 
Linaly1 propionate 1324 prog 2 Farnesene trans-13- 1426 150 20 
Myrcenyl propionate 1327 prog 2 Terpinyl propionate 1426 prog -) 
Terpinyl acetate 1333 prog 2 Bergamotene trans-fl- 1427 proe 22 
Terpinyl formate 1333 prog 2 Citronellyl propionate 1427 prog 2 
Citronellyl acetate 1335 prog / Pinonic acid cis- 1427 165 23 
Citronellyl acetate 1335 135 28 Sibirene 1427 170 4 
Citronellyl acetate . 1335 140 23 CaryophvIlene 1428 prog 2 
Terpinyl acetate 1337 140 23 Thujopsene 1430 130 3 
Neryl acetate 1343 135 23 Caryophyllane b 1432 150 25 
Neryl acetate 1345 prog 2 Longipinene 13- 1432 170 4 
Geranic acid 1347 140 23 Gurjunene 13- (calarene) 1435 130 3 
Longipiriene 7- 1359 130 3 Bergamotene 7- 1436 prog 24 
Cubebene a- 1362 150 20 Caryophyllene 1436 150 20 
Geranyl acetate 1363 135 28 Cedrene a- 1436 prog 2 
Linalyl isobutyrate 1366 prog 2 Neryl propionate 1436 prog 2 
Ylangene a- 1368 prog 22 Humulene 1437 prog 22 
Copaene a- 1369 prog 22 Santalene epi-I3- 1437 prog 22 
Longicyclene 1371 130 3 Barbatene a- 1440 170 4 
lsobornyl propionate 1376 prog 2 Carvyl propionate 1440 proe 2 
Copaene 7- 1378 130 3 lsosativene 1441 170 3 
Patchoulene 13- 1378 prog 22 Himachalene a- 1442 prog 22 
Cubebene 7- 1381 prog 22 Himachalene a- 1444 130 3 
Cubebene /3- 1381 prog 22 Copaene [3- 1445 prog 2 
Elemene 6- 1381 prog 22 Muurolene t- 1445 130 3 
Bourbonene /3- 1386 130 3 Cedrene fl- 1446 prog 2 
Anastreptene ,1391 170 4 Humulene 1447 130 3 
Ylangene a- 1396 170 3 Bisabolane a 1448 150 25 
Copaene a- 1398 prog 2 Dihydrocurcumene 1448 150 25 
Cyperene 1398 130 3 Fa rnesene trans-fl- 1448 prog 36 
Cyperene 1398 prog 22 Farnesene trans-fl- 1449 170 4 
Longifolene 1398 prog 22 Caryophyllane c 1450 150 25 
(Continued on p. 22) 
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TABLE 3 (continued) 
N.W. DAVIES 
Compound 1 T 12(J: Compound 1 T Ref 
Caryophyllane d 1450 150 25 Linalvl pentanoate 1500 prog 
Linalyl 2-meihvlbutyrate 1450 prog ) Muurolene a- 1500 proe 
Santalene ff- 1450 proe 21 Farnesene trans,trans-7- 1501 150 20 
Arnorphene a- 1451 prog .).) Bulnesene 7.- 1502 prog ).) 
Sinuene 1451 170 4 Calamenene 1502 prog 22 
Thujopsene 1451 proe .) Guaiene (5- 1502 prog 22 
Guaiene a- 1454 prog 22 Cadinene 6. - 1504 130 3 
Valencene 1457 130 3 Bisabolene 1505 170 3 
Bisabolane b 1458 150 25 Cuparene 1506 150 20 
Cedrane 8/3H- 1458 150 25 Selinene /3- 1506 170 3 
Longifolane 7aH- 1460 150 25 Cadinene y- 1507 130 3 
Linaly1 isopentanoate 1461 prog 2 Tetrahydrothujopsane b 1508 150 25 
Cedrane 8.xH- 1465 150 25 Curcumene /1- 1510 170 3 
H umulene 1465 prog 2 Citronellyl butyrate 1511 prog 
Scapanene 1465 170 4 Bornyl isopentanoate 1512 prog 2 
Helmiscapene  fi- 1466 170 4 Sesquiphellandrene /3- 1512 prog 22 
Helmiscapene a- 1467 170 4 Selinene a- 1513 170 3 
Longifolane 701- 1467 150 25 Terpinyl butyrate 1514 prog 2 
Terpinyl isobutyrate 1467 prog 2 Cuparene 1516 170 4 
Germacrene D 1468 prog 22 Himachalene fl- 1517 170 4 
Citronellyl isobutyrate 1469 prog 2 Cadina-1,4-diene 1518 prog 22 
Barbatene  fi- 1473 170 4 Calamenene 1518 prog 
Bornyl butyrate 1473 prog 2 Pyrovetivene a- 1522 170 3 
Neryl isobutyrate 1474 prog 2 Chamigrene a 1523 170 4 
Alloaromadendrene 1475 150 20 Cadinene (5- 1524 prog 2 
Curcumene 	(ar-) 1475 130 3 Calamenene 1524 170 4 
Selina-4(14),7-diene 1476 170 3 Nerolidol cis- 1524 prog 2 
Germacrane h 1477 150 25 Geranvl butyrate 1532 prog 2 
Selinene [1- 1477 prog 22 Elemol 1540 prog 24 
Alloaromadendrene 1478 prog 2 Nerolidol cis- 1540 175 27 
Zingiberene 1480 170 3 Himachalene ar- 1542 170 4 
Germacrane c 1482 150 25 Vetivenene fl- 1544 prog 22 
Guaiene [1- 1482 prog 22 Chamigrene /3- 1550 170 4 
Valencene 1482 prog 22 Nerolidol trans- 1553 prog 2 
Zizaene 1482 170 3 Undulatene 1557 170 4 
Aequilobene 1483 170 4 Caryophyllene alcohol 1559 prog 24 
Selinene a- 1484 prog 22 Vetivenene /3- 1563 170 3 
Viridiflorene 1484 prog 22 Terpinyl isopentanoate 1565 prog 2 
M uurolene y- 1486 150 20 Neryl isopentanoate 1574 prog 2 
Zingiberene 1486 prog 22 Caryophyllene oxide 1576 prog 24 
Valencene 1487 prog 2 Cedrene epoxide a- 1585 prog 2 
Germacrene D 1488 150 20 Viridiflorol 1588 150 20 
Germacrane d 1489 150 25 Geranyl isopentanoate 1593 prog 2 
Bicyclogermacrene 1490 prog 22 Citronellyl pentanoate 1608 prog 2 
Amorphene a- 1492 170 3 Cedrol 	. 1609 prog 2 
Geranyl isobutyrate 1493 prog 2 Terpinyl pentanoate 1614 prog 2 
Valencane (nootkatane) 1493 150 25 Cedrol 1616 175 27 
Farnesene trans,trans-a- 1494 prog 22 Geranyl pentanoate 1632 prog 2 
Himachalene f3- 1494 prog 22 Cadalene 1646 prog 22 
Muurolene a- 1495 130 3 Santalol a- 1660 175 27 
Bisabolene cis-a- 1496 prog 22 Bisabolol )3- 1666 175 27 
Bisabolene /3- 1496 130 3 Farnesol trans ,trans- 1745 175 27 
Tetrahydrothujopsane a 1496 150 25 Bornyl benzoate 1749 prog 2 
Eudesmane 4/1-1,5/H- 1497 150 25 Farnesyl acetate 1787 200 28 
Himachalene y- 1499 170 4 Nootkatone 1802 prog 2 
215 
RETENTION INDICES OF MONOTERPENES AND SESQU1TERPENES 	 23 
3. ACKNOWLEDGEMENTS 
Drs. J. Brophy and M. Ridd are thanked for their comments and provision of 
some of the references. 
4. SUMMARY 
Gas chromatographic retention indices (Kovitts' indices) are a valuable aid in the 
identification of monoterpenes and sesquiterpenes in essential oils and related natural 
and synthetic products. Some 900 Kovats* indices of 400 individual compounds on 
methyl silicone (dimethyl polysiloxane) and/or Carbowax 20M liquid phases are 
summarized from the general literature. 
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ESSENTIAL OILS OF TASMANIAN GROWN HOPS* 
Br N. W. DAVIES 
(Central Science Laboratory. University of Tasmania. GPO Box 252C". Hobart. Tasmania. Australia. 7001) 
AND R. C. MENARY 
(Department of.4grtcultural Science. University of Tasmania) 
Received 2 June 1981 
The hop varieties Northern Brewer, Brewers' Gold, Bullion, Cluster, Pride of Ringwood and the 
new variety '823' were grown in Tasmania and their essential oils analysed, primarily by combined 
gas chromatography/mass spectrometry. The results for those varieties previously studied were 
similar to the published reports, while Pride of Ringwood and B23 are reported for the first time. 
In particular, the selinadiene content of the six oils was examined. High levels of a - and P-selinenes 
were recorded in Pride of Ringwood. Mass spectral data for these two selinadienes is presented in 
full to facilitate future identification. An attempt is made to clarify some of the confusion in the 
area of sesquiterpene hydrocarbons in hops. 
Key words: hops, essential oils. sesquiterpenes. selin-
.adienes. 
INTRODUCTION 
The numerous commercial varieties of hops (Humultes 
lupulus) exhibit large qualitative and quantitative differences 
in the composition of their essential oils. Several commercial 
varieties were grown to confirm the integrity of varietal oil 
composition. and to report for the first time on the 
Australian high a-acid cultivar 'Pride of Ringwood', upon 
which the Australian hop industry is largely based, and on 
the as yet experimental variety 'B23'. The other varieties 
studied included Bullion, Brewers' Gold. Cluster and 
Northern Brewer. The interrelationship between oil compo-
sition and 'aroma and 'non-aroma' hop types is discussed. 
EXPERIMENTAL 
The cultivars were grown in individual experimental plots 
within a commercial garden. A sample of the dried cones 
(approximately 100 g) of each variety was steam distilled in a 
British Pharmacopaeia still, the oil collected and dried over 
anhydrous sodium sulphate. 
Analyses were carried out by combined gas chromato-
graphy/mass spectrometry (GC/MS) using a Pye 204 Gas 
Chromatograph directly coupled via a glass-lined steel 
tube to a VG70/70 mass spectrometer. Support Coated 
Open Tubular (SCOT) columns, with either Carbowax 20 NI 
(CW20m) or SP2100 liquid phases. were used, with a Helium 
flow rate of 2 ml per min. The mass spectrometer was 
operated at an ionising energy of 70eV, a 4 Kv accelerating 
voltage, and an ion source temperature of 200*C. The range 
m/z 300 to 20 was scanned exponentially downward at 
1 s/dec,ade, resulting in a full mass spectrum every 2 s. The 
data was stored in VG2000 datasystem. Spectra were 
enhanced by background subtraction, and generation of 
reconstructed spectra and gas chromatograms' where 
necessary to help resolve partially resolved components. Gas 
chromatograms were represented by Total Ion Current (TIC) 
change with time. 
Quantities were determined on separate runs using a Pye 
104 Gas Chromatograph coupled to a Flame Ionisation 
Detector and a Pye Unicam DP88 Computer Integrator. 
Preparative gas chromatography was carried out on a 
Pye 104 with a 10% SE30 on Chromosorb W/AW 
(80-100 mesh) packed column (8 mm x 2 m). 
Hydrogenations were carried out in 1 ml sealed vials 
under a hydrogen atmosphere, with 1320 catalyst. 
*A brief presentation of some of this work was made at VIllth 
International Congress on Essential Oils, Cannes, 1980. 
fl-Selinene (Fig. I. (I)) was isolated by preparative gas 
chromatography from celery oil, and a-selinene (Fig. I. (II)) 
was isolated from Brazilian rosewood oil. 6-Selinene (selina-
4.6-diene) was synthesised from fl-eudesmol.''' 
Spectra of selina-4(14), 7(I1)diene (Fig. I. (111)). selina-3. 
7(1 I )-diene (Fig. I. (IV)) and Germacrene B (Fig. I.. (V)) 
were obtained from Sunshine hop oil. 
Identification of components was based on reported 
Kovats' Indices (I k 's) ,, (e.g. for sesquiterpene hydrocarbons 
see references I and 2), mass spectre , ' and where 
possible by comparison with authentic compounds. 
RESULTS 
The yield of oil from the various cultivars is summarized 
in Table I. The percentage of oil recorded for each cultivar is 
similar to those recorded in the literature."-" 
Chromatograms for Northern Brewer. 'Pride of 
Ringwood' and '1323' are shown in Fig. 2. A detailed table of 
components and quantities is presented in Table II. 
Numbers on peaks in Fig. 2 correspond to the components in 
the table. 
(VI) 
Fig. I. Structural formulae. 
TABLE I. Yield of Essential Oil for the 
Different Varieties as Percentage of Dry Matter. 
Variety Yield (% DM) 
Brewers' Gold 1 -4 
Bullion 3 - 5 
Cluster 1 - 3 
Northern Brewer 2 - 2 
Pride of Ringwood 2-4 
B23 1-8 
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TABLE II. Essential Oil Composition of the Hop Varieties Studied. Figures are Percentages of Total Oil. 
Peak Compound Bullion Cluster 
Brewers 
Gold 
Northern 
Brewer 
Pride of 
Ringwood B23 
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z-pinene 0.04 Sr Ir Sr tr tr 
isobutyl isobutyrate 0.18 0.66 0•34 0 - 58 0- 20 tr 
fl-pinene 1-3 1-47 1-20 0 - 97 1 - 80 0- 28 
myrcenc 51 57 5 7 52 60 53 
2-methylbutylpropionate . 0- 80 0 - 28 0•40 0 - 25 0-20 0 - 08 
2-methylbutyltsobutyrate 4-09 4 - 20 1-71 2 - 20 3 . 31 0- 34 
methyl 6-methylhexanoate 0•43 0 - 31 0-20 0 . 31 0- 10 tr 
ocimene 0 . 36 0-17 0.35 0 . 10 0.10 Sr 
methyl n-heptanoate 0 - 26 0-30 0 - 23 0-71 0-41 0 - 20 
unknown 0 - 04 0 - 24 0.07 tr 0. 05 tr 
unknown 0 - 06 0 - 07 0 . 1 I tr 0 - I I tr 
methyl 4-methylhex-2-enoate 0- 04 0•12 0- 08 0•25 0. 40 0-31 
methyl 6-methylheptanoate 0 - 49 0 - 75 0•22 0-31 0. 71 0-26 
2-nonanone 0 - 20 0. 55 tr 0 - 52 0 . 20 0 - 08 
methyl n-octanoate 0 - 38 0•94 0.22 0.68 1•25 0 - 35 
unknown 0 - 12 0 . 26 0 - 07 0-23 Sr 0-06 
3 (4-methy1-3-pentenyl)furan 0 - 23 0-12 tr 0 - 36 - tr 
methyl nonanoate (branched) 0 - 08 0 . 14 - - tr - 
methyl nonanoate (branched) 0•12 0 -04 tr tr tr - 
2-decanone 0-14 tr tr 0- 18 0•15 0-15 
methyl n-nonanoate 0 - 13 0•25 0 . 10 0 . 37 0 . 50 0 . 15 
methyl nonenoate isomer tr 0 - 14 tr tr 0.17 Sr 
linalool 0 - 27 0-08 0- 27 0- 21 0•15 tr 
9-methyl decan-2-one 0.12 0-09 tr 0.11 0 . 15 0 . 30 
methyl 8-methylnonanoate 0 - 10 0- 17 tr 0 -08 0 . 25 0 . 21 
caryophyllene 6-20 2-30 8 . 60 7.00 4 . 20 6 . 60 
2-undecanone 0.61 0.62 0 . 53 0•82 1 - 50 1 . 00 
methyl n-decanoate 0. 31 1.21 0 . 25 0.43 0 - 30 0 - 31 
undecen-2-one isomer - - tr - If Sr 
methyl dec-4-enoate 1.31 3 - 13 0- 50 1.01 5.62 1-02 
humulene 18.20 7 . 80 21 - 10 20 . 2 0 . 50 20 - 9 
selina-4. 11-diene - - - - 0. 90 - 
germacrene D 0.36 - 0 . 23 0. 20 - - 
methyl decadienoate isomer Sr - ' 	tr 0 . 13 0 . 36 0-38 
unknown - 1.20 - - - - 
methyl decadienoate isomer 0. 49 2.40 1.21 1-05 1 . 26 0.81 
fi-selinene 0. 15 0.13 0- 30 0 - 35 6 .07 3•40 
a-selinene 0 . 15 0.17 0.32 0.45 7 -01 4-69 
2-dodecanone Sr 0 . 20 Sr tr Sr tr 
unknown - - - - tr tr 
y-cadinene Sr - - - 0.40 0-10 
4-cadinene 0. 98 0 - 14 1 -01 0 . 51 0•60 0 - 97 
unknown 0.47 tr tr tr 	• - tr 
unknown 
(branched) 
- 
Sr 
- 
0 - 07 
-
2-tridecanone 
- 
tr 
- 
tr 
0.41 
Sr Sr 
calamenene 0 . 20 - 0-16 tr 0-10 Sr 
2-tridecanone Sr 0 - 23 Sr 0 - 32 0-34 0-40 
methyl dodecenoate isomer - 0•66 tr tr 0-17 tr 
unknown . 0 - 57 0 . 30 0•17 0 . 11 0 - 08 0-07 
unknown - Sr 0 - 75 - 0-10 - 
tridecene-2-one isomer 0- 23 - Sr - - - 
methyl dodecadienoate isomer 0-36 0- 19 0 - 10 0 . 32 0 - 18 0-09 
unknown - - - tr 0 - 06 - 
unknown 0- 17 Sr - tr 0 - 09 Sr 
unknown 0 . 19 Sr 0.11 0. 13 0 . 1 I tr 
caryophyllene epoxide 0.64 0-54 0-52 0- 64 0 - 18 0 - 17 
unknown - 0.12 - Sr 0 . 10 - 
humulene epoxide 1 Sr 0. 13 0 . 10 0 - 15 - tr 
humulene epoxide II 1 . 20 0.68 1 . 23 1 - 86 - 0 - 40 
unknown sesquiterpene 0- 12 Sr Sr 0 . 20 0.18 Sr 
2-pentadecanone 0.08 Sr Sr 0 - 15 0-08 Sr 
pentadecene-2-one isomer 0.07 Sr - Sr 0'18 Sr 
pentadecadienone isomer 0- 23 0 - 16 - 0 - 26 1 - 24 0 . 24 
unknown sesquiterpene Sr tr tr Sr 0 - 20 Sr 
Sr = trace ( < 0.04%) 
The varieties Brewers' Gold, Bullion, Cluster and 
Northern Brewer show little difference to previous reports 
for the same varieties grown in the northern hemisphere. 4." 
The poorly resolved region of peaks 37 and 38 (Fig. 2 (b)) 
was clearly resolved on a SCOT SP2100 column (see Fig. 3). 
For purposes of quantitation this column also resolved some 
of the methyl esters and ketones unresolved on CW20m.) 
These major peaks in Pride of Ringwood were initially diffi-
cult to identify, due to errors for the entry for fl-selinene 
(Fig. I, (I)) in the mass spectral atlases, 9a , and for a-selinene 
(Fig. I, (11)) in the literature." The mass spectra (Fig. 4) were 
consistent with partial spectra from other literature refer- 
ences"." and also with authentic samples of each sesquiter-
pene. The initial evidence for both being selinadienes was 
based on isolated samples both producing eudesmane upon 
hydrogenation. 
Peak 32 which had M* 204 (60%) and base m/z 189, has 
been tentatively identified as selina-4,11-diene (Fig. 1, 
(VI)), on the basis of its Kovat's Index and eudesmane 
skeleton on hydrogenation, and appears to be previously 
unreported from hops. (5-Selinene, which has a similar 
Kovat's Index' was excluded by comparison with a synthetic 
sample. 
No selina-4(14),7(11)-diene (Fig. 1, (III)), selina-3,7(I 1)- 
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. Fig 2. Gas chromatograms (total ion currents) of three of the hop 
varieties. The column was a 30 m x 0.5 mm glass SCOT 
CW20 M. programmed from 80°-200°C at 4°C/min. Injector 
and detector temperature was 200°C. Numbered peaks corre-
spond to the components listed in Table II. Carrier gas was 
helium at 2 ml/min. The top number on the bottom axis rep-
resents scan number, and the lower number represents time 
in minutes from the injection. 
diene (Fig. I, (IV)) or Germaerene B (Fig. I. (VII. 
characteristic of varieties such as Sunshine, Hersbruck 
Gebirg and Tasmanian White Vine,' was found in these six 
varieties. 
The most obvious differences between Pride of Ringwood 
and the varieties Northern Brewer. Brewers' Gold. Bullion 
and Cluster is the extremely low humulene content, and the 
relatively large levels of 2- and fl-selinenes. In addition. the 
combined ketones and esters represent a significantly larger 
total percentage in Pride of Ringwood than in any of the 
other varieties. The new variety B23 maintains a high 
humulene level, with levels of a- and p-selinene somewhat 
higher than the four previously reported varieties. 
DISCUSSION 
The close agreement of the results for Brewers' Gold, 
Bullion, Cluster and Northern Brewer with previously 
published data" supports the work of Likens & Vickersen , ' 
who showed that soil, climatic and even disease influences 
had almost no effect on the oil composition of hop varieties, 
and so the results for 'Pride' and 'B23' are solely representa-
tive varietal differences. 
In all cases myrcene is by far the major component in the 
fresh oils. Myrcene is considered a less desirable component 
in the so-called 'aroma' varieties.' although autoxidation of 
myrcene as well as of the hop resins.' is thought to be partly 
responsible for flavour and aroma in finished beer. Myrcene 
tends to be highest in high a-acid (and consequently 'non-
aroma') varieties) , 'Aroma' varieties generally have a high 
level of humulene and correspondingly lower myrcene 
levels)" Pride of Ringwood is consistent with the 'non-
aroma' stereotype, in that it is an acknowledged high 2-acid 
variety and has a myrcene level of 60% and humulene of 
only 0.5%. 
To what extent the selinadienes contribute to (or detract 
from) the final aroma of the finished beer is not clear. 
Recognised 'aroma' hops have not been reported with 
significant levels of selinadienes. However, the German 
220 
Vol. 88.1982] 83 DAVIES AND SO NAR',: TASMANIAN HOPS 
literature cites components designated as 'Posthumulene I 
'and 'Posthumulene 2, which are particularly large in the 
'aroma' variety •Hersbrucker Spat'." This variety was not 
available for comparative analysis, but it would seem that 
these correspond to sesquiterpene hydrocarbons-probably 
from among the group of selinadienes. cadinenes or 
a-muurolene on the basis of comparison of reports of these 
•posthumulene components in Northern Brewer. Until 
these two components are correlated with the known 
sesquiterpenes comparison between varieties will remain 
difficult. 
The variety B23, which maintains a high level of a-acids 
=•-• I0%)" is somewhat unusual in that it also has a 
humulene content of 21% of the oil, and may prove to be a 
useful hop for both bittering and aroma, and is high yielding 
under Tasmanian conditions. 
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Volatile Constituents of Boronia 
Megastigma Flowers 
By N. W. Davies, Central Science Laboratory, and R. C. Menary, Faculty of 
Agricultural Science, University of Tasmania, Hobart, Tasmania, Australia 
rilhe concrete obtained from the flowers of 
Boronia megastignia (Nees) by solvent ex-
traction has been employed on a small scale for 
many years in the production of cosmetics, and is 
finding increased usage in both the perfume and 
flavour industries. However, little attention has 
been paid to the chemical nature of the compo-
nents responsible for the characteristic Boronia 
fragrance. Beta-ionone (1) was identified in 
Boronia by Penfold,' the first report of this im-
portant odour substance as a natural product. 
Naves and Parry did further chemical analyses 
and confirmed the work of Penfold, as well as 
identifying other components principally from 
the involatile portion of the concrete. 2 A brief 
summary of the botany and physicochemical 
properties of Boronia concretes is presented by 
Guenther. 
In a preliminary communication some twenty 
constituents of Boronia concretes were reported.' 
The variability within a seed population was dis-
cussed, along with horticultural aspects of 
Boronia production. This paper presents a much 
more detailed analysis of the volatile components 
of Boronia, including the identification of several 
relatively major components. In all, over 150 
compounds were detected by gas chromatog-
raphy, of which some 50% have been identified. 
Experimental 
The plants used were from plots in southern 
Tasmania, which were originally planted for the 
cut flower market. The flowers were harvested 
with hand combs, and the concretes were ob-
tained by mixing for twelve hours with petro-
leum ether (B.P. 40-60'). Individual plant har-
vests were extracted separately in many cases to 
determine the type and degree of variation 
within the population. The bulk of the solvent 
was removed under reduced pressure at room 
temperature, with residual levels of about 1% 
remaining. 
Initial analyses were carried out by combined 
GC/MS, using SCOT or fused silica OV101 
capillary columns in a Pye 204 GC directly cou-
pled to a V.G. 70/70F mass spectrometer and V.G. 
2035 datasystem, Preparative gas chromato-
graphy was carried out on a Pye 104 GC fitted with 
a 10% SE30 2m x 8mm glass column using glass 
capillary traps. Quantitative data was obtained 
from separate analytical runs on the Pye 104 with 
Flame Ionization Detector and Perkin-Elmer 
Sigma 10 Data Station. Raman spectra were re-
corded on a Cary 82 Laser Raman Spectrometer. 
Empirical formulae of unknowns were deter-
mined by high resolution mass spectrometry. 
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Table I 
1 alpha-thujene 	40 dihydroactinidiolide 
2 alpha-pinene 41 n-pentadecane 
3 camphene 	 42 isoamyl salicylate 
4 myrcene 43 'sesquicineole' 
5 beta-pinene 	 44 dodecyl acetate 
6 octanal 45 methyl jasmonate 
7 hmonene 	 46 methyl jasmonate 
.8 delta-3-carene 	 isomer 
9 ocimene 	 47 iso-heptadecane 
10 nonanal 48 (Z)-heptadec-8-ene 
11 linalool 	 49 n-heptadecane 
12 methyl octanoate 	50 methyl-p-hydroxy 
13 camphor 	 cinnamate 
14 octanoic acid 51 tetradecenyl acetate 
15 2,6-dimethy1-3,7- 	52 tetradecyl acetate 
octadiene-2,6-diol 53 n-nonadecane 
16 ethyl octanoate 	54 methyl palmitate 
17 menthone 	 55 ethyl palmitate 
18 undecanal 56 iso-heneicosane 
19 methyl nonanoate 	57 n-heneicosane 
20 nerol 	 58 methyl oleate 
21 methyl naphthalene 	59 methyl stearate 
22 nonanoic acid 	60 ethyl stearate 
23 bornyl acetate 61 n-docosane 
24 ethyl nonanoate 	62 iso-tricosane 
25 decyl acetate 63 n-tricosane 
26 acyclic monoterpene 	64 n-tetracosane 
27 methyl decanoate 65 iso-pentacosane 
28 benzyl pentanoate 	66 n-pentacosane 
29 decanoic acid 67 n-hexacosane 
30 ethyl decanoate 	68 iso-heptacosane 
31 alpha-ionone 69 n-heptacosane 
32 dihydro-beta-ionone 	70 n-octacosane 
33 5,6-epoxy ionone 71 iso-nonacosane 
34 phenylethyl pentanoate 	72 n-nonacosane 
35 tetrahydroionone 	73 n-triacontane 
36 caryophyllene 74 iso-hentriacontane 
37 dodecanol 	 75 n-hentriacontane 
38 beta-ionone 76 iso-tritriacontane 
39 humulene 	 77 n-tritriacontane 
This table shows the components identified so far 
from Boronia megastigma concretes. The numbers 
refer to peaks in the chromatograms on OV101 col-
umns, as indicated for several components in figures 
1,2 and 3. Not all components listed In this table were 
necessarily present in the clones Illustrated In the fig-
ures. 
Fractions for further detailed chemical study 
were obtained by chromatography on silica gel 
H, eluting with chloroform. Hydrogenations 
were carried out in solution at room temperature 
with palladium on charcoal as catalyst, or else 
using the method of Stanley et al. 5 in sealed 
capillaries before crushing in the injection port of 
the GC. Hydrogenolyses were carried out by the 
latter method. Double bond positions were de- 
termined by the methoxymercuration technique.° 
4/Perfumer & Flavorist 
An initial 'volatile' fraction was defined as that 
portion of the concrete eluting up to the retention 
time of n-eicosane. Quantitative data is quoted as 
percentage of this fraction. The percentage of the 
whole concrete that this fraction represented was 
determined by adding a known weight of internal 
standard to a known weight of concrete, and re-
lating the total F.I.D. peak area up to n-eicosane 
to the area of the internal standard. 
Initial identification of most components was 
based on reference mass spectra coupled with 
GC retention indices. Compounds not readily 
identified by this means were subjected to the 
microchemical techniques and additional mass 
spectrometric measurements outlined above. 
Results 
Figure 1 shows the Total Ion Current (TIC) 
trace for a typical Boronia flower extract from a 
single plant. The components are summarized in 
Table I, in which the numbers refer to the peaks 
marked in figures 1,2 and 3. The higher boiling 
end of the chromatogram is now shown, and was 
determined from independent high temperature 
GC-Ms analyses. 
Figure 2 shows the TIC trace of a series of 
clones in which a component not generally pres-
ent in other clones (peak 43) represents one of 
the major volatile's. This compound is a previ- 
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Figure 1. Total Ion Current (TIC) trace versus retention 
time for a GC-MS analysis of a Boronia megastigma 
floral concrete for a typical individual clone. Peak 
numbers refer to compounds listed in Table I. The GC 
column was a 50m x 0.2mm fused silica OV101 capil-
lary, temperature programmed from 100° to 300°C at 3° 
per minute. Hydrogen was used as carrier gar at a 
flow rate of 1.4mIs per minute. Samples were injected 
at 300°C with a split ratio of 10:1, with the column 
connected directly to the mass spectrometer result-
ing in sub-ambient outlet pressure. The mass spec-
trometer was repetitively scanned every two seconds 
from rn/z 500 to m/z 20, and the results stored In the 
datasystem. 
Figure 2. TIC trace versus retention time for a con-
crete characterised by the presence of a major com-
ponent, given the trivial name 'sesquicineole,' not 
found In the majority of clones. Conditions were as for 
figure 1. 
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Figure 3. TIC trace versus retention time for concrete 
from a clone characterised by the presence of a series 
of ethyl esters In addition to the normal major con-
stituents. Conditions were as for figure 1. 
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ously unreported natural product, and has been 
given the trivial name 'sesquicineole' from a par-
tial structural elucidation (see below). 
Figure 3 shows the TIC trace for a clone typical 
of a series characterised by the presence of a 
number of ethyl esters (peaks 16, 24, 30 and 55) 
in addition to the normal major components. In 
general there was a high degree of variability 
between individual concretes, especially among 
the minor components. Beta-ionone, dodecyl 
acetate, methyl jasmonate and (Z)-heptadec-8- 
ene were always present as relatively major com-
ponents, as were the wax hydrocarbons from 
heneicosane to tritriacontane. The monoterpene 
hydrocarbons alpha-pinene, beta-pinene and 
limonene, on the other hand, showed very large 
differences in proportions, being virtually absent 
in some clones. 
Quantitative data for several representative 
compounds are presented in Table II. The per-
centages quoted are for the 1982 harvest, and rep-
resent the proportion of the total peak area of 
the initial 'volatile' fraction up to n-eicosane. A 
sample of bulked 1981 concrete was vacuum dis-
tilled to remove this portion of the concrete 
(100°C,0.02 Ton), and a 14% reduction in weight 
Perfumer & Flavorist/5 
224 
Boronia 
was recorded. The same result was obtained 
using internal standard GC technique, implying 
FID response factors had little overall effect. 
By far the majority of the typical Boronia fra-
grance was found in the latter portion of the 'vol-
atile' fraction (b.p. 40°-100°C, 0.02 Torr), corre-
sponding to the region on the chromatogram 
starting around peak 15 and going through to 
peak 52 (as elution order on a non-polar station-
ary phase is approximately proportional to boil-
ing point). 
Table II 
Compound Clone 
1 2 3 
alpha-pinene 2.3 4.4 11.0 
beta-pinene 1.5 4.6 15.0 
limonene 1.0 2.2 2.7 
linalool 0.9 1.7 1.5 
peak 26 43.8 1.5 1.3 
ethyl decanoate 2.0 
beta-ionone 22.5 11.9 21.1 
.sesquicineole' 19.3 
dodecyl acetate 11.1 7.2 5.6 
methyl jasmonate 7.2 4.3 3. 6 
(Z)-heptadec-6-ene 31.2 19.7 24.1 
% volatiles to C20 16.0 25.9 19.2 
This table shows the relative proportions, as per-
centages of total FID peak area, of representative 
compounds from the clones shown In figures 1 to 3 
from the 1982 harvest. Only compounds up to the re-
tention time of n-eicosane have been Included in de-
termining total peak area. The total percentage that 
this fraction represents of the concretes Is shown on 
the bottom line. 
Peaks 15 and 26-Hotrienol Related Compounds 
The mass spectrum of peak 15 showed m/z 
82(100%), 71(77), 43(58), 67(42), 55(16) and 59(8), 
and was similar in some respects to that of hot-
rienol (2) (m/z 71(100%), 82(68), 43(50), 67(31) 
and 55(14)). However, a pure sample of hotrienol 
eluted just after linalool and well before peak 15 
on OV101. The difference in retention times 
could not readily be explained by geometric or 
positional isomers of hotrienol. A 'stereoisomer' 
of hotrienol was reported recently as a major 
component responsible for the aroma of ripe 
baelfruit, but in view of the retention time and 
mass spectral differences reported between this 
compound and hotrienol, it seems that this com-
pound is more likely to be one of the hydrated 
forms of hotrienol first found in ho-leaf oil.° 
These are 2,6-dimethy1-3,7-octadiene-2,6-diol 
6/Perfumer & Flavorist 
and 3,7-dimethy1-1,7-octadiene-3,6-diol, and the 
data presented would appear to indicate the 'un-
known' is the former isomer.' These hydrated 
forms were also considered for peak 15, and it 
was found that 2,6-dimethy1-3,7-octadiene-2,6- 
diol (3) was indistinguishable in mass spectrum 
and retention time from the Boronia compound, 
thus confirming its identity. This diol is a known 
linalool oxidation product' and is related to the 
furanoid linalool oxides by cyclization. 
Peak 26 gave a mass spectrum with m/z 
71(100%), 43(86), 82(77), and 67(59) which also 
was very similar to that of hotrienol. This compo-
nent eluted well after both diols on OV101. On 
Carbowax 20M stationary phase this component 
elutes before 2,6-dimethy1-3,7-octadiene-2,6- 
diol, implying a less polar nature than the diol 
and may possibly represent an ester of the diol. 
Peak 43 2Sesquicineole' 
As shown in figure 2, some clones were 
characterized by a large component which was 
not present in the majority of clones. The mass 
spectrum of this component showed M 4 222 (1%) 
(found, C15 H26 01), m/z 43 (95%), 69 (27%), 95 
(25%), 109 (27%) and 139 (100%). This compound 
on hydrogenation gave a product with M4 224 
(0.2%), m/z 43 (98%), 95 (45%), 139 (100%) and 
209 (2%), indicating the presence of one double 
bond in the original compound. The ion at m/z 
139 was found to be C9 H15 0 from high resolu-
tion mass spectrometry, thus containing two de-
grees of unsaturation but no carbon-carbon dou-
ble bonds as it was unaltered in the hydroge-
nated product. This evidence suggested an 
oxygenated sesquiterpene, with a cyclic C9 H15 
0 nucleus, and a C6 H11 side chain with one 
double bond. The compound failed to form any 
oxime, 2,4-dinitrophenylhydrazone or trimethyl-
say] derivatives, indicating that the oxygen func-
tion was not present as a carbonyl group or as an 
alcohol. Thus the oxygen would appear to be 
present as an ether linkage, and to maintain an 
intact sesquiterpene skeleton this must be a 
cyclic ether. 
One of the degrees of unsaturation is then ac-
counted for by the cyclic ether function, while 
the other must be a cyclic carbon system. 
Hydrogenolysis of this compound yielded 
mixed bisabolane isomers as the major product 
(M+ 210, base m/z 97). The hydrogenolysis of ter-
pene cyclohexane cyclic ethers (e.g., 1,8-cineole) 
has been studied,'° and it was found that they 
produce a mixture of the stereoisomeric saturated 
compounds, and the fully aromatic compound 
(cis- and trans-p-menthane and p-cymene from 
Vol. 8, December 1983/January 1984 
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1,8-cineole), with the aromatic compound pre-
dominating at higher reaction temperatures. 
However, when cineole was run under the same 
experimental conditions as peak 43, the only sig-
nificant products were the mixed p-menthanes. 
Thus the production of bisabolane is consistent 
with the expected hydrogenolysis product of a 
cyclic ether with the bisabolane carbon skeleton. 
The stability of the ion at m/z 139 could be 
accounted for if one of the ether linkage points 
was carbon atom 8, in which case alpha cleavage 
would be favoured with the production of a C9 
H15 0 ion. The other linkage point could be at 
carbons 1,2,3,4,7 or 9. From biosynthetic consid-
erations, the most likely positions would be car-
bons 1 (analagous to 1,8-cineole) or 2 (analagous 
to dihydropinol). The former is closely related 
to the known alpha-bisabolol, from which it 
could be obtained biosynthetically, and would 
appear the more likely position. Thus with the 
double bond in the normal position in the side 
chain of bisabolene compounds, a tentative 
structure for this compound is 1,3-dimethy1- 
3(4-methyl)-pent- 4-eny1-2-oxabicyclo(2.2.2 )- 
octane (4). The early retention time of this sub-
stance is consistent with this structure, analagous 
to the early retention time of 1,8-cineole relative 
to other oxygenated monoterpenes. 
The related components marked on figure 2 
also showed a base peak rraz 139, and would 
therefore appear to represent other components 
with the same C9 H15 0 nucleus. 
Peaks 45 and 46-Methyl Jasmonates 
These two components were both found to 
match the mass spectrum of methyl jasmonate (5). 
Initial evidence was based on high resolution 
mass spectrometry of the molecular ion (found 
C13 H20 03) and major fragment ions 83 (found 
C5 H7 0), 151 (C10 H15 01) and 156 (C8 H12 
03). This suggested the compounds could be 
substituted cyclopentanones, with a C5 H9 side 
chain on the carbon adjacent to the carbonyl to 
give a McLafferty rearrangement at in/z 156, and 
also a CH2COOCH3 side chain. Other minor 
peaks in the mass spectrum (m/z 59,74) also sup-
ported the methyl ester function being present. 
Hydrogenation yielded a product C13 H22 03, 
with an ion at m/z 153 instead of in/z 151, indi-
cating the double bond to be in the C5 H9 por-
tion. 
The only known natural product that was con-
sistent with this data was methyl jasmonate, first 
reported in jasmine concrete." Peak 45 was 
found to match the mass spectrum and retention 
time of methyl jasmonate from an Egyptian Jas- 
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mine absolute, confirming this identification. 
Peak 46 would appear to be a stereoisomer about 
the cyclopentanone ring (i.e., cis substitution 
rather than trans), or else the trans geometric 
isomer about the double bond. A very small peak 
was also observed in the Egyptian Jasmine ab-
solute with the same retention index and mass 
spectrum as the second methyl jasmonate isomer. 
In Boronia this peak is occasionally larger than 
the first isomer. 
Methyl jasmonate has only been reported as a 
component of a few other species in addition to 
jasmine, but is widely used in the perfume in-
dustry as a synthetic product. It has only a subtle 
odour of its own, but is considered to enhance the 
odours of other substances. 
Peak 48-(Z)-Heptadec-8-ene 	- 
This alkene is often the major volatile in the 
concretes. Methoxymercuration/demercuration 
yielded a mixture of 8- and 9-methoxy hep-
tadecanes, which indicated the double bond was 
between carbons 8 and 9. The cis geometry was 
determined from a Raman spectrum of the 
purified product, which showed an absorption at 
1657 cm- ', characteristic of cis double bonds, and 
the absence of absorption in the 1665-1676 cm - ' 
for a trans double bond. This alkene could be 
obtained biosynthetically by the simple decar-
boxylation of the common oleic acid. Neverthe-
less simple long chain alkenes are seldom re-
ported as components of floral concretes or es-
sential oils. (Z)-Heptadece-8-ene has been previ-
ously reported as a major volatile of Yucca 
gloriosa flowers" and in neroli oil.' 3 
Discussion 
It is clear from the study of extracts of indi-
vidual Boronia plants that a considerable amount 
of chemical variation occurs within the popula-
tion. This ranges from differences in percentages 
of common components, to the presence or ab-
sence of relatively minor components (which 
may nevertheless be extremely important to the 
overall aroma), to the occurrence of major peaks 
in some clones not normally found among the 
rest of the population. A considerable variation 
was also observed in the yield of 'volatiles' from 
the concrete, as distinct from the total yield of 
concrete. (These aspects will be discussed 
elsewhere in a paper on the horticultural aspects 
of Boronia megastigma.) All these factors are im-
portant in the selection of the most suitable 
clones for large scale vegetative propagation. 
From vacuum distillation studies, and several 
GC runs in which the effluent was split and 
Perfumer & Flovorisf/7 
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aromas assessed as they eluted from the column, 
it is clear that the important aroma components 
are found from peak 15 through to peak 52. The 
monoterpene hydrocarbons appear to have very 
little favourable effect. (Z)-Heptadec-8-ene, al-
though a major component of all concretes, 
would not seem to have an important role in the 
overall aroma impression. Of the compounds 
identified, the most important would seem 
therefore to be the ionones and related epoxides 
and dihydro compounds; the esters including 
fatty acid•methyl and ethyl esters and acetates of 
decyl, dodecyl and tetradecyl alcohols; dihyd-
roactinidiolide; methyl jasmonate isomers. 'Ses-
quicineole' would also appear to markedly mod-
ify the aroma. 
The occurrence of the long chain acetates in 
the Boronia flowers parallels the reports of these 
substances as insect pheromones. The acetates 
with 12 to 18 carbons in the alcohol residue in 
particular, with or without double bonds, are 
typical of the sex pheromones of female moths. 
Dodecyl acetate has been found as a component 
in several dozen moth pheromones, for example, 
that of the cotton bollworm." In its native habitat 
of western Australia, Boronia rnegastigma is 
known to be pollinated by a single species of 
night-flying moth, so it is tempting to suggest that 
this is an instance of the Boronia producing spe-
cific sex attractants for the pollinating insect, 
rather than general chemical attractants. This 
view is supported by the failure of Boronia to set 
seed outside of western Australia, and the obser-
vation that dodecyl and tetradecyl acetates are 
concentrated in the stigma of the flower,' 5 en-
suring good 'pollination' by incoming moths. 
Again, however, alkyl acetates are not com-
monly reported as major components of essential 
oils or floral concretes. Bulgarian rose concrete 
has been shown to contain tetradecyl acetates," 
along with a small number of other oils of flower 
or leaf origin. Dodecyl acetate was reported as a 
component in Cest rum diurnum flower oil" and 
subsequently in a few other oils. It is neverthe-
less used as a synthetic product in the fragrance 
industry." 
The petal waxes clearly contribute the bulk of 
the weight of the concrete from Boronia flowers, 
and the C17 to C33 saturated branched and linear 
hydrocarbons represent the proportion of these 
waxes amenable to GC analysis. The major in-
volatile compounds of the concrete were beyond 
the scope of this study. 
Great care should be used in the storage and 
handling of Boronia concretes, due to the relative 
ease with which some of the components can be 
8/Perfumer es Flavorist 
altered. Dihydroactinidiolide, a known break-
down product of beta-ionone, was observed to 
increase slowly with time at the expense of 
beta-ionone in small samples stored under air. A 
24 hour exposure of a concrete in solution to day-
light caused radical changes in composition, in-
cluding the almost complete disappearance of 
betalionone and heptadec-8-ene, and the occur-
rence of several new components derived from 
these. 
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Abstract—Five out of the nine bud exudates of Fijian Gardenia species examined contained triterpenoids. Three new 
triterpenoids have been characterized. They are: 9,19-cyclolanostane-3,24-dione; 9,19-cyclolanost-24-ene-3,23-dione; 
4-nor-9,19-cyclolanost-24-ene-3,23-dione. 
INTRODUCTION 
The genus Gardenia consists of more than 80 species 
spread among the tropical forests of certain regions of the 
world, including Fiji. Nine Gardenia species are recorded 
in Fiji. In the Fijian traditional system of medicine the 
indigenous Fijians have used the bud exudates of Gar-
denia species as dental masticants [1]. The most inter-
esting use of the Gardenia bud exudates appears to be in 
the control of insects [2-4]. Chemical constituents of the 
bud exudates are reported to be mainly flavanoids [2-4] 
except for one report which showed the presence of p-
coumaric esters of straight chain aliphatic alcohols [5]. 
We have recently [6] completed our phytochemical in-
vestigation of bud exudates of all Gardenia species indi-
genous to Fiji. Five out of the nine species studied [6] 
contained triterpenoids and we report the character-
ization of several triterpenoids, including three new triter-
penoids: 9,19-cyclolanostane-3,24-dione (2); 9,19-cyclo-
lanost-24-ene-3,23-dione (3); and 4-nor-9,19-cyclolanost-
24-ene-3,23-dione (4). . 
RESULTS AND DISCUSSION 
The bud exudates of the nine Gardenia species collected 
in different locations in Fiji were separately extracted 
with chloroform–methanol. The syrup obtained on con-
centration of the extract in each case, was extracted with 
n-hexane, chloroform, ethyl acetate and methanol. The 
chloroform and ethyl acetate extracts of all the syrups 
contained mainly flavonoids [6], whereas the n-hexane 
extracts of the bud exudates of five Gardenia species 
(Table 1) contained terpenoids. 
Cycloartenone (1) was found in the bud exudates of 
four (Table 1) Gardenia species. Mass spectral data of 1 
was useful in its structural identification, and key frag-
ment ions are given. The mass spectral fragmentation 
mechanisms of cycloartane triterpenes have been exten-
sively studied with a view to enabling structural assign-
ments [7-9]. The base peak was observed at m/z 69 due to 
the ion (Me) 2 C = CHCHI . The presence of the cluster of 
t Author to whom correspondence should be addressed.  
ions at m/z 339, 340 and 341 in the mass spectrum of I was 
taken as evidence for the C-24 double bond [10] and 
hence the structure of 1 has been identified as cycloarten-
one (1). The identity of 1 was further confirmed by 
comparison with an authentic sample of cycloartenone 
(co-TLC, 'H and "C NMR). The presence of key dia-
gnostic ions and additional characteristic ions enabled 
the initial structural assignment in most of the triterpen-
oids where the cycloartane skeleton was present. This is 
discussed separately for each triterpenoid characterized. 
A second triterpenoid, 9.19-cyclolanostane-3,24-dione 
(2), co-occurred with cycloartenone (1) in all of the four 
species (Table 1). Compound 2 could not be readily 
separated from two other minor triterpenoids. 3 and 4, in 
the hexane extracts of three species (Table 1). GC-MS 
analysis was used to separate and characterize compound 
2. The mass spectrum of compound 2 showed ions at m/z 
440, 354, 313, 302, 203, 175, 127, 95, 71 and 43. The base 
peak was at m/z 43 and was due to the ion, Me 2CH . The 
molecular ion was at m/z 440 (C 30-48 - ) These data are 0 
in agreement with the cycloartan-3-one frame work. The 
extra oxygen function was located on the side chain of 2 
from its mass spectral fragmentation pattern. The pre-
sence of the McLafferty rearrangement product at m/z 
354 indicated the presence of a carbonyl group in the side 
chain of 2 at C-24. This was further confirmed by the 
presence of the fragment ions at m/z 71, 127 and 302. 
From these data, 2 is 9,19-cyclolanostane-3,24-dione, 
which is a new cycloartane derivative. 
Triterpenoids 3 and 4 were minor constituents. The 
GC-MS analysis showed that 3 is another new triterpenz 
oid and it has been identified as 9,19-cyclolanost-24-ene-
3,23-dione. The key ions in the mass spectrum of 3 which 
were useful in obtaining the structure were at m/z 438 
[M] +, (C30 1-1 4602 ), 340, 12, 98 and 83 (base peak). The 
molecular ion at m/z 438 showed that 3 is a dehydro 
derivative of 2. The fragment ion at m/z 125 for C li ff , 30 
indicated that the unsaturation and the carbonyl group 
are located in the side chain of compound 3. Further 
evidence for this was forthcoming from the presence of 
the ions at miz 83 (base peak) for C 5 H 70 and at m/z 55 for 
C4HI . The ions at m/z 98 and 340 resulted from a 
McLafferty rearrangement involving the hydrogen and 
carbonyl in the side chain of 3. The 'H NMR spectrum of 
159 
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Table I. Distribution of terpenoids from the bud exudates of Fijian Gardenia* species 
% Yield of triterpenoids 
Species 1 2 3 4 5 6 7 8 9 10 
Gardenia storckii 
Gardenia gordonii 
Gardenia hillii (Labasa) 
Gardenia hillii (Bua) 
Gardenia taitensis 
Gardenia grievei 
2.6 
2.9 
1.2 
1.7 
— 
0.07 
1.6 
1.3 
0.2 
0.8 
— 
0.03 
1.7 
1.5 
0.8 
0.6 
— 
0.5 . 
0.7 
0.1 
0.1 
— 
— 
0.9 
0.4 
0.4 • 
0.3 
— 0.4 
— 
0.05 
— 
— 
0.1 
— 
0.1 
0.01 
*No triterpenoids were isolated from the other Gardenia species. 
tYield per cent reported with respect to the bud exudate. 
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3 showed a prominent signal at 6, 6.07 due to the olefinic 
proton adjacent to the carbonyl group. The GC-MS 
analysis of the mixture containing 2 and 3 showed that a 
minor compound, but with a significant peak in GC-MS 
with [M] + at m/z 424 (C29 1-1 4,0 2 ), m/z 326, 147, 125, 83, 
is in fact the 4-nor-homologue of compound 3. The 
"C NMR signals at 6201 (singlet) (C=0 at C-23), 154 
(singlet) (C=C at C-25), 124 (doublet) (C=C at C-24) for 3 
and its 4-nor-homologue were in agreement with the 
structures assigned for these compounds. The 4-nor-
homologue of 3 is also a new natural product 4. The 
distribution of 1-4 in the Gardenia bud exudates is given 
in Table 1. Three species, G. storckii, G. gordonii, and G. 
hillii, contained all the four triterpenoids. Gardenia grievei 
contained only two triterpenoids. I and 2. 
Another triterpenoid which was present in three out of 
the five species (Table 1) was identified as a cycloartadien-
one (5). It was separated from cycloartenone (I) by GC 
and a GC-MS study showed 5 to have a [M] + at m/z 422 
(C 30 1-1460). The mass spectral fragmentations of 5 were 
similar to those of I with the base peak at m/z 69 (C 5 H 9 ) 
suggesting the presence of a Me,C=C group. The frag-
ment ion at m/z 109 for 5 showed the presence of two 
olefinic double bonds in its side chain. The presence of 
two C=C bonds were confirmed by catalytic hydrogena-
tion over Pd-C. The reduced product had [Mr at m/z 
426 (C 30 H SO0) with fragment ions at m/z 313, 288, 113 
and 95. 
The triterpenoid composition of the bud exudates of 
G. taitensis was different from the other Gardenia species 
discussed above. Four triterpenoids were isolated from G. 
taitensis and one has been characterized as 9,19-cyclolan-
ostane- 3,23-dione (7). Three other terpenoids, 6, 8 and 9, 
could not be characterized due to lack of materials. 
Compound 7 could not be separated easily by chro-
matographic methods from 8. However, GC-MS analysis 
was useful in elucidating the structure of 7 which had a 
[M] 4 at m/z 440 (C 30 11490 2 ) and was isomeric with 2. 
The presence of the fragment ions at m/z 355, 340, 313, 
311, 302, 127 and 57 in the mass spectrum of compound 7 
was the key to identifying 7.as 9,19-cyclolanostane-3,23- 
dione. Two species of Gardenia hillii collected in different 
locations in Fiji gave similar triterpenoid profiles 
(Tables 1 and 2). 
EXPERIMENTAL 
Gardenia species were collected in .Fiji during 1986-1988. 
Voucher specimens for all the shrubs and trees sampled and a 
map indicating the place of collection are deposited in the South 
Pacific Herbarium, Suva, Fiji. Selected duplicate vouchers are 
deposited in the Bernie Bishop Museum, Honolulu, Hawaii 
(BISH) and Rancho Santa Ana Botanic Garden, Claremont, 
California (RSA-POM). The bud exudates were dissolved in 
CHC1 3—Me0H. The residue on evaporation was extracted with 
n-hexane to give fractions containing terpenoids. Out of the 9 
species studied [6], only the Gardenia species listed in Table 1 
contained terperioids in their bud exudates. The distribution of 
terpenoids is also given in Table I. The bud exudates of three 
species, G. storckii, G. gordonii, and G. hillii gave two main 
terpenoid fractions when separated by VLC (silica gel) [11]. 
These have been labelled as terpenoid fractions A and B (Table 
2). The GC-MS determinations were carried out on a HP-MSD, 
using a 25 m x 0.32 mm HP-5 column (0.52 pm film), with an 
SGE on-column injector, and temp. programming from 30 to 
240° at 30° min then to 300° at 10° min using He as carrier 
Table 2. Terpenoid fractions from Fijian Gardenia species 
Species Terpenoid fraction % Yield 
G. gordonii A 3.9 
3.4 
G. hillii A 2.0 
(collected from Labasa) 1.8 
G. hillii A 1.9 
(collected from Bua) 1.5 
G. storckii A 3.5 
2.9 
G. taitensis 6 0.4 
7 and 8 0.6 
8 and 9 0.7 
G. grievei e 0.1 
0.2 
gas. The HR 'H and ' 3C NMR spectra were recorded at 
ambient temp. at 250 and 300 MHz, respectively, using TMS as 
int. ref. 
The terpenoid fraction A showed a distinct pink spot on silica 
gel TLC (60% CHCI 3—n-hexane) when sprayed with ceric sulph-
ate reagent. This fr. was purified further by prep. TLC on silica 
gel and using 60% CHC1 3—n-hexane as eluting solvent. On GC 
analysis this fraction was found to contain cycloartenone (I) and 
cycloartadienone (5) in GLC peak ratio of 74% : 26%. 
Terpenoid fraction A. Cycloartenone (I). GC- IR (gas phase) 
cm': 1720 max (C=0). NMR (CDCI 3 ): (50.8-1.8 (—CH 2 —, 
Me), 2.3 (—CH 2—00—), 4.7, (-CH=). ' 3 C NM R (CDCI 3 ): 6216.52 
(C=0), 130.79 (C-25), 125.08 (d, C-24), 52.16 (d, C-17). 50.11 (C-4), 
48.60(C-14), 48.30 (d, C-5), 47.78 (d, C-8), 45.19 (C-13). 37.36 (t. C-
2) 36.20 (t, C-22), 35.75 (d, C-20), 35.45 (t, C-15), 33.30 (t. C-1) 
32.66 (t, C-12),29.45 (t, C-19), 28.03 (t, C-7), 26.60 (t, C-16), 25.83 
(C-10), 25.75 (t, C711), 25.63 (q, C-27), 24.81 (r, C-23), 22.096 (q. C- 
30), 21.39 (t, C-6), 20.96 (C-9), 20.66 (q, C-29), 19.18 (q, C- 18), 
18.11 (q, C-28), 17.98 (q, C-21), 17.54 (q, C-26). MS m/z (rel. int.): 
424 (18) [M]*, 409 (24), 340 (17), 313 (20), 311 (22), 286 (24), 271 
(20), 205 (18), 147 (20), 111 (187), 95 (57), 69 (100). HR-MS: 
424.370 [M] + (C30 F1 4 80 requires 424.3705), 340.278 (C 24H 380 
requires 340.2766), 313.250 (C 22 H 330 requires 313.2530), 
286.265 (C21H34 requires 286.2660). Cycloartadienone (5): GC-
IR (gas phase): 1720 cm (—C=0). MS m/z (rd. int.): 422 (26) 
[M] + (C301-1460), 313 (18), 311 (25), 259 (20), 121 (68), Ill  (12). 94 
(42), 69 (100). HR-MS: m/z 422.358 (C 30 H460 requires 422.3548). 
Reduced fraction A. MS m/z (rd. int.): 426 (15) [M] 
(C 30H 300), 313 (17), 288 (10), 109 (30), 95(28). 
Terpenoid fraction B (Table 2). The terpenoid fraction B was 
purified on prep. on TLC (silica gel). GC-MS analysis showed 
that this fraction contained three compounds in the GC ratio 
indicated in parentheses. 9,19-cyclolanostane-3,24-dione (2) (40): 
9,19-cyclolanost-24-ene-3,23-dione (3) (30): 4-nor-homologue of 
3 (4) (19). 'H NMR (CDC1 3 ): (50.78-2.00 (CH 2 and Me). 121 
(MeC= ), 2.31 (CH 2C0), 6.07 (=CHCO). 2: MS (rd. int.): mlz 440 
(18) [M] (C 38 I-1 4802 ), 354 (24), 313 (45), 302 (21), 203 (24), 175 
(38), 127(40), 95(64), 71(60), 43 (100). HR-MS: m/z 440.363 [M]* 
(C38 I-1480 2 requires 440.3654), 354.290 (C 23H 380 requires 
354.2922), 302.262 (C 21 H 340 requires 302.2609), 127.112 
(C 8 H 130 requires 127.1123), 71.051 (C 4H-,0 requires 71.0497). 
3: MS m/z (rd. int.): 438 (10) [N] + (C301-14802), 340(45), 125 (75), 
98(46), 83 (100), HR-MS: m/z 438.351 [M] + (C30H4802 requires 
230 
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438.3497), 340.275 (C 24 H 3 ,0 requires 340.2766), 125.098 
(C8 14, 3 0 requires 125.0966), 98.073 (C 6 H 00 requires 98.0731) 
83.049 (C 5 1-1,0 requires 83.0497). 4: MS m/z (rel. int.): 424 (10) 
[M] * (C 29 H 440 2 ). 326 (39), 147 (71), 125 (86), 83 (100). HR-MS: 
ml: 424.334 [M]' (C 29 H 440 2 requires 424.3341), 326.259 
(C 23 H 340 requires 326.2609). 
The fractions of the bud exudates of G. taiterisis containing 
terpenes on GC-MS analyses showed that they were chemically 
different to those of the bud exudates of the three Gardenia 
species discussed above (Table 1). The terpenoids and their GC 
peak ratios (in parentheses) are given below: 9,19- 
Cycloanostane-3.23-dione (7) (25%): Three yet unidentified tri-
terpenoids (6, 8 and 9) (75%). GC-MS of the triterpenoids of the 
bud exudates of G. taitensis. 6: ml: (rd. int.): 424 (100) [M] 
(C 30 F1 480), 409 (5), 218 (100), 189 (15). 7 m/z (rd. int.): 440 (14) 
[M]* (C 30 H 480 2 ), 355 (17), 340(78), 313 (12), 311 (15), 302 (28), 
175 (22), 127(60), 85(65), 57(42). 8 ml: (rd. int.): 424 (22) [Mr 
(C 30 H 480), 355 (40), 340 (50), 298 (60), 221 (100), 205 (75), 147 
(58), 111 (55), 85 (78), 55 (90). 9 m/z (rd. int.): 438 (10) [M] + 
(C 30 1-1 460 2 ), 353 (16), 338 (34), 323 (15), 202 (26), 147 (100), 121 
(77), 85 (22), 57 (48). 
Two triterpenoid fractions C and D (Table 2) were obtained 
from the bud exudates of Gardenia grievei. GC-MS analyses 
showed that the terpenoid fraction c contained cycloartenone (1) 
and a triterpenoid (10). The terpenoid fraction D was mainly 
9,19-cyclolanostane-3,24-dione (2) mp. 175-177'. GC-MS of 10 
(mp 183-185'). ml: (rel. int.): 424 (16) [M]* (C 30 1-1 480), 409 (52), 
339 (2), 271 (20), 257 (100), 137 (38), 95(36), 55(30). '1-1NMR 
(CDCI 3 , 250 MHz) of 10: (50.6-1.58 (CH 2 and CH 3 , 2.69 
(CH 2C0), 5.11 ( =CH). 
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Eight peak spectra, indexed by name 
Ions/Intensities 	 Mol.Wt. Formula Compound Name 
190(100), 
125(100), 
138(100), 
143(100), 
108(100), 
157(100), 
125(100), 
138(100), 
154(100), 
108(100), 
43(100), 
43(100), 
341(100), 
136(100), 
58(100), 
44(100), 
156(100) 
148(100) 
106(100) 
108(100) 
116(100) 
72(100), 
156(100) 
135(100) 
238(100) 
91(100), 
43(100), 
202(100) 
125(29), 	134(28), 	162(27), 	91(14), 	112(13), 	191(12), 	161(11) 
167(27), 	43(23), 	96(14), 	124(10), 	126(8), 	52(7), 	80(5) 
153(73), 	195(72), 	43(31) 	110(19), 	52(13), 	95(12), 	139(11) 
43(42), 	145(33), 	185(19) 	80(12), 	51(10), 	144(9), 	114(9) 
123(80), 	165(57), 	43(42) 	80(31), 	52(21), 	65(17), 	92(8) 
142(92), 	43(60), 	199(53) 	159(34), 	144(32), 	114(24), 	201(19) 
167(46), 	43(33), 	79(30), 	52(12), 	124(10), 	126(8), 	51(8) 
195(71), 	153(31), 	43(31) 	110(24), 	139(19), 	15(9), 	196(9) 
211(95), 	43(40), 	110(36) 	169(34), 	109(13), 	212(11), 	155(9) 
123(62), 	165(56), 	43(26) 	80(10), 	52(10), 	122(10), 	109(8) 
161(57), 	163(35), 	177(24) 	179(15), 	203(11), 	162(10), 	160(9) 
157(40), 	126(31), 	159(24) 	127(21), 	111(15), 	142(13), 	128(13) 
282(58), 	43(39), 	42(34), 	229(30), 	59(23), 	342(22), 	204(17) 
29(33), 	52(30), 	135(13) 	53(12), 	51(9), 	137(7), 	39(7) 
59(18), 	42(11), 	30(8), 	202(7), 	203(5), 	215(), 	91(4) 
91(6), 	42(4), 	65(4), 	45(3), 	39(3), 	51(2), 	120(2) 
141(60), 	41(45), 	157(33), 	55(30), 	43(30), 	27(28), 	29(22) 
147(35), 	77(22), 	133(22), 	117(22), 	105(20), 	121(18), 	79(13) 
107(83), 	77(32), 	51(24), 	39(23), 	79(16), 	65(15), 	78(12) 
65(95), 	78(67), 	39(46), 	51(24), 	77(22), 	79(17), 	93(16) 
43(88), 	29(71), 	85(59), 	31(49), 	44(46), 	61(29), 	42(28) 
30(57), 	43(10), 	56(9), 	41(7), 	57(6), 	107(6), 	73( 5 ) 
141(76), 	41(36), 	27(33), 	29(30), 	39(30), 	55(29), 	98(22) 
136(69), 	77(27), 	92(14), 	107(11), 	39(10), 	63(8), 	65(8) 
223(31), 	43(26), 	192(19), 	239(15), 	191(11), 	163(11), 	39(10) 
92(89), 	41(17), 	65(13), 	29(13), 	39(12), 	27(12), 	105(9) 
171(89), 	188(83), 	230(61), 	79(44), 	52(19), 	51(18), 	95(16) 
244(75), 	43(74), 	138(42), 	186(34), 	92(25), 	107(24), 	79(12) 
278 
167 
195 
185 
165 
199 
167 
195 
211 
165 
219 
199 
341 
136 
277 
135 
226 
148 
107 
108 
176 
266 
184 
136 
238 
162 
230 
244 
C16H2204 
C8H9NO3 
C10H13NO3 
C8H8NO2C1 
C9H11NO2 
C9H10NO2C1 
C8H9NO3 
C10H13NO3 
C10H13NO2S 
C9H11NO2 
C8H7NO2C1 2 
C8H8NO2C1 
C20H23N04 
C5H4N40 
C20H23N 
C9H13N 
C11H18N203 
C10H120 
C7H9N 
C7H80 
C6H806 
C1422N203 
C8 1112N203 
C8H802 
C13111804 
C12H18 
C8 1110N204 S 
C9H12N204 S 
.abscisic acid, methyl ester 
acetanilide, 2,4-d1hydroxy-
acetanilide, 2,4-dimethoxy-
acetanilide, 2-hydroxy-4-chloro-
acetanilide, 2-methoxy-
acetanilide, 2-methoxy-4-chloro-
acetanilide, 3,4-dihydroxy-
acetanilide, 3,4-dimethoxy- 
acetanilide, 3-methylthio-4-methoxy- 
acetanilide, 4-methoxy- 
acetanilide, N-hydroxy-3,4-dichloro- 
acetanilide, N-hydroxy-4-chloro-
acetyl codeine 
allopurinol 
amltryptaline 
amphetamine 
amylobarbitone 
anethole 
aniline, N-methyl- 
anisole 
ascorbic acid 
atenolol 
barbitone 
benzaldehyde, 	methoxy- 
benzene, 2,3,4,5-tetramethoxy-allyl- 
benzene, n-hexyl 
benzenesulfonamide, 3-hydroxy-4-acetylamlno- 
benzenesulfonamide, 3-methoxy-4-acetylamino- 
Ions! Intensities Mol.Wt. Formula Compound Name 
43(100), 	121(53), 	202(24), 	185(15), 	64(9), 	63(9), 	122(8), 	90(7) 
43(100), 	188(27), 	172(21), 	60(19), 	107(18), 	108(12), 	92(9), 	156(8) 
120(100), 	151(59), 	193(38), 	43(36), 	65(20), 	92(19), 	121(11), 	161(10) 
105(100), 	91(61), 	77(39), 	212(23), 	51(22), 	65(14), 	106(11), 	90(10) 
91(100), 	57(46), 	108(31), 	192(27), 	85(24), 	41(15), 	43(11), 	92(8) 
91(100), 	108(83), 	57(34), 	192(26), 	85(25), 	92(14), 	65(12), 	90(12) 
169(100), 	185(60), 	43(47), 	168(32), 	211(28), 	141(22), 	167(21), 	170(14) 
169(100), 	211(39), 	168(30), 	185(24), 	43(23), 	170(15), 	141(11), 	167(10) 
199(100), 	43(93), 	168(51), 	184(27), 	200(17), 	241(17), 	169(16), 	153(13) 
168(100), 	199(77), 	43(46), 	169(40), 	167(32), 	198(30), 	241(29), 	141(22) 
69(100), 	41(90), 	93(85), 	67(58), 	94(53), 	109(47), 	79(45), 	204(33) 
43(100), 	143(83), 	85(67), 	105(62), 	81(60), 	59(53), 	134(49), 	71(48) 
143(100), 	43(71), 	93(43), 	71(34), 	125(34), 	121(31), 	68(30), 	134(25) 
43(100), 	41(89), 	69(80), 	109(50), 	119(40), 	93(39), 	55(35), 	67(28) 
93(100), 	141(87), 	43(85), 	94(62), 	68(51), 	121(49), 	95(46), 	41(39) 
95(100), 	41(20), 	110(17), 	55(11), 	43(10), 	67(8), 	93(8), 	96(8) 
95(100), 	43(66), 	93(38), 	121(36), 	136(33), 	55(17), 	69(16), 	108(16) 
41(100), 	79(82), 	67(82), 	119(80), 	55(68), 	81(68), 	84(65), 	93(9) 
317(100), 	315(96), 	236(92), 	288(69), 	78(57), 	286(57), 	77(56), 	51(51) 
202(100), 	200(18), 	203(17), 	101(11), 	202(10), 	88(6), 	150(5), 	100(4) 
59(100), 	43(49), 	31(42), 	41(29), 	39(14), 	69(11), 	42(7), 	87(4) 
43(100), 	105(43), 	91(36), 	148(28), 	77(13), 	79(12), 	51(10), 	67(9) 
156(100), 	141(94), 	41(44), 	29(40), 	27(31), 	39(21), 	98(19), 	142(15) 
161(100), 	134(58), 	119(46), 	105(45), 	204(41), 	41(34), 	81(27), 	91(25) 
159(100), 	16a(13), 	202(9), 	129(7), 	128(7), 	131(5), 	105(5), 	144(4) 
93(100), 	121(67), 	79(38), 	41(38), 	67(33), 	91(28), 	107(28), 	39(27) 
43(100), 	71(99), 	69(48), 	41(44), 	67(33), 	96(31), 	84(28), 	39(28) 
108(100), 	93(42), 	95(25), 	41(24), 	109(19), 	67(19), 	91(13), 	81(12) 
95(100), 	81(65), 	41(61), 	69(38), 	108(35), 	55(35), 	83(33), 	109(26) 
242 
230 
193 
212 
192 
192 
227 
227 
241 
241 
204 
238 
238 
222 
236 
154 
196 
280 
315 
202 
102 
148 
212 
204 
202 
136 
154 
152 
152 
C9H12N204 S 
C8H10N204 S 
C10H11NO3 
C14H1202 
C12H1602 
C12H1602 
C14H13NO2 
C14 	31402 
C15H15NO2 
C15H15NO2 
C15H24 
C15H2602 
C15H2602 
C15H260 
C1 5 112402 
C10H180 
C12H2002 
C16H2404 
C14H10N30B1  
C16H10 
C5111 002 
C10H120 
C10 111 61 23 
C15H24 
C15H22 
C1 0H16 
C10H180 
C19H160 
C10H160 
benzenesulfonamide, N-methoxy-4-acetYlamino -
benzenesulfonamide, N-OH-4-acetyla5%ino-
benzoic acid, N-acetyl-4-amino-, me. ester 
benzyl benzoate 
benzyl isopentanoate 
benzyl pentanoate 
biphenyl, N-hydroxy-3-acetYlamino-
biphenyl, N-hydroxy-4-acetylamino-
biphenyl, N-methoxy-3-acetylamino -
biphenyl, N-methoxy-4-acetylamino -
bisabolene, p- 
bisabolol oxide B 
bisabolol oxide B 
bisabolol, 	a- 
bisabolone oxide 
borneol 
bornyl acetate 
Brefeldin A 
bromazepam 
butadiyne, 1,4-diphenyl- 
butan-2-one, 3-hydroxy-3-methyl-
butan-2-one, 4-phenyl- 
butabarhitene 
cadinene, 8- 
cal amenene 
camphene 
camphene hydrate 
campholene aldehyde, a-
camphor 
Ions/Intensities Mol.Wt. Formula Compound Name 
295(100) , 
140 (100) , 
193 (100) , 
186(100) , 
93(100) , 
161 (100) 
135(100) 
84 (100) , 
109 (100) 
43(100) , 
82(100) , 
41(100) , 
124(100) 
119(100) 
95(100) , 
184 (100) 
282 (100) 
86(100) , 
266(100) 
203 (100) 
58(100) , 
43(100) , 
123 (100) 
121 (100) 
131 (100) 
131 (100) 
185(100) 
41 (100) , 
41 (100) , 
296(21) 
139(90) 
192(34) 
29(77) , 
43(31) , 
, 	41 (65) , 
, 	150(27) 
134 (65) , 
, 84(85) , 
84 (71) , 
54(44) , 
69(98) , 
, 	123(63) 
, 	93(49) , 
151 (84) , 
, 169(91) 
, .283(80) 
30 (13) , 
, 	264(76) 
, 	58(92) , 
86(21) , 
81 (27) , 
, 	121 (28) 
107(97) 
, 	103(37) 
, 	162(58) 
, 	185(57) 
69(81) , 
69 (85) , 
, 	238(12) , 	310(12) , 	26(8) , 	251 (6) , 	27(6) , 	55(5) 
, 	91 (65) , 	168 (51) , 	51 (36) , 	63(35) , 	77(30) , 	39(20) 
, 	236(23) , 	191 (20) , 	165(16) , 	194 (15) , 	63(7) , 	167 (6) 
114 (68) , 	42(48) , 	72(45) , 	27(32) , 	113(31) , 	81 (20) 
91 (31) , 	79(29) , 	77(29) , 	27(28) , 	80(22) , 	92(21) 
84 (49) , 	69(45) , 	55(41) , 	97 (40) , 	43(39) , 	81 (37) 
, 	91 (20) , 	41 (12) , 	77(11) , 	39 (10) , 	136(10) , 	107(9) 
41 (50) , 	79(47) , 	109(47) , 	119 (40) , 	55(39) , 	91 (37) 
41 (46) , 	55(37) , 	119(35) , 	83 (33) , 	91 (33) , 	39(28) 
119(55) , 	109 (35) , 	134 (35) , 	152 (34) , 	41 (29) , 	91 (29) 
39(34) , 	93(26) 	108(25) , 	41 (23) , 	53 (17) , 	107(16) 
93(94) , 	133(65) , 	79(61) , 	91 (55) , 	107(39) , 	39(35) 
, 	78(48) , 	77(20) , 	51 (19) , 	39(18) , 	55(10) , 	52(9) 
41 (34) , 	69(30) , 	105(28) , 	161 (23) , 	204 (20) , 	120 (17) 
43(68) , 	150(61) , 	41 (51) , 	69 (44) , 	81 (42) , 	152 (35) 
, 	183(26) , 	153 (23) , 	155(22) , 	152 (17) , 	185(15) , 	154 (13) 
, 	284 (44) , 	285(25) , 	77(15) , 	220 (13) , 	247 (12) , 	219 (11) 
58 (11) , 	87 (6) , 	41 (6) , 	73(5) , 	42(5) , 	319(3) 
, 	268(47) , 	109(25) , 	124(19) , 	98(14) , 	133(14) , 	62(12) 
205(33) , 	72 (26) , 	204 (15) , 	42 (13) , 	167(13) , 	202 (12) 
318(16) , 	85(8) , 	42(8) , 	272(6) , 	320(6) , 	232(5) 
55(26) , 	69(26) , 	71 (22) , 	108 (18) , 	84 (18) , 	111 (13) 
, 	150 (27) , 	41 (20) , 	93(19) , 	81 (17) , 	43 (17) , 	55 (16) 
, 	149(65) , 	93(56) , 	167 (55) , 	150 (29) , 	91 (25) , 	55(25) 
, 	176(30) , 	77 (26) , 	51 (15) , 	104 (13) , 	132 (12) , 	147 (11) 
, 	103(45) , 	77 (24) , 	51 (14) , 	102 (11) , 	132 (10) , 	163(6) 
, 	259(54) , 	43(54) , 	57(38) , 	29(27) , 	41 (24) , 	157(22) 
55(46) , 	95(36) , 	43(32) , 	56(29) , 	57(27) , 	39(21) 
55(42) , 	82(37) , 	67(34) , 	81 (29) , 	71 (25) , 	95(24) 
310 
168 
236 
186 
136 
222 
150 
152 
152 
194 
150 
204 
124 
204 
222 
184 
299 
319 
264 
274 
318 
154 
316 
360 
176 
162 
402 
154 
156 
C21H2602 
C12 1180 
C15H12N2 
C7 H10N202S 
C10 1116 
C1511260 
C10 1114 0 
C10 11160 
C108160 
C128180 
C108140 
C15824 
C7 E1 802 
C15824 
C158260 
C14 1116 
C16 1114N30C1 
C18 1126N3C1  
C8N2C1 4 
C16H19N2Cl 
C17H19N 2SC1 
C10 11180 
C20 1.1 2803 
C21 112805 
C11 111202 
C1081002 
C20H 34 08 
C10 11 180 
C10H200 
cannabinol 
capillin 
carbarnazepine 
carbirnazole 
carene , A3- 
carotol 
carvacrol 
carveol , cis-
carveol , 	trans- 
carveyl acetate 
carvone 
caryophyllene 
catechol , 4 -methyl-
cedrene , a- 
cedrol 
chaznazulene 
chlordiazepoxide 
chloroquine 
chlorothalonil 
chlorpheniraznine 
chlorpromazine 
cineole, 	1 , 8- 
cinerin 
cinerin II 
cinnamic acid, ethyl 
cinnamic acid, methyl 
citric acid, acetyl-, 
citronellal 
citronellol 
ester 
ester 
tri-n-butyl ester 
a u pueipAquatidTP 
ToualldsoTP 
atoTdeTTTP 
auTap000ipAqFP 
auoAaeooxpAtITP 
To qqaueoxpAqTp 
treingoavbroxpAqTp 
atiouoT-d-oxPAUP 
uoTdoictrAtilaTP 
wedzeTP 
auatidAxodoldoilxap 
uegdootioamoiqxap 
/also TAttlaw 'PT 0E 0T0u3-t-3aP 
Toonep 
-TAqaor 'auosdep 
auauamAo 
-d 'To-s-auomAo 
-TAquad-u 'auexattotoAo 
-TAxaq-u 'auexagoToAo 
TollopTe TAuTinno 
-d 'epAtiapie oTupsno 
-n 'auagagno 
-n 'auaedoo 
anTquATaap TATTsTAtioawTag 'auTapoo 
auTe000 
aurpTuoTo 
wedazeuoTo 
wedazecioTo 
eqeouaonq TATTauollTD 
ONTZHLT0 
Z09IHOT0 
VIH  ZI 0 
CONCZH8TO 
09THOT0 
VI OT 0 	H 	0 
0SIZHg tD 
0ZZHELD 
ON6IREID 
T3OZNEIH9I0 
ZoN6ZHZZ0 
ONSZHBT0 
Z OZ TT 0 	0 	0 
Zo9ZHSI0 
SEOZNVTHPIO 
ZTHO TO 
PI OT 0 	H 	0 
ZZHITO 
VZHZ TO 
VT OT 0 	H 	0 
0ZIHOT0 
VZHGTO 
VZHST0 
TSE0N6ZHIZ0 
PONTZHLI0 
Z TOEN6H60 
T3E0CNOTHGTO 
13Z0ZNE 1H9 TO 
Z PZ VI 0 	H 	0 
9GZ 
891 
ZZZ 
TOE 
ZGT 
OST 
ZZZ 
46T 
G6Z 
P8Z 
6EE 
ILZ 
08T 
BE Z 
06Z 
ZET 
OGI 
PST 
891 
OGT 
8VI 
VOZ 
POZ 
TLC 
EOE 
6ZZ 
STE 
00E 
VZZ 
	
(1I)L91 	(V1)591 	' (VI) ZO 	(9T) 65 	(ZZ) VP 	(6V)SV 	(08)EL 	' (001) 85 
(GE) 69 	' (9E)6E 	' (9E) SS 	' (6E) SZT 	' (SP)891 	' (95)0, 	' (Z8) TV 	' (001) 9ZI 
(0I) Z6T 	(01)E9 	' (TT) TS 	(ZI)EZZ 	' (E1)86 	' (ST)LOZ 	(TO LLI 	(00I) ZZZ 
(tZ) ZOE 	' (VZ) LE 	' (9Z) P91 	' (IC) OL 	' (LE) 6G 	' (80 ZP 	' (04) VP 	' (001) TOE 
(6E)601 	' (EV) ZSI 	' (LP) IP 	(P5) I8 	' (09) Z8 	' (99)89 	' (60 L9 	' (001)96 
' (0 S9 	' (V) ZZT 	(S) 6E 	' 	81. 	' (L) 16 	' (8)1.1. 	' (OZ)O51 	' (001) TZT 
(LI)Ls 	(81) 661 	(OZ) 6i 	(IC) 19 	(CC) 601 	'(ve)LET 	'(e9)L0Z 	(001) 6Z 
(CE) 611 	' (9E) 96 	' (9E) 9E1 	' (80 E6 	' (8E) EZT 	' (09) 19I 	(17L) Et 	' (000 TZT 
(V) 95 	' (9) ZP 	' (L)6Z 	' (L) LL 	(L) TOT 	' (6) ZL 	(LT) PP 	' (00T) 00T 
(ZZ)98Z 	' (EE) 852 	' (TV) G8Z 	' (IV) LSZ 	(ZV) GGZ 	' (99) V8Z 	' (18)E8Z 	' (001) 95Z 
(Z)0E 	.(Z)GOT 	'(E)LL 	'(E)Z0 	'(P)69 	'(G)LG 	'(5)16 	'(00T)85 
(9I) OC 	' (61) VIZ 	' (EZ) ZP 	' (9Z) OLZ 	' (9E) 051 	' (6E) 'LE 	' (84) ILZ 	(00T) 65 
(906Z 	' (GO) L9 	' (8V) VG 	' (05) OTT 	' (00 SS 	' (PL)CV 	' (SL) TV 	' (001) VI. 
(ZI)S5 	' (DT) CET 	( VZ) IV 	' (SZ)9ET 	' (8Z) V61 	' (EV) EV 	' (ZL)E6 	' (001) 'EST 
(EZ) Z6 	' (12) 99 	(12) 85 	' (OS) OVT 	(E9) 06Z 	' (OL)80I 	(GO 8VZ 	' (00T) EP 
(ST) 	' (61)59 	' (61)6E 	(OZ) Z6 	' (EE) Sri 	' (8E) 16 	' (18) LIT 	' (001) ZET 
(9)6E 	' 	SIT 	'(8)59 	' (ET) LIT 	' (VT) ZET 	' (L T) SIT 	' (ES)SET 	(00T)EP 
(ZT) PST 	' (ET) Et 	' (9I) 6Z 	' (91)1.9 	' (8E) IV 	' (00 Z8 	' (IL)SS 	' (001)E8 
(TT) 89T 	' (I1)6Z 	' (ET) EV 	' (sI) 1.9 	' (8E) IV 	' (80 SS 	' (00I)E8 
(9T)LL 	' (EZ) 16 	' (SZ)6TI 	' (ZE)6L 	' (SE) LOT 	' (ZV)SOT 	' (0)0ST 	' (00T) SET 
(ZE) 6TI 	(E) 1V 	' (VE)6L 	(PE) T6 	' (6E) LL 	' (80 8PT 	' (99)501 	' (00T) EEI 
(9Z) E6 	' (6Z) 16 	' (6Z) OZT 	' (ZE) 18 	(CC) IV 	' (c6)611 	' (L6)G01 	' (001) 191 
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Ions/Intensities Mol.Wt. Formula Compound Name 
124(100), 
161(100), 
43(100), 
55(100), 
43(100), 
137(100) 
105(100) 
93(100), 
160(100) 
163(100) 
58(100), 
144(100) 
164(100) 
139(100) 
121(100) 
177(100) 
120(100), 
71(100), 
71(100), 
112(100), 
74(100), 
43(100), 
123(100, 
161(100), 
123(100), 
163(100), 
43(100), 
86(100), 
68(100), 
109(56), 	198(21), 	77(18), 	81(14), 	122(11), 	123(10), 	52(9) 
59(70), 	107(57), 	105(53), 	93(42), 	81(42), 	41(39), 	91(37) 
41(61), 	55(29), 	69(27), 	39(27), 	108(16), 	67(12), 	111(11) 
43(94), 	41(88), 	69(78), 	83(70), 	57(68), 	56(60), 	70(53) 
57(87), 	82(70), 	55(59), 	41(53), 	96(48), 	83(45), 	69(44) 
109(26), 	69(25), 	41(23), 	93(15), 	55(12), 	67(11), 	39(11) 
77(66), 	135(31), 	51(26), 	134(15), 	106(8), 	78(6), 	161(4) 
41(34), 	80(32), 	121(29), 	55(19), 	43(17), 	92(16), 	69(15) 
103(63), 	76(30), 	130(29), 	131(25), 	89(24), 	115(23), 	50(22) 
161(93), 	91(68), 	119(52), 	206(45), 	117(29), 	41(28), 	43(25) 
235(58), 	85(52), 	234(44), 	280(22), 	193(20), 	195(19), 	208(16) 
175(53), 	116(17), 	89(17), 	145(11), 	63(7), 	176(6), 	72(5) 
166(33), 	223(23), 	55(21), 	43(21), 	41(20), 	99(17), 	165(11) 
141(37), 	357(26), 	111(23), 	140(10), 	358(9), 	75(8), 	113(8) 
93(80), 	43(68), 	136(59), 	41(29), 	91(27), 	77(25), 	109(23) 
43(84), 	41(26), 	93(20), 	91(15), 	178(14), 	121(12), 	77(12) 
41(42), 	43(37), 	138(31), 	121(31), 	39(28), 	59(28), 	55(28) 
43(93), 	70(53), 	41(24), 	55(18), 	27(13), 	29(11), 	42(11) 
43(99), 	56(51), 	57(45), 	41(41), 	29(24), 	89(23), 	27(17) 
69(55), 	41(53), 	55(46), 	139(33), 	56(30), 	70(28), 	43(25) 
87(53), 	43(48), 	41(35), 	55(30), 	57(19), 	69(18), 	82(17) 
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133(92), 	107(23), 	91(22), 	41(19), 	105(18), 	162(17), 	93(15) 
43(54), 	41(34), 	55(28), 	81(23), 	164(22), 	93(22), 	135(16) 
135(89), 	93(87), 	107(79), 	167(76), 	55(55), 	121(48), 	41(43) 
41(77),69(55), 	109(44), 	81(43), 	55(36), 	122(39), 	107(32) 
30(17), 	58(10), 	87(6), 	41(4), 	72(3), 	56(3), 	27(3) 
67(44), 	93(35), 	39(25), 	79(24), 	53(23), 	94(18), 	77(15) 
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222 
126 
238 
380 
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204 
160 
206 
280 
175 
223 
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192 
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208 
158 
144 
154 
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328 
372 
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374 
222 
234 
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C22H2805 
C21H3003 
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C15H260 
c14 2N20 
C10H16 
guaifenesin 
guaiol 
hept-5-en-2-one, trans 6-methyl-
heptadec-8-ene, Z- 
hexacosanal, n-
hexahydrobenzofuran, 3,6-dimethyl - 
hippuric acid 
humulene 
hydralazine 
ibuprofen 
imipramine 
indole-2-carboxylic acid, methyl ester 
indoleacetic acid, 4-chloro-, methyl ester 
indomethacin 
ionone, a- 
ionone, 
isoamyl salicylate 
isobutyric acid, 2-methylbutyl ester 
isobutyyl isobutyrate 
isomenthone 
isooctanoic acid, methyl ester 
isopropyl myristate 
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Ions/Intensities 	 Mol.Wt. Formula 	Compound Name 
259(100), 161(62), 81(42), 163(10), 54(9), 89(8), 27(7), 160(7) 
41(100), 93(91), 69(76), 39(34), 27(30), 53(21), 77(13), 29(12) 
192(100), 91(24), 165(22), 119(16), 65(15), 39(14), 161(13), 193(12) 
69(100), 67(94), 93(91), 123(85), 41(83), 81(73), 82(70), 55(61) 
43(100), 93(94), 82(71), 69(53), 121(45), 67(44), 41(44), 95(38) 
79(100), 91(31), 108(17), 31(13), 77(12), 43(11), 41(11), 39(9) 
173(100), 115(81), 142(80), 43(69), 215(46), 141(41), 127(35), 172(29) 
185(100), 230(48), 186(15), 141(14), 115(12), 170(11), 139(11), 153(8) 
185(100), 244(35), 186(17), 170(10), 141(7), 154(6), 245(6), 153(6) 
159(100), 142(73), 43(71), 115(70), 143(41), 201(37), 128(25), 140(22) 
69(100), 41(60), 68(19), 39(11), 93(10), 123(2), 67(8), 53(7) 
84(100), 133(30), 162(21), 42(19), 161(18), 92(7), 119(7), 65(6) 
253(100), 280(99), 234(68), 206(66), 252(62), 281(59), 251(54), 77(51) 
57(100), 43(21), 29(17), 72(14), 27(13), 55(10), 58(7), 39(7) 
67(100), 68(89), 55(75), 43(65), 41(47), 27(41), 39(24), 82(22) 
59(100), 55(55), 41(48), 83(47), 31(31), 29(28), 43(22), 101(22) 
43(100), 41(15), 55(13), 70(13), 56(11), 112(10), 57(9), 83(9) 
59(100), 72(51), 41(49), 55(41), 43(41), 29(23), 57(20), 81(12) 
297(100), 42(53), 298(20), 296(19), 58(18), 283(17), 241(15), 240(15) 
72(100), 30(78), 41(20), 56(13), 43(9), 57(6), 73(6), 39(5) 
93(100), 199(89), 324(66), 77(56), 109(48), 55(45), 65(32), 41(31) 
324(100), 338(73), 339(62), 325(22), 308(20), 51(15), 293(14), 151(13) 
140(100), 197(93), 155(86), 43(47), 51(11), 198(11), 156(10), 96(10) 
43(100), 141(49), 183(28), 87(24), 42(22), 41(17), 140(10), 108(B) 
135(100), 93(96), 107(86), 108(85), 204(51), 91(51), 105(50) 
161(100), 119(66), 189(66), 93(60), 41(59), 105(55), 81(46), 204(45) 
43(100), 41(99), 81(89), 83(88), 98(83), 55(69), 222(67), 138(59) 
55(100), 27(52), 43(21), 70(17), 44(10), 41(9), 56(8), 98(7) 
71(100), 42(82), 70(62), 57(49), 43(35), 103(26), 91(25), 247(23) 
414 	C18H14N20C1 4 
136 	C10H16 
192 	C11H1203 
154 	C10H180 
196 	C12H2002 
152 	C10H160 
215 	C11 H13 402 
230 	C14H1403 
244 	C15H1603 
201 	C10H11NO2 
154 	C10H180 
162 	C10H14N2 
281 	C15H11N30 3 
128 	C8H160 
152 	C1011160 
130 	C8H180 
172 	C10H2002 
281 	C18H35NO 
297 	C18H19NO3 
265 	C15H23NO3 
324 	C19H20N203 
339 	C20H21NO4 
197 	C9811NO28 
312 	C13H16N205S 
204 	C15H24 
204 	C15H24 
222 	C15H260 
98 	C6H100 
247 	C15021NO2 
miconazole 
myrcene 
myristicine 
myrtanol 
myrtanyl acetate 
myrtenol 
naphthalene, N-methoxy-2-acetylamlno-
naproxen 
naproxen, methyl ester 
napthalene, N-hydroxy-2-acetylamlno -
nerol 
nicotine 
nitrazepam 
oct-1-en-3-ol 
octa-1,4,6-trien-3-0l, 3,7-dimethyl-
octan-3-ol 
octan-3-y1 acetate 
oleamide 
oripavine 
oxprenolol 
oxyphenbutazone 
papaverine 
paracetamol, 3-methythio -
paracetamo1 -3 -mercapturic acid 
patchoulene, a- 
patchoulene, p- 
patchouli alcohol 
pent-1-en-2-one, 4-methyl- 
pethidine 
Ions/Intensities Mol.Wt. Formula Compound Name 
93(100), 	77(33), 	91(31), 	92(23), 	41(16), 	136(13), 	29(12), 	39(10) 136 C1 0H16 phellandrene, a- 
108(100), 	109(86), 179(64) , 	137(42), 	43(34), 	81(11), 	80(11), 	180(7) 179 C10H13NO2 phenacetin 
124(100), 	153(96), 125(69) , 	195(54), 	43(38), 	149(27), 	96(20), 	177(13) 195 C10H13NO3 phenacetin, 2-hydroxy- 
138(100), 	209(72), 167(51) , 	43(31) 	139(27), 	124(21), 	108(18), 	152(11) 209 C11H15NO3 phenacetin, 2-methoxy- 
124(100), 	195(52), 125(40) , 	43(34) 	96(16), 	153(7), 	68(6), 	196(6) 195 C10H13NO3 phenacetin, 3-hydroxy- 
138(100), 	209(51), 139(36) , 	43(31) 	110(121), 	180(10), 	210(7), 	167(6) 209 C11 H15NO3 phenacetin, 3-methoxy- 
108(100), 	109(81), 179(64) , 	43(62) 	137(44), 	153(14), 	136(14), 	81(13) 195 C10H13NO3 phenacetin, N-hydroxy- 
108(100), 	43(84), 138(64), 136(47) 	167(39), 	81(32), 	107(30), 	135(26) 209 C11 H15NO3 phenacetin, N-methoxy- 
124(100), 	153(76), 125(55) , 	96(16) 	80(7), 	154(7), 	52(7), 	53(4) 153 C8H11NO2 phenetidine, 2-hydroxy 
137(100), 	108(70), 109(56) , 	207(47), 	43(26), 	138(10), 	71(9), 	110(9) 207 C12H17NO2 phenetidine, N-butyryl- 
137(100), 	108(99), 109(91) , 	193(67), 	52(9), 	194(8), 	81(8), 	80(7) 193 C11H15NO2 phenetidine, N-propionyl- 
167(100), 	138(95), 223(70) , 	139(25), 	124(18), 	29(15), 	168(11), 	152(10) 223 C12H17NO3 phenetidine, N-propiony1-2-methoxy- 
169(100), 	58(70), 168(29), 72(17), 	170(17), 	167(13), 	42(10), 	30(6) 239 C17H21N pheniramlne 
204(100), 	117(35), 232(24), 51(20), 	77(18), 	161(17), 	103(17), 	146(16) 232 C12H12N203 phenobarbitone 
232(100), 	118(24), 146(23) , 	175(21), 	117(18), 	233(14), 	91(9), 	103(8) 260 C14H16N203 phenobarbitone, N,N-dimethyl 
196(100), 	198(89), 97(68), 132(37), 	62(33), 	200(30), 	99(27), 	61(26) 196 C6H30C1 3 phenol, 2,4,6-trichloro- 
162(100), 	164(72), 63(49), 98(33), 	99(12), 	100(12), 	62(12), 	126(11) 162 C6H40C1 2 phenol, 2,4-dichloro- 
184(100), 	63(65), 53(58), 30(47), 	91(47), 	107(32), 	62(29), 	92(26) 184 C6H4N205 phenol, 2,4-dinitro- 
128(100), 	64(71), 63(36), 130(31), 	39(24), 	65(22), 	38(16), 	92(13) 128 C6H5OC1 phenol, 2-chloro- 
139(100), 	39(63), 65(46), 63(36), 	64(30), 	81(24), 	53(22), 	38(21) 139 C 6H5NO3 phenol, 2-nitro- 
107(100), 	142(89), 77(45), 51(28), 	144(25), 	39(20), 	78(14), 	50(12) 142 C7H7OCI phenol, 3-methy1-4-chloro- 
266(100), 	264(62), 268(60) , 	165(38), 	167(35), 	95(29), 	60(21), 	202(20) 264 C6HOC1 5 phenol, pentachloro- 
162 (100) , 	164 (66) , 220 (58) , 	22 (39) , 	161 (32) , 	133 (28) , 	175 (28) , 	163 (27) 220 c8H 6Cl203 phenoxyacetic acid, 2,4-dichloro- 
234(100), 	175(98), 199(68) , 	177(64), 	236(59), 	147(40), 	145(37), 	111(33) 234 C9H8Cl 203 phencxyacetic acid, 2,4-dichloro-, 
180(100), 	104(74), 77(66), 223(48), 	209(43), 	252(41), 	51(39), 	181(27) 252 C15H12N202 phentoin 
105(100), 	120(51), 77(51), 51(16), 	39(9), 	78(9), 	106(8), 	41(7) 176 C12H160 phenyl-l-hexanone, 1- 
77(100), 	183(93), 308(44), 184(27), 	105(19), 	55(15), 	51(14), 	91(11) 308 C19H20N202 phenylbutazone 
44(100), 	45(3), 	77(3), 	42(3), 	39(3), 	95(2), 	65(2), 	43(1) 165 C9H13NO2 phenylephrine 
139(100), 	140(68), 	63(12), 	62(9), 	51(9), 	141(7), 	39(7), 	114(6) 140 C11 H8 phenylpenta-2,4-dlyne, 1- 
me.ester 
Ions/Intensities Mol.Wt. Formula Compound Name 
44(100), 	77(6), 	42(5), 	79(4), 	51(4), 	45(3), 	91(2), 	105(2) 
114(100), 	100(83), 	42(14), 	56(9), 	115(8), 	70(6), 	101(6), 	55(5) 
76(100), 	50(78), 	147(71), 	104(69), 	103(31), 	74(29), 	75(22), 	38(17) 
30(100), 	72(91), 	133(73), 	56(16), 	43(15), 	116(13), 	41(12), 	104(11) 
93(100), 	41(88), 	43(58), 	27(50), 	69(47), 	49(46), 	77(42), 	29(31) 
70(100), 	92(98), 	41(97), 	55(92), 	83(89), 	91(61), 	69(54), 	81(35) 
53(100), 	41(88), 	81(85), 	108(57), 	39(37), 	69(37), 	43(36), 	79(32) 
84(100), 	43(28), 	41(27), 	83(25), 	93(24), 	139(23), 	55(18), 	39(14) 
84(100), 	41(27), 	83(26), 	93(25), 	43(25), 	139(24), 	55(18), 	39(15) 
82(100), 	110(71), 	39(33), 	41(32), 	95(28), 	27(21), 	54(19), 	109(19) 
176(100), 	177(36), 	57(22), 	45(18), 	149(13), 	29(12), 	119(9) 
233(100), 	383(41), 	259(30), 	245(30), 	95(29), 	56(25), 	43(19), 	41(19) 
77(100), 	93(71), 	91(68), 	80(43), 	147(37), 	53(36), 	105(33), 	65(30) 
146(100), 	190(64), 	117(50), 	118(35), 	30(22), 	161(22), 	189(22), 	103(21) 
86(100), 	99(19), 	30(17), 	69(14), 	58(11), 	41(11), 	43(9), 	120(9) 
86(100), 	99(25), 	120(14), 	30(10), 	58(8), 	87(6), 	91(6), 	92(5) 
113(100), 	70(92), 	43(51), 	42(56), 	373(39), 	141(34), 	26(28), 	71(25) 
58(100), 	86(21), 	284(20), 	238(10), 	85(9), 	199(8), 	42(8), 	198(7) 
137(100), 	180(20), 	122(13), 	138(11), 	43(7), 	94(7), 	51(5), 	77(4) 
43(100), 	136(85), 	165(82), 	120(25), 	57(23), 	29(22), 	162(15), 	90(14) 
179(100), 	43(84), 	150(56), 	57(23), 	119(16), 	164(15), 	134(12), 	180(12) 
70(100), 	44(67), 	191(58), 	189(13), 	192(11), 	165(8), 	59(6), 	71(5) 
58(100), 	30(10), 	56(5), 	42(5), 	77(4), 	59(4), 	51(3), 	57(2) 
125(100), 	43(95), 	41(88), 	168(75), 	55(54), 	39(43), 	69(42), 	153(39) 
81(100), 	152(63), 	67(63), 	41(50), 	109(46), 	82(36), 	39(28), 	69(25) 
123(100), 	41(34), 	133(20), 	162(18), 	81(17), 	91(17), 	55(17), 	105(12) 
133(100), 	160(77), 	107(69), 	161(68), 	41(67), 	167(58), 	91(56), 	105(41) 
168(100), 	167(85), 	41(84), 	43(71), 	27(33), 	97(29), 	39(28), 	29(26) 
136(100), 	41(13), 	42(12), 	137(12), 	81(10), 	55(9), 	39(5), 	117(5) 
151 
398 
147 
248 
136 
152 
150 
156 
156 
152 
338 
383 
162 
218 
271 
236 
373 
284 
180 
207 
221 
263 
165 
168 
152 
328 
372 
238 
324 
C9813N0 
C231130N204 
C8H5NO2 
C14 H20N202 
C10H16 
C10 11160 
C10H14 0 
C10 11200 
C10 11200 
C10H160 
C19H3005 
C18H21N504 
C12H18 
C12H14N202 
C131122N30C1 
C13H20N202 
C20H24N2SC1 
C17H20N2 S 
C10H2203 
C11H13NO3 
C12H15NO3 
C19H21N 
C101115N0 
C10H1602 
C10H160 
C21H2803 
C2282805 
C12H18N203 
C20H24N202 
phenylpropanolamine 
pholcodine 
phthalimide 
pindolol 
pinene, p- 
pinocarveol, trans- 
pinocarvone 
piperitol, cis- 
piperitol, 	trans- 
piperi tone 
piperonyl butoxide 
prazosin 
pregeijerene 
primidone 
procainamide 
procaine 
prochlorperazine 
promazine 
propan-2-one, 1-(4-hydroxy-3-methoxYphenY1) - 
propiophenone, N-hydroxy-4-acetylamino -
propiophenone, N-methoxy-4-acetylamino -
protryptyline 
pseudoephedrine 
psi-diosphenol 
pulegone 
pyrethrin I 
pyrethrin II 
quinalbarbitone 
quinine 
Ions/Intensities Mol.Wt. Formula Compound Name 
184(100), 	65(81), 	39(68), 	121(44), 	69(39), 	41(38), 	94(35), 	186(32) 
59(100), 	149(99), 	81(44), 	108(36), 	93(30), 	41(18), 	43(16), 	121(16) 
93(100), 	77(31), 	41(28), 	43(25), 	91(25), 	79(21), 	57(18), 	94(13) 
92(100), 	91(77), 	81(35), 	41(35), 	109(24), 	79(23), 	134(21), 	27(21) 
91(100), 	43(54), 	92(43), 	41(11), 	119(9), 	108(8), 	39(6), 	134(5) 
162(100), 	104(58), 	51(47), 	77(47), 	103(40), 	131(40), 	135(38), 	43(33) 
120(100), 	92(81), 	138(45), 	39(36), 	43(35), 	64(35), 	45(32), 	63(21) 
121(100), 	120(95), 	92(70), 	65(44), 	195(28), 	43(28), 	39(26), 	92(21) 
161(100), 	122(71), 	107(51), 	204(51), 	41(33), 	105(31), 	93(30), 	121(29) 
161(100), 	204(86), 	41(69), 	91(51), 	189(50), 	105(48), 	133(44), 	135(43) 
189(100), 	204(76), 	93(75), 	81(64), 	107(64), 	41(63), 	105(50), 	91(45) 
41(100), 	105(90), 	107(89), 	204(88), 	93(86), 	81(78), 	121(69), 	79(68) 
161(100), 	189(98), 	204(94), 	41(40), 	91(40), 	105(39), 	133(28), 	81(24) 
233(100), 	340(72), 	341(59), 	248(55), 	247(32), 	356(30), 	139(29), 	234(28) 
172(100), 	92(95), 	156(79), 	65(75), 	108(50), 	39(25), 	43(15), 	63(14) 
43(100) 	109(51), 	151(38), 	65(20), 	92(17), 	45(15), 	156(15), 	108(13) 
109(100) , 	92(95), 	65(67), 	156(61), 	108(56), 	214(29), 	39(23), 	43(22) 
172(100) , 	43(90), 	45(64), 	156(46), 	92(37), 	214(33), 	108(28), 	65(25) 
77(100) 	278(56), 	78(36), 	51(29), 	105(23), 	39(16), 	279(15), 	126(14) 
271(100) , 	273(35), 	77(24), 	256(20), 	300(19), 	272(19), 	255(14), 	228(13) 
93(100) 	43(36), 	91(35), 	77(35), 	41(25), 	121(24), 	136(22), 	92(21) 
71(100) 	93(46), 	111(46), 	41(34), 	43(32), 	86(26), 	69(22), 	55(18) 
59(100) 	93(50), 	43(37), 	121(35), 	81(32), 	136(32), 	41(22), 	67(16) 
93(100) 	121(91), 	136(69), 	91(46), 	79(43), 	77(40), 	119(38), 	41(36) 
43(100) 	121(88), 	93(71), 	136(57), 	41(26), 	59(22), 	81(18), 	68(10 
43(100) 	55(68), 	41(5B), 	69(57), 	83(52), 	57(48), 	61(41), 	70(36) 
73(100) 	69(50), 	55(43), 	43(32), 	41(30), 	70(20), 	27(16), 	56(8) 
180(100) , 	95(59), 	68(48), 	53(32), 	41(32), 	67(14), 	42(11), 	96(10) 
98(100) 	370(22), 	126(14), 	99(13), 	70(12), 	42(9), 	371(5), 	258(5) 
364 
222 
136 
152 
194 
162 
138 
195 
204 
204 
204 
204 
204 
356 
172 
256 
214 
214 
404 
300 
136 
154 
154 
136 
196 
256 
158 
180 
370 
C18H1706C1 
C15260 
C1016 
C10160 
C121802 
C101002 
C7603 
C9H9N04 
C15H24 
C15H24 
C15H24 
C15H24 
C15H24 
C201703SF 
C68N202 S 
C1012N204 S 
C 10N2039 
C8H10N203S 
C23H20N203S 
C1613N202C1 
C1016 
C108180 
C10 H180 
C1016 
C12H2002 
C16H3202 
C10220 
C78N402 
C21 1126N2S2 
radicicol 
rosifoliol 
sabinene 
sabinol 
sabinyl acetate 
safrole 
salicylic acid 
salicyluric acid 
selina-3,7(11)-diene 
selina-4(14),7(11)-diene 
selinene, a- 
selinene, p-
selinene, 8- 
sulindac 
sulphanilamide 
sulphanilamide, 81,84-diacetyl-
sulphanilamide, 81-acetyl-
sulphanilamide, N4-acetyl-
sulphinpyrazone 
temazepam 
terpinene, 7- 
terpinene-4-01 
terpineol, a- 
terpinolene, a- 
terpinyl acetate, a-
tetradecyl acetate 
tetrahydrolinalool 
theophylline 
thioridazine 
Ions/Intensities 	 Mol.Wt. Formula 	Compound Name 
81(100), 41(81), 68(74), 110(66), 69(60), 67(49), 39(47), 109(42) 
135(100), 150(26), 91(18), 39(10), 117(10), 115(10), 136(10), 77(8) 
157(100), 43(55), 115(45), 203(21), 31(16), 42(15), 45(13), 111(10) 
113(100), 70(94), 43(70), 42(44), 407(39), 71(33), 141(27), 58(22) 
58(100), 249(37), 208(17), 193(14), 99(13), 248(11), 84(11), 234(10) 
208(100), 209(86), 278(52), 84(28), 42(25), 96(24), 193(23), 194(21) 
58(100), 43(70), 59(29), 71(28), 41(26), 55(14), 57(12), 85(5) 
107(100), 135)88), 91(86), 41(68), 80(68), 39(61), 150(59), 79(49) 
41(100), 43(68), 69(63), 105(62), 79(61), 93(61), 81(55), 91(52) 
265(100), 43(46), 121(36), 308(29), 77(22), 187(17), 115(17), 266(17) 
202(100), 166(82), 135(60), 160(60), 136(57), 201(53), 119(47), 186(40) 
93(100), 119(78), 41(44), 69(40), 77(26), 91(26), 56(18), 55(17) 
152 C10H160 
150 	C10H140 
276 	C128200 6 
407 	C21 H24N3F39 
294 	C20H26N2 
278 	C19H22N2 
170 	C11H220 
150 	C10140 
222 	C15H260 
308 	C191604 
219 	C10H13N50 
204 	C15H24 
thujone 
thymol 
triethyl citrate 
trifluoperazine 
trimipramine 
triprolidine 
undecan-2-one 
verbenone 
viridiflorol 
warfarin 
zeatin 
zingiberene 
Eight peak spectra, indexed by major ions 
Ions/Intensities Mol.Wt. Formula 
29(100), 
30(100), 
30(100), 
207(63), 	137(34), 	109(32), 	41(31), 	149(20), 	189(18), 	67(17) 
72(91), 	133(73), 	56(16), 	43(15), 	116(13), 	41(12), 	104(11) 
229(48), 	231(30), 	172(19), 	194(13), 	174(12), 	42(12), 	230(8) 
222 
248 
229 
C15H260 
C14H20N202 
C9H9N3Cl 2 
41(100), 43(68), 	69(63), 	105(62), 	79(61), 	93(61), 	81(55), 	91(52) 222 C15H260 
41(100), 69(81), 	55(46), 	95(36), 	43(32), 	56(29), 	57(27), 	39(21) 154 C10H180 
41(100), 69(85), 	55(42), 	82(37), 	67(34), 	81(29), 	71(25), 	95(24) 156 C10H200 
41(100), 69(98), 	93(94), 	133(65), 	79(61), 	91(55), 	107(39), 	39(35) 204 C15H24 
41(100), 79(82), 	67(82), 	119(80), 	55(68), 	81(68), 	84(65), 	93(9) 280 C16H2404 
41(100), 93(91), 	69(76), 	39(34), 	27(30), 	53(21), 	77(13), 	29(12) 136 C10H16 
41(100), 93(93), 	69(75), 	43(42), 	45(28), 	121(22), 	79(22), 	77(19) 196 C12H2002 
41(100), 105(90), 	107(89), 	204(88), 	93(86), 	81(78), 	121(69), 	79(68) 204 C15H24 
43(100), 41(15), 	55(13), 	70(13) 	56(11), 	112(10), 	57(9), 	83(9) 172 C10H2002 
43(100), 41(61), 	55(29), 	69(27) 	39(27), 	108(16), 	67(12), 	111(11) 126 C8H140 
43(100), 41(77),69(55), 	109(44) 	81(43), 	55(36), 	122(39), 	107(32) 222 C15H260 
43(100), 41(89), 	69(80), 	109(50) , 	119(40), 	93(39), 	55(35), 	67(28) 222 C1 5H260 
43(100), 41(99), 	81(89), 	83(88) 	98(83), 	55(69), 	222(67), 	138(59) 222 C15H260 
43(100), 55(50), 	69(40), 	56(40) 	41(38), 	61(36), 	83(34), 	70(33) 228 C14H2802 
43(100), 55(68), 	41(58), 	69(57) 	83(52), 	57(48), 	61(41), 	70(36) 256 C16H3202 
43(100), 57(87), 	82(70), 	55(59) 	41(53), 	96(48), 	83(45), 	69(44) 380 C26H520 
43(100), 60(60), 	41(54), 	57(48) 	102(39), 	61(25), 	71(21), 	228(19) 270 C17H2402 
43(100), 71(99), 	69(48), 	41(44) 	67(33), 	96(31), 	84(28), 	39(28) 154 C10H180 
43(100), 81(27), 	55(26), 	69(26) 	71(22), 	108(18), 	84(18), 	111(13) 154 C10H180 
43(100), 84(71), 	119(55), 	109(35), 	134(35), 	152(34), 	41(29), 	91(29) 194 C12 11180 
43(100), 93(94), 	82(71), 	69(53), 	121(45), 	67(44), 	41(44), 	95(38) 196 C12H2002 
43(100), 105(43), 	91(36), 	148(28), 	77(13), 	79(12), 	51(10), 	67(9) 148 C10H120 
43(100), 109(51), 	151(38), 	65(20), 	92(17), 	45(15), 	156(15), 	108(13) 256 C10H12N20 4 S 
43(100), 121(88), 	93(71), 	136(57), 	41(26), 	59(22), 	81(18), 	68(16) 196 C12H2002 
43(100), 121(53), 	202(24), 	185(15), 	64(9), 	63(9), 	122(8), 	90(7) 242 C9H12N204 S 
Compound Name 
dihydroagarofuran 
pindolol 
clonldine 
citronellal 
citronellol 
caryophyllene 
Hrefeldin A 
myrcene 
linalyl acetate 
selinene, 0- 
octan-31,1 acetate 
hept-5-en-2-one, trans 6-methyl- 
ledol 
bisabolol, a-
patchouli alcohol 
dodecyl acetate 
tetradecyl acetate 
hexacosanal, n-
isopropyl myristate 
camphene hydrate 
cineole, 1,8 - 
carveyl acetate 
myrtanyl acetate 
butan-2-one, 4-phenyl- 
sulphanilamide, N1,N4-dlacetyl- 
terpinyl acetate, a- 
benzenesulfonamlde, N-methoxy-4-acetylamino- 
Ions/Intensities Mol.Wt. Formula Compound Name 
43(100), 
43(100), 
43(100), 
43(100), 
43(100), 
43(100), 
43(100), 
43(100), 
43(100), 
44(100), 
44(100), 
44(100), 
53(100), 
54(100), 
55(100), 
55(100), 
55(100), 
55(100), 
56(100), 
57(100), 
58(100), 
58(100), 
58(100), 
58(100), 
58(100), 
58(100), 
58(100), 
58(100), 
58(100), 
135(53), 	115(17), 	132(14), 	117(13), 	65(8), 	115(7), 	39(6) 
136(85), 	165(82), 	120(25), 	57(23), 	29(22), 	162(15), 	90(14) 
141(49), 	183(28), 	87(24), 	42(22), 	41(17), 	140(10), 	108(8) 
143(83), 	85(67), 	105(62), 	81(60), 	59(53), 	134(49), 	71(48) 
157(40), 	126(31), 	159(24), 	127(21), 	111(15), 	142(13), 	128(13) 
161(57), 	163(35), 	177(24), 	179(15), 	203(11), 	162(10), 	160(9) 
171(89), 	188(83), 	230(61), 	79(44), 	52(19), 	51(18), 	95(16) 
188(27), 	172(21), 	60(19), 	107(18), 	108(12), 	92(9), 	156(8) 
248(75), 	108(70), 	290(63), 	140(50), 	58(27), 	65(27), 	92(23) 
45(3), 	77(3), 	42(3), 	39(3), 	95(2), 	65(2), 	43(1) 
77(6), 	42(5), 	79(4), 	51(4), 	45(3), 	91(2), 	105(2) 
91(6), 	42(4), 	65(4), 	45(3), 	39(3), 	51(2), 	120(2) 
41(88), 	81(85), 	108(57), 	39(37), 	69(37), 	43(36), 	79(32) 
81(92), 	53(81), 	45(53), 	124(50), 	42(47), 	27(44), 	52(41) 
27(52), 	43(21), 	70(17), 	44(10), 	41(9), 	56(8), 	98(7) 
41(63), 	97(61), 	96(34), 	27(21), 	39(20), 	43(17), 	81(16) 
41(77), 	69(69), 	74(68), 	83(43), 	87(40), 	84(34), 	43(41) 
43(94), 	41(88), 	69(78), 	83(70), 	57(68), 	56(60), 	70(53) 
169(39), 	43(28), 	67(22), 	82(16), 	39(14), 	171(13), 	54(13) 
43(21), 	29(17), 	72(14), 	27(13), 	55(10), 	58(7), 	39(7) 
30(10), 	56(5), 	42(5), 	77(4), 	59(4), 	51(3), 	57(2) 
30(7), 	91(5), 	42(4), 	59(4), 	56(3), 	65(3), 	39(2) 
43(70), 	59(29), 	71(28), 	41(26), 	55(14), 	57(12), 	05(5) 
59(18), 	42(11), 	30(8), 	202(7), 	203(5), 	215(), 	91(4) 
71(60), 	42(51), 	44(26), 	43(26), 	51(22), 	30(21), 	27(11) 
73(80), 	45(49), 	44(22), 	59(16), 	42(14), 	165(14), 	167(11) 
86(21), 	284(20), 	238(10), 	85(9), 	199(8), 	42(8), 	198(7) 
86(21), 	318(16), 	85(8), 	42(8), 	272(6), 	323(6), 	232(5) 
91(5), 	57(5), 	59(4), 	42(3), 	77(3), 	105(2), 	30(2) 
150 
207 
312 
238 
199 
219 
230 
230 
290 
165 
151 
135 
150 
171 
98 
140 
268 
238 
494 
128 
165 
149 
170 
277 
270 
256 
284 
318 
339 
C10H140 
C11H13NO3 
C13H16N205S 
C15H2602 
c8H8NO2C1 
C8H7NO2C1 2 
C8H10N204 s 
c8H10N204 s 
C14H14N203S 
c9H13NO2 
C9H13N0 
C9H13N 
C10H140 
C6H9N303 
CH10o 
c10H20 
c17H3202 
C17H34 
C23H28N305SC1 
c8H16o 
C10H15N0 
C10H15N 
C11H220 
C20 1123N 
C17H22N20 
C17H21N0 
C17H20N2S 
c17 14 19N2sc1 
c22H29No2 
cymene-8-ol, p- 
propiophenone, N-hydroxy-4-acetylamino-
paracetamol-3-mercapturic acid 
bisabolol oxide B 
acetanilide, N-hydroxy-4-chloro- 
acetanilide, N-hydroxy-3,4-dichloro-
benzenesulfonamide, 3-hydroxy-4-acetylamino-
benzenesulfonamide, N-OH-4-acetylamino- 
dapsone, acetyl-
phenylephrine 
phenylpropanolamine 
amphetamine 
pinocarvone 
metromidazole 
pent-1-en-2-one, 4-methyl- 
menthane, cis p-
methyl palmitoleate 
heptadec-8-ene, Z- 
glibenclamide 
oct-l-en-3-ol 
pseudoephedsine 
methylamphetamine 
undecan-2-one 
amitryptaline 
doxylamine 
diphenhydramine 
promazine 
chlorpromazine 
dextropropoxyphene 
 aagsa TA4mITAglow-Z 'PT oe 0T2414flgosT 
aquaAlnclasT 1AA4nollosT 
-d 'To-T-uegquaw 
T00TuuTT 
auTPT4lad 
_ruva.4 'ToanaeDouTd 
auTTAqdAaqoid 
Totreq2Aw 
aaqsa TAqqaw Jp1Ton oTunaab 
'ToT44-8-u0gluam 
aqeouaqnq TATTau0a4TD 
'aaaToqvsTq 
Toaau 
auauomIT 
-TAq4awTP-L'E 'To-E-uaT14-9'V'T-eloo 
ungdaolnawaxqxap 
'Towsapna 
ToTT03Tsoa 
-HDS'Hnt 'Ta-ii-untssapna 
-11110S 'Hilt 'To-TT-urwsapna 
-73  'TaauTdiaq 
TowaTa 
apTureaTo 
-d 'To-e-untiquaw 
Ta-c-unquo 
-TAqqam-c-AxoapAq-c 'auo-z-uvqnq 
auTweadIsIT24 
auTweadTwT 
auTapatida 
08H63 
091H83 Z9180 
OZ OI 0 H 0 
08IHOT0 
ZONTZHSI0 
09IH010 
HTZH6T 
081HOT0 
Z08I1.1II0 
OS81HOT0 
Z0VZHPI0 
tZHST0 
81 OT 0 H 0 
9IHOT0 
0919013 
ONSZH8T0 
09ZHST0 
09ZHST0 
08Z95 13
08ZHSI0 
0819013 
09ZHST0 
ONSEH8I0 
OZ OT 0 H 0 
081983 
Z OT S 0 H 0 
Zii9ZHOZD 
ZHVZH6T0 
ONSTHOT0 
8ST 
VPI 
9S1 
PST 
LVZ 
ZSt 
C9Z 
PST 
Z81 
981 
PZZ 
VOZ 
VST 
9ET 
ZST 
TLZ 
ZZZ 
ZZZ 
VZZ 
VZZ 
PSI 
ZZZ 
T8Z 
951 
OCT 
ZOT 
P6Z 
08Z 
S9T 
(11)n, '(T1)6z '(EI)LZ '(81)55 '(tZ)TO '(ES)OL '(c6)c, '(00T)IL 
(Lt)12 '(EZ)68 '(P)6Z '(10)I9 '(SV)LS '(I5)95 '(66)EP 	Cool) IL 
	
(8)LS '(1I)SS '(CI)86 '(01)85 '(VT)ZL '(91)I9 '(LE)Et 	Cool) IL 
(8Z)6E .(TE)E6 '(EE)LZ 'MOSS '(Lt)69 
	
(L9) 19 '(1)L)EV 'CC/01)U 
(EZ)LVZ .(s)I6 '(9Z)EOT '(SE)E0 '(69)1.5 (z9)0L '(Z8)ZP Cool) IL 
(SE)T8 '(VS)69 '(19)I6 '(68)E8 '(Z6)SS '(L6)TV '(86)Z6 '(001)01. 
(5) IL '(9)69 (8) 991 (11) 61 (CI) 681 '(1.9)09 '(00I)OL 
(19)55 '(OL) Z8 (CL) 18 '(E8) TV '(58)EZ1 '(16)E6 '(116)1.9 '(00T)69 
(0I) LL '(01)501 '(II)E6 '(EI)EZT '(SZ)E8 '(9Z)V11 '(66)19 '(001)69 
(8E)L9 '(ZP)SS '030zIT '(05)18 '(is)6c '0060T 'MOT)/ '(00I)69 
(ZZ)89 '(LZ)EZT '(8Z)L9 '(IV)S6 	(LV)Z8 	(05)18 '(S6)It .(001)69 
(EOPOZ '(St)6L .(LP)60I '(ES)96 	(8S)L9 .(58)E6 '(06)TV '(00T)69 
(L)ES '(8)L9 '(Z)EZT '(0I)E6 	(IT)6E '(6I)89 	(09)19 '(00T)69 
(TOLL 	(81)96 '(EZ)ES '(PZ)6L 	(se) 6C 'CSE)E6 	(v#) 1.9 	(001)89 
(ZZ)Z8 '(VZ)6E '(ItOLZ 'CLOT!? (59)EV '(SL)SS '(68)89 .(001)L9 
(91)0E '(6I)OTZ '(EZ)ZV '(9Z)0LZ '(9E)OST '(60TE '(39)Ti2 .(00T)6s 
(51)96 '(LT)TV '(LT) I8 '(OZ)80I '(IZ)60I .(12)991 '(LE)60I '(001)6S 
(9I)TZT '(9T)Et '(81)I9 	'(0E)E6 '(9E)801 '(V9)I8 '(66)6VT '(00T)6S 
(ET) 96 '(EI)T8 '(Lt)S6 '(LT)SS '(8I)19 '(12)991 	(90601 '(00I)65 
(COSS '(1.I)OTT '(8T)TV '(61)991 '(IZ)56 	(L?) 151 '(LZ)60I '(00I)6S 
(91)1.9 '(ZZ)TV '(ZE)9EI '(CC)Isz) '(sc)TzT '(LC)CV '(os)Eis 	(301)65 
(Vi) 11 '(sz)cot 	(cc) 18 '(CC) 191 '(9E)E1) '(SV)TV '(E5)E6 '(001)6S 
(ZT)I8 '(OZ)LS .(EZ)6Z '(IV)ED '(TOSS '(6V)It .(TOZL '(001)69 
(0)EZT '(S)09 '(9)18 '(8)EP '(1T)IP '(ET)SS '(S1)8S '(001)65 
(ZZ)TOT .(ZZ)EV '(8Z)6Z '(TE)TE 'CLOce '(39)It '(ss)ss '(00T)Iss 
'(L)za '(11)69 '(VI)6E '(6Z)117 .(ZOTE '(6V)EP 	(001) 69 
(01) 9C 	'((1)99 '(ET)evz '(ci)66 '(VI)E6T '(ci)eoz '((x)stz '(00T)Els 
(9T)80Z '(61)961 '(OZ)E6T '(ZZ)08Z '(VP) VC '(ZS)S8 '(8S)SEZ '(00I)8S 
(8)LI1 '(PI)SOT '(ST)0E '(9T)LL '(61)9S '(IZ)ZP '(vi)strI '(00I)es 
 
we punodwoo 	einmioa —414—(0141 	saT4Tsua4tuisuoi 
 
      
Ions/Intensities Mol.Wt. Formula Compound Name 
71(100), 
71(100), 
72(100), 
72(100), 
72(100), 
73(100), 
73(100), 
74(100), 
74(100), 
76(100), 
77(100), 
77(100), 
77(100), 
79(100), 
81(100), 
81(100), 
81(100), 
81(100), 
81(100), 
82(100), 
82(100), 
82(100), 
83(100), 
83(100), 
83(100), 
83(100), 
84(100), 
84(100), 
84(100), 
81(67), 
93(46), 
30(55), 
30(57), 
30(78), 
69(50), 
371(76), 
41(75), 
87(53), 
50(78), 
93(71), 
183(93), 
278(56), 
91(31), 
152(63), 
41(81), 
68(87), 
80(50), 
69(57), 
54(44), 
110(71), 
182(45)
41(53), 
55(58), 
55(71), 
82(28), 
41(27), 
43(28), 
56(7), 
41(62), 	95(61), 	55(48), 	43(33), 	82(33), 	69(32) 
111(46), 	41(34), 	43(32), 	86(26), 	69(22), 	55(18) 
45(13), 	43(7), 	41(7), 	56(7), 	107(6), 	57(5) 
43(10), 	56(9), 	41(7), 	57(6), 	107(6), 	73(5) 
41(20), 	56(13), 	43(9), 	57(6), 	73(6), 	39(5) 
55(43), 	43(32), 	41(30), 	70(20), 	27(16), 	56(8) 
	
178(41), 	196(39), 	42(29), 	372(23), 	59(21), 	70(21) 
43(74), 	55(70), 	110(50), 	54(48), 	67(45), 	29(36) 
43(48), 	41(35), 	55(30), 	57(19), 	69(18), 	82(17) 
147(71), 	104(69), 	103(31), 	74(29), 	75(22), 	38(17) 
91(68), 	80(43), 	147(37), 	53(36), 	105(33), 	65(30) 
308(44), 	184(27), 	105(19), 	55(15), 	51(14), 	91(11) 
78(36), 	51(29), 	105(23), 	39(16), 	279(15), 	126(14) 
108(17), 	31(13), 	77(12), 	43(11), 	41(11), 	39(9) 
67(63), 	41(50), 	109(46), 	82(36), 	39(28), 	69(25) 
68(74), 	110(66), 	69(60), 	67(49), 	39(47), 	109(42) 
93(69), 	41(57), 	67(48), 	107(45), 	55(41), 	79(36) 
41(39), 	71(31), 	69(30), 	43(28), 	55(24), 	84(21) 
41(24), 	82(13), 	152(12), 	29(12), 	80(10), 	39(9) 
39(34), 	93(26), 	108(25), 	41(23), 	53(17), 	107(16) 
39(33), 	41(32), 	95(28), 	27(21), 	54(19), 	109(19) 
, 	83(29), 	105(21), 	42(16), 	77(13), 	96(11), 	97 ( 8 ) 
151(45), 	67(33), 	95(32), 	55(29), 	93(28), 	224(23) 
41(38), 	67(15), 	43(13), 	29(11), 	168(11) 
82(70), 	41(38), 	67(16), 	29(16), 	43(13), 	154(12) 
153(26), 	55(20), 	156(19), 	41(16), 	67(12), 	96(11) 
83(26), 	93(25), 	43(25), 	139(24), 	55(18), 	39(15) 
41(27), 	83(25), 	93(24), 	139(23), 	55(18), 	39(14) 
85(6), 	91(5), 	55(4), 	30(3), 	39(2), 	77(2) 
156 
154 
267 
266 
265 
158 
371 
184 
158 
147 
162 
308 
404 
152 
152 
152 
204 
154 
152 
150 
152 
303 
224 
168 
154 
226 
156 
156 
233 
C10H200 
C10180 
C15H25NO3 
C14H22N203 
C15H23NO3 
C10220 
C2129NO3Si 
C1 1 C2002
C9H1802 
C85NO2 
C1 2q18 
C1 920N202 
C2320N203S 
C10160 
C10H160 
C10160 
C15H24 
C10H180 
C10H160 
C10H140 
C10H16 
C17H21NO4 
C13H2003 
C12H24 
C1122 
C13H2203 
C10200 
C 	H 	0 .10 20 
C14 H19No2 
menthol 
terpinene-4-ol 
metoprolol 
atenolol 
oxprenolol 
tetrahydrolinalool 
codeine, trimethylsilyl derivative 
dec-4-enoic acid, methyl ester 
isooctanoic acid, methyl ester 
phthalimide 
pregeijerene 
phenylbutazone 
sulphinpyrazone 
myrtenol 
pulegone 
thujone 
elemene, 13- 
fenchol 
fenchone 
carvone 
piperitone 
cocaine 
methyl jasmonate 
cyclohexane, n-hexyl- 
cyclohexane, n-pentyl- 
methyl dihydrojasmonate 
piperitol, trans- 
piperitol, cis- 
methylphenidate 
Ions/Intensities Mol.Wt. Formula Compound Name 
84 (100) , 
84 (100) , 
86 (100) , 
86 (100) , 
86(100) , 
86(100) , 
86(100) , 
86(100) , 
91 (100) , 
91 (100) , 
91 (100) , 
91 (100) , 
92 (100) , 
93(100) , 
93(100) , 
93(100) , 
93(100) , 
93(100) , 
93(100) , 
93(100) , 
93(100) , 
93(100), 
93(100), 
93(100) , 
95(100), 
95(100) , 
95(100) , 
95(100), 
95(100) , 
133(30) , 
134 (65) , 
30 (13) , 
30 (16) , 
30(17) , 
58 (23) , 
99(19) , 
99(25) , 
43(54) , 
57 (46) , 
92 (89) , 
108 (83) , 
91 (77) , 
41 (34) , 
41 (88) , 
43(31) , 
43(36) , 
77 (31) , 
77(33) , 
119 (78) , 
121 (67) , 
121(91), 
141(87), 
199(89), 
41(20), 
43(66) , 
67 (78) , 
81(65), 
81 (67) , 
162 (21) , 	42 (19) , 	161 (18) , 	92(7) , 	119(7) , 	65(6) 
41 (50) , 	79 (47) , 	109(47) , 	119(40) , 	55(39) , 	91 (37) 
58 (11) , 	87(6) , 	41 (6) , 	73 (5) , 	42 (5) , 	319(3) 
87(10) , 	58 (8) , 	99(8) , 	42 (4) , 	56(4) , 	84 (3) 
58(10) , 	87 (6) , 	41 (4) , 	72 (3) , 	56(3) , 	27(3) 
42(7) , 	29 (6) , 	87(6) , 	30(5) , 	27 (4) , 	51 (3) 
30 (17) , 	69(14) , 	58 (11) , 	41 (11) , 	43 (9) , 	120 (9) 
120(14) , 	30 (10) , 	58 (8) , 	87 (6) , 	91 (6) , 	92 (5) 
92 (43) , 	41 (11) , 	119(9) , 	108 (8) , 	39 (6) , 	134 (5) 
108 (31) , 	192(27) , 	85(24) , 	41 (15) , 	43(11) , 	92 (8) 
41 (17) , 	65(13) , 	29(13) , 	39(12) , 	27 (12) , 	105(9) 
57 (34) , 	192 (26) , 	85(25) , 	92 (14) , 	65(12) , 	90 (12) 
81 (35) , 	41 (35) , 	109(24) , 	79 (23) , 	134 (21) , 	27(21) 
80 (32) , 	121 (29) , 	55(19) , 	43 (17) , 	92 (16) , 	69(15) 
43(58) , 	27(50) , 	69(47) , 	49(46) , 	77 (42) , 	29(31) 
91 (31) , 	79(29) , 	77(29) , 	27 (28) , 	80(22) , 	92 (21) 
91 (35) , 	77(35) , 	41 (25) , 	121 (24) , 	136(22) , 	92 (21) 
41 (28) , 	43(25) , 	91 (25) , 	79(21) , 	57(18) , 	94 (13) 
91 (31) , 	92(23) , 	41 (16) , 	136 (13) , 	29 (12) , 	39(10) 
41 (44) , 	69(40) , 	77(26) , 	91 (26) , 	56 (18) , 	55(17) 
79(38) , 	41 (38) , 	67(33) , 	91 (28) , 	107 (28) , 	39(27) 
136(69), 	91(46), 	79(43), 	77(40), 	119(38), 	41(36) 
43(85), 	94(62), 	68(51), 	121(49), 	95(46), 	41(39) 
324(66), 	77(56), 	109(48), 	55(45), 	65(32), 	41(31) 
110(17), 	55(11), 	43(10), 	67(8) , 	93(8) , 	96(8) 
93(38), 	121(36), 	136(33), 	55(17) , 	69(16) , 	108 (16) 
68 (66) , 	82 (60) , 	81 (54) , 	41 (47) , 	152 (43) , 	109 (39) 
41(61), 	69(38), 	108(35), 	55(35), 	83(33), 	109(26) 
138 (52) , 	41 (50) , 	55(44) , 	123 (33) , 	43(31) , 	96(27) 
162 
152 
319 
387 
234 
193 
271 
236 
194 
192 
162 
192 
152 
204 
136 
136 
136 
136 
136 
204 
136 
136 
236 
324 
154 
196 
152 
152 
198 
C10H14N2 
C10H160 
C18H26N3Cl 
C21H23N30FC1 
Cl4H22N20 
C12H19NO 
C13H22N30C1 
C1 320N22 
C12H1802 
C12H1602 
C12818 
C12H1602 
C10H160 
C15H24 
C10816 
C10H16 
C10H16 
C10H16 
C10H16 
C15H24 
C10H16 
C10H16 
C15H2402 
C19H20N203 
C108180 
C12H2002 
C10H160 
C10H160 
C1 282202 
nicotine 
carveol, cis-
chloroquine 
flu razepam 
lignocaine 
etafedrine 
procainamide 
procaine 
sabinyl acetate 
benzyl isopentanoate 
benzene, n-hexyl 
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zingiberene 
camphene 
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bisabolone oxide 
oxyphenbu ta z one 
borneol 
bornyl acetate 
dihydrocarvone 
camphor 
menthyl acetate 
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C23H30N204 
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thioridazine 
dlethylpropion 
methyl 3-phenyl propanoate 
hippuric acid 
benzyl benzoate 
phenyl-l-hexanone, 1- 
guaiene, a- 
aniline, N-methyl-
guaiene, 8- 
verbenone 
phenol, 3-methy1-4-chloro-
phenacetin, N-methoxy-
anisole 
campholene aldehyde, a-
phenacetin, N-hydroxy-
phenacetin 
acetanilide, 4-methoxy-
acetanilide, 2-methoxy-
menthofuran 
carveol, trans-
sulphanilamide, N1-acetyl-
eudesmane, 	AlotH,SaH- 
menthone 
isomenthone 
menthan-4-ol, 	p- 
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trifluoperazine 
pholcodine 
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L9T 
891 
861 
S6T 
EST 
t7ZT 
861 
8ZE 
9TE 
OEE 
SZE 
OST 
9IE 
S6T 
09E 
POZ 
361 
P6T 
£61 
BET 
903 
tOZ 
POZ 
PET 
9LT 
ialsa TAqqa 'pToe opumooTo 
-nanTg3-6 'inuatid 
TouatidsoTP 
-AxozpAqTp -(7'6 'aPTITurquor 
-AxoxpAqTP-V'E 'aPTITueqaon 
Toungdsorp-Tsd 
-AxoxpAq-c 'uTqaeuatui 
-AxoxpAq-Z '0T4apeualid 
AxnrpAq-Z 'auTPTlauaqd 
-TA1440111-p 'Totioa4ED 
uTsauagTenn 
I oTiqqaaAdosT 
wrzanTD 
I TITTowsec 
I oTiqqaaAd 
wunnauroxpAlap 
aqe.rewTd TAqqaw 
PToe DT/Ili/CDT-Ens 
II uTiauTo 
-1 'auamaTa 
'auouoT 
nuounT-0-oxpA4Tp 
/also 'OM '-ouTure-t-TAqape-N 'pToe oTozuaq 
PT 0E *T1A0T1es 
alyTitoTTes TdrullyosT 
-n 'auaedon 
-n 'aupapao 
-d 'nuar.24-6'C'I-utiguam 
pToe oTqaoosy 
603 I TT  H 0 
TOOSH90 
Z09IH010 
EON6H80 
EON6H80 
Z09IHOT0 
EOKCIH0 
EONEIHOI0 
ZONIIH80 
Z08HL0 
0• DiHOTD 
E8Z TZ 0 H 0 
E08ZHOZ0 
E00EHIZ0 
E08ZTZ0 
0  DIH  OT 0 
Z ZE IZ 0 H 0 
VON6H60 
083H 13D 
VZHSI0 
0OZHET0 
ZZ ET 0 H 0 
EONIIHOT0 
E09HL0 
E09THZI0 
VZHST0 
VZHSI0 
PIHOT0 
908H90 
(TI)LVI 'W06E1 (El) PI 'CTOIs '(93)LL 'CoOsILT '(LE)EOT .(00I)TET 
(EI)66 '(91)8E '(ZZ)S9 '(pZ)6E (IE)OCI '(9E)C9 '(IL)D9 '(00I)861 
(SE)69 '(906E '(9E)SS '(6E)53I '(SD) 891 .(9S)ED '(Z8)Ite '(001)9ZI 
	
(5)08 .(L)ZS '(8)9ZI '(01)VZT 	(V1)96 '(EZ)CO '(LZ)L9I '(001)SZT 
(B)IS .(8)931 	(01) P31 '(ZI)ZS 	(OE) 6L '(EE)EP .(9P)L91 '(001)931 
(6E)ESI .(34)69 '(ED)6E .(pOSS 	(SL)891 	(88) ID '(sOct '(001)53E 
(9)961 '(9)89 'WEST 	(91)96 '(VE)CV 	(0V)St '(ZOSiST 	(001) #1 
(COLLT 	(03) 96 '(L6)61,1 .(8E)E11 '(t/5)961 '(69)531 	(96) £51 	(001) P61 
(V)ES '(L)ZS '(L)4ST '(L)08 '(91)96 '(SS)SZT '(9L)CSI '(ooT)03T 
(6)3S '(01)55 '(EIT)6E '(61)IS 	(06) LL '03t0eL 	(€9) £31 	(001) P31 
(6)69 '(0T)E6I '(1I)ZZT '(0I)18 '(8I)LL '(13)861 
	(90601 	(001) P61 
'(53)E4 .(96)16 '(63)18 '(IC)Z9I 	(3D) ID '(96)CET '(66)I9T 	(001) €61 
(91)95 .(LT)CI7 	'(L1)I8 '(6T)E6 '(OZ)TO '(LZ)OST '(83)131 	(001) €31 
(9T) SET '(33)E6 .(36)179I (€3) 18 'CeOss '(ac)Ip '(as)ca 
 
(001) €31 
Czosot 'cLOss '(LI)T6 'CLtrce (81) 391 'ConEET (001) €61 
'(E)59 '(V)ZZI '(S)6C .(S)81. 	(076 '(8)LL '(OZ)OST 	(001) 161 
(LI)LSZ '(O3)9IC '(OZ)EEI '(63)08T '(cz)ss '(la)9vc 'CootrE3T 
(16)36 '(93) 6€ '(az)cp '(36)56T '(ap)s9 '(oL)66 '(s6)061 '(ooT)I6T 
csnss '(s3)T6 '(6z)osT '(gs)L91 '(9s)E6 '(s9)6yi 'CLIO/An 'CooOtzt 
(53) 9E1 (93) 18 '(96)16 'Csnas '(zE)6L 'CLOLOT '(ooT)T3I 
(€3) 601'(g3)LL '(L3)16 '(63)To 'C609E1 '(89)13' '(0EI)E6 'CocaraI 
(E061I '(9E)S6 '(9E)9EI '(ac)E6 'CsOczi '(09)I9T '(PLIED 	(001) 161 
(01) 191 .(TI)TZT '(6I)Z6 '(06)99 '(9C)CD, '(8E)E6I 	(69) 151 '(00I)OZT 
(T3)E9 '(ZE)St, '(SE)1,9 '(SE)Et '(9C)6E '(St7)8ET '(18)36 .(001)OZT 
(83)55 '(83)6S .(86)6E '(TE)TZT '(TE)8ET '(LE)Et, '(Zt)T4 '(00I)OZT 
(L3) 031 '(36)55 (D€) 16 '(s9)E6 '010ID '(p6)I9T 'CsOsca '(001)6TI 
CLO031 '(06)poz '(cz)Tscc 'Cansca '(oc)69 '(I,E)T0 'C6c0c6 .(001)6IT 
 
(L1)66 'c'Enso-c '(IZ)LL '(96)6E '(0E)T17 '(99)tET '(VL)T6 	(001) 611 
(83) 3D '(66)19 '(9V)14, 	(61') 1€ '(60S8 '(IL)6Z '(88)ED 	(001) 911 
aueN punodulop 	rTnw10.3 '4M T0141 	swnTsua4ui/suoi 
auoppuTad 
304SO IAglaw 'PToe 0TTAxacpea-Z-0I0PuT 
-caotqa-17-Axo1pA4-Z 'aPTITueqape 
H DPIxo I0ToctesTq 
-oTtnAglaw-E 'Toureqapeied 
uTITTdeu 
uTnemqamopuT 
JauATp-V'Z-eluadiAuaqd 
-ox3Tu-z Jiouatid 
-Axotpain-Z 'uT4a3yuat4d 
-Axoqqaw-E 'uTqaoeuatid 
-AxotnawTP-V'E 'aPTITuelape 
-AxolnaluTP-V'Z 'aPTITueqane 
-(TRuagdAxoqqaw-E-Axo1pA4-10-T 'auo-z-uvdoad 
- IAtI4awTP-9'E 'uvanjozuaciozpAllexam 
-TAuoTdoid-H 'auTpTqauaqd 
'unTPT4anaqd 
auTuTnb 
InuTindune 
TogooTy TAurmun 
TOIDEASE0 
ToinAtiq 
-Axotpaw 'apitqapTnzuaq 
-n 'auaTnoquqed 
uTTnaTuaj 
II nTitnaiAd 
-d 'apAtiapie oTuTtnno 
auauauan 
aaqsa IAqqam 'pToe opreuuTo 
BIZ 
SLI 
SBT 
BEZ 
L6I 
891 
LSE 
OVI 
6CT 
60Z 
60Z 
G6T 
561 
081 
ZSI 
E6T 
LOZ 
VZE 
9E1 
OS' 
OGI 
OST 
9ET 
VOZ 
ZOZ 
ZLE 
8VI 
ZET 
Z91 
Z0ZNVIHZID 
ZON6HOI0 
TOZON8H80 
Zo9ZHSID 
SZONITH6D 
08HZ I0 
TODOH9TH6I 
89113 
ONSH90 
EONSIHTT0 
CONS 19113
CONETHOT0 
EONETHOT 
C0ZZHOT0 
0919013  
ZONGIHTT0 
ZONLTHZT 
Z0ZNVZHOZ0 
OVNVHSO 
0 VIH  OT 
OT OT 0 H 0 
VT OT 0 H 0 
Z08980 
VZHSI0 
08IHVT0 
So8ZHZZ0 
0ZIHOT 
ZTHOTO 
Z0OTHOT0 
(I)Cot (ZZ) 68T 	(ZZ) 19I 	(ZZ) OE ' (SE) BIT ' (0G) LIT ( V9) 06i 
(S)ZL ' (9)9L1. (L)E9 ' (IT)SVI ' (L1)68 ' (L1)91I (CS)SLI 
(6) VII ' (6) Via ' (0I) IS ' (I) o8 ' (6I)581 ' (CC) SDI ' (Z0) CV 
(Se) VET ' (OE) 89 ' (IC) ' (DC)S1 ' (VC) IL ' (00 C6 ' (IL)Et' 
(01)96 ' COI) 951 ' (I1)86I 	(TT)IS ' (0) CV ' (98)551 	(C6)L61 
	
(OZ) 6E ' (OE) LL (SE)E9 ' (90 IS ' (TO 89T ' (S9) T6 (o6) 6C1 
(13) EVE 	(8) SC. 	(6) 8SE 	(0I) 04T 	(EZ) ILL 	(9Z) LSE 	(LE) "CPI 
(S) VII ' (L) 6E ' (L) IVI ' (6) TS ' (6) Z9 ' (ZI)E9 	(89) OVI 
(TZ) BE ' (z) Cc 	(VZ) 18 ' (00 V9 ' (9E) C9 ' (91')59 ' (C9) 6C 
(II)ZS' 	(8I) 801 ' (ti) DI ' (La) 6C1 ' (IC) EV ' (IS) L9I 	(ZL) 60Z 
(9)L91 ' 	) OTZ ' COI) 081 ' (TZ I) OT I ' (IC)CD ' (9E)6E1 	(IS) 60Z 
(6)961 ' (6)SI ' (61)6E1 ' (VZ)OTT 	(TE)EV ' (IE)ESI (TO56I 
(TT) 6E1 	CI) S6 ' (CT) ZS ' (6I) OTT ' (IC)CV ' (ZOS6I (EL) EST 
(V) LL ' (G) IS ' (L) V6 ' (00, ' (TT) BET ' (ET) ZZT 	(OZ)08I 
(IT) 6E ' (TI) L9 ' (I)Ss ' (ST) E6 ' (CZ) TV ' (s)69 	(9Z) 601 
 
(L) 08 ' (8) T8 '(8) V6I ' (6) ZS ' (L9) C61 ' (16) 601 	(66)801 
(6) OTT ' (6) IL ' (0I) BEI ' C9) CD ' (Lt') LOZ ' (90601 (00 80T 
(S) LIT ' (G) 6E ' (6)55 ' (0T) T8 ' (Z I) LEI ' (ZI)ZV ' (ET) TV 
(L) 6E ' (0 LET ' (6) TS ' (CI) ES ' (ET) SET ' (00 ZS (EC) 6Z 
(91) LL ' (EZ) 16 ' (SZ)61I ' (ZE)6L ' (SE) LOT 	(ZO)GOT 	(0) Oct 
(6) LOT ' (OD 9ET (01) 6E ' (II) LL ' (ZT) IV 	(OZ) 16 	(LZ) OSI 
(8) LL ' (01) 9E1 	(01) 	' (0T) LIT ' (0I) 6E 	(81)16 	(9Z) OST 
(8)59 ' (8)E9 ' (OT)6E 	(TI) LOT ' (VI) Z6 	(L)LL (69)9E1 
(OS) SOT ' (TS) T6 ' (1S) D0 	(58) 801 	(98) LOT ' (96) C6 
(9) LL (6)6C ' (6)1.01 ' (0T) GET ' (TE) 69 	(SE) EEI ' (9E) TV 
(IV) SOI ' (9016 ' (80 L9I ' (L9) TV ' (89)191 ' (69)L01 	(LL) 09i 
(ZE)6T1 	(ZE) TV 	(DC)6L 	(DE) 16 ' (6E) LL (89) BPI ' (99) SOT 
(ST) 	' (6I) G9 	(6I) 6E 	(OZ) Z6 ' (EC) SIT ' (8016 '(I8)LII 
(9)C91 ' (0T) ZET ' (I1) 0I ' (VI) TS ' (VZ)LL (SD)COT 	(BS) Z9I 
(001) 9 ta 
'(00T)VVI 
'(00I) CPT 
.(00I)EVI 
'(00I)OVI 
' (001) OPT 
' (00t) 6E1 
' (001) 6ET 
(00T) 6CT 
'(00I)8ET 
' (001) 8EI 
' (00T) BEI 
' (00T) BET 
'(00T) LET 
'(00T)LCI 
'(00I) LET 
'(00I) LET 
' (001) 9EI 
' (001) 9C1 
' (001) GET 
' (00T) SCI 
' (OW SCI 
' (00I)SEI 
(00I) SET 
' (00T) VEI 
' (00T) CET 
' (00I) CET 
' (001) ZET 
' (OW LEI 
aureN punodmoo 	eTnwaol .414.-row saT4Tsu3guI/suoI 
Ions/Intensities Mol.Wt. Formula Compound Name 
148(100), 
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151(100), 
154(100), 
155(100), 
156(100), 
156(100), 
156(100), 
157(100), 
157(100), 
159(100), 
159(100), 
160(100), 
161(100), 
161(100), 
161(100), 
161(100), 
161(100), 
161(100), 
161(100), 
161(100), 
161(100), 
161(100), 
162(100), 
162(100), 
162(100), 
163(100), 
163(100), 
164(100), 
147(35), 
147(42), 
93(72), 
211(95), 
140(80), 
141(76), 
141(94), 
141(60), 
43(55), 
142(92), 
142(73), 
160(13), 
103(63), 
41(65), 
59(70), 
105(45), 
105(97), 
119(66), 
122(71), 
133(92), 
134(58), 
189(98), 
204(86), 
104(58), 
164(72), 
164(66), 
135(89), 
161(93), 
166(33), 
77(22), 	133(22), 	117(22), 	105(20), 	121(18), 	79(13) 
121(39), 	117(30), 	77(22), 	133(21), 	105(17), 	51(15) 
43(43), 	194(28), 	136(25), 	41(24), 	133(14), 	55(12) 
43(40), 	110(36), 	169(34), 	109(13), 	212(11), 	155(9) 
83(58), 	41(56), 	98(54), 	55(42), 	29(26), 	27(26) 
41(36), 	27(33), 	29(30), 	39(30), 	55(29), 	98(22) 
41(44), 	29(40), 	27(31), 	39(21), 	98(19), 	142(15) 
41(45), 	157(33), 	55(30), 	43(30), 	27(28), 	29(22) 
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selina -4(14),7(11) -diene 
saf role 
phenol, 2,4-dichloro- 
phenoxyacetic acid, 2,4-dichloro- 
jasmolin II 
ibuprofen 
indoleacetic acid, 4-chloro-, methyl ester 
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Ions/Intensities Mol.Wt. Formula Compound Name 
282(100), 
295(100), 
283(80), 
296(21), 
284(44), 
238(12), 
	
285(25), 	77(15) , 	220(13), 	247(12), 	219(11) 
310(12), 	26(8), 	251(6), 	27(6), 	55(5) 
299 
310 
C16H14N30CI 
C21 H2602 
chlordiazepoxide 
cannabinol 
297(100), 42(53), 298(20), 296(19), 	58(18), 	283(17), 241(15), 	240(15) 297 C18H19 4O3 oripavine 
300(100), 77(85), 258(67), 51(58), 	255(52), 	259(47), 256(38), 	283(38) 300 C16H13N202C1 clobazepam 
301(100), 44(40), 42(38), 	59(37), 	70(31), 	164(26), 	31(24), 	302(21) 301 C18H23NO3 dihydrocodeine 
312(100), 285(99), 286(67), 313(63), 	266(48), 	238(43) , 	283(40), 	284(33) 313 C16H12N303F flunitrazepam 
313(100), 
316(100), 
42(38), 
256(88), 
59(29), 	162(28), 	314(19), 	284(18), 
241(52), 	121(50), 	136(42), 	105(39) 
124(18), 	243(16) 
, 	213(37), 	257(34) 
313 
316 
C19H23NO3 
C21 H3202 
ethylmorphine 
methyl abietate 
317(100), 315(96), 236(92), 288(69), 	78(57), 	286(57), 77(56), 	51(51) 315 C14 H10N3OBr bromazepam 
323(100), 221(81), 181(56), 222(45), 	207(40), 	72(37), 223(34), 	196(24) 323 C20H25N30 lysergic acid diethylamide 
324(100), 338(73), 339(62), 325(22), 	308(20), 	51(15), 293(14), 	151(13) 339 C20H21N04 papaverine 
341(100), 282(58), 43(39), 42(34), 	229(30), 	59(23), 	342(22) , 	204(17) 341 C20 1123N04 acetyl codeine 
(LSD) 
Eight peak spectra, indexed by molecular weight 
Ions/Intensities Mol.Wt. Formula 
55(100), 27(52), 43(21), 70(17), 44(10), 	41(9), 	56(8), 	98(7) 98 C6H100 
59(100), 43(49), 31(42), 41(29), 39(14), 	69(11), 	42(7), 	87(4) 102 C5H1002 
106(100), 107(83) , 	77(32) , 	51(24) , 	39(23), 	79(16), 	65(15), 	78(12) 107 C7H9N 
108(100), 65(95), 78(67), 39(46), 51(24), 	77(22), 	79(17), 	93(16) 108 C7 H80 
124(100), 123(63) , 	78(48), 77(20) , 	51(19), 	39(18), 	55(10), 	52(9) 124 C7H802 
43(100), 41(61), 55(29), 69(27), 39(27), 	108(16), 	67(12), 	111(11) 126 C8H140 
57(100), 43(21), 29(17), 72(14), 27(13), 	55(10), 	58(7), 	39(7) 128 C8H160 
128(100), 64(71), 63(36), 130(31) , 	39(24), 	65(22), 	38(16), 	92(13) 128 C6H50C1 
59(100), 55(55), 41(48), 83(47), 31(31), 	29(28), 	43(22), 	101(22) 130 C8H180 
132(100), 117(81) , 	91(38) , 	115(33) , 	92(20), 	39(19), 	65(19), 	131(15) 132 C10H12 
119(100), 91(74), 134(66), 41(30) , 	39(26), 	77(21), 	105(21), 	92(17) 134 C10H14 
44(100), 91(6), 	42(4), 	65(4), 	45(3), 	39(3), 	51(2), 	120(2) 135 C 9H13N 
136(100), 29(33), 52(30), 135(13) , 	53(12), 	51(9), 	137(7), 	39(7) 136 C5H4N40 
135(100), 136(69), 77(27) , 	92(14) , 	107(11), 	39(10), 	63(8), 	6 5 ( 8 ) 136 C8H802 
93(100), 121(67), 79(38), 41(38), 67(33), 	91(28), 	107(28), 	39(27) 136 C10H16 
93(100), 43(31) 91(31), 79(29), 77(29), 	27(28), 	80(22), 	92(21) 136 C10H16 
68(100), 67(44) 93(35), 39(25), 79(24), 	53(23), 	94(18), 	77(15) 136 C10H16 
41(100), 93(91) 69(76), 39(34), 27(30), 	53(21), 	77(13), 	29(12) 136 C10H16 
93(100), 77(33) 91(31), 92(23), 41(16), 	136(13), 	29(12), 	39(10) 136 C10H16 
93(100), 41(88) 43(58), 27(50), 69(47), 	49(46), 	77(42), 	29(31) 136 C10H16 
93(100), 77(31) 41(28), 43(25), 91(25), 	79(21), 	57(18), 	94(13) 136 C10H16 
93(100), 43(36) 91(35), 77(35), 41(25), 	121(24), 	136(22), 	92(21) 136 C10516 
93(100), 121(91), 136(69) , 	91(46) , 	79(43), 	77(40), 	119(38), 	41(36) 136 C10H16 
120(100), 92(81), 1313(45), 	39(36) , 	43(35), 	64(35), 	45(32), 	63(21) 138 C7H603 
139(100), 39(63), 65(46), 63(36), 64(30), 	81(24). 	53(22), 	38(21) 139 C6 11 5NO3 
55(100), 41(63), 97(61), 96(34), 27(21), 	39(20), 	43(17), 	81(16) 140 C10H20 
139(100), 140(68) , 	63(12) , 	62(9), 51(9), 	141( 7 ), 	39(7), 	114(6) 140 C11 H8 
107(100), 142(89) , 	77(45) , 	51(28) , 	144(25), 	39(20), 	78(14), 	50(12) 142 C7H70C1 
Compound Name 
pent-1-en-2-one, 4-methyl- 
butan-2-one, 3-hydroxy-3-methyl- 
aniline, N-methyl- 
anisole 
catechol, 4-methyl- 
hept-5-en-2-one, trans 6-methyl- 
oct-l-en-3-ol 
phenol, 2-chloro- 
octan-3-ol 
cymenene 
mentha-1,3,9-triene, p- 
amphetamine 
allopurinol 
benzaldehyde, methoxy- 
camphene 
carene, A3- 
limonene 
myrcene 
phellandrene, a- 
pinene, p-
sabinene 
terpinene, y- 
terpinolene, a-
salicylic acid 
phenol, 2-nitro-
menthane, cis p-
phenylpenta-2,4-diyne, 1 - 
phenol, 3-methy1-4-chloro- 
Ions/Intensities Mol.Wt. Formula Compound Name 
71(100), 	43(99), 	56(51), 	57(45), 	41(41), 	29(24), 	89(23), 	27(17) 144 C8H1602 isobutyyl isobutyrate 
76(100), 	50(78), 	147(71), 	104(69), 	103(31), 	74(29), 	75(22), 	38(17) 147 C885NO2 phthalimide 
148(100), 	147(35), 	77(22), 	133(22), 	117(22), 	105(20), 	121(18), 	79(13) 148 C10H120 anethole 
43(100), 	105(43), 	91(36), 	148(28), 	77(13), 	79(12), 	51(10), 	67(9) 148 C1011120 butan-2-one, 4-phenyl- 
133(100), 	105(66), 	148(58), 	77(39), 	91(34), 	79(34), 	41(32), 	119(32) 148 C10H120 cuminic aldehyde, p- 
148(100), 	147(42), 	121(39), 	117(30), 	77(22), 	133(21), 	105(17), 	51(15) 148 C10H1202 estragole 
58(100), 	30(7), 	91(5), 	42(4), 	59(4), 	56(3), 	65(3), 	39(2) 149 C10H15N methylamphetamlne 
135(100), 	150(27), 	91(20), 	41(12), 	77(11), 	39(10), 	136(10), 	107(9) 150 C10H140 carvacrol 
82(100), 	54(44), 	39(34), 	93(26), 	108(25), 	41(23), 	53(17), 	107(16) 150 C108140 carvcne 
135(100), 	150(43), 	105(42), 	107(35), 	79(32), 	119(25), 	91(23), 	77(16) 150 C10H140 cuminyl alcohol 
43(100), 	135(53), 	115(17), 	132(14), 	117(13), 	65(8), 	115(7), 	39(6) 150 C10H140 cymene-8-ol, p- 
121(100), 	150(20), 	77(8), 	91(7), 	78(5), 	39(5), 	122(4), 	65(3), 150 C10H140 dihydroanethole 
tv 108(100), 	150(21), 	79(17), 	39(9), 	109(8), 	77(7), 	41(6), 	51(5) 150 C108140 menthofuran 
cri 
co 53(100), 	41(88), 	81(85), 	108(57), 	39(37), 	69(37), 	43(36), 	79(32) 150 C10H140 pinocarvone 
135(100), 	150(26), 	91(18), 	39(10), 	117(10), 	115(10), 	136(10), 	77(8) 150 C10H140 thymol 
107(100), 	135)88), 	91(86), 	41(68), 	80(68), 	39(61), 	150(59), 	79(49) 150 C10H140 verbenone 
44(100) 	77(6), 	42(5), 	79(4), 	51(4), 	45(3), 	91(2), 	105(2) 151 C9H13N0 phenylpropanolamine 
108(100), 	93(42), 	95(25), 	41(24), 	109(19), 	67(19), 	91(13), 	81(12) 152 C19H160 campholene aldehyde, a- 
95(100) 	81(65), 	41(61), 	69(38), 	108(35), 	55(35), 	83(33), 	109(26) 152 C10H160 camphor 
84(100) 	134(65), 	41(50), 	79(47), 	109(47), 	119(40), 	55(39), 	91(37) 152 C108160 carveol, cis- 
109(100) , 	84(85), 	41(46), 	55(37), 	119(35), 	83(33), 	91(33), 	39(28) 
95(100) 	67(78), 	68(66), 	82(60), 	81(54), 	41(47), 	152(43), 	109(39) 
152 
152 
C108160 
C.-A lu-16° 
carveol, 	trans- 
dihydrocarvone 
81(100) , 	69(57) , 	41 (24) , 	82 (13) , 	152 (12) , 	29 (12) , 	80 (10) , 	39 (9) 152 C1014160 
fenchone 
137(100), 	109(26), 	69(25), 	41(23), 	93(15), 	55(12), 	67(11), 	39(11) 152 C108160 hexahydrobenzofuran, 3,6-dimethyl - 
79(100) 	91(31), 	108(17), 	31(13), 	77(12), 	43(11), 	41(11), 	39(9) 152 C10H160 myrtenol 
67(100) 	68(89), 	55(75), 	43(65), 	41(47), 	27(41), 	39(24), 	82(22) 152 C10H160 octa-1,4,6-trien-3-ol, 3,7-dimethyl- 
70(100) 	92(98), 	41(97), 	55(92), 	83(89), 	91(61), 	69(54), 	81(35) 152 C108160 pinocarveol, trans- 
82(100) 	110(71), 	39(33), 	41(32), 	95(20), 	27(21), 	54(19), 	109(19) 152 C10H160 piperitone 
81(100) 	152(63), 	67(63), 	41(50), 	109(46), 	82(36), 	39(28), 	69(25) 152 C10H160 pulegone 
lt) 
Ions/Intensities Mol.Wt. Formula Compound Name 
92(100), 	91(77), 	81(35), 	41(35), 	109(24), 	79(23), 	134(21), 	27(21) 152 C10 1,1160 sabinol 
81(100), 	41(81), 	68(74), 	110(66), 	69(60), 	67(49), 	39(47), 	109(42) 152 C1011160 thujone 
124(100), 	153(76), 	125(55), 	96(16), 	80(7), 	154(7), 	52(7), 	53(4) 153 C8H11NO2 phenetidine, 2-hydroxy 
95(100), 	41(20), 	110(17), 	55(11), 	43(10), 	67(8), 	93(8), 	96(8) 154 C1010 }3180 borneol 
	
43(100), 	71(99), 	69(48), 	41(44), 	67(33) 	96(31), 	84(28), 	39(28) 
43(100), 	81(27), 	55(26), 	69(26), 	71(22) 	108(18), 	84(18), 	111(13) 
41(100), 	69(81), 	55(46), 	95(36), 	43(32) 	56(29), 	57(27), 	39(21) 
154 
154 
154 
C10H180 
C10180 
C10180 
camphene hydrate 
cineole, 	1,8- 
citronellal 
83(100), 	55(71), 	82(70), 	41(38), 	67(16) 	29(16), 	43(13), 	154(12) 154 C11H22 cyclohexane, n-pentyl- 
81(100), 	80(50), 	41(39), 	71(31), 	69(30) 	43(28), 	55(24), 	84(21) 
112(100), 	69(55), 	41(53), 	55(46), 	139(33), 	56(30), 	70(28), 	43(25) 
154 
154 
C10 14180 
C10H180 
fenchol 
somenthone i 
71(100), 	43(74), 	41(67), 	69(47), 	55(44), 	27(33), 	93(31), 	39(28) 154 C10H180 linalool 
112(100), 	41(85), 	69(67), 	55(63), 	56(39), 	139(37), 	70(36), 	43(35) 154 C10H180 menthone 
69(100), 	67(94), 	93(91), 	123(85), 	41(83), 	81(73), 	82(70), 	55(61) 154 C10H180 myrtanol 
69(100), 	41(60), 	68(19), 	39(11), 	93(10), 	123(2), 	67(8), 	53(7) 
71(100), 	93(46), 	111(46), 	41(34), 	43(32), 	86(26), 	69(22), 	55(18) 
154 
154 
C10II180 
C10II180 
nerol 
terpinene-4-ol 
59(100), 	93(50), 	43(37), 	121(35), 	81(32), 	136(32), 	41(22), 	67(16) 
41(100), 	69(85), 	55(42), 	82(37), 	67(34), 	81(29), 	71(25), 	95(24) 
71(100), 	43(37), 	41(16), 	72(14), 	58(14), 	98(13), 	55(11), 	57(8) 
113(100), 	43(96), 	95(66), 	41(35), 	99(32), 	71(24), 	55(20), 	69(12) 
154 
156 
156 
156 
C10II180 
C10 11200 
C1011200 
C10II 200 
terpineol, a- 
citronellol 
menthan-l-ol, p-
menthan-4-01, 	p- 
59(100), 	58(15), 	55(13), 	41(11), 	43(8), 	81(6), 	60(5), 	123(4) 156 C108200 menthan- 8 -ol, p- 
71(100), 	81(67), 	41(62), 	95(61), 	55(48), 	43(33), 	82(33), 	69(32) 156 C10H200 menthol 
84(100), 	43(28), 	41(27), 	83(25), 	93(24), 	139(23), 	55(18), 	39(14) 156 C10200 piperitol, cis- 
84(100), 	41(27), 	83(26), 	93(25), 	43(25), 	139(24), 	55 ( 18 ), 	39( 15 ) 156 C10200 piperitol, 	trans- 
71(100), 	43(93), 	70(53), 	41(24), 	55(18), 	27(13), 	29(11), 	42(11) 158 C9 II802 isobutyric acid, 2-methylbutyl ester 
74(100), 	87(53), 	43(48), 	41(35), 	55(30), 	57(19), 	69(18), 	82(17) 158 C9 11 1802 isooctanoic acid, methyl ester 
73(100), 	69(50), 	55(43), 	43(32), 	41(30), 	70(20), 	27(16), 	56(8) 158 C10H220 tetrahydrolinalool 
160(100), 	103(63), 	76(30), 	130(29), 	131(25), 	89(24), 	115(23), 	50(22) 160 C8H8N4 hydralazine 
91(100), 	92(89), 	41(17), 	65(13), 	29(13), 	39(12), 	27(12), 	105(9) 162 C12 1118 benzene, n-hexyl 
131(100), 	162(58), 	103(45), 	77(24), 	51(14), 	102(11), 	132(10), 	163(6) 162 C101002 cinnamic acid, methyl ester 
Ions/Intensities 	 Mol.Wt. Formula 	Compound Name 
84(100), 133(30), 162(21), 42(19), 161(18), 92(7), 119(7), 65(6) 
162(100), 164(72), 63(49), 98(33), 99(12), 100(12), 62(12), 126(11) 
77(100), 93(71), 91(68), 80(43), 147(37), 53(36), 105(33), 65(30) 
162(100), 104(58), 51(47), 77(47), 103(40), 131(40), 135(38), 43(33) 
104(100), 91(91), 82(69), 105(43), 119(31), 39(28), 164(27), 77(25) 
108(100), 123(80), 165(57), 43(42), 80(31), 52(21), 65(17), 92(8) 
108(100), 123(62), 165(56), 43(26), 80(10), 52(10), 122(10), 109(8) 
58(100), 146(24), 42(21), 56(19), 77(16), 30(15), 105(14), 117(8) 
44(100), 45(3), 77(3), 42(3), 39(3), 95(2), 65(2), 43(1) 
58(100), 30(10), 56(5), 42(5), 77(4), 59(4), 51(3), 57(2) 
125(100), 167(27), 43(23), 96(14), 124(10), 126(8), 52(7), 80(5) 
125(100), 167(46), 43(33), 79(30), 52(12), 124(10), 126(8), 51(8) 
140(100), 139(90), 91(65), 168(51), 51(36), 63(35), 77(30), 39(20) 
83(100), 55(58), 41(38), 67(15), 43(13), 29(11), 168(11) 
126(100), 41(82), 43(56), 168(45), 125(39), 55(36), 39(36), 69(35) 
125(100), 43(95), 41(88), 168(75), 55(54), 39(43), 69(42), 153(39) 
58(100), 43(70), 59(29), 71(28), 41(26), 55(14), 57(12), 85(5) 
54(100), 81(92), 53(81), 45(53), 124(50), 42(47), 27(44), 52(41) 
43(100), 41(15), 55(13), 70(13), 56(11), 112(10), 57(9), 83(9) 
172(100), 92(95), 156(79), 65(75), 108(50), 39(25), 43(15), 63(14) 
144(100). 175(53),116(17), 89(17), 145(11), 63(7), 176(6), 72(5) 
116(100), 43(88), 29(71), 85(59), 31(49), 44(46), 61(29), 42(28) 
131(100), 103(37), 176(30), 77(26), 51(15), 104(13), 132(12), 147(11) 
105(100), 120(51), 77(51), 51(16), 39(9), 78(9), 106(8), 41(7) 
178(100), 134(96), 160(47), 78(28), 77(26), 51(26), 39(25), 135(23) 
105(100), 77(66), 135(31), 51(26), 134(15), 106(8), 78(6), 161(4) 
108(100), 109(86), 179(64), 137(42), 43(34), 81(11), 80(11), 180(7) 
137(100), 180(20), 122(13), 138(11), 43(7), 94(7), 51(5), 77(4) 
180(100), 95(59), 68(48), 53(32), 41(32), 67(14), 42(11), 96(10) 
162 	C1014N2 
162 	C6H40C1 2 
162 C1218 
162 C101002 
164 	C10H1202 
165 	C9111402 
165 	C911NO2 
165 C1015N0 
165 	C913NO2 
165 C1015N0 
167 	C89NO3 
167 	C891403 
168 	C1280 
168 	C12H24 
168 	C10111602 
168 	C101602 
170 	C11 11220 
171 	C69N303 
172 	C10H2002 
172 	C68N202 S 
175 	C10H9NO2 
176 	C6806 
176 	C11H1202 
176 	C12160 
178 	C10H1003 
179 	C9H9NO3 
179 	C1013NO2 
180 	C10 112203 
180 	C78N402 
nicotine 
phenol, 2,4-dichloro- 
pregeijerene 
safrole 
methyl 3-phenyl propanoate 
acetanilide, 2-methoxy- 
acetanilide, 4-methoxy- 
ephedrine 
phenylephrine 
pseudoephedrine 
acetanilide, 2,4-dihydroxy- 
acetanilide, 3,4-dihydroxy- 
capi11in 
cyclohexane, n-hexyl- 
diosphenol 
psi-diosphenol 
undecan-2-one 
metromidazole 
octan-3-y1 acetate 
sulphanilamide 
indole-2-carboxylic acid, methyl ester 
ascorbic acid 
cinnamic acid, ethyl ester 
phenyl-l-hexanone, 1- 
mellein 
hippuric acid 
phenacetin 
propan-2-one, 1-(4-hydroxy-3-methoxypheny1) - 
theophylline 
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(61) LL ' (ZZ)6L ' (ZZ) 11 ' (8Z) S9 ' (Z9) Et ' (SL) 69 ' (E6) C6 ' (001) Ii' 
(91) 801 ' (91)69 ' (LT) SS ' (EE)9E1 ' (9E) 	' (8E) E6 ' (99) EV ' (001)56 
( 'CZ) Z6 ' (9)6C ' (8Z) EV ' (8Z)561 ' (99)59 ' (00 Z6 ' (S6) OZT 	(001) UT 
(ET) 18 ' (VT) 9E1 ' (VT) EST ' (99) LEI ' (Z9) CV ' (P9)6L1 ' (18)601 ' (001)80T 
(9)961 ' (9)89 ' 	EST ' (91)96 ' (PC) CV ' (0V)SZ1 ' (ZS) 56T ' (001) VZT 
(cI)LLI '(Or)96 	(Li) 691 '(8E)E9 	(PS) 561 	(69) S1 '(96)CSI '(001)I,ZI 
(6)961 ' (6)51 ' (61) 6E1 	( VZ) 01 I ' (TE) EV ' (1E)CST 	(IL)561 ' (001)8E1 
(IT) 6E1 ' (1)S6 ' (ET) ZS ' (61) OTT ' (TE) C9 ' (ZL)561 ' (EL)E51 ' (00T) BET 
(5)9E' ' (9)6C '(8)801 ' (6)611 '(11) TV ' (EP)6 ' (95)E9 '(001)16 
(CO 611 ' (9C) 56 ' (9E) 9C1 ' (8C) £6 ' (8C) EZI ' (09) 191 ' (PL) EP ' (001) UT 
(6Z) 16 ' (6z) TV ' (PE) ZGT '(SE) VET ' (SE) 601 ' (SS) 611 ' (IL) 98 ' (001)E9 
(L) 08 ' (8) T8 '(8) 961 ' (6) Z5 ' (L9) E61 ' (16)601 ' (66)801 ' (00T) LET 
(C) TS ' (9) LZ 	(S) OE ' (9) L8 ' (9)6Z ' 	Z9 ' (c) a5 '(001)98 
191 ' (TT) TZI (6I) Z6 ' (0Z)59 ' (9E) EP ' (80E61 ' (60 IST ' (001) OZI 
(Z1)E61 ' (ET) 191 ' (PI) 6E ' (51)59 ' (9.0 6TT 	(ZZ)S91 	(VZ) 16 ' (001) Z6T 
(z1)LL 	(ZT) 	' (p1) 8L1 ' (51) 16 	(OZ)E6 ' (9Z) It ' (P8)E0 ' (001) LLT 
(E) 6O1 	(Si) LL (12)16 ' (6Z)19 ' (65) 9E1 	(89)CV ' (08) C6 ' (001) TZT 
(at) 06 	(Z1)59 ' (9T) Z6 ' (SZ) 58 ' (9Z) Z61 ' (9E) LS ' (E8) 801 ' (001) 16 
(8) Z6 	(tC) Et ' (St)1D ' (P) S8 ' (LZ) Z6T ' (TE) 80T ' (99)L5 ' (001) 16 
(8E) L9 	(Z9) SS ' (89) ZIT ' (05) 18 ' (TS)6E 	(85)601 ' (16)19 ' (00T) 69 
(OZ) 18 ' (IE)E11 ' (ZE)LZ (St) ZL ' (89) Z9 ' (89)91T ' (LL)6Z ' (001)98T 
(6) PIT ' 6) PVT ' (01)19 ' (ZT) 08 '(61)981 ' (EC) SVI ' (P) EP ' (001) Et T 
(9Z) Z6 (6Z) Z9 ' (ZE) LOT ' (L9) 16 ' (L9) OC (85)E5 ' (59) E9 (OOT) 981 
(9E) 6Z '(99) L9 ' (89)95 ' (05)01T ' (00 SS ' (00E9 ' (5019 '(001) PL 
(ET) PSI ' (51) S8T ' (L1) Z51 ' (z)SST ' (EZ) CST ' (9Z)E8T 	(16)691 ' (001) 981 
(ZZ) 86 ' (6Z) SS ' (0E) 6E ' (0E)6 	' (EE)L2 ' (9E) T9 ' (90 TOT ' (001) 951 
(9Z) LZ ' (9Z) 6Z ' (Z9) SS ' (P9)86 ' (95) TV ' (85)E8 ' (08)091 ' (001) SST 
(01) LL (0T) SOT ' (11)E6 ' (E1) E1 ' (s) E8 ' (9Z) VTI ' (66) Ii' ' (001)69 
 
auleN punodmoo 	rInulloa '414.TON 
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Ions/Intensities Mol.Wt. Formula Compound Name 
196(100), 	198(89), 	97(68), 	132(37), 	62(33), 	200(30), 	99(27), 	61(26) 
43(100), 	121(88), 	93(71), 	136(57), 	41(26), 	59(22), 	81(18), 	68(16) 
140(100), 	197(93), 	155(86), 	43(47), 	51(11), 	198(11), 	156(10), 	96(10) 
124(100), 	109(56), 	198(21), 	77(18), 	81(14), 	122(11), 	123(10), 	52(9) 
95(100), 	81(67), 	138(52), 	41(50), 	55(44), 	123(33), 	43(31), 	96(27) 
157(100), 	142(92), 	43(60), 	199(53), 	159(34), 	144(32), 	114(24), 	201(19) 
43(100), 	157(40), 	126(31), 	159(24), 	127(21), 	111(15), 	142(13), 	128(13) 
159(100), 	142(73), 	43(71), 	115(70), 	143(41), 	201(37), 	128(25), 	140(22) 
202(100), 	200(18), 	203(17), 	101(11), 	202(10), 	88(6), 	150(5), 	100(4) 
159(100), 	160(13), 	202(9), 	129(7), 	128(7), 	131(5), 	105(5), 	144(4) 
134(100), 	41(36), 	133(35), 	69(31), 	135(10), 	107(9), 	39(9), 	77(6) 
69(100), 	41(90), 	93(85), 	67(58), 	94(53), 	109(47), 	79(45), 	204(33) 
161(100), 	134(58), 	119(46), 	105(45), 	204(41), 	41(34), 	81(27), 	91(25) 
41(100), 	69(98), 	93(94), 	133(65), 	79(61), 	91(55), 	107(39), 	39(35) 
119(100), 	93(49), 	41(34), 	69(30), 	105(28), 	161(23), 	204(20), 	120(17) 
119(100), 	105(95), 	161(94), 	41(46), 	93(65), 	91(34), 	55(28), 	120(27) 
161(100), 	105(97), 	119(93), 	41(33), 	81(32), 	120(29), 	91(29), 	93(26) 
81(100), 	68(87), 	93(69), 	41(57), 	67(48), 	107(45), 	55(41), 	79(36) 
121(100), 	93(74), 	107(47), 	79(32), 	94(29), 	91(26), 	81(26), 	136(25) 
161(100), 	105(45), 	91(41), 	41(36), 	119(30), 	77(29), 	55(27), 	120(26) 
105(100), 	147(87), 	41(85), 	93(78), 	79(58), 	91(58), 	204(56), 	133(54) 
107(100), 	108(99), 	93(96), 	41(83), 	105(66), 	79(62), 	81(62), 	95(61) 
93(100) , 	41(34), 	80(32), 	121(29) , 	55(19) , 	43(17) , 	92(16) , 	69(15) 
135(100), 	93(96), 	107(86), 	108(85), 	204(51), 	91(51), 	105(50) 
161(100), 	119(66), 	189(66), 	93(60), 	41(59), 	105(55;, 	81(46), 	204(45) 
161(100), 	122(71), 	107(51), 	204(51), 	41(33), 	105(31), 	93(30), 	121(29) 
161(100), 	204(86), 	41(69), 	91(51), 	189(50), 	105(48), 	133(44), 	135(43) 
189(100), 	204(76), 	93(75), 	81(64), 	107(64), 	41(63), 	105(50), 	91(45) 
41(100), 	105(90), 	107(89), 	204(88), 	93(86), 	81(78), 	121(69), 	79(68) 
196 
196 
197 
198 
198 
199 
199 
201 
202 
202 
202 
204 
204 
204 
204 
204 
204 
204 
204 
204 
204 
204 
204 
204 
204 
204 
204 
204 
204 
C6H30C1 3 
C12 H2002 
C 9H11NO 2S 
C10H1404 
C12H2202 
C9H10NO2Cl 
C8H8NO2Cl 
C10H11NO2 
C16H10 
C15H22 
C14H180 
C15H24 
C15H24 
C15H24 
C1 5H 4 
C15H24 
Cl 
C15H24 
C15H24 
C15H24 
C15H24 
C15H24 
C15824 
C15H24 
C15H24 
C15H24 
C15H24 
C15H24 
Cl 
phenol, 2,4,6-trichloro- 
terpinyl acetate, a- 
paracetamol, 3-methythlo-
guaifenesin 
menthyl acetate 
acetanilide, 2-methoxy-4-ohloro-
acetanilide, N-hydroxy-4-chloro-
napthalene, N-hydroxy-2-acetylamino-
butadlyne, 1,4-diphenyl- 
calamenene 
feniculin 
bisabolene, p- 
cadinene, 8- 
caryophyllene 
cedrene, a-
copaene, a-
cubebene, a-
elemene, p-
elemene, y-
Germacrene D 
guaiene, a-
guaiene, 8- 
humulene 
patchoulene, a-
patchoulene, p-
selina-3,7(11)-diene 
selina-4(14),7(11)-diene 
selinene, a- 
selinene, p- 
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Ions/Intensities Mol.Wt. Formula Compound Name 
59(100), 
189(100), 
161(100), 
43(100), 
43(100), 
59(100), 
41(100), 
164(100), 
167(100), 
69(100) 
59(100) 
59(100) 
83(100) 
156(100) , 
83(100) 
169(100) , 
169(100 , 
43(100) 
30(100) 
43(100) 
202(100) , 
43(100) 
185(100) , 
204(100) , 
84(100) 
86(100) 
234(100) 
93(100) 
193(100) 
149(37), 	164(27), 	109(21), 	108(20), 	81(17), 	41(17), 	95(15) 
204(69), 	161(61), 	59(50), 	133(45), 	105(32), 	81(30), 	107(26) 
59(70), 	107(57), 	105(53), 	93(42), 	81(42), 	41(39), 	91(37) 
41(77),69(55), 	109(44), 	81(43), 	55(36), 	122(39), 	107(32) 
41(99), 	81(89), 	83(88), 	98(83), 	55(69), 	222(67), 	138(59) 
149(99), 	81(44), 	108(36), 	93(30), 	41(18), 	43(16), 	121(16) 
43(68), 	69(63), 	105(62), 	79(61), 	93(61), 	81(55), 	91(52) 
166(33), 	223(23), 	55(21), 	43(21), 	41(20), 	99(17), 	165(11) 
138(95), 	223(70), 	139(25), 	124(18), 	29(15), 	168(11), 	152(10) 
41(95), 	81(50), 	82(47), 	95(41), 	67(28), 	123(27), 	68(22) 
109(36), 	166(27), 	41(18), 	55(17), 	95(17), 	81(13), 	96(13) 
109(27), 	151(27), 	95(21), 	166(19), 	41(18), 	110(17), 	55(13) 
41(53), 	151(45), 	67(33), 	95(32), 	55(29), 	93(28), 	224(23) 
141(60), 	41(45), 	157(33), 	55(30), 	43(30), 	27(28), 	29(22) 
82(28), 	153(26), 	55(20), 	156(19), 	41(16), 	67(12), 	96(11) 
185(60), 	43(47), 	168(32), 	211(28), 	141(22), 	167(21), 	170(14) 
211(39), 	168(30), 	185(24), 	43(23), 	170(15), 	141(11), 	167(10) 
55(50), 	69(40), 	56(40), 	41(38), 	61(36), 	83(34), 	70(33) 
229(48), 	231(30), 	172(19), 	194(13), 	174(12), 	42(12), 	230(8) 
171(89), 	188(83), 	230(61), 	79(44), 	52(19), 	51(18), 	95(16) 
244(75), 	43(74), 	138(42), 	186(34), 	92(25), 	107(24), 	79(12) 
188(27), 	172(21), 	60(19), 	107(18), 	108(12), 	92(9), 	156(8) 
230(48), 	186(15), 	141(14), 	115(12), 	170(11), 	139(11), 	153(8) 
117(35), 	232(24), 	51(20), 	77(18), 	161(17), 	103(17), 	146(16) 
56(7), 	85(6), 	91(5), 	55(4), 	30(3), 	39(2), 	77(2) 
30(17), 	58(10), 	87(6), 	41(4), 	72(3), 	56(3), 	27(3) 
, 	175(98), 	199(68), 	177(64), 	236(59), 	147(40), 	145(37), 	111(33) 
141(67), 	43(85), 	94(62), 	68(51), 	121(49), 	95(46), 	41(39) 
, 	192(34), 	236(23), 	191(20), 	165(16), 	194(15), 	63(7), 	167(6) 
222 
222 
222 
222 
222 
222 
222 
223 
223 
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224 
224 
224 
226 
226 
227 
227 
228 
229 
230 
244 
230 
230 
232 
233 
234 
234 
236 
236 
C15H260 
C15H260 
C15H260 
C15H260 
C15H260 
C15H260 
C15H260 
C11010NO2Cl 
C12H17NO3 
C14H2402 
C15H280 
C15H280 
C13H2003 
C11H18N203 
C13H2203 
C14H13NO2 
C14H13NO2 
C14H2002 
C 9H9N3Cl 2 
C8H10N204 S 
C 9H12N204 S 
C8H10N204 S 
C14 H1403 
C12H12N203 
C14 111 9NO2 
C14 H22N20 
C9H8Cl 203 
C1524 02 
C15H12N20 
eudesmol, 0- 
eudesmol, y- 
guaiol 
ledol 
patchouli alcohol 
rosifoliol 
viridiflor01 
indoleacetic acid, 4-chloro-, methyl ester 
phenetidine, N-propiony1-2-methoxy- 
citronellyl butenoate 
eudesman-11-ol, 4a8,5a5- 
eudesman-11-ol, 413H, 505- 
methyl jasmonate 
amylobarbitone 
methyl dihydrojasmonate 
biphenyl, N-hydroxy-3-acetylamino - 
biphenyl, N-hydroxy-4-acetylamino - 
dodecyl acetate 
clonidine 
benzenesulfonamide, 3-hydroxy-4-acetylamino -
benzenesulfonamide, 3-methoxy-4-acetylamino -
benzenesulfonamide, N-OH-4-acetylamino-
naproxen 
phenobarbitone 
methylphenidate 
lignocaine 
phenoxyaeetie acid, 2,4 -dichloro - , me.ester 
bisabolone oxide 
carbamazepine 
Ions/Intensities Mol.Wt. Formula Compound Name 
86(100), 
238(100), 
43(100), 
143(100), 
151(100), 
55(100), 
168(100), 
181(100), 
239(100), 
169(100), 
199(100), 
168(100), 
43(100), 
185(100), 
71(100), 
30(100), 
235(100), 
180(100), 
180(100), 
58(100), 
43(100), 
43(100), 
232(100), 
70(100), 
266(100), 
266(100), 
72(100), 
72(100), 
72(100), 
	
99(25), 	120(14), 	30(10), 	58(8), 	87(6), 	91(6), 	92(5) 
223(31), 	43(26), 	192(19), 	239(15), 	191(11), 	163(11), 	39(10) 
143(03), 	85(67), 	105(62), 	81(60), 	59(53), 	134(49), 	71(48) 
43(71), 	93(43), 	71(34), 	125(34), 	121(31), 	68(30), 	134(25) 
93(72), 	43(43), 	194(28), 	136(25), 	41(24), 	133(14), 	55(12) 
43(94), 	41(88), 	69(78), 	83(70), 	57(68), 	56(60), 	70(53) 
167(85), 	41(84), 	43(71), 	27(33), 	97(29), 	39(28), 	29(26) 
180(71), 	223(57), 	152(23), 	43(21), 	197(19), 	182(16), 	165(15) 
180(62), 	197(61), 	196(51), 	181(23), 	152(21), 	240(16), 	168(14) 
58(70), 	168(29), 	72(17), 	170(17), 	167(13), 	42(10), 	30(6) 
43(93), 	168(51), 	184(27), 	200(17), 	241(17), 	169(16), 	153(13) 
199(77), 	43(46), 	169(40), 	167(32), 	198(30), 	241(29), 	141(22) 
121(53), 	202(24), 	185(15), 	64(9), 	63(9), 	122(8), 	90(7) 
244(35), 	186(17), 	170(10), 	141(7), 	154(6), 	245(6), 	153(6) 
42(82), 	70(62), 	57(49), 	43(35), 	103(26), 	91(25), 	247(23) 
72(91), 	133(73), 	56(16), 	43(15), 	116(13), 	41(12), 	104(11) 
91(52), 	250(42), 	233(30), 	65(25), 	76(21), 	236(16), 	39(15) 
104(74), 	77(66), 	223(48), 	209(43), 	252(41), 	51(39), 	181(27) 
181(63), 	210(51), 	179(39), 	211(38), 	43(37), 	253(36), 	165(33) 
73(80), 	45(49), 	44(22), 	59(16), 	42(14), 	165(14), 	167(11) 
109(51), 	151(38), 	65(20), 	92(17), 	45(15), 	156(15), 	108(13) 
55(68), 	41(58), 	69(57), 	83(52), 	57(48), 	61(41), 	70(36) 
118(24), 	146(23), 	175(21), 	117(18), 	233(14), 	91(9), 	103(8) 
44(67), 	191(58), 	189(13), 	192(11), 	165(8), 	59(6), 	71(5) 
264(76), 	268(47), 	109(25), 	124(19), 	98(14), 	133(14), 	62(12) 
264(62), 	268(60), 	165(38), 	167(35), 	95(29), 	60(21), 	202(20) 
30(78), 	41(20), 	56(13), 	43(9), 	57(6), 	73(6), 	39(5) 
30(57), 	43(10), 	56(9), 	41(7), 	57(6), 	107(6), 	73(5) 
30(55), 	45(13), 	43(7), 	41(7), 	56(7), 	1076), 	57(5) 
236 
238 
238 
238 
238 
238 
238 
239 
239 
239 
241 
241 
242 
244 
247 
248 
250 
252 
253 
256 
256 
256 
260 
263 
264 
264 
265 
266 
267 
C13H20N202 
C13H180 4 
C152602 
C152602 
C152602 
C17H34 
C12H18N203 
C15H13NO2 
C15H13NO2 
C17H21N 
C15H15NO2 
C15H15NO2 
C9H12N204 S 
C15H1603 
C15H21NO2 
C1420N202 
C16H14N20 
C1512N202 
C16H15NO2 
C17H21NO 
C10H12N204 
C16H3202 
C14 1,116N203 
C19H21N 
C8N2Cl 4 
C6HOC1 5 
C15H23NO3 
C14 H22N203 
C15H25NO3 
S 
procaine 
benzene, 2,3,4,5-tetramethoxy-allyl -
bisabolol oxide B 
bisabolol oxide B 
daucol 
heptadec-8-ene, Z- 
quinalbarbitone 
fluorene, N-hydroxy-2-acetylamino -
fluorene-9-ol, 2-acetlamino-. 
pheniramine 
biphenyl, N-methoxy-3-acetylamino -
biphenyl, N-methoxy-4-acetylamino - 
benzenesulfonamide, N -methoxy-4 -acetylamino-
naproxen, methyl ester 
pethidine 
pindolol 
methaqualone 
phentoin 
fluorene, N-methoxy-2-acetylamino -
diphenhydramine 
sulphanilamide, 81,84-diacetyl-
tetradecyl acetate 
phenobarbitone, N,N -dimethyl 
protryptyline 
chlorothalonil 
phenol, pentachloro- 
oxprenolol 
atenolol 
metoprolol 
Ions/Intensities Mol.Wt. Formula Compound Name 
55(100), 
58(100), 
43(100), 
242(100), 
59(100), 
86(100), 
203(100), 
157(100), 
58(100), 
190(100), 
208(100), 
41(100), 
58(100), 
253(100), 
59(100), 
256(100), 
58(100), 
43(100), 
58(100), 
100(100), 
297(100), 
282(100), 
300(100), 
271(100), 
301(100), 
82(100), 
77(100), 
265(100), 
295(100), 
	
41(77), 	69(69), 	74(68), 	B3(43), 	87(40), 	84(34), 	43(41) 
71(60), 	42(51), 	44(26), 	43(26), 	51(22), 	30(21), 	27(11) 
60(60), 	41(54), 	57(48), 	102(39), 	61(25), 	71(21), 	228(19) 
207(94), 	244(33), 	270(20), 	200(17), 	165(16), 	243(16), 	269(13) 
271(48), 	31(39), 	150(36), 	270(26), 	42(23), 	214(19), 	30(16) 
99(19), 	30(17), 	69(14), 	58(11), 	41(11), 	43(9), 	120(9) 
58(92), 	205(33), 	72(26), 	204(15), 	42(13), 	167(13), 	202(12) 
43(55), 	115(45), 	203(21), 	31(16), 	42(15), 	45(13), 	111(10) 
59(18), 	42(11), 	30(8), 	202(7), 	203(5), 	215(), 	91(4) 
125(29), 	134(28), 	162(27), 	91(14), 	112(13), 	191(12), 	161(11) 
209(86), 	278(52), 	84(28), 	42(25), 	96(24), 	193(23), 	194(21) 
79(82), 	67(82), 	119(80), 	55(68), 	81(68), 	84(65), 	93(9) 
235(58), 	85(52), 	234(44), 	280(22), 	193(20), 	195(19), 	208(16) 
280(99), 	234(68), 	206(66), 	252(62), 	281(59), 	251(54), 	77(51) 
72(51), 	41(49), 	55(41), 	43(41), 	29(23), 	57(20), 	81(12) 
283(81), 	284(66), 	255(42), 	257(41), 	285(41), 	258(33), 	286(22) 
86(21), 	284(20), 	238(10), 	85(9), 	199(8), 	42(8), 	198(7) 
248(75) 	108(70), 	290(63), 	140(50), 	58(27), 	65(27), 	92(23) 
249(37) 	208(17), 	193(14), 	99(13), 	248(11), 	84(11), 	234(10) 
44(17) 	72(9), 	101(7), 	77(7), 	29(7), 	42(6), 	56(4) 
42(53) 	298(20), 	296(19), 	58(18), 	283(17), 	241(15), 	240(15) 
283(80) , 	284(44), 	285(25), 	77(15), 	220(13), 	247(12), 	219(11) 
77(85) 	258(67), 	51(58), 	255(52), 	259(47), 	256(38), 	283(38) 
273(35) , 	77(24), 	256(20), 	300(19), 	272(19), 	255(14), 	228(13) 
44(40) 	42(38), 	59(37), 	70(31), 	164(26), 	31(24), 	302(21) 
182(45) 	83(29), 	105(21), 	42(16), 	77(13), 	96(11), 	97(8) 
183(93) 	308(44), 	184(27), 	105(19), 	55(15), 	51(14), 	91(11) 
43(46) 	121(36), 	308(29), 	77(22), 	187(17), 	115(17), 	266(17) 
296(21), 	258(12), 	310(12), 	26(8), 	251(6), 	27(6), 	55(5) 
268 
270 
270 
270 
271 
271 
274 
276 
277 
278 
278 
280 
280 
281 
281 
284 
284 
290 
294 
295 
297 
299 
300 
300 
301 
303 
308 
308 
310 
C17H3202 
C17H22N20 
C17H2402 
C16H15N2CI 
C18H25NO 
C13H22N30C1 
C16H19N2CI 
C12H2006 
C20H23N 
C16H2204 
C19H22N2 
C16H240 4 
C19H24N2 
C15H11N303 
C18H35NO 
C16H13N20C1 
C17H20N2 S 
C14H14N2039 
C20H26N2 
C13H19NO 
C18H19NO3 
C16 1114N30C1 
C16H13N202C1 
C16H13N202C1 
C18H23NO3 
C17H21NO4 
C19H20N202 
C19H1604 
C21H2602 
methyl palmitoleate 
doxylamine 
isopropyl myristate 
medazepam 
dextromethorphan 
procainamide 
chlorpheniramine 
triethyl citrate 
amitryptaline 
abscisic acid, methyl 
triprolidine 
Hrefeldin A 
imipramine 
nitrazepam 
oleamide 
diazepam 
promazine 
dapsone, acetyl-
trimipramine 
diethylpropion 
oripavine 
chlordiazepoxide 
clobazepam 
temazepam 
dihydrocodeine 
cocaine 
phenylbutazone 
warfarin 
cannabinol 
ester 
Ions/Intensities Mol.Wt. Formula Compound Name 
43(100), 	141(49), 	183(28), 	87(24), 	42(22), 	41(17), 	140(10), 	108(8) 312 C13H16N205S paracetamol-3-mercapturic acid 
313(100), 	42(38), 	59(29), 	162(28), 	314(19), 	284(18), 	124(18), 	243(16) 313 C19H23NO3 ethylmorphine 
312(100), 	285(99), 	286(67), 	313(63), 	266(40), 	238(43), 	283(40), 	284(33) 313 C16812N303F flunitrazepam 
239(100), 	299(20), 	240(20), 	314(14), 	197(6), 	173(5), 	141(5), 	143(4) 314 C21H3002 methyl dehydroabietate 
317(100), 	315(96), 	236(92), 	288(69), 	78(57), 	286(57), 	77(56), 	51(51) 315 C14 H10N3OBr bromazepam 
280(100), 	286(72), 	315(72), 	288(56), 	240(53), 	234(53), 	75(48), 	287(44) 315 C1510N303C1 clonazepam 
123(100), 	121(28), 	150(27), 	41(20), 	93(19), 	81(17), 	43(17), 	55(16) 316 C202803 cinerin I 
316(100), 	256(88), 	241(52), 	121(50), 	136(42), 	105(39), 	213(37), 	257(34) 316 C213202 methyl abietate 
121(100), 	146(24), 	55(23), 	41(23), 	180(22), 	133(20), 	316(20), 	257(17) 316 C21 H3202 methyl pimarate 
58(100), 	86(21), 	318(16), 	85(8), 	42(8), 	272(6), 	320(6), 	232(5) 318 C17H19N2SCI chlorpromazine 
86(100), 	30(13), 	58(11), 	87(6), 	41(6), 	73(5), 	42(5), 	319(3) 319 C18H26N3C1 chloroquine 
239(100), 	284(72), 	75(67), 	276(49), 	138(48), 	302(46), 	111(43), 	304(35) 320 C151120N202C1 2 lorazepam 
323(100), 	221(81), 	181(56), 	222(45), 	207(40), 	72(37), 	223(34), 	196(24) 
93(100), 	199(89), 	324(66), 	77(56), 	109(48), 	55(45), 	65(32), 	41(31) 
136(100), 	41(13), 	42(12), 	137(12), 	81(10), 	55(9), 	39(5), 	117(5) 
123(100, 	161(99), 	133(95), 	41(42), 	162(31), 	81(29), 	91(26), 	43(25), 
323 
324 
324 
328 
C20H25N30 
C19H20N203 
C20H24N202 
C21H2803 
lysergic acid diethylamide (LSD) 
oxyphenbutazone 
quinine 
isopyrethrin I 
	
123(100), 	41(34), 	133(20), 	162(18), 	81(17), 	91(17), 	55(17), 	105(12) 
123(100), 	43(54), 	41(34), 	55(28), 	81(23), 	164(22), 	93(22), 	135(16) 
328 
330 
C212803 
C213003 
pyrethrin I 
jasmolin I 
176(100), 	177(36), 	57(22), 	45(18), 	149(13), 	29(12), 	119(9) 338 C19H3005 piperonyl butoxide 
58(100), 	91(5), 	57(5), 	59(4), 	42(3), 	77(3), 	105(2), 	30(2) 339 C22H29NO2 dextraprapoxyphene 
324(100), 	338(73), 	339(62), 	325(22), 	308(20), 	51(15), 	293(14), 	151(13) 339 C20H21N04 papaverine 
341(100), 	282(58), 	43(39), 	42(34), 	229(30), 	59(23), 	342(22), 	204(17) 341 C2023N04 acetyl codeine 
233(100), 	340(72), 	341(59), 	248(55), 	247(32), 	356(30), 	139(29), 	234(28) 356 C20II1703SF sulindac 
139(100),.141(37), 	357(26), 	111(23), 	140(10), 	358(9), 	75(8), 	113(8) 
121(100), 	107(97), 	149(65), 	93(56), 	167(55), 	150(29), 	91(25), 	55(25) 
357 
360 
C19H16NO4Cl 
C21H2805 
indomethacin 
cinerin II 
184(100), 	65(81), 	39(68), 	121(44), 	69(39), 	41(38), 	94(35), 	186(32) 
98(100), 	370(22), 	126(14), 	99(13), 	70(12), 	42(9), 	371(5), 	258(5) 
364 
370 
C18H1706C1 
C21H26N2S2 
radicicol 
thioridazine 
73(100), 	371(76), 	178(41), 	196(39), 	42(29), 	372(23), 	59(21), 	70(21) 
161(100), 	133(92), 	107(23), 	91(22), 	41(19), 	105(18), 	162(17), 	93(15) 
371 
372 
C21 H29NO3S1 
C222805 
codeine, trimethylsilyl derivative 
isapyrethrin II 
Ions/Intensities Mol.Wt. Formula Compound Name 
133(100), 	160(77), 	107(69), 	161(68), 	41(67), 	167(58), 	91(56), 	105(41) 
113(100), 	70(92), 	43(51), 	42(56), 	373(39), 	141(34), 	26(28), 	71(25) 
163(100), 	135(89), 	93(87), 	107(79), 	167(76), 	55(55), 	121(48), 	41(43) 
43(100), 	57(87), 	82(70), 	55(59), 	41(53), 	96(48), 	83(45), 	69(44) 
233(100), 	383(41), 	259(30), 	245(30), 	95(29), 	56(25), 	43(19), 	41(19) 
86(100), 	30(16), 	87(10), 	58(8), 	99(8), 	42(4), 	56(4), 	84(3) 
114(100), 	100(83), 	42(14): 56(9), 	115(8), 	70(6), 	101(6), 	55(5) 
185(100), 	185(57), 	259(54), 	43(54), 	57(38), 	29(27), 	41(24), 	157(22) 
77(100), 	278(56), 	78(36), 	51(29), 	105(23), 	39(16), 	279(15), 	126(14) 
113(100), 	70(94), 	43(70), 	42(44), 	407(39), 	71(33), 	141(27), 	58(22) 
259(100), 	161(62), 	81(42), 	163(10), 	54(9), 	89(8), 	27(7), 	160(7) 
56(100), 	169(39), 	43(28), 	67(22), 	82(16), 	39(14), 	171(13), 	54(13) 
372 
373 
374 
380 
383 
387 
398 
402 
404 
407 
414 
494 
C22H2805 
C20H24N2SC1 
C22H3005 
C2 6H520 
C18H21N504 
C21H23N30FC1 
C23H30N204 
C20H3408 
C23H20N203S 
C21H24N3F3S 
C18H14N20C14 
C23H28N305SC1 
pyrethrin II 
prochlorperazine 
jasmolin II 
hexacosanal, n-
prazosin 
flurazepam 
pholcodine 
citric acid, acetyl-, 
sulphinpyrazone 
trifluoperazine 
miconazole 
glibenclamide 
tri-n-butyl ester 
